Improved Survival with Vemurafenib in Melanoma wit

New England Journal of Medicine
364, 2507-2516
DOI: 10.1056/nejmoa1103782

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 440.	0.6	1
2	Role of prostaglandin E2 in contractile abnormality induced by calcium ionophore, A23187. Neurology, 1984, 34, 91-91.	1.5	3
3	Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2695-2706.	0.9	32
4	Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Medicine, 2011, 3, 76.	3.6	28
5	Discontinued drugs in 2010: oncology drugs. Expert Opinion on Investigational Drugs, 2011, 20, 1479-1496.	1.9	13
6	Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032. Neoplasia, 2011, 13, 1132-IN17.	2.3	89
7	Inhibition of Ras for cancer treatment: the search continues. Future Medicinal Chemistry, 2011, 3, 1787-1808.	1.1	349
8	Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma. Drugs, 2011, 71, 1233-1250.	4.9	20
9	The Emperor of All Maladies â€" The Beginning of the Beginning. New England Journal of Medicine, 2011, 365, 2353-2355.	13.9	0
10	Vemurafenib for Melanoma Metastases to the Brain. New England Journal of Medicine, 2011, 365, 2439-2441.	13.9	80
11	Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. Molecular Pharmaceutics, 2011, 8, 2039-2049.	2.3	109
12	Fotemustine for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2891-2904.	0.9	24
13	Advances in personalized cancer management. , 2011, , .		0
14	Cancer genome sequencing and functional genomics: from translational to clinical medicine. Pharmacogenomics, 2011, 12, 1371-1374.	0.6	1
15	Cancer immunotherapy comes of age. Nature, 2011, 480, 480-489.	13.7	3,115
16	Vemurafenib. Nature Reviews Drug Discovery, 2011, 10, 811-812.	21.5	135
18	Genomics Reaches the Clinic: From Basic Discoveries to Clinical Impact. Cell, 2011, 147, 14-16.	13.5	30
19	Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology, 2011, 29, 587-601.	0.8	19

#	Article	IF	Citations
20	Current Surgical Treatment in Melanoma. Current Problems in Cancer, 2011, 35, 173-184.	1.0	5
21	Molecular Alternations in Uveal Melanoma. Current Problems in Cancer, 2011, 35, 211-224.	1.0	9
22	Signaling Pathways in Hepatocellular Carcinoma. Oncology, 2011, 81, 18-23.	0.9	39
23	The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology, 2011, 8, 562-566.	12.5	17
24	Cancer immunotherapy â€“ revisited. Nature Reviews Drug Discovery, 2011, 10, 591-600.	21.5	346
25	Virchow 2011 or How to ID(H) Human Glioblastoma. Journal of Clinical Oncology, 2011, 29, 4473-4474.	0.8	22
26	Les applications en rhumatologie : perspectives. Revue Du Rhumatisme (Edition Francaise), 2011, 78, S191-S195.	0.0	0
27	Regulation, Role, and Targeting of Akt in Cancer. Journal of Clinical Oncology, 2011, 29, 4715-4717.	0.8	48
28	The role of mitogenâ€•and stressâ€activated protein kinase pathways in melanoma. Pigment Cell and Melanoma Research, 2011, 24, 902-921.	1.5	59
29	The three Mâ€™s: melanoma, microphthalmiaâ€associated transcription factor and microRNA. Pigment Cell and Melanoma Research, 2011, 24, 1088-1106.	1.5	60
30	Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews Endocrinology, 2011, 7, 617-624.	4.3	130
31	Progress in the management of metastatic melanoma. Community Oncology, 2011, 8, 17-19.	0.2	0
32	Personalized medicine: myth to reality. Community Oncology, 2011, 8, 395-396.	0.2	1
33	Cell transfer immunotherapy for metastatic solid cancerâ€”what clinicians need to know. Nature Reviews Clinical Oncology, 2011, 8, 577-585.	12.5	285
35	Brentuximab Vedotin and Vemurafenib. Hospital Pharmacy, 2011, 46, 934-942.	0.4	0
36	Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies. Frontiers in Pharmacology, 2011, 2, 59.	1.6	19
37	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
38	The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. PLoS ONE, 2011, 6, e25264.	1.1	60

#	Article	IF	Citations
39	Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. PLoS ONE, 2011, 6, e28973.	1.1	196
40	Industry Update: The latest developments in therapeutic delivery. Therapeutic Delivery, 2011, 2, 975-985.	1.2	0
45	Crizotinib and Testing for ALK. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1335-1341.	2.3	102
46	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	2.3	227
47	Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?. Experimental Dermatology, 2011, 20, 1030-1032.	1.4	20
48	A decade of molecular cell biology: achievements and challenges. Nature Reviews Molecular Cell Biology, 2011, 12, 669-674.	16.1	20
49	How to reduce the incidence of neuropathic pain: Sentinel node biopsy for diagnosis of metastatic malignant melanoma. Pain, 2011, 152, 2681-2682.	2.0	2
50	Î²-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell, 2011, 20, 741-754.	7.7	317
51	Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges. Cancer Discovery, 2011, 1, 297-311.	7.7	47
52	Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma. Annals of Pharmacotherapy, 2011, 45, 1399-1405.	0.9	44
53	Whole Cancer Genome Sequencing by Next-Generation Methods. American Journal of Clinical Pathology, 2011, 136, 527-539.	0.4	155
54	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. Science Translational Medicine, 2011, 3, 111ra121.	5.8	531
55	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 6958-6962.	3.2	438
56	Ipilimumab: showing survival benefit in metastatic melanoma. Future Oncology, 2011, 7, 1255-1264.	1.1	6
57	Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 1268-1284.	2.2	31
59	A new era in the treatment of melanoma: from biology to clinical practice. Clinical and Translational Oncology, 2011, 13, 787-792.	1.2	9
60	Melanoma: a new landmark in targeted oncology. Targeted Oncology, 2011, 6, 131-131.	1.7	1
61	The â€œSWOTâ€•of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports, 2011, 13, 479-487.	1.8	33

#	Article	IF	Citations
62	A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Molecular Cancer, 2011, 10, 114.	7.9	24
63	Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine - A metastatic disease 17 Years after complete surgical resection. World Journal of Surgical Oncology, 2011, 9, 150.	0.8	7
64	Systemic treatment of metastatic melanoma: New approaches. Journal of Surgical Oncology, 2011, 104, 425-429.	0.8	11
65	A drug-resistant duo. Nature, 2011, 480, 329-330.	13.7	10
66	Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Review of Molecular Diagnostics, 2011, 11, 663-666.	1.5	11
67	Targeted cancer therapy. Cell Cycle, 2011, 10, 3830-3833.	1.3	13
68	Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 365, 1448-1450.	13.9	99
69	Been There, Not Done That â€" Melanoma in the Age of Molecular Therapy. New England Journal of Medicine, 2011, 364, 2547-2548.	13.9	11
70	Therapeutic options in cutaneous melanoma: latest developments. Therapeutic Advances in Medical Oncology, 2011, 3, 245-251.	1.4	8
71	Improved outcomes for patients with metastatic melanoma. Nature Reviews Clinical Oncology, 2011, 8, 513-515.	12.5	20
72	Expression of the embryological morphogen Nodal in stage III/IV melanoma. Melanoma Research, 2011, 21, 491-501.	0.6	11
73	BRAF Inhibitors and Melanoma. Cancer Journal (Sudbury, Mass), 2011, 17, 505-511.	1.0	28
74	Implementing Personalized Medicine in a Cancer Center. Cancer Journal (Sudbury, Mass), 2011, 17, 528-536.	1.0	119
75	Emerging Technologies for Improved Stratification of Cancer Patients. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	6
76	Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	3.2	143
77	Understanding the Enemy. Science Translational Medicine, 2011, 3, 98ps37.	5.8	4
78	Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options. Cancer Research, 2011, 71, 7137-7140.	0.4	148
79	Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1621-32.	1.4	10

#	Article	IF	Citations
80	BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. Journal of Skin Cancer, 2011, 2011, 1-8.	0.5	46
81	Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?. Journal of Skin Cancer, 2011, 2011, 1-13.	0.5	6
82	Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies. Therapeutic Delivery, 2011, 2, 1467-1484.	1.2	8
83	Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents. Cell Cycle, 2011, 10, 2883-2893.	1.3	21
84	New Drug for Metastatic Melanoma Increases Survival Rate. American Journal of Nursing, 2011, 111, 16.	0.2	0
85	Diagnosis and management of malignant melanoma. Cancer Nursing Practice, 2011, 10, 30-37.	0.2	0
86	Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine, 2011, 8, 633-640.	0.8	4
87	A personal noteâ€”40 years after the signing of the Cancer Act. Nature Reviews Clinical Oncology, 2011, 8, 693-694.	12.5	0
88	Advanced NSCLCâ€”should we use doublets in elderly patients?. Nature Reviews Clinical Oncology, 2011, 8, 694-696.	12.5	4
89	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology, 2011, 22, 2616-2624.	0.6	326
91	Adjuvant Therapy: Melanoma. Journal of Skin Cancer, 2011, 2011, 1-19.	0.5	13
92	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 7732-7742.	3.2	134
93	Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics and Personalized Medicine, 2012, 5, 139.	0.4	3
94	Rapid Detection and Quantitation ofBRAFMutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. American Journal of Clinical Pathology, 2012, 138, 153-156.	0.4	37
95	Metastatic Melanoma and Vemurafenib: Novel Approaches. Rare Tumors, 2012, 4, 96-97.	0.3	2
96	Identity, Potency,In VivoViability, and Scaling Up Production of Lentiviral Vector-Induced Dendritic Cells for Melanoma Immunotherapy. Human Gene Therapy Methods, 2012, 23, 38-55.	2.1	18
98	Tracking and Treating Malignant Melanoma Metastases. Dermatology Research and Practice, 2012, 2012, 1-2.	0.3	1
99	BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance. Clinical Cancer Research, 2012, 18, 33-39.	3.2	120

#	Article	IF	Citations
100	Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier. Clinical Cancer Research, 2012, 18, 3952-3960.	3.2	77
101	Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901. Molecular Cancer Therapeutics, 2012, 11, 2274-2283.	1.9	9
102	Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab. Journal of Clinical Oncology, 2012, 30, e156-e159.	0.8	177
103	Mining Gene Expression Signature for the Detection of Pre-Malignant Melanocytes and Early Melanomas with Risk for Metastasis. PLoS ONE, 2012, 7, e44800.	1.1	20
106	Systematic Review and Network Metaâ€Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma. Oncologist, 2012, 17, 1376-1385.	1.9	23
107	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle, 2012, 11, 1455-1467.	1.3	29
108	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	3.5	110
109	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii86-vii91.	0.6	336
110	How Epidemiology Has Contributed to a Better Understanding of Skin Disease. Journal of Investigative Dermatology, 2012, 132, 994-1002.	0.3	14
111	BRAF^{V600E}Mutation and Papillary Thyroid Cancer: Chicken or Egg?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2295-2298.	1.8	24
112	Clinical Implementation of KRAS Testing in Metastatic Colorectal Carcinoma: The Pathologist's Perspective. Archives of Pathology and Laboratory Medicine, 2012, 136, 1298-1307.	1.2	19
113	Molecular Pathways: Targeting Hsp90â€"Who Benefits and Who Does Not. Clinical Cancer Research, 2012, 18, 4508-4513.	3.2	56
114	Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma. Journal of Biological Chemistry, 2012, 287, 28087-28098.	1.6	171
115	Promises from Trametinib in RAF Active Tumors. New England Journal of Medicine, 2012, 367, 171-172.	13.9	7
116	p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. Journal of Investigative Dermatology, 2012, 132, 356-364.	0.3	66
117	New vitamin D analogs as potential therapeutics in melanoma. Expert Review of Anticancer Therapy, 2012, 12, 585-599.	1.1	36
118	A tale of two pities. Human Vaccines and Immunotherapeutics, 2012, 8, 1146-1151.	1.4	7
119	Sequential therapy in metastatic clear cell renal carcinoma: TKIâ€"TKI vs TKIâ€"mTOR. Expert Review of Anticancer Therapy, 2012, 12, 1545-1557.	1.1	13

#	Article	IF	Citations
120	The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 149-154.	3.3	136
121	Hurdles in anticancer drug development from a regulatory perspective. Nature Reviews Clinical Oncology, 2012, 9, 236-243.	12.5	28
122	Targeting protein-trafficking pathways alters melanoma treatment sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 553-558.	3.3	41
123	Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142.	1.2	11
124	Molecular Pathways: Dysregulated Glutamatergic Signaling Pathways in Cancer. Clinical Cancer Research, 2012, 18, 4240-4246.	3.2	102
125	The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms. Clinical Cancer Research, 2012, 18, 2502-2514.	3.2	145
126	Investigation of theBRAFV600E Mutation by Pyrosequencing in Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2012, 138, 877-883.	0.4	29
127	Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2012, 4, 255-270.	1.4	42
128	TIL therapy broadens the tumor-reactive CD8⁺T cell compartment in melanoma patients. OncoImmunology, 2012, 1, 409-418.	2.1	171
129	CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 2039-2047.	3.2	459
130	Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma. Journal of the National Cancer Institute, 2012, 104, 1673-1679.	3.0	35
131	Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma. Cancer Research, 2012, 72, 4909-4919.	0.4	61
132	BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy. Cancer Research, 2012, 72, 3928-3937.	0.4	210
133	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. Journal of Clinical Oncology, 2012, 30, 1750-1754.	0.8	63
134	Biomarkers in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 530-538.	1.0	101
135	A brief history of melanoma. Melanoma Research, 2012, 22, 114-122.	0.6	111
136	Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma. Diagnostic Molecular Pathology, 2012, 21, 1-8.	2.1	145
137	Targeting Mutant BRAF in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 124-131.	1.0	70

#	Article	IF	Citations
138	Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Research, 2012, 22, 287-293.	0.6	48
139	Targeting NRAS in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 132-136.	1.0	61
140	Melanoma in the brain. Melanoma Research, 2012, 22, 177-183.	0.6	43
141	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2012, 41, D955-D961.	6.5	2,363
142	Molecular Testing in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 117-123.	1.0	22
143	Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth. Melanoma Research, 2012, 22, 184-194.	0.6	20
144	The Role of the PI3K-AKT Pathway in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 142-147.	1.0	197
145	Personalized management of patients with solid cancers. Current Opinion in Oncology, 2012, 24, 297-304.	1.1	16
146	Vemurafenib-induced neutrophilic panniculitis. Melanoma Research, 2012, 22, 399-401.	0.6	46
147	Special Issue on Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 115-116.	1.0	1
148	Human Correlates of Provocative Questions in Pancreatic Pathology. Advances in Anatomic Pathology, 2012, 19, 351-362.	2.4	29
149	Molecular predictors of outcome in low-grade glioma. Current Opinion in Neurology, 2012, 25, 767-773.	1.8	54
150	Treatment of Melanoma Brain Metastases. Cancer Journal (Sudbury, Mass), 2012, 18, 208-212.	1.0	43
151	Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Research, 2012, 22, 244-251.	0.6	30
152	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 160-175.	1.0	176
153	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. Clinical Cancer Research, 2012, 18, 555-567.	3.2	267
154	Personalized ovarian cancer treatment. Current Opinion in Obstetrics and Gynecology, 2012, 24, 1-2.	0.9	0
155	Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Research, 2012, 22, 466-472.	0.6	112

#	Article	IF	Citations
156	Update in Molecular Diagnostics in Melanocytic Neoplasms. Advances in Anatomic Pathology, 2012, 19, 410-416.	2.4	17
157	Adjuvant Therapy for Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 192-202.	1.0	47
158	Metastatic Uveal Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 148-152.	1.0	89
159	Therapeutic Implications of KIT in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 137-141.	1.0	51
160	Pharmacogenetics and dermatology. , 2012, , 1-14.		0
161	Using companion and coupled diagnostics within strategy to personalize targeted medicines. Personalized Medicine, 2012, 9, 751-761.	0.8	8
162	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 2012, 30, 2375-2383.	0.8	216
163	Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 2012, 18, 783-795.	3.2	98
164	Advances in the treatment of melanoma. Clinical Medicine, 2012, 12, 168-171.	0.8	12
165	Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma. Journal of Clinical Oncology, 2012, 30, 322-328.	0.8	131
166	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery, 2012, 2, 414-424.	7.7	91
167	Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma. PLoS ONE, 2012, 7, e29336.	1.1	250
168	New therapies in the treatment of melanoma. Expert Opinion on Investigational Drugs, 2012, 21, 1643-1659.	1.9	9
169	CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity. Molecular Cancer Therapeutics, 2012, 11, 930-941.	1.9	42
170	Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2â€"Tumor and Immunological Responses. Science Translational Medicine, 2012, 4, 137ra74.	5.8	272
171	The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. Journal of Cell Biology, 2012, 199, 15-19.	2.3	7
172	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	3.2	589
173	The Challenge of Choosing Appropriate End Points in Single-Arm Phase II Studies of Rare Diseases. Journal of Clinical Oncology, 2012, 30, 896-898.	0.8	22

#	Article	IF	Citations
174	The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Therapeutic Advances in Medical Oncology, 2012, 4, 61-73.	1.4	26
177	Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice?. Current Medicinal Chemistry, 2012, 19, 2638-2651.	1.2	28
179	Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opinion on Investigational Drugs, 2012, 21, 531-539.	1.9	22
180	Molecular prescreening to select patient population in early clinical trials. Nature Reviews Clinical Oncology, 2012, 9, 359-366.	12.5	68
181	Response: Re: Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 718-718.	3.0	0
182	Phase II Trial of Intravenous Administration of ReolysinÂ® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. Molecular Therapy, 2012, 20, 1998-2003.	3.7	135
183	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. Clinical Cancer Research, 2012, 18, 3316-3327.	3.2	27
184	Making Sense of MEK1 Mutations in Intrinsic and Acquired BRAF Inhibitor Resistance: Figure 1.. Cancer Discovery, 2012, 2, 390-392.	7.7	10
185	Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas. Pharmacogenomics, 2012, 13, 125-128.	0.6	17
186	Emerging personalized oncology: sequencing and systems strategies. Future Oncology, 2012, 8, 637-641.	1.1	16
187	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 2012, 1, 997-999.	2.1	27
188	Intratumoral Heterogeneity as a Therapy Resistance Mechanism. Advances in Pharmacology, 2012, 65, 335-359.	1.2	76
189	Research Highlights: Highlights from the latest articles in cancer immunotherapy. Immunotherapy, 2012, 4, 473-475.	1.0	1
190	The Mutation Profiles of Common Oncogenes Involved in Melanoma in Southern China. Journal of Investigative Dermatology, 2012, 132, 1935-1937.	0.3	15
191	Vemurafenib Sensitivity Skin Reaction after Ipilimumab. New England Journal of Medicine, 2012, 366, 866-868.	13.9	82
192	MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 1364-1365.	13.9	8
193	Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 2012, 366, 480-481.	13.9	156
194	Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis. Cancer Biology and Therapy, 2012, 13, 92-100.	1.5	41

#	Article	IF	Citations
195	HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients. Journal of Investigative Dermatology, 2012, 132, 2395-2406.	0.3	37
196	Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. Journal of Investigative Dermatology, 2012, 132, 1850-1859.	0.3	76
197	Narrowing the knowledge gaps for melanoma. Upsala Journal of Medical Sciences, 2012, 117, 237-243.	0.4	15
199	Targeted treatment for melanoma. Expert Review of Anticancer Therapy, 2012, 12, 1113-1115.	1.1	1
200	A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma. Cancer Biology and Therapy, 2012, 13, 1443-1448.	1.5	3
201	Too much or too little. Cell Cycle, 2012, 11, 3147-3148.	1.3	4
202	BRAF inhibition improves tumor recognition by the immune system. OncoImmunology, 2012, 1, 1476-1483.	2.1	82
203	What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?. Immunotherapy, 2012, 4, 749-751.	1.0	3
204	Continual and partial MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. DMM Disease Models and Mechanisms, 2012, 5, 546-52.	1.2	44
205	Targeted Therapy at the End of Life in Advanced Cancer Patients. Journal of Palliative Medicine, 2012, 15, 991-997.	0.6	20
206	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2012, 18, 4806-4819.	3.2	136
207	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology, 2012, 30, 316-321.	0.8	366
208	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research, 2012, 18, 6373-6383.	3.2	458
209	Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	1.9	78
210	LOW GRADE GLIOMAS. Neuro-Oncology, 2012, 14, i69-i81.	0.6	5
211	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology, 2012, 1, 609-617.	2.1	67
213	Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. British Journal of Cancer, 2012, 106, 939-946.	2.9	91
214	Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Therapy, 2012, 19, 811-817.	2.2	16

#	Article	IF	Citations
215	NF-Î²B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the Î²-catenin pathway. Oncogene, 2012, 31, 2580-2592.	2.6	40
216	Desmoplastic Malignant Melanoma: A Study of Ten Cases and Status of BRAF Mutation. Dermatology, 2012, 225, 168-171.	0.9	12
217	Sorafenib in advanced melanoma: a critical role for pharmacokinetics?. British Journal of Cancer, 2012, 107, 455-461.	2.9	44
218	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. British Journal of Cancer, 2012, 106, 85-91.	2.9	38
219	BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death and Disease, 2012, 3, e259-e259.	2.7	74
220	Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells. Journal of Biological Chemistry, 2012, 287, 29887-29898.	1.6	70
221	A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib. Journal of Thoracic Oncology, 2012, 7, e23-e24.	0.5	131
222	BRAF Inhibition in Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2012, 366, 2038-2040.	13.9	240
223	Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7067-7072.	3.3	39
224	Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?. Journal of Clinical Oncology, 2012, 30, 898-901.	0.8	29
225	BEAM Trial: Lighting the Way Ahead?. Journal of Clinical Oncology, 2012, 30, 6-7.	0.8	5
226	Drug Development: Portals of Discovery. Clinical Cancer Research, 2012, 18, 23-32.	3.2	37
227	BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. Journal of Clinical Oncology, 2012, 30, 2522-2529.	0.8	419
228	Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 3242-3249.	3.2	405
229	SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor. Journal of Biological Chemistry, 2012, 287, 41797-41807.	1.6	55
230	Fragment Based Drug Design: From Experimental to Computational Approaches. Current Medicinal Chemistry, 2012, 19, 5128-5147.	1.2	130
231	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E353-9.	3.3	51
232	Targeted therapy: overcoming drug resistance with clinical cancer genome. Expert Review of Anticancer Therapy, 2012, 12, 861-864.	1.1	4

#	Article	IF	Citations
233	Prevention and treatment of bone metastases. Nature Reviews Clinical Oncology, 2012, 9, 76-78.	12.5	72
234	Molecular targets in melanoma: time for â€˜ethnic personalizationâ€™. Expert Review of Anticancer Therapy, 2012, 12, 601-608.	1.1	8
235	Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma. Archives of Pathology and Laboratory Medicine, 2012, 136, 1385-1391.	1.2	134
236	The economic value of companion diagnostics and stratified medicines. Expert Review of Molecular Diagnostics, 2012, 12, 791-794.	1.5	7
237	Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocrine-Related Cancer, 2012, 19, C19-C22.	1.6	7
238	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. Clinical Cancer Research, 2012, 18, 2326-2335.	3.2	109
239	Unusual Complication of Vemurafenib Treatment of Metastatic Melanoma: Exacerbation of Acantholytic Dyskeratosis Complicated by Kaposi Varicelliform Eruption. Archives of Dermatology, 2012, 148, 966.	1.7	22
240	Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer. Journal of Clinical Oncology, 2012, 30, 119-121.	0.8	22
241	Marked, Homogeneous, and Early [¹⁸F]Fluorodeoxyglucoseâ€“Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 1628-1634.	0.8	172
242	Early [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography Responses in Metastatic Melanoma: What Do They Mean?. Journal of Clinical Oncology, 2012, 30, 1581-1583.	0.8	1
243	Erdheim-Chester Disease Harboring the BRAF V600E Mutation. Journal of Clinical Oncology, 2012, 30, e331-e332.	0.8	46
244	New Challenges in Endpoints for Drug Development in Advanced Melanoma. Clinical Cancer Research, 2012, 18, 336-341.	3.2	72
245	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1120-1128.	3.2	57
246	Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety. Clinical Cancer Research, 2012, 18, 1192-1194.	3.2	6
247	The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e47054.	1.1	184
248	Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway. Archives of Dermatology, 2012, 148, 628-33.	1.7	89
249	Photodynamic Therapy for Multiple Eruptive Keratoacanthomas Associated With Vemurafenib Treatment for Metastatic Melanoma. Archives of Dermatology, 2012, 148, 363.	1.7	48
250	Improving Risk Assessment. Science Translational Medicine, 2012, 4, 159ps22.	5.8	14

#	Article	IF	Citations
251	Melanoma as a model tumour for immuno-oncology. Annals of Oncology, 2012, 23, viii10-viii14.	0.6	92
252	Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?. Frontiers in Oncology, 2012, 2, 49.	1.3	22
253	Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S5855.	0.6	47
254	Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. , 2012, 2012, 1-11.		37
255	Lessons from Cancer Immunoediting in Cutaneous Melanoma. Clinical and Developmental Immunology, 2012, 2012, 1-14.	3.3	18
256	Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases. Dermatology Research and Practice, 2012, 2012, 1-14.	0.3	17
257	RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatology Research and Practice, 2012, 2012, 1-5.	0.3	113
258	Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. Lung Cancer International, 2012, 2012, 1-12.	1.2	17
259	BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. Cancer Discovery, 2012, 2, 791-797.	7.7	194
260	Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro-Oncology, 2012, 14, 777-789.	0.6	125
261	BREAKing a path for progressâ€"dabrafenib confirms class effect. Nature Reviews Clinical Oncology, 2012, 9, 496-497.	12.5	7
262	Wnt/Î²-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAF ^{V600E} in Human Melanoma. Science Signaling, 2012, 5, ra3.	1.6	150
263	The intermediate-activity ^{L597V}BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes and Development, 2012, 26, 1945-1958.	2.7	54
264	Targeted therapy in brain metastasis. Current Opinion in Oncology, 2012, 24, 679-686.	1.1	64
265	Ipilimumab in advanced melanoma. Melanoma Research, 2012, 22, 263-270.	0.6	47
266	Surgery for Distant Melanoma Metastasis. Cancer Journal (Sudbury, Mass), 2012, 18, 176-184.	1.0	81
267	Use of Fluorescence In Situ Hybridization to Distinguish Metastatic Uveal From Cutaneous Melanoma. International Journal of Surgical Pathology, 2012, 20, 246-251.	0.4	10
268	Randomized Phase II Trial Designs With Biomarkers. Journal of Clinical Oncology, 2012, 30, 3304-3309.	0.8	86

#	Article	IF	Citations
270	Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Reports in Oncology, 2012, 5, 280-289.	0.3	8
271	Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated byNRASorMEKMutations. Molecular Cancer Therapeutics, 2012, 11, 909-920.	1.9	312
272	Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma. Molecular Cancer Therapeutics, 2012, 11, 2505-2515.	1.9	32
273	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 33-40.	1.3	151
274	Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. Expert Opinion on Medical Diagnostics, 2012, 6, 407-419.	1.6	6
275	Therapeutic Additions and Possible Deletions in Oncology in 2011. Clinical Pharmacology and Therapeutics, 2012, 91, 15-17.	2.3	8
276	Board of Education Trainee Poster Prize. Pathology, 2012, 44, S58-S63.	0.3	0
277	Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology, 2012, 44, 357-359.	0.3	50
278	Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. Pathology, 2012, 44, 661-664.	0.3	3
279	Improvements and continued challenges in the early detection of skin cancers. Expert Review of Dermatology, 2012, 7, 459-471.	0.3	2
280	Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 403-412.	2.3	22
281	Immunologic Effects of an Orally Available BRAFV600E Inhibitor in BRAF Wild-type Murine Models. Journal of Immunotherapy, 2012, 35, 473-477.	1.2	6
282	Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition. American Journal of Dermatopathology, 2012, 34, 822-826.	0.3	44
283	Brain metastasis. Current Opinion in Neurology, 2012, 25, 786-794.	1.8	20
284	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. Yearbook of Surgery, 2012, 2012, 353-356.	0.1	2
285	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. Journal of Immunotherapy, 2012, 35, 66-72.	1.2	111
286	Circumventing Melanoma Chemoresistance by Targeting DNA Repair. Current Medicinal Chemistry, 2012, 19, 3893-3899.	1.2	8
287	Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue. Current Drug Targets, 2012, 13, 1475-1487.	1.0	35

#	Article	IF	Citations
290	Sarcomatoid transformation of a pleomorphic xanthoastrocytoma. Pathology, 2012, 44, S59.	0.3	0
291	The prognostic significance of the V600E B-Raf mutation in papillary thyroid carcinoma: data from an Australian population. Pathology, 2012, 44, S58-S59.	0.3	0
292	Cellular blue naevus involving the urinary bladder. Pathology, 2012, 44, 664-668.	0.3	5
293	Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. Journal of Immunotherapy, 2012, 35, 400-408.	1.2	88
294	Cutaneous Reactions to Novel Therapeutics. American Journal of Dermatopathology, 2012, 34, 679-690.	0.3	5
295	Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?. Anti-Cancer Drugs, 2012, 23, 579-583.	0.7	7
296	Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. European Journal of Gastroenterology and Hepatology, 2012, 24, 1430-1437.	0.8	54
297	Management of Melanomas in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2012, 34, S51-S54.	0.3	27
298	Clinical trials in drug development. Current Opinion in Oncology, 2012, 24, 332-337.	1.1	3
300	Combined Intralesional Bacille Calmette-GuÃ©rin (BCG) and Topical Imiquimod for In-transit Melanoma. Journal of Immunotherapy, 2012, 35, 716-720.	1.2	75
301	Benefitâ€“risk management in the age of personalized healthcare. Personalized Medicine, 2012, 9, 507-514.	0.8	0
303	Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy. Journal of Immunotherapy, 2012, 35, 641-649.	1.2	72
304	Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. Journal of Immunotherapy, 2012, 35, 711-715.	1.2	24
305	A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). Anti-Cancer Drugs, 2012, 23, 761-764.	0.7	9
306	Resistance patterns with tyrosine kinase inhibitors in melanoma. Current Opinion in Oncology, 2012, 24, 150-154.	1.1	53
307	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.2	204
308	Targeted Therapies in Melanoma: Knowledge, Resistance and Perspectives. Journal of Carcinogenesis & Mutagenesis, 2012, S4`, .	0.3	0
309	BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1456-1458.	2.3	9

#	Article	IF	Citations
310	Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 345-356.	2.3	117
315	Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 303-309.	2.3	7
316	Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 366-400.	2.3	63
317	Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management. Archives of Dermatology, 2012, 148, 357.	1.7	96
318	Long-term Survival in Metastatic Malignant Melanoma: Ipilimumab Followed by Vemurafenib in a Patient with Brain Metastasis. Internal Medicine, 2012, 51, 2819-2823.	0.3	13
320	Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib. Archives of Dermatology, 2012, 148, 1183.	1.7	55
321	Cancer genomics meets clinical trials: the challenge ahead. Personalized Medicine, 2012, 9, 459-461.	0.8	3
322	Fluid biopsy for solid tumors: a patientâ€™s companion for lifelong characterization of their disease. Future Oncology, 2012, 8, 989-998.	1.1	22
324	Type-Specific Response to Neoadjuvant Chemotherapy: Ovarian High-Grade Serous Carcinoma Versus Colorectal Mucinous Carcinoma. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 678-682.	0.3	4
325	Lichenoid drug reaction to vemurafenib. Pathology, 2012, 44, S59.	0.3	1
326	Angioleiomyoma of soft tissue: clinicopathology, immunohistochemistry, and MRI findings. Pathology, 2012, 44, S59-S60.	0.3	0
327	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. Clinical Investigation, 2012, 2, 883-893.	0.0	1
328	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports, 2012, 28, 654-658.	1.2	29
329	Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochemical Society Transactions, 2012, 40, 73-78.	1.6	21
330	BRAF mutation: supporting diversity in HCL. Blood, 2012, 119, 3193-3194.	0.6	5
331	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	0.6	589
332	Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies. Clinical Investigation, 2012, 2, 133-138.	0.0	1
333	Targeting ALK, ROS1, and BRAF Kinases. Journal of Thoracic Oncology, 2012, 7, S375-S376.	0.5	10

#	Article	IF	Citations
334	Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches. Clinical Investigation, 2012, 2, 957-959.	0.0	0
335	Pharmacodynamic end points in early-phase oncology trials. Clinical Investigation, 2012, 2, 679-687.	0.0	0
336	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, The, 2012, 379, 1893-1901.	6.3	856
337	Extending the reach of BRAF-targeted cancer therapy. Lancet, The, 2012, 379, 1858-1859.	6.3	7
338	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	6.3	2,691
339	Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. Journal of Clinical Oncology, 2012, 30, 3819-3826.	0.8	77
340	Metastatic melanoma: the new era of targeted therapy. Expert Opinion on Therapeutic Targets, 2012, 16, S61-S70.	1.5	21
341	Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Veterinary and Comparative Oncology, 2012, 10, 163-173.	0.8	25
342	Mechanisms of intrinsic and acquired resistance to kinaseâ€targeted therapies. Pigment Cell and Melanoma Research, 2012, 25, 819-831.	1.5	43
343	ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research, 2012, 66, 105-143.	3.1	1,246
344	The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets, 2012, 16, S7-S16.	1.5	17
345	BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines. PLoS ONE, 2012, 7, e42598.	1.1	51
346	Prostate cancer: germline prediction for a commonly variable malignancy. BJU International, 2012, 110, E809-18.	1.3	10
347	KRAS and BRAF Mutation Analysis in Routine Molecular Diagnostics. Journal of Molecular Diagnostics, 2012, 14, 247-255.	1.2	51
348	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	4.2	96
349	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Review of Anticancer Therapy, 2012, 12, 1437-1448.	1.1	24
350	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 2012, 120, e28-e34.	0.6	199
351	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. New England Journal of Medicine, 2012, 367, 1694-1703.	13.9	2,445

#	Article	IF	Citations
352	Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 2091-2103.	2.0	69
353	Molecular Diagnostics of Melanoma Fine-Needle Aspirates. American Journal of Clinical Pathology, 2012, 138, 670-677.	0.4	29
354	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	2.3	113
355	Immunotherapy for melanoma. Expert Review of Dermatology, 2012, 7, 51-68.	0.3	0
356	Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 267-273.	1.6	48
357	Survival in BRAF V600â€“Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	13.9	1,955
358	Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization. Organic and Biomolecular Chemistry, 2012, 10, 7402.	1.5	20
359	Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Research, 2012, 65, 9-22.	3.1	119
360	Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. Journal of Immunotoxicology, 2012, 9, 241-247.	0.9	81
361	Convergent Multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis. Cell, 2012, 151, 1068-1082.	13.5	334
362	The Yinâ€Yang of RAF inhibitors. Pigment Cell and Melanoma Research, 2012, 25, 127-128.	1.5	0
363	Role and therapeutic potential of PI3Kâ€mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell and Melanoma Research, 2012, 25, 248-258.	1.5	98
364	Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell and Melanoma Research, 2012, 25, 144-154.	1.5	46
365	Delving into somatic variation in sporadic melanoma. Pigment Cell and Melanoma Research, 2012, 25, 155-170.	1.5	35
366	MicroRNAs and signaling, complex interaction by feedback loops. Pigment Cell and Melanoma Research, 2012, 25, 128-130.	1.5	3
367	Glutamatergic signaling in cellular transformation. Pigment Cell and Melanoma Research, 2012, 25, 331-342.	1.5	47
368	Systematic classification of melanoma cells by phenotypeâ€specific gene expression mapping. Pigment Cell and Melanoma Research, 2012, 25, 343-353.	1.5	155
369	Active surrender. Pigment Cell and Melanoma Research, 2012, 25, 292-293.	1.5	0

#	Article	IF	Citations
370	Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?. Journal of Clinical Oncology, 2012, 30, 329-330.	0.8	62
371	6 Communication in Genetics and Genomics. European Journal of Oncology Nursing, 2012, 16, S2-S3.	0.9	0
372	7 New Developments in the Systemic Treatment of Melanoma. European Journal of Oncology Nursing, 2012, 16, S3.	0.9	0
373	8 Impact and Management of Malignant Wounds. European Journal of Oncology Nursing, 2012, 16, S3-S4.	0.9	0
374	A tale of two tumours and a plea for progress. Lancet Oncology, The, 2012, 13, 124-125.	5.1	2
375	Treatment of brain metastases in patients with melanoma. Lancet Oncology, The, 2012, 13, 434-435.	5.1	11
376	Predictive value of loci in VEGF pathway genes in bevacizumab treatment. Lancet Oncology, The, 2012, 13, 659-660.	5.1	6
377	Whole Genome and Exome Sequencing of Melanoma. Advances in Pharmacology, 2012, 65, 399-435.	1.2	10
378	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	13.9	222
379	Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Current Oncology Reports, 2012, 14, 449-457.	1.8	56
380	Companion Diagnostics and the Drugâ€“Diagnostic Codevelopment Model. Drug Development Research, 2012, 73, 390-397.	1.4	10
381	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology, 2012, 56, 2416-2419.	3.6	16
383	Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. Journal of Molecular Medicine, 2012, 90, 1421-1438.	1.7	82
384	Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Cancer Immunology, Immunotherapy, 2012, 61, 1169-1182.	2.0	4
385	AERIO News in brief. Oncologie, 2012, 14, 491-494.	0.2	0
386	Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 205-216.	1.0	77
387	Tumor Type-Dependent Function of the Par3 Polarity Protein in Skin Tumorigenesis. Cancer Cell, 2012, 22, 389-403.	7.7	107
388	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	7.7	469

#	Article	IF	Citations
389	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	13.5	371
390	BRAF Mutations in Metanephric Adenoma of the Kidney. European Urology, 2012, 62, 917-922.	0.9	95
392	Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA Journal, 2012, 3, 1.	3.3	18
393	Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Expert Opinion on Drug Safety, 2012, 11, 445-457.	1.0	15
394	Moving Toward Personalized Medicine in Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 483-490.	0.8	6
395	Something Old and Something New About Molecular Diagnostics in Gliomas. Surgical Pathology Clinics, 2012, 5, 919-939.	0.7	12
396	Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer. Surgical Pathology Clinics, 2012, 5, 859-878.	0.7	6
397	My Treatment Approach to Hairy Cell Leukemia. Mayo Clinic Proceedings, 2012, 87, 67-76.	1.4	38
399	The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost. Cancer Investigation, 2012, 30, 637-641.	0.6	6
400	Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Medicine, 2012, 4, 90.	3.6	38
401	Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Review of Endocrinology and Metabolism, 2012, 7, 541-554.	1.2	42
402	Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Review of Neurotherapeutics, 2012, 12, 1207-1215.	1.4	69
404	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of Surgical Oncology, 2012, 19, 2547-2555.	0.7	155
405	Melanoma: New Insights and New Therapies. Journal of Investigative Dermatology, 2012, 132, 854-863.	0.3	136
406	RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. New England Journal of Medicine, 2012, 366, 207-215.	13.9	978
407	Sorafenib in melanoma. Expert Opinion on Investigational Drugs, 2012, 21, 557-568.	1.9	48
408	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clinical and Experimental Metastasis, 2012, 29, 841-846.	1.7	14
409	Surgery for Distant Metastatic Melanoma Improves Survival. Annals of Surgical Oncology, 2012, 19, 2426-2427.	0.7	6

#	Article	IF	Citations
410	Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. Annals of Surgical Oncology, 2012, 19, 4314-4321.	0.7	91
411	Surgeonsâ€™ Opinions on Lymphadenectomy in Melanoma Patients with Positive Sentinel Nodes: A Worldwide Web-Based Survey. Annals of Surgical Oncology, 2012, 19, 4322-4329.	0.7	42
412	Identification of a Novel Family of BRAF^{V600E} Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5220-5230.	2.9	66
413	Sorafenib in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1417-1426.	1.9	25
414	Malignant Melanoma: Advances in Diagnosis, Prognosis, and Treatment. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 45-49.	1.6	7
415	NF-Î²B as potential target in the treatment of melanoma. Journal of Translational Medicine, 2012, 10, 53.	1.8	118
416	MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine, 2012, 18, 1239-1247.	15.2	266
417	Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery, 2012, 11, 201-214.	21.5	225
418	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	13.7	671
419	How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Annals of Oncology, 2012, 23, viii15-viii21.	0.6	49
420	What are we learning from the cancer genome?. Nature Reviews Clinical Oncology, 2012, 9, 621-630.	12.5	50
421	New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clinical Cancer Research, 2012, 18, 1195-1200.	3.2	61
422	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research, 2012, 18, 2184-2198.	3.2	61
423	Autism spectrum disorders. Nature Reviews Drug Discovery, 2012, 11, 745-746.	21.5	29
424	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 2012, 44, 1006-1014.	9.4	1,052
425	Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 2012, 11, 191-200.	21.5	1,520
426	Targeting the TGFÎ² signalling pathway in disease. Nature Reviews Drug Discovery, 2012, 11, 790-811.	21.5	1,207
427	Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Review of Molecular Diagnostics, 2012, 12, 593-602.	1.5	87

#	Article	IF	Citations
428	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	1.5	13
429	Preconditioning Chemotherapy with Cisplatin Enhances the Antitumor Activity of Cytokine-Induced Killer Cells in a Murine Melanoma Model. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 210-220.	0.7	41
430	A new paradigm tumor for drug development. Nature Reviews Clinical Oncology, 2012, 9, 74-76.	12.5	29
431	Targeted therapy in rare cancersâ€"adopting the orphans. Nature Reviews Clinical Oncology, 2012, 9, 631-642.	12.5	39
432	Why RECIST Works and Why It Should Stayâ€"Counterpoint. Cancer Research, 2012, 72, 5151-5157.	0.4	28
433	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolboxâ€"Point. Cancer Research, 2012, 72, 5145-5149.	0.4	77
434	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. American Journal of Pathology, 2012, 180, 1179-1188.	1.9	29
435	Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 1198-1200.	1.8	3
436	Targeting the RAS pathway in melanoma. Trends in Molecular Medicine, 2012, 18, 27-35.	3.5	70
437	Liquid chromatographyâ€“tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 144-147.	1.2	14
438	Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. Biochemical Pharmacology, 2012, 84, 598-611.	2.0	26
439	Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Letters, 2012, 314, 244-255.	3.2	60
440	The Genetic Basis for Cancer Treatment Decisions. Cell, 2012, 148, 409-420.	13.5	299
441	ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. European Journal of Cancer, 2012, 48, 961-973.	1.3	84
442	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study). European Journal of Cancer, 2012, 48, 2175-2182.	1.3	39
443	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2012. European Journal of Cancer, 2012, 48, 2375-2390.	1.3	407
444	Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer. European Journal of Cancer, 2012, 48, 2293-2299.	1.3	21
445	The current status of S-100B as a biomarker in melanoma. European Journal of Surgical Oncology, 2012, 38, 281-285.	0.5	43

#	Article	IF	Citations
447	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Current Opinion in Genetics and Development, 2012, 22, 45-49.	1.5	43
448	Screens, maps & networks: from genome sequences to personalized medicine. Current Opinion in Genetics and Development, 2012, 22, 36-44.	1.5	15
449	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology, 2012, 8, 890-896.	3.9	698
450	The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology. Science Signaling, 2012, 5, pe46.	1.6	20
451	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 2012, 10, 169.	1.8	134
452	Beyond PSA: The Next Generation of Prostate Cancer Biomarkers. Science Translational Medicine, 2012, 4, 127rv3.	5.8	378
453	Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E. Journal of Medicinal Chemistry, 2012, 55, 1082-1105.	2.9	51
454	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. Clinical Cancer Research, 2012, 18, 1824-1826.	3.2	86
455	Pulmonary nodules in patients with melanomaâ€"assume nothing. Annals of Oncology, 2012, 23, 545-546.	0.6	0
456	A Missing Link in Genotype-Directed Cancer Therapy. Cell, 2012, 151, 465-468.	13.5	81
457	From drug discovery to biomarker-driven clinical trials in lymphoma. Nature Reviews Clinical Oncology, 2012, 9, 643-653.	12.5	25
458	Primed for resistance. Nature, 2012, 483, 44-45.	13.7	13
459	HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells. Stem Cells, 2012, 30, 1808-1818.	1.4	134
460	Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Molecular Cancer, 2012, 11, 22.	7.9	65
461	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 2012, 10, 66.	1.0	55
462	Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. World Journal of Surgical Oncology, 2012, 10, 113.	0.8	10
463	Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World Journal of Surgical Oncology, 2012, 10, 155.	0.8	8
464	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. Journal of Translational Medicine, 2012, 10, 107.	1.8	112

#	Article	IF	Citations
465	Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine, 2012, 10, 246.	1.8	74
467	The role of BRAF V600 mutation in melanoma. Journal of Translational Medicine, 2012, 10, 85.	1.8	563
468	Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagnostic Pathology, 2012, 7, 56.	0.9	23
469	Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. European Journal of Medical Research, 2012, 17, 4.	0.9	20
470	Overcoming implementation challenges of personalized cancer therapy. Nature Reviews Clinical Oncology, 2012, 9, 542-548.	12.5	115
471	Arginine deprivation therapy for malignant melanoma. Clinical Pharmacology: Advances and Applications, 2013, 5, 11.	0.8	23
472	Resistance to Chemotherapy. Advances in Pharmacology, 2012, 65, 315-334.	1.2	17
473	Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. British Journal of Dermatology, 2012, 167, 987-994.	1.4	102
474	How cutaneous eruptions help to understand the mode of action of kinase inhibitors. British Journal of Dermatology, 2012, 167, 965-967.	1.4	10
475	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. British Journal of Dermatology, 2012, 167, 1153-1160.	1.4	163
476	Molecular diagnostic strategies: a role in the practice of dermatology. International Journal of Dermatology, 2012, 51, 1292-1302.	0.5	5
477	Drug development and clinical trialsâ€"the path to an approved cancer drug. Nature Reviews Clinical Oncology, 2012, 9, 215-222.	12.5	107
478	Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology, 2012, 9, 208-214.	12.5	46
479	Cancer treatment according to BRCA1 and BRCA2 mutations. Nature Reviews Clinical Oncology, 2012, 9, 520-528.	12.5	69
480	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492, 108-112.	13.7	1,558
481	Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene, 2012, 31, 2412-2422.	2.6	81
482	New therapeutical strategies in the treatment of metastatic disease. Dermatologic Therapy, 2012, 25, 452-457.	0.8	11
483	Thymosin Î±1 in melanoma: from the clinical trial setting to the daily practice and beyond. Annals of the New York Academy of Sciences, 2012, 1270, 8-12.	1.8	14

#	Article	IF	Citations
484	MicroScale: miniaturizing cell arrays for macrogenetic screens. Pigment Cell and Melanoma Research, 2012, 25, 711-712.	1.5	0
485	Hepatocyte growth factor in the neighborhood reverses resistance to <scp>BRAF</scp> inhibitor in melanoma. Pigment Cell and Melanoma Research, 2012, 25, 758-761.	1.5	1
486	Management of Small Cell Lung Cancer. Drugs, 2012, 72, 471-490.	4.9	63
487	Vemurafenib. Drugs, 2012, 72, 2207-2222.	4.9	89
488	Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 9-14.	3.2	59
489	Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis, 2012, 4, 2499-2511.	0.6	8
490	Ipilimumab for advanced metastatic melanoma. Expert Opinion on Biological Therapy, 2012, 12, 981-982.	1.4	4
491	Targeted Therapies for Metastatic Melanoma. Dermatologic Clinics, 2012, 30, 517-524.	1.0	5
492	Ipilimumab in melanoma. Expert Review of Anticancer Therapy, 2012, 12, 1511-1521.	1.1	6
493	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics Journal, 2012, 12, 277-286.	0.9	32
495	A new era for the management of metastatic melanoma. Expert Review of Dermatology, 2012, 7, 27-35.	0.3	1
496	MEK and RAF inhibitors for BRAF-mutated cancers. Expert Reviews in Molecular Medicine, 2012, 14, e17.	1.6	26
497	Melanoma of the Skin. , 2012, , 385-416.		7
498	Regulating the response to targeted MEK inhibition in melanoma. Cell Cycle, 2012, 11, 3724-3730.	1.3	40
499	Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice. Gastroenterology, 2012, 143, 1660-1669.e7.	0.6	262
500	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncology, The, 2012, 13, 782-789.	5.1	479
501	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	5.1	841
502	Eccrine squamous syringometaplasia associated with vemurafenib therapy. Journal of the American Academy of Dermatology, 2012, 67, e208-e210.	0.6	20

#	Article	IF	Citations
503	Keratoacanthoma: Clinical and histopathologic features of regression. Journal of the American Academy of Dermatology, 2012, 67, 1008-1012.	0.6	25
504	Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. Journal of the American Academy of Dermatology, 2012, 67, 488-491.	0.6	51
505	Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. Journal of the American Academy of Dermatology, 2012, 67, 1265-1272.	0.6	166
506	Vasculitis and panniculitis associated with vemurafenib. Journal of the American Academy of Dermatology, 2012, 67, e271-e272.	0.6	21
507	Heat-induced squamous cell carcinoma of the lower extremities in a wildlands firefighter. Journal of the American Academy of Dermatology, 2012, 67, e272-e273.	0.6	4
508	Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib. Journal of the American Academy of Dermatology, 2012, 67, e275-e276.	0.6	14
509	Sialoblastoma: An unexpected diagnosis. Journal of the American Academy of Dermatology, 2012, 67, e276-e277.	0.6	3
510	Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. Journal of the American Academy of Dermatology, 2012, 67, 1375-1379.	0.6	49
511	Decreased repair of singlet oxygen-induced DNA damage in xeroderma pigmentosum group A cells determined by plasmid host cell reactivation. Journal of Dermatological Science, 2012, 66, 242-244.	1.0	3
512	Assessment of BRAF and KIT mutations in Japanese melanoma patients. Journal of Dermatological Science, 2012, 66, 240-242.	1.0	55
513	Vemurafenib in melanoma with the BRAF V600E mutation. Community Oncology, 2012, 9, 85-86.	0.2	2
514	Best practices in integrating novel agents in melanoma. Community Oncology, 2012, 9, S44-S46.	0.2	0
515	New Targeted Agents on the Therapeutic Horizon. Community Oncology, 2012, 9, S23-S25.	0.2	0
516	Cancer chemotherapy: A critical analysis of its 60 years of history. Critical Reviews in Oncology/Hematology, 2012, 84, 181-199.	2.0	87
517	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. Critical Reviews in Oncology/Hematology, 2012, 84, 301-313.	2.0	76
518	Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e83-e90.	0.5	16
519	Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resistance Updates, 2012, 15, 268-275.	6.5	31
520	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). European Journal of Cancer, 2012, 48, 3205-3214.	1.3	24

#	Article	IF	Citations
521	Anaplastic thyroid cancer: Rare, fatal, and neglected. Surgery, 2012, 152, 1088-1089.	1.0	34
522	Cutting Edge in Medical Management of Cutaneous Oncology. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 140-149.	1.6	7
523	Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. Lung Cancer, 2012, 77, 293-298.	0.9	23
524	Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation. Mayo Clinic Proceedings, 2012, 87, 976-981.	1.4	41
525	Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design. Molecular Oncology, 2012, 6, 196-203.	2.1	23
526	Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Molecular Oncology, 2012, 6, 155-176.	2.1	447
527	Co-development of a companion diagnostic for targeted cancer therapy. New Biotechnology, 2012, 29, 682-688.	2.4	40
528	Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids, 2012, 43, 2203-2230.	1.2	54
529	Molecular simulations of drugâ€“receptor complexes in anticancer research. Future Medicinal Chemistry, 2012, 4, 1961-1970.	1.1	5
530	Vemurafenibfor the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2012, 13, 2533-2543.	0.9	28
531	Driving transcriptional regulators in melanoma metastasis. Cancer and Metastasis Reviews, 2012, 31, 621-632.	2.7	38
532	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology, 2012, 132, 2652-2660.	0.3	41
533	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	12.5	94
534	Preferential induction of apoptotic cell death in melanoma cells as compared with normal keratinocytes using a non-thermal plasma torch. Cancer Biology and Therapy, 2012, 13, 1299-1306.	1.5	115
535	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
536	Depicting the evolving scenario of translational-guided drug development. Clinical and Translational Oncology, 2012, 14, 881-882.	1.2	0
537	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. Memo - Magazine of European Medical Oncology, 2012, 5, 302-308.	0.3	0
538	Targeting BRAF in an Inducible Murine Model of Melanoma. American Journal of Pathology, 2012, 181, 785-794.	1.9	58

#	Article	IF	Citations
540	A potential role for nilotinib inKIT-mutated melanoma. Expert Opinion on Investigational Drugs, 2012, 21, 861-869.	1.9	21
542	Cytogenetic and Mutational Analyses of Melanocytic Tumors. Dermatologic Clinics, 2012, 30, 555-566.	1.0	15
545	Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report. Journal of Gastrointestinal Cancer, 2012, 43, 145-147.	0.6	0
547	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine, 2012, 18, 382-384.	15.2	782
548	Central Nervous System Metastasis, the Biological Basis and Clinical Considerations. Cancer Metastasis - Biology and Treatment, 2012, , .	0.1	9
549	From genes to drugs: targeted strategies for melanoma. Nature Reviews Cancer, 2012, 12, 349-361.	12.8	323
550	Management of Pigmented Conjunctival Lesions. Ocular Surface, 2012, 10, 251-263.	2.2	50
551	Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 337-343.	0.7	21
552	An update on pegylated IFN-Î±2b for the adjuvant treatment of melanoma. Expert Review of Anticancer Therapy, 2012, 12, 1449-1459.	1.1	8
553	Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Therapy, 2012, 19, 852-861.	2.2	28
554	Vemurafenib: the first drug approved for BRAF-mutant cancer. Nature Reviews Drug Discovery, 2012, 11, 873-886.	21.5	667
555	Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene, 2012, 31, 2471-2479.	2.6	52
556	BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death and Differentiation, 2012, 19, 2029-2039.	5.0	61
557	Identifying the status of genetic lesions in cancer clinical trial documents using machine learning. BMC Genomics, 2012, 13, S21.	1.2	11
558	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	2.0	102
559	Personalizing Lung Cancer Prevention Through a Reverse Migration Strategy. Topics in Current Chemistry, 2012, 329, 221-240.	4.0	4
560	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	24
561	Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation. PLoS ONE, 2012, 7, e36084.	1.1	55

#	Article	IF	Citations
562	High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations. PLoS ONE, 2012, 7, e41655.	1.1	35
563	Merlin Is a Negative Regulator of Human Melanoma Growth. PLoS ONE, 2012, 7, e43295.	1.1	29
564	Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma. PLoS ONE, 2012, 7, e45492.	1.1	14
565	CD3 expression in plasma cell neoplasm (multiple myeloma): A diagnostic pitfall. Pathology, 2012, 44, 668-670.	0.3	9
566	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	0.8	279
567	Metastatic Melanoma: A Regional Review and Future Directions. Tumori, 2012, 98, 575-580.	0.6	14
568	Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors. Tumori, 2012, 98, 185-190.	0.6	8
569	Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatology Research and Practice, 2012, 2012, 1-9.	0.3	12
571	Aligning the Economic Value of Companion Diagnostics and Stratified Medicines. Journal of Personalized Medicine, 2012, 2, 257-266.	1.1	8
572	Clinical Outcome, Role of BRAFV600E, and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?. Frontiers in Endocrinology, 2012, 3, 33.	1.5	15
574	Cutaneous Side Effects of New Antitumor Drugs. Deutsches Ärzteblatt International, 2012, 109, 133-40.	0.6	40
575	Cancer Gene Sequencing: Ethical Challenges and Promises. AMA Journal of Ethics, 2012, 14, 868-872.	0.4	2
576	Preface: Targeting the Human Kinome for Cancer Therapy. Critical Reviews in Oncogenesis, 2012, 17, i.	0.2	4
577	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
578	Pharmacogenetics: transforming clinical medicine. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 244-247.	0.2	2
579	Ten Years of Progress in Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 932-935.	2.3	3
580	Aberrant B-Raf Signaling in Human Cancer â^' 10 Years from Bench to Bedside. Critical Reviews in Oncogenesis, 2012, 17, 97-121.	0.2	56
581	Genetic Alterations in Childhood Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 589-592.	1.8	2

#	Article	IF	Citations
582	Early Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients. American Surgeon, 2012, 78, 808-813.	0.4	4
583	Approval of New Agents after Phase II Trials. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e1-e3.	1.8	3
584	ADDENBROOKE'S HOSPITAL. , 0, , 148-153.		1
585	Ipilimumab: report and comment about the MDX010-020 clinical trial. Expert Review of Dermatology, 2012, 7, 507-512.	0.3	0
586	Targeting Immune Checkpoints. Cancer Journal (Sudbury, Mass), 2012, 18, 153-159.	1.0	41
587	Drug treatment for melanoma: progress, but who pays?. Medical Journal of Australia, 2012, 197, 198-199.	0.8	13
588	EvaluaciÃ³n positiva de medicamentos: 4Âº Trimestre 2011. Sanidad Militar, 2012, 68, 44-46.	0.0	0
589	Comparison of DNA Extraction Methods from Formalin-Fixed, Paraffin- Embedded Tissue and their Impact on Real-Time PCR-Based Mutation Assays. Journal of Medical Diagnostic Methods, 2012, 01, .	0.0	2
590	Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Reports, 2012, 2012, bcr2012007034-bcr2012007034.	0.2	14
591	Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma. Thrombosis and Haemostasis, 2012, 108, 798-800.	1.8	8
593	What is new in the treatment of advanced melanoma? State of the art. Wspolczesna Onkologia, 2012, 5, 363-370.	0.7	8
594	Targeted agents for the treatment of metastatic melanoma. OncoTargets and Therapy, 2012, 5, 31.	1.0	13
595	Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Management and Research, 2012, 4, 243.	0.9	50
596	Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Management and Research, 2012, 4, 299.	0.9	64
597	Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Management and Research, 2012, 4, 137.	0.9	26
598	Current management and novel agents for malignant melanoma. Journal of Hematology and Oncology, 2012, 5, 3.	6.9	39
599	Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2012, 4, 367-383.	6.6	40
600	Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 2012, 12, 237-251.	12.8	1,261

#	Article	IF	Citations
601	Targeting the MAPKâ€“RASâ€“RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 103-119.	1.5	740
602	20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters. Annals of Surgical Oncology, 2012, 19, 627-635.	0.7	61
603	Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483, 570-575.	13.7	2,173
604	Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 2012, 30, 647-660.	0.8	173
605	BRAFmutation testing in clinical practice. Expert Review of Molecular Diagnostics, 2012, 12, 127-138.	1.5	39
606	Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. Annals of Surgical Oncology, 2012, 19, 620-626.	0.7	18
607	Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery, 2012, 2, 214-226.	7.7	419
608	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487, 505-509.	13.7	1,029
609	Genetics and Epigenetics of the Skin Meet Deep Sequence. Journal of Investigative Dermatology, 2012, 132, 923-932.	0.3	15
610	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research, 2012, 72, 779-789.	0.4	199
611	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opinion on Therapeutic Targets, 2012, 16, S17-S27.	1.5	580
612	Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692.	9.4	883
613	Advances in cutaneous melanoma. Clinical and Translational Oncology, 2012, 14, 325-332.	1.2	6
614	Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?. Clinical Cancer Research, 2012, 18, 2420-2422.	3.2	15
615	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 2012, 3, 724.	5.8	567
616	Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology, 2012, 9, 98-109.	12.5	90
617	Clinically useful biomarkers in neurooncology. Memo - Magazine of European Medical Oncology, 2012, 5, 201-204.	0.3	1
618	Tumour molecular profiling for deciding therapyâ€”the French initiative. Nature Reviews Clinical Oncology, 2012, 9, 479-486.	12.5	81

#	Article	IF	Citations
619	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	2.7	463
620	Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A. Cancer Discovery, 2012, 2, 344-355.	7.7	133
621	Drugging Wnt signalling in cancer. EMBO Journal, 2012, 31, 2737-2746.	3.5	199
622	Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology, 2012, 228, 20-30.	2.1	261
623	Absence of BRAF mutation in pediatric and adolescent germ cell tumors indicate biological differences to adult tumors. Pediatric Blood and Cancer, 2012, 59, 732-735.	0.8	10
624	Personalized cancer care: Opportunities and challenges in pediatric neuroâ€oncology. Pediatric Blood and Cancer, 2012, 59, 1-2.	0.8	3
625	Association of activated câ€Met with NRASâ€mutated human melanomas. International Journal of Cancer, 2012, 131, E56-65.	2.3	33
626	Cytotoxicity of new duplex drugs linking 3â€²â€Câ€ethynylcytidine and 5â€fluorâ€²â€deoxyuridine against human melanoma cells. International Journal of Cancer, 2012, 131, 2165-2174.	2.3	10
627	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103.	13.7	1,769
628	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 2012, 11, 888-897.	1.9	45
629	Melanoma: from mutations to medicine. Genes and Development, 2012, 26, 1131-1155.	2.7	415
630	Managing drug resistance in cancer: lessons from HIV therapy. Nature Reviews Cancer, 2012, 12, 494-501.	12.8	150
631	Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. Science Translational Medicine, 2012, 4, 127ps8.	5.8	218
632	Conformation-Specific Effects of Raf Kinase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7332-7341.	2.9	46
633	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. British Journal of Surgery, 2012, 99, 821-830.	0.1	89
634	NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023.	2.0	589
635	Targeting ALK in neuroblastomaâ€"preclinical and clinical advancements. Nature Reviews Clinical Oncology, 2012, 9, 391-399.	12.5	148
636	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 2012, 367, 107-114.	13.9	1,976

#	Article	IF	Citations
637	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. Current Oncology Reports, 2012, 14, 441-448.	1.8	138
638	Molecular testing in malignant melanoma. Diagnostic Cytopathology, 2012, 40, 503-510.	0.5	27
639	Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development. Clinical Cancer Research, 2012, 18, 1515-1523.	3.2	41
640	Two Hundred Years of Cancer Research. New England Journal of Medicine, 2012, 366, 2207-2214.	13.9	228
641	Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds. Journal of Medicinal Chemistry, 2012, 55, 3452-3478.	2.9	58
642	Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. Future Oncology, 2012, 8, 509-523.	1.1	22
643	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487, 500-504.	13.7	1,561
644	Integrating New Therapies in the Treatment of Advanced Melanoma. Current Treatment Options in Oncology, 2012, 13, 327-339.	1.3	8
645	Targeting Metastatic Melanoma. Annual Review of Medicine, 2012, 63, 171-183.	5.0	57
646	Targeting embryonic signaling pathways in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 131-145.	1.5	36
647	Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opinion on Therapeutic Targets, 2012, 16, 689-705.	1.5	34
648	Advocating Sentinel Node Biopsy in the Management of Cutaneous Melanoma. Current Dermatology Reports, 2012, 1, 76-81.	1.1	0
649	Genetic alterations of PTEN in human melanoma. Cellular and Molecular Life Sciences, 2012, 69, 1475-1491.	2.4	128
650	A more sensitive platform for the detection of low-abundance BRAFV600E mutations. Molecular and Cellular Biochemistry, 2012, 366, 49-58.	1.4	10
651	A review on various targeted anticancer therapies. Targeted Oncology, 2012, 7, 69-85.	1.7	62
652	An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 2012, 61, 1019-1031.	2.0	703
654	Upcoming strategies for the treatment of metastatic melanoma. Archives of Dermatological Research, 2012, 304, 177-184.	1.1	44
656	Recent advances in the understanding of Langerhans cell histiocytosis. British Journal of Haematology, 2012, 156, 163-172.	1.2	110

#	Article	IF	Citations
657	Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction. Clinical and Experimental Immunology, 2012, 167, 188-194.	1.1	24
658	The RAF Inhibitor Paradox Revisited. Cancer Cell, 2012, 21, 147-149.	7.7	23
660	Vemurafenib in Patients With BRAF V600E Mutationâ€“Positive Advanced Melanoma. Clinical Therapeutics, 2012, 34, 1474-1486.	1.1	80
661	Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. Clinical Oncology, 2012, 24, 410-412.	0.6	3
662	Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discovery Today, 2012, 17, 188-193.	3.2	14
663	Stratified medicine for cancer therapy. Drug Discovery Today, 2012, 17, 261-268.	3.2	5
664	HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 756-766.	1.9	74
665	Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 89-102.	3.3	46
666	Small molecule inhibitors of BRAF in clinical trials. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 789-792.	1.0	58
667	Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy. Seminars in Oncology, 2012, 39, 215-226.	0.8	34
668	The Current State of Targeted Therapy in Melanoma: This Time It's Personal. Seminars in Oncology, 2012, 39, 204-214.	0.8	27
669	Vaccines for Melanoma and Renal Cell Carcinoma. Seminars in Oncology, 2012, 39, 263-275.	0.8	29
670	Current advances and perspectives in the treatment of advanced melanoma. JDDG - Journal of the German Society of Dermatology, 2012, 10, 319-325.	0.4	15
671	Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. JDDG - Journal of the German Society of Dermatology, 2012, 10, 319-325.	0.4	13
672	Side effects of systemic oncological therapies in dermatology. JDDG - Journal of the German Society of Dermatology, 2012, 10, 475-486.	0.4	20
675	When will selective lymphadenectomy become standard of care in melanoma?. International Journal of Clinical Practice, 2012, 66, 671-674.	0.8	3
676	The Value Proposition of Molecular Medicine. Clinical and Translational Science, 2012, 5, 108-110.	1.5	8
677	Patientâ€oriented Research in the Era of Personalized Medicine. Clinical and Translational Science, 2012, 5, 119-120.	1.5	0

#	Article	IF	Citations
678	From bedding to bedside: genetically engineered mouse models of cancer inform concurrent clinical trials. Pigment Cell and Melanoma Research, 2012, 25, 404-405.	1.5	3
679	Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. Journal of Cellular and Molecular Medicine, 2012, 16, 237-248.	1.6	81
680	<scp>BRAF</scp>, <scp>NRAS</scp> and <scp>KIT</scp> sequencing analysis of spindle cell melanoma. Journal of Cutaneous Pathology, 2012, 39, 821-825.	0.7	22
681	Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology, 2012, 22, 3-13.	4.3	141
682	The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer. Seminars in Radiation Oncology, 2012, 22, 254-262.	1.0	43
683	Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research. Tetrahedron Letters, 2012, 53, 4161-4165.	0.7	18
685	Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. Cytopathology, 2012, 23, 286-294.	0.4	11
686	Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma. Respirology, 2012, 17, 991-996.	1.3	13
687	Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 2012, 10, 23.	2.3	179
688	Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry, 2012, 113, 725-734.	1.2	14
689	Identification of TFG (TRKâ€fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosomes and Cancer, 2012, 51, 452-461.	1.5	25
691	MÃ©canismes de rÃ©sistances aux inhibiteurs de RAF : revue de la littÃ©rature. Oncologie, 2012, 14, 2-4.	0.2	2
692	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	3.9	204
693	Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica, 2012, 123, 205-222.	3.9	163
694	Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. Journal of Surgical Oncology, 2013, 107, 15-22.	0.8	200
695	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational New Drugs, 2013, 31, 425-434.	1.2	123
696	Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 11-18.	1.3	78
697	Medical students and sun prevention: knowledge and behaviours in France. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e247-51.	1.3	33

#	Article	IF	Citations
698	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. Journal of Translational Medicine, 2013, 11, 180.	1.8	61
700	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Î± in advanced malignant melanoma. Journal of Translational Medicine, 2013, 11, 38.	1.8	21
701	Cancer Pain. , 2013, , .		9
702	Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagnostic Pathology, 2013, 8, 87.	0.9	27
703	A pilot study of temsirolimus and body composition. Journal of Cachexia, Sarcopenia and Muscle, 2013, 4, 259-265.	2.9	25
704	The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. Current Dermatology Reports, 2013, 2, 84-100.	1.1	6
705	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Cancer, 2013, 119, 3043-3051.	2.0	19
706	Clinical trials for precision oncology using next-generation sequencing. Personalized Medicine, 2013, 10, 485-495.	0.8	21
707	Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death and Disease, 2013, 4, e655-e655.	2.7	37
708	<scp>R</scp>ho<scp>J</scp> modulates melanoma invasion by altering actin cytoskeletal dynamics. Pigment Cell and Melanoma Research, 2013, 26, 218-225.	1.5	25
709	Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. Journal of Neuro-Oncology, 2013, 114, 237-240.	1.4	124
710	Vemurafenib and radiation therapy in melanoma brain metastases. Journal of Neuro-Oncology, 2013, 113, 411-416.	1.4	105
711	Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. IUBMB Life, 2013, 65, 748-758.	1.5	53
712	Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives. Journal of Medicinal Chemistry, 2013, 56, 6478-6494.	2.9	95
713	<scp>KRAS</scp> and <scp>BRAF</scp> mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. International Journal of Cancer, 2013, 133, 130-141.	2.3	128
714	TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. British Journal of Cancer, 2013, 109, 497-501.	2.9	103
715	Targeted chemotherapy of metastatic melanoma: the impact of tumor cell heterogeneity. Expert Review of Dermatology, 2013, 8, 131-134.	0.3	1
716	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. Expert Opinion on Orphan Drugs, 2013, 1, 67-76.	0.5	0

#	Article	IF	Citations
717	MicroRNA Cancer Regulation. Advances in Experimental Medicine and Biology, 2013, , .	0.8	17
718	Case 21-2013. New England Journal of Medicine, 2013, 369, 173-183.	13.9	30
719	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	13.9	3,776
720	The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. Cancer Treatment Reviews, 2013, 39, 833-838.	3.4	21
721	Foolâ€™s gold, lost treasures, and the randomized clinical trial. BMC Cancer, 2013, 13, 193.	1.1	42
722	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. BMC Cancer, 2013, 13, 17.	1.1	38
723	Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 893-899.	1.5	64
724	Systemic therapies for inflammatory eye disease: Past, Present and Future. BMC Ophthalmology, 2013, 13, 18.	0.6	25
725	Optimization of personalized therapies for anticancer treatment. BMC Systems Biology, 2013, 7, 31.	3.0	17
726	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemotherapy and Pharmacology, 2013, 71, 1395-1409.	1.1	190
727	Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Molecular Cancer, 2013, 12, 37.	7.9	21
728	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
729	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. Cancer Treatment Reviews, 2013, 39, 305-312.	3.4	13
730	New Targets in Non-Small Cell Lung Cancer. Current Oncology Reports, 2013, 15, 411-423.	1.8	12
731	Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem. Current Oncology Reports, 2013, 15, 249-259.	1.8	53
734	Side Effects of Medical Cancer Therapy. , 2013, , .		4
735	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer, 2013, 119, 3821-3829.	2.0	87
736	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. Current Treatment Options in Oncology, 2013, 14, 264-279.	1.3	19

#	Article	IF	Citations
737	Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield. Current Atherosclerosis Reports, 2013, 15, 321.	2.0	5
738	Hairy Cell Leukemiaâ€"New Genes, New Targets. Current Hematologic Malignancy Reports, 2013, 8, 184-195.	1.2	20
739	S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIBâ€"C Melanoma. Annals of Surgical Oncology, 2013, 20, 2772-2779.	0.7	40
740	Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Investigational New Drugs, 2013, 31, 937-942.	1.2	11
741	Adjuvant hypofractionated intensity modulated radiation therapy after resection of regional lymph node metastases in patients with cutaneous malignant melanoma of the head and neck. Practical Radiation Oncology, 2013, 3, e71-e77.	1.1	6
742	Targets, Structures, and Recent Approaches in Malignant Melanoma Chemotherapy. ChemMedChem, 2013, 8, 1751-1765.	1.6	8
743	New Approaches to Molecular Diagnosis. JAMA - Journal of the American Medical Association, 2013, 309, 1511.	3.8	116
744	Next Generation Sequencing in Cancer Research. , 2013, , .		5
745	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. British Journal of Cancer, 2013, 109, 827-835.	2.9	91
746	Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunology, Immunotherapy, 2013, 62, 811-822.	2.0	97
747	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Annals of Hematology, 2013, 92, 1149-1149.	0.8	9
748	Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 72, 577-584.	1.1	26
749	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemotherapy and Pharmacology, 2013, 71, 183-191.	1.1	40
750	Selective <scp>RAF</scp> inhibitor impairs <scp>ERK</scp>1/2 phosphorylation and growth in mutant <scp>NRAS</scp>, vemurafenibâ€resistant melanoma cells. Pigment Cell and Melanoma Research, 2013, 26, 509-517.	1.5	65
751	BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathologica, 2013, 125, 901-910.	3.9	149
752	Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clinical and Translational Medicine, 2013, 2, 7.	1.7	15
753	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 1582-1590.	0.3	122
755	Immunohistochemistry using the <scp>BRAF</scp> V600E mutationâ€specific monoclonal antibody <scp>VE</scp>1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology, 2013, 63, 187-193.	1.6	74

#	Article	IF	Citations
756	Mutationâ€specific antibody detects mutant BRAF^{V600E} protein expression in human colon carcinomas. Cancer, 2013, 119, 2765-2770.	2.0	60
758	Emerging phytochemicals for prevention of melanoma invasion. Cancer Letters, 2013, 335, 251-258.	3.2	22
759	Safety and feasibility of targeted agent combinations in solid tumours. Nature Reviews Clinical Oncology, 2013, 10, 154-168.	12.5	57
760	Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death and Differentiation, 2013, 20, 1521-1531.	5.0	35
761	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. Cell, 2013, 154, 1074-1084.	13.5	257
762	New therapeutic options in systemic treatment of advanced cutaneous melanoma. Expert Opinion on Investigational Drugs, 2013, 22, 181-190.	1.9	12
763	Lupus erythematosus panniculitisâ€“induced facial atrophy: Effective treatment with poly-L-lactic acid and hyaluronic acid dermal fillers. Journal of the American Academy of Dermatology, 2013, 69, e260-e262.	0.6	20
764	Current Applications of Molecular Genetic Technologies to the Diagnosis and Treatment of Cutaneous Melanocytic Neoplasms. Clinics in Laboratory Medicine, 2013, 33, 881-890.	0.7	1
766	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Current Problems in Cancer, 2013, 37, 110-144.	1.0	50
767	V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. Cancer Letters, 2013, 335, 232-241.	3.2	49
768	Adjuvant therapy for high-risk melanoma. European Journal of Cancer, Supplement, 2013, 11, 106-108.	2.2	0
769	Targeting Receptor Tyrosine Kinases in Solid Tumors. Surgical Oncology Clinics of North America, 2013, 22, 685-703.	0.6	8
771	Cancerâ€induced immunosuppressive cascades and their reversal by molecularâ€targeted therapy. Annals of the New York Academy of Sciences, 2013, 1284, 80-86.	1.8	18
772	Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors. Cancer Discovery, 2013, 3, 742-750.	7.7	559
773	Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study. Human Gene Therapy Clinical Development, 2013, 24, 99-107.	3.2	64
774	The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. Clinical Cancer Research, 2013, 19, 5320-5328.	3.2	226
775	Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery, 2013, 153, 333-343.	1.0	24
776	Metastatic melanoma: New paradigms of treatment and new toxicities. European Journal of Cancer, Supplement, 2013, 11, 278-280.	2.2	1

#	Article	IF	Citations
777	ERK Pathway Inhibitors: How Low Should We Go?. Cancer Discovery, 2013, 3, 719-721.	7.7	47
779	Management of Primary Cutaneous and Metastatic Melanoma. Seminars in Oncology Nursing, 2013, 29, 195-205.	0.7	14
780	Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy, 2013, 13, 1401-1412.	1.4	42
781	Influence of tumour micro-environment heterogeneity on therapeutic response. Nature, 2013, 501, 346-354.	13.7	2,093
782	Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Human Pathology, 2013, 44, 2563-2570.	1.1	103
783	Systematic review and meta-analysis of liver resection for metastatic melanoma. British Journal of Surgery, 2013, 100, 1138-1147.	0.1	36
784	Companion Diagnostics in Oncology - Current Status and Future Aspects. Oncology, 2013, 85, 59-68.	0.9	32
785	Detection of BRAF V600 Mutations in Metastatic Melanoma. Journal of Molecular Diagnostics, 2013, 15, 790-795.	1.2	46
786	Nanotechnology in Dermatology. , 2013, , .		8
787	Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treatment Reviews, 2013, 39, 879-885.	3.4	44
788	p53 in the Clinics. , 2013, , .		1
789	Pharmacogenomics: Historical Perspective and Current Status. Methods in Molecular Biology, 2013, 1015, 3-22.	0.4	17
790	Cancer Genome Landscapes. Science, 2013, 339, 1546-1558.	6.0	6,507
791	Randomized International Phase III Trial of ERCC1 and RRM1 Expressionâ€“Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 2404-2412.	0.8	143
792	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. Expert Review of Anticancer Therapy, 2013, 13, 1307-1318.	1.1	5
793	Photodynamic therapy in treatment of cutaneous and choroidal melanoma. Photodiagnosis and Photodynamic Therapy, 2013, 10, 503-509.	1.3	46
794	Clinical Analysis and Interpretation of Cancer Genome Data. Journal of Clinical Oncology, 2013, 31, 1825-1833.	0.8	123
795	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. Journal of Clinical Pathology, 2013, 66, 839-846.	1.0	27

#	Article	IF	Citations
796	Advancing Precision Medicine for Prostate Cancer Through Genomics. Journal of Clinical Oncology, 2013, 31, 1866-1873.	0.8	84
797	Advances in therapy for melanoma brain metastases. Clinics in Dermatology, 2013, 31, 264-281.	0.8	36
798	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
799	Challenging resistance mechanisms to therapies for metastatic melanoma. Trends in Pharmacological Sciences, 2013, 34, 656-666.	4.0	90
800	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 2013, 155, 1309-1322.	13.5	801
801	A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14717-14722.	3.3	59
802	Tumor metastasis: moving new biological insights into the clinic. Nature Medicine, 2013, 19, 1450-1464.	15.2	685
803	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis, 2013, 34, 725-738.	1.3	86
804	Can we deconstruct cancer, one patient at a time?. Trends in Genetics, 2013, 29, 6-10.	2.9	20
805	Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 303-311.	0.8	55
806	Tumor adaptation and resistance to RAF inhibitors. Nature Medicine, 2013, 19, 1401-1409.	15.2	512
807	Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. , 2013, , 359-371.		0
808	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 3205-3211.	0.8	395
809	Use of diagnostic and therapeutic biomarkers in personalized oncology based on adult T-cell leukemia/lymphoma research. Personalized Medicine Universe, 2013, 2, 7-11.	0.1	0
810	The Small GTPase ARF6 Stimulates Î²-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. Science Signaling, 2013, 6, ra14.	1.6	122
811	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. Cancer Immunology Research, 2013, 1, 373-377.	1.6	100
812	Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy. International Journal of Molecular Sciences, 2013, 14, 14771-14784.	1.8	67
813	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature, 2013, 504, 138-142.	13.7	401

#	Article	IF	Citations
814	A potential role for resveratrol as a radiation sensitizer for melanoma treatment. Journal of Surgical Research, 2013, 183, 645-653.	0.8	50
815	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Nonâ€“Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 2013, 14, 609-626.	1.1	15
816	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	0.8	282
817	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	1.1	11
818	Effect of inhibition of the FGFRâ€“MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews, 2013, 39, 664-672.	3.4	84
819	The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 2013, 45, 1113-1120.	9.4	6,265
820	Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action. Critical Reviews in Oncology/Hematology, 2013, 88, 318-337.	2.0	28
821	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research, 2013, 19, 5300-5309.	3.2	596
822	Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation. Molecular Cell, 2013, 52, 161-172.	4.5	118
823	A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. European Journal of Cancer, 2013, 49, 2022-2033.	1.3	44
824	MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. Journal of Translational Medicine, 2013, 11, 218.	1.8	22
825	Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surgery, 2013, 13, S44.	0.6	77
826	Clinical impact of 18F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insights Into Imaging, 2013, 4, 701-709.	1.6	10
827	Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiation Oncology, 2013, 8, 204.	1.2	14
828	Functional features of cancer stem cells in melanoma cell lines. Cancer Cell International, 2013, 13, 78.	1.8	54
829	Immunotherapy for the Management of Advanced Melanoma: The Next Steps. American Journal of Clinical Dermatology, 2013, 14, 261-272.	3.3	15
830	Stage IV Melanoma: Completely Resectable Patients are Scarce. Annals of Surgical Oncology, 2013, 20, 2352-2356.	0.7	19
831	How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?. Annals of Surgical Oncology, 2013, 20, 2056-2064.	0.7	16

#	Article	IF	Citations
832	Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Investigational New Drugs, 2013, 31, 769-773.	1.2	41
833	Systems Pathology. , 2013, , 197-207.		1
834	Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment. SpringerPlus, 2013, 2, 679.	1.2	8
835	Safety and efficacy of vemurafenib in end stage renal failure. BMC Cancer, 2013, 13, 581.	1.1	12
836	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. BMC Cancer, 2013, 13, 561.	1.1	27
837	Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 1121-1129.	1.7	16
838	Targeting MAPK pathway in melanoma therapy. Cancer and Metastasis Reviews, 2013, 32, 567-584.	2.7	72
839	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis, 2013, 30, 867-876.	1.7	16
840	Neoadjuvant treatment of melanoma: case reports and review. Experimental Hematology and Oncology, 2013, 2, 30.	2.0	7
841	Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset. American Journal of Clinical Dermatology, 2013, 14, 461-471.	3.3	13
842	Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Medicine, 2013, 5, 91.	3.6	146
843	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, 2013, 26, 1255-1263.	2.9	52
844	Current management of melanoma. Current Problems in Surgery, 2013, 50, 351-382.	0.6	36
845	Integration of cancer genomics with treatment selection. Cancer, 2013, 119, 3914-3928.	2.0	15
846	Immunotherapy and the concept of a clinical cure. European Journal of Cancer, 2013, 49, 2965-2967.	1.3	41
847	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. Current Oncology Reports, 2013, 15, 500-508.	1.8	20
848	Mechanisms of Targeted Therapy Resistance Take a De-TOR. Cancer Cell, 2013, 24, 284-286.	7.7	5
849	Systems Biology of Tumor Dormancy. Advances in Experimental Medicine and Biology, 2013, , .	0.8	9

#	Article	IF	Citations
850	Tumor Dormancy, Oncogene Addiction, Cellular Senescence, and Self-Renewal Programs. Advances in Experimental Medicine and Biology, 2013, 734, 91-107.	0.8	36
851	Abiraterone and its place in the treatment of metastatic CRPC. Nature Reviews Clinical Oncology, 2013, 10, 6-8.	12.5	14
852	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 2013, 49, 3229-3241.	1.3	40
853	Kinase Inhibitors: Adverse Effects Related to the Endocrine System. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1333-1342.	1.8	85
854	BRAF V600E Inhibition in Anaplastic Thyroid Cancer. New England Journal of Medicine, 2013, 368, 684-685.	13.9	162
855	Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 2013, 13, 714-726.	12.8	3,667
856	Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. British Journal of Cancer, 2013, 109, 1562-1569.	2.9	22
857	<scp>AKT</scp> signalling is required for ribosomal <scp>RNA</scp> synthesis and progression of <scp>E</scp>Ì¼â€‹Myc <scp>B</scp>â€œcell lymphoma inÂvivo. FEBS Journal, 2013, 280, 5307-5316.	2.2	19
858	Synthesis, Radiofluorination, and in Vivo Evaluation of Novel Fluorinated and Iodinated Radiotracers for PET Imaging and Targeted Radionuclide Therapy of Melanoma. Journal of Medicinal Chemistry, 2013, 56, 8455-8467.	2.9	22
859	The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo. Veterinary Journal, 2013, 198, 577-582.	0.6	14
860	Interferon alpha for the adjuvant treatment of cutaneous melanoma. The Cochrane Library, 2015, 2015, CD008955.	1.5	110
861	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	12.5	177
862	Case History. Annual Reports in Medicinal Chemistry, 2013, 48, 435-449.	0.5	3
863	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology ofBRAFmutations. Future Oncology, 2013, 9, 245-253.	1.1	12
864	The potential role of sunitinib targeting melanomas. Expert Opinion on Investigational Drugs, 2013, 22, 1473-1483.	1.9	15
865	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. American Journal of Clinical Dermatology, 2013, 14, 179-194.	3.3	89
866	Regorafenib for Gastrointestinal Malignancies. BioDrugs, 2013, 27, 213-224.	2.2	37
867	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clinical Cancer Research, 2013, 19, 657-667.	3.2	250

#	Article	IF	Citations
868	Drug safety evaluation of vemurafenib in the treatment of melanoma. Expert Opinion on Drug Safety, 2013, 12, 767-775.	1.0	4
869	Effects of <scp>BRAF</scp> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell and Melanoma Research, 2013, 26, 499-508.	1.5	37
870	Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas. Journal of Investigative Dermatology, 2013, 133, 2041-2049.	0.3	95
871	The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel. Pigment Cell and Melanoma Research, 2013, 26, 597-600.	1.5	49
872	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Molecular Systems Biology, 2013, 9, 637.	3.2	267
873	Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. British Journal of Dermatology, 2013, 168, 708-716.	1.4	20
874	Reply to Amiodarone and the risk of cancer: A nationwide populationâ€based study. Cancer, 2013, 119, 3578-3579.	2.0	0
875	Pathologic and gene expression features of metastatic melanomas to the brain. Cancer, 2013, 119, 2737-2746.	2.0	42
876	Response to a costly revolution for a subgroup of patients with metastatic melanoma. British Journal of Dermatology, 2013, 168, 470-471.	1.4	0
877	A group sequential Holm procedure with multiple primary endpoints. Statistics in Medicine, 2013, 32, 1112-1124.	0.8	43
879	Isolation of a Novel Thioflavin Sâ€"Derived Compound That Inhibits BAG-1â€"Mediated Protein Interactions and Targets BRAF Inhibitorâ€"Resistant Cell Lines. Molecular Cancer Therapeutics, 2013, 12, 2400-2414.	1.9	23
880	Challenges and opportunities for oncology biomarker discovery. Drug Discovery Today, 2013, 18, 614-624.	3.2	44
881	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	21.5	111
882	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nature Reviews Clinical Oncology, 2013, 10, 14-26.	12.5	281
883	Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. Journal of Molecular Diagnostics, 2013, 15, 220-226.	1.2	195
885	Nano-Based Gene Therapy for Dermatologic Diseases. , 2013, , 109-117.		2
886	A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition. Cancer Discovery, 2013, 3, 350-362.	7.7	299
887	Targeting Oncogenic Drivers and the Immune System in Melanoma. Journal of Clinical Oncology, 2013, 31, 499-506.	0.8	98

#	Article	IF	Citations
888	Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas. Journal of Molecular Diagnostics, 2013, 15, 70-80.	1.2	68
889	BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. Critical Reviews in Oncology/Hematology, 2013, 87, 55-68.	2.0	56
890	Toward personalized cancer nanomedicine â€“ past, present, and future. Integrative Biology (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	41
891	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.4	131
892	The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. Clinical Cancer Research, 2013, 19, 598-609.	3.2	410
893	RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance. Oncogene, 2013, 32, 4480-4489.	2.6	32
894	Pathological and Molecular Advances in Pediatric Low-Grade Astrocytoma. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 361-379.	9.6	68
895	Glioblastoma: Molecular Analysis and Clinical Implications. Annual Review of Medicine, 2013, 64, 59-70.	5.0	81
896	Pathogenesis of Langerhans Cell Histiocytosis. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 1-20.	9.6	145
897	Targeting Mutant p53 for Improved Cancer Therapy. , 2013, , 257-273.		0
898	Microenvironment and tumor progression of melanoma: New therapeutic prospectives. Journal of Immunotoxicology, 2013, 10, 235-252.	0.9	37
899	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
900	ERCC1 and RRM1: Ready for Prime Time?. Journal of Clinical Oncology, 2013, 31, 1050-1060.	0.8	73
901	Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Medicinal Chemistry Letters, 2013, 4, 358-362.	1.3	186
902	Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10, 143-153.	12.5	694
903	Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance. Clinical Cancer Research, 2013, 19, 2301-2309.	3.2	77
904	Histone acetyltransferases: Rising ancient counterparts to protein kinases. Biopolymers, 2013, 99, 98-111.	1.2	61
905	Surgery and the management of cutaneous melanoma. British Journal of Surgery, 2013, 100, 313-315.	0.1	2

#	Article	IF	Citations
906	Ovarian cancer. Cancer, 2013, 119, 474-476.	2.0	11
907	Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. Journal of Cellular Biochemistry, 2013, 114, 514-524.	1.2	66
908	Why imatinib remains an exception of cancer research. Journal of Cellular Physiology, 2013, 228, 665-670.	2.0	46
909	Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncology, The, 2013, 14, 186-188.	5.1	4
910	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochemical Pharmacology, 2013, 85, 325-334.	2.0	70
911	The Challenges of Comparing a Clinically Validated Test to Other Methods. Journal of Molecular Diagnostics, 2013, 15, 535-537.	1.2	0
912	Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. Translational Oncology, 2013, 6, 470-IN15.	1.7	7
913	Eruptive milia secondary to vemurafenib. Journal of the American Academy of Dermatology, 2013, 69, e258-e260.	0.6	4
914	Novedades en el diagnÃ³stico de las toxicodermias. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 782-788.	0.2	9
915	Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?. Medical Hypotheses, 2013, 81, 846-850.	0.8	8
916	Inhibition of autophagy with chloroquine is effective inÂmelanoma. Journal of Surgical Research, 2013, 184, 274-281.	0.8	53
917	Targeted Therapy for Cancer. Surgical Oncology Clinics of North America, 2013, 22, 805-821.	0.6	12
918	Modifying phase I methodology to facilitate enrolment of molecularly selected patients. European Journal of Cancer, 2013, 49, 1515-1520.	1.3	15
919	Targeting BRAF in melanoma: Biological and clinical challenges. Critical Reviews in Oncology/Hematology, 2013, 87, 239-255.	2.0	41
920	Radiation-induced dermatitis with vemurafenib therapy. Practical Radiation Oncology, 2013, 3, e195-e198.	1.1	6
921	Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2013, 69, 708-720.	0.6	94
922	Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Journal of Clinical Oncology, 2013, 31, 3987-3996.	0.8	299
923	Treatment of Metastatic Malignant Melanoma With Vemurafenib During Pregnancy. Journal of Clinical Oncology, 2013, 31, e192-e193.	0.8	52

#	Article	IF	Citations
924	Targeting melanoma by small molecules: challenges ahead. Pigment Cell and Melanoma Research, 2013, 26, 464-469.	1.5	10
925	ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Oncogene, 2013, 32, 3207-3212.	2.6	66
926	Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. Journal of Clinical Oncology, 2013, 31, 4252-4259.	0.8	232
928	Melanomaâ€associated leukoderma â€“ immunology in black and white?. Pigment Cell and Melanoma Research, 2013, 26, 796-804.	1.5	38
929	Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. Oncologist, 2013, 18, 717-725.	1.9	72
930	Advances in the Diagnosis of Drug Eruptions. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 782-788.	0.2	1
931	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. Academic Radiology, 2013, 20, 423-429.	1.3	6
932	Noncanonical roles of the immune system in eliciting oncogene addiction. Current Opinion in Immunology, 2013, 25, 246-258.	2.4	11
933	Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Annals of Diagnostic Pathology, 2013, 17, 322-326.	0.6	88
934	Developing companion diagnostics for delivering personalised medicine: opportunities and challenges. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e175-e181.	0.5	3
935	Molecular pathology of melanocytic tumors. Seminars in Diagnostic Pathology, 2013, 30, 362-374.	1.0	38
937	Inhibition of the mitochondrial Hsp90 chaperone network: A novel, efficient treatment strategy for cancer?. Cancer Letters, 2013, 333, 133-146.	3.2	50
940	Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden. European Journal of Cancer, 2013, 49, 2705-2716.	1.3	55
941	The role of radiotherapy in the overall treatment of melanoma. Clinics in Dermatology, 2013, 31, 282-289.	0.8	10
942	Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. Critical Reviews in Oncology/Hematology, 2013, 85, 149-161.	2.0	33
943	Targeted therapy in melanoma. Clinics in Dermatology, 2013, 31, 200-208.	0.8	23
944	KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. Journal of Dermatological Science, 2013, 72, 284-289.	1.0	86
945	Fotosensibilidad secundaria al tratamiento con Vemurafenib. Piel, 2013, 28, 248-249.	0.0	2

#	Article	IF	Citations
946	The European Medicines Agency review of vemurafenib (ZelborafÂ®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. European Journal of Cancer, 2013, 49, 1654-1661.	1.3	55
947	Rationale and clinical use of multitargeting anticancer agents. Current Opinion in Pharmacology, 2013, 13, 536-542.	1.7	29
948	Body composition and survival in the early clinical trials setting. European Journal of Cancer, 2013, 49, 3068-3075.	1.3	29
949	A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling. Toxicology in Vitro, 2013, 27, 2076-2083.	1.1	16
950	Translational Research in Melanoma. Surgical Oncology Clinics of North America, 2013, 22, 785-804.	0.6	0
952	Somatic evolution of head and neck cancer â€" Biological robustness and latent vulnerability. Molecular Oncology, 2013, 7, 14-28.	2.1	18
954	Chemotherapy in the management of advanced cutaneous malignant melanoma. Clinics in Dermatology, 2013, 31, 290-297.	0.8	80
955	Targeted therapy in melanoma â€" the role of BRAF, RAS and KIT mutations. European Journal of Cancer, Supplement, 2013, 11, 92-96.	2.2	41
956	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, The, 2013, 14, 249-256.	5.1	587
957	Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors. Journal of Molecular Diagnostics, 2013, 15, 263-269.	1.2	66
958	Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. Current Oncology Reports, 2013, 15, 33-46.	1.8	1
959	Cutaneous toxicities of RAF inhibitors. Lancet Oncology, The, 2013, 14, e11-e18.	5.1	190
960	NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. Lancet Oncology, The, 2013, 14, 21-22.	5.1	0
961	Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas. Cancer Discovery, 2013, 3, 14-19.	7.7	8
963	Highâ€throughput sequencing of the melanoma genome. Experimental Dermatology, 2013, 22, 10-17.	1.4	33
964	BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. British Journal of Dermatology, 2013, 168, 428-430.	1.4	13
965	Kinase dysfunction and kinase inhibitors. Veterinary Dermatology, 2013, 24, 181.	0.4	17
966	How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Information Science and Systems, 2013, 1, 2.	3.4	32

#	Article	IF	Citations
967	Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomarker Research, 2013, 1, 1.	2.8	57
968	Melanoma Prognostics and Personalized Therapeutics at a Crossroad. Journal of Investigative Dermatology, 2013, 133, 292-295.	0.3	1
969	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF. Cancer Cell, 2013, 23, 302-315.	7.7	689
970	Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 1996-2015.	2.9	29
971	Molecular/Targeted Therapy of Cancer. , 2013, , 215-244.		0
972	In vivo efficacy of melanoma internal radionuclide therapy with a ¹³¹Iâ€labelled melaninâ€targeting heteroarylcarboxamide molecule. International Journal of Cancer, 2013, 133, 1042-1053.	2.3	25
973	Vemurafenib Induces Senescence Features in Melanoma Cells. Journal of Investigative Dermatology, 2013, 133, 1601-1609.	0.3	95
974	Commentary: BRAF inhibitors for metastatic melanoma. British Journal of Dermatology, 2013, 168, 471-473.	1.4	0
975	Translating Genomics to the Clinic: Implications of Cancer Heterogeneity. Clinical Chemistry, 2013, 59, 127-137.	1.5	25
976	The role of tumourâ€“stromal interactions in modifying drug response: challenges and opportunities. Nature Reviews Drug Discovery, 2013, 12, 217-228.	21.5	394
977	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 34-42.	8.2	277
978	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.4	295
979	BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4321-4326.	3.3	200
980	Resistance to BRAF-targeted therapy in melanoma. European Journal of Cancer, 2013, 49, 1297-1304.	1.3	311
981	Immune correlates of melanoma survival in adoptive cell therapy. OncoImmunology, 2013, 2, e22889.	2.1	12
982	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. Nature Reviews Cancer, 2013, 13, 365-376.	12.8	242
983	Lessons from the Cancer Genome. Cell, 2013, 153, 17-37.	13.5	1,133
984	Human cancer regression antigens. Current Opinion in Immunology, 2013, 25, 284-290.	2.4	38

#	Article	IF	Citations
985	Polymer Nanofiberâ€Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells. Angewandte Chemie - International Edition, 2013, 52, 3379-3383.	7.2	194
986	BRAFmutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. British Journal of Dermatology, 2013, 168, 700-707.	1.4	36
987	Targeting mechanisms of resistance to anti-EGF receptor therapy inKRASwild-type colorectal cancer: the path to more personalized medicine. Future Oncology, 2013, 9, 551-560.	1.1	9
988	The war on cancer: are we winning?. Tumor Biology, 2013, 34, 1275-1284.	0.8	42
989	Melanoma genetics: the other side. Clinics in Dermatology, 2013, 31, 148-155.	0.8	11
990	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opinion on Biological Therapy, 2013, 13, 643-656.	1.4	27
991	Coinhibitory molecules in cancer biology and therapy. Cytokine and Growth Factor Reviews, 2013, 24, 147-161.	3.2	26
992	Melanoma. Facial Plastic Surgery Clinics of North America, 2013, 21, 33-42.	0.9	22
993	Innovative Therapeutic Strategies in the Treatment of Brain Metastases. International Journal of Molecular Sciences, 2013, 14, 2135-2174.	1.8	41
994	Existing and Emerging Technologies for Tumor Genomic Profiling. Journal of Clinical Oncology, 2013, 31, 1815-1824.	0.8	129
995	BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 2013, 49, 1073-1079.	1.3	105
996	Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. Bioorganic and Medicinal Chemistry, 2013, 21, 1284-1304.	1.4	34
997	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF^{V600E}Mutation. Thyroid, 2013, 23, 1277-1283.	2.4	184
998	Molecular and cellular pathogenesis of melanoma initiation and progression. Cellular and Molecular Life Sciences, 2013, 70, 4055-4065.	2.4	51
999	MEK and the inhibitors: from bench to bedside. Journal of Hematology and Oncology, 2013, 6, 27.	6.9	219
1000	18F-labelled fluorodeoxyglucoseâ€“positron emission tomography (FDGâ€“PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 2013, 49, 395-402.	1.3	42
1001	Targeting the RAS oncogene. Expert Opinion on Therapeutic Targets, 2013, 17, 507-531.	1.5	105
1002	Viable biobanking of primary head and neck squamous cell carcinoma. Laryngoscope, 2013, 123, 641-645.	1.1	2

#	Article	IF	Citations
1003	Update Guidelines Dermatologic Oncology. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-45.	0.4	1
1004	Developing melanoma therapeutics: overview and update. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 257-271.	6.6	13
1005	Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opinion on Investigational Drugs, 2013, 22, 739-749.	1.9	11
1006	Mind the IQGAP. Cancer Cell, 2013, 23, 715-717.	7.7	23
1007	Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure. , 2013, 139, 405-411.		12
1008	Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance. Clinical Pharmacology and Therapeutics, 2013, 93, 252-259.	2.3	209
1009	CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 187-196.	3.3	42
1010	Immunohistochemical Detection of Mutated BRAF V600E Supports the Clonal Origin of BRAF-Induced Thyroid Cancers Along the Spectrum of Disease Progression. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1414-E1421.	1.8	76
1011	Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. Journal of Investigative Dermatology, 2013, 133, 1278-1285.	0.3	44
1012	Role of targeted agents in metastatic colorectal cancer. Targeted Oncology, 2013, 8, 83-96.	1.7	58
1013	Update on the Targeted Therapy of Melanoma. Current Treatment Options in Oncology, 2013, 14, 280-292.	1.3	46
1014	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. Journal of Human Genetics, 2013, 58, 346-352.	1.1	52
1015	Erdheim-Chester Disease. Rheumatic Disease Clinics of North America, 2013, 39, 299-311.	0.8	91
1016	Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options. Annals of Pharmacotherapy, 2013, 47, 519-526.	0.9	16
1017	Paradoxical oncogenesisâ€"the long-term effects of BRAF inhibition in melanoma. Nature Reviews Clinical Oncology, 2013, 10, 390-399.	12.5	171
1018	Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. British Journal of Cancer, 2013, 108, 2164-2171.	2.9	82
1019	Vemurafenib in melanoma. Expert Review of Anticancer Therapy, 2013, 13, 513-522.	1.1	9
1020	Integrating Companion Diagnostic Assays into Drug Development: Addressing the Challenges from the Diagnostic Perspective. Drug Development Research, 2013, 74, 148-154.	1.4	5

#	Article	IF	Citations
1021	Vemurafenib. American Journal of Clinical Dermatology, 2013, 14, 65-69.	3.3	3
1022	Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Clinical Chemistry, 2013, 59, 1447-1456.	1.5	44
1023	Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment. Journal of Investigative Dermatology, 2013, 133, 2576-2584.	0.3	15
1024	Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clinics in Dermatology, 2013, 31, 237-250.	0.8	40
1025	Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 394-401.	1.0	27
1026	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncology, The, 2013, 14, 733-740.	5.1	151
1027	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences, 2013, 1291, 1-13.	1.8	270
1028	MicroRNAs in Melanoma Biology. Advances in Experimental Medicine and Biology, 2013, 774, 103-120.	0.8	60
1029	BRAF as a therapeutic target: a patent review (2006 â€“ 2012). Expert Opinion on Therapeutic Patents, 2013, 23, 155-164.	2.4	12
1030	Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncology, The, 2013, 14, e60-e69.	5.1	164
1031	Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clinics in Dermatology, 2013, 31, 191-199.	0.8	57
1032	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemotherapy and Pharmacology, 2013, 72, 13-33.	1.1	81
1033	Involvement of mixed lineage kinase 3 in cancer. Canadian Journal of Physiology and Pharmacology, 2013, 91, 268-274.	0.7	16
1036	Has targeted therapy for melanoma made chemotherapy obsolete?. Lancet Oncology, The, 2013, 14, 676-677.	5.1	3
1037	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current Opinion in Pharmacology, 2013, 13, 486-496.	1.7	55
1038	The Tumor Immunoenvironment. , 2013, , .		4
1039	Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview. Genetic Testing and Molecular Biomarkers, 2013, 17, 515-523.	0.3	14
1040	Improving outcomes in colorectal cancer: Where do we go from here?. European Journal of Cancer, 2013, 49, 2476-2485.	1.3	43

#	Article	IF	Citations
1041	Complications of Targeted Drug Therapies for Solid Malignancies: Manifestations and Mechanisms. American Journal of Roentgenology, 2013, 200, 475-483.	1.0	33
1042	Current and Future Trials of Targeted Therapies in Cutaneous Melanoma. Advances in Experimental Medicine and Biology, 2013, 779, 223-255.	0.8	27
1043	Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. Drugs, 2013, 73, 767-777.	4.9	11
1044	Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist. Journal of the American Academy of Dermatology, 2013, 68, 13.e1-13.e13.	0.6	11
1045	Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death and Disease, 2013, 4, e719-e719.	2.7	129
1046	Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. British Journal of Dermatology, 2013, 169, 320-328.	1.4	24
1047	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	2.3	81
1048	Ipilimumab and Its Toxicities: A Multidisciplinary Approach. Oncologist, 2013, 18, 733-743.	1.9	288
1049	Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. British Journal of Cancer, 2013, 109, 2833-2841.	2.9	88
1050	Molecularly targeted therapies for melanoma. International Journal of Dermatology, 2013, 52, 523-530.	0.5	13
1051	Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy. Clinical Cancer Research, 2013, 19, 5292-5299.	3.2	13
1055	Skin Tumorigenesis Stimulated by Raf Inhibitors Relies Upon Raf Functions That Are Dependent and Independent of ERK. Cancer Research, 2013, 73, 6926-6937.	0.4	20
1056	The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities. Cancer Research, 2013, 73, 6106-6110.	0.4	55
1057	<scp>T</scp> cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. Pigment Cell and Melanoma Research, 2013, 26, 441-456.	1.5	11
1058	Detection of BRAF p.V600E Mutations in Melanomas. Journal of Molecular Diagnostics, 2013, 15, 94-100.	1.2	144
1059	Systemic treatment in the management of head and neck cutaneous malignancies. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2013, 24, 63-68.	0.1	1
1060	Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time PCR. Journal of Molecular Diagnostics, 2013, 15, 355-361.	1.2	8
1061	Tumour heterogeneity in the clinic. Nature, 2013, 501, 355-364.	13.7	993

#	Article	IF	Citations
1062	Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. Current Oncology Reports, 2013, 15, 492-499.	1.8	5
1063	Melanoma Brain Metastases: an Unmet Challenge in the Era of Active Therapy. Current Oncology Reports, 2013, 15, 483-491.	1.8	32
1064	MEK Inhibition in the Treatment of Advanced Melanoma. Current Oncology Reports, 2013, 15, 473-482.	1.8	21
1065	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opinion on Pharmacotherapy, 2013, 14, 597-608.	0.9	6
1066	The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be. Clinical Cancer Research, 2013, 19, 5283-5291.	3.2	54
1067	Protein kinase inhibitors in melanoma. Expert Opinion on Pharmacotherapy, 2013, 14, 2195-2201.	0.9	9
1068	Building a Personalized Medicine Infrastructure at a Major Cancer Center. Journal of Clinical Oncology, 2013, 31, 1849-1857.	0.8	101
1069	Emerging BRAF inhibitors for melanoma. Expert Opinion on Emerging Drugs, 2013, 18, 431-443.	1.0	5
1070	Evolving Approaches to Patients with Advanced Differentiated Thyroid Cancer. Endocrine Reviews, 2013, 34, 439-455.	8.9	105
1071	Understanding, recognizing, and managing toxicities of targeted anticancer therapies. Ca-A Cancer Journal for Clinicians, 2013, 63, 249-279.	157.7	274
1072	Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma. Journal of Clinical Oncology, 2013, 31, 4311-4318.	0.8	515
1073	Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. Cancer Immunology, Immunotherapy, 2013, 62, 1547-1551.	2.0	20
1076	Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Investigational New Drugs, 2013, 31, 1136-1141.	1.2	18
1077	Targeted therapy for melanoma: is double hitting a home run?. Nature Reviews Clinical Oncology, 2013, 10, 5-6.	12.5	12
1078	Designing Transformative Clinical Trials in the Cancer Genome Era. Journal of Clinical Oncology, 2013, 31, 1834-1841.	0.8	166
1079	Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene, 2013, 32, 1207-1215.	2.6	95
1080	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene, 2013, 32, 3009-3018.	2.6	127
1081	A randomized phase 2 study of temozolomide and bevacizumab or nabâ€paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma. Cancer, 2013, 119, 586-592.	2.0	81

#	Article	IF	Citations
1082	Clinical responses to selumetinib (AZD6244; ARRYâ€142886)â€based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer, 2013, 119, 799-805.	2.0	63
1083	Targeting tyrosine kinases in cancer. Cancer Cytopathology, 2013, 121, 61-71.	1.4	12
1084	Cutaneous effects of BRAF inhibitor therapy: a case series. Annals of Oncology, 2013, 24, 530-537.	0.6	73
1085	MAP kinase signaling and inhibition in melanoma. Oncogene, 2013, 32, 2373-2379.	2.6	127
1086	A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. Journal of Chemotherapy, 2013, 25, 362-368.	0.7	3
1088	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. Expert Review of Dermatology, 2013, 8, 479-487.	0.3	4
1089	Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient. Case Reports in Dermatology, 2013, 5, 69-72.	0.3	11
1090	Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas. Cancer Discovery, 2013, 3, 520-533.	7.7	328
1091	The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. Personalized Medicine, 2013, 10, 405-412.	0.8	7
1092	Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. OncoImmunology, 2013, 2, e22691.	2.1	32
1093	AACR Cancer Progress Report 2013. Clinical Cancer Research, 2013, 19, S1-S98.	3.2	55
1095	Harnessing massively parallel DNA sequencing for the personalization of cancer management. Personalized Medicine, 2013, 10, 183-190.	0.8	2
1096	DÃ©jÃ Vu: EGF Receptors Drive Resistance to BRAF Inhibitors. Cancer Discovery, 2013, 3, 487-490.	7.7	25
1097	Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy, 2013, 5, 357-364.	1.0	11
1098	Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye, 2013, 27, 142-152.	1.1	59
1099	BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate. AJP Reports, 2013, 03, 063-066.	0.4	7
1100	Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer, 2013, 2, 487-489.	0.8	1
1101	From targeted monotherapy to combined BRAFâ€“MEK inhibitors and integrated genome analysis for melanoma treatment. Future Oncology, 2013, 9, 5-8.	1.1	1

#	Article	IF	Citations
1102	Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. Journal of Cell Science, 2014, 127, 788-800.	1.2	70
1103	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	2.9	55
1104	Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1Î±-Dependent Phenotype Switching. Journal of Investigative Dermatology, 2013, 133, 2436-2443.	0.3	127
1105	Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. Expert Review of Anticancer Therapy, 2013, 13, 559-567.	1.1	6
1106	Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4532-4540.	3.2	307
1107	The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 2013, 34, 237-247.	1.3	57
1108	Genetic Profiling of BRAF Inhibitorâ€“Induced Keratoacanthomas Reveals No Induction of MAP Kinase Pathway Expression. Journal of Investigative Dermatology, 2013, 133, 830-833.	0.3	8
1109	Plasma MicroRNA-21 Is Associated with Tumor Burden in Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 1381-1384.	0.3	38
1110	Targeting Brain Metastases in Patients with Melanoma. BioMed Research International, 2013, 2013, 1-6.	0.9	4
1111	Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. Clinical Cancer Research, 2013, 19, 2688-2698.	3.2	76
1112	Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clinical Cancer Research, 2013, 19, 5749-5757.	3.2	113
1113	Biologics in Dermatology. Pharmaceuticals, 2013, 6, 557-578.	1.7	9
1114	Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and braf v600e mutation study. North American Journal of Medical Sciences, 2013, 5, 386.	1.7	48
1115	Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status. Annals of Oncology, 2013, 24, 1712-1713.	0.6	2
1116	Circulating Melanoma Cells: Scoping the Target. Frontiers in Oncology, 2013, 3, 189.	1.3	3
1117	Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy. Frontiers in Oncology, 2013, 3, 136.	1.3	22
1118	Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncology, 2013, 2013, 1-14.	2.1	21
1119	Vemurafenib-Induced DRESS. JAMA Dermatology, 2013, 149, 1242.	2.0	39

#	Article	IF	Citations
1120	Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function. Frontiers in Immunology, 2013, 4, 346.	2.2	36
1121	Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, e215-e217.	0.8	34
1122	Adjuvant Treatment of Melanoma. ISRN Dermatology, 2013, 2013, 1-17.	1.9	8
1123	The Combination of Novel Targeted Molecular Agents and Radiation in the Treatment of Pediatric Gliomas. Frontiers in Oncology, 2013, 3, 110.	1.3	31
1124	Phenotypic Identification of the Redox Dye Methylene Blue as an Antagonist of Heat Shock Response Gene Expression in Metastatic Melanoma Cells. International Journal of Molecular Sciences, 2013, 14, 4185-4202.	1.8	11
1125	Vemurafenib and ipilimumab: New agents for metastatic melanoma. American Journal of Health-System Pharmacy, 2013, 70, 1205-1210.	0.5	16
1126	Treatment ofBRAFinhibitor-induced hyperkeratosis. Acta OncolÃ³gica, 2013, 52, 874-876.	0.8	3
1127	Paradigm Shift in Metastatic Malignant Melanoma. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2013, 23, 3-9.	0.1	1
1128	Five Top Stories in Cytopathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 894-906.	1.2	13
1129	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology, 2013, 24, 1697-1703.	0.6	280
1130	Triage of Cytologic Direct Smears for Ancillary Studies: A Case-Based Illustration and Review. Archives of Pathology and Laboratory Medicine, 2013, 137, 1185-1190.	1.2	11
1131	Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitorâ€“Induced Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2013, 133, 274-276.	0.3	14
1132	The Immunocytokine L19â€“IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF. Journal of Investigative Dermatology, 2013, 133, 751-758.	0.3	86
1133	Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research, 2013, 19, 3611-3620.	3.2	46
1134	Erythema Nodosumâ€“Like Panniculitis in Patients With Melanoma Treated With Vemurafenib. Journal of Clinical Oncology, 2013, 31, e320-e321.	0.8	29
1135	Targeting Activated KIT Signaling for Melanoma Therapy. Journal of Clinical Oncology, 2013, 31, 3288-3290.	0.8	16
1136	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Tumors. Ophthalmic Plastic and Reconstructive Surgery, 2013, 29, 57-62.	0.4	61
1137	Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma. Melanoma Research, 2013, 23, 468-473.	0.6	28

#	Article	IF	Citations
1138	C-kit-mutated melanomas. Current Opinion in Oncology, 2013, 25, 160-165.	1.1	15
1139	Genomic stratification for the treatment of lymphomas. Hematology American Society of Hematology Education Program, 2013, 2013, 331-334.	0.9	2
1140	Data Set for Pathology Reporting of Cutaneous Invasive Melanoma. American Journal of Surgical Pathology, 2013, 37, 1797-1814.	2.1	106
1141	Parthenolide enhances dacarbazine activity against melanoma cells. Anti-Cancer Drugs, 2013, 24, 835-845.	0.7	23
1142	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Therapeutic Drug Monitoring, 2013, 35, 562-587.	1.0	77
1143	BRAF Mutation-Positive Folliculotropic Metastatic Melanoma. American Journal of Dermatopathology, 2013, 35, 609-612.	0.3	3
1144	Hematopoietic Expression of Oncogenic BRAF Promotes Aberrant Growth of Monocyte-Lineage Cells Resistant to PLX4720. Molecular Cancer Research, 2013, 11, 1530-1541.	1.5	7
1145	Pilot Studies for Personalized Cancer Medicine: Focusing on the Patient for Treatment Selection. Oncologist, 2013, 18, 1180-1188.	1.9	22
1146	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Research, 2013, 23, 396-401.	0.6	22
1147	Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. Melanoma Research, 2013, 23, 373-380.	0.6	12
1148	Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Research, 2013, 23, 360-365.	0.6	22
1149	BRAF V600E Mutations in Endometrial Adenocarcinoma. Diagnostic Molecular Pathology, 2013, 22, 35-40.	2.1	10
1150	Personalized medicine for metastatic breast cancer. Current Opinion in Oncology, 2013, 25, 615-624.	1.1	6
1151	Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 25-33.	1.0	13
1152	Update on the role of ipilimumab in melanoma and first data on new combination therapies. Current Opinion in Oncology, 2013, 25, 166-172.	1.1	27
1153	Ras, Raf, and MAP Kinase in Melanoma. Advances in Anatomic Pathology, 2013, 20, 217-226.	2.4	60
1154	Indicators of the standard of care for melanoma. Melanoma Research, 2013, 23, 283-289.	0.6	9
1155	A large retrospective multicenter study of vaginal melanomas. Melanoma Research, 2013, 23, 138-146.	0.6	24

#	Article	IF	Citations
1156	Implementing Genomic Medicine in Pathology. Advances in Anatomic Pathology, 2013, 20, 238-244.	2.4	20
1157	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Research, 2013, 23, 366-372.	0.6	57
1158	What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Research, 2013, 23, 167-174.	0.6	17
1159	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. Journal of Clinical Oncology, 2013, 31, 482-489.	0.8	439
1160	Targeted therapies and clinical trials in ovarian cancer. Annals of Oncology, 2013, 24, x59-x63.	0.6	11
1161	The burden of metastatic melanoma. Melanoma Research, 2013, 23, 159-166.	0.6	17
1162	New developments in biomarkers for melanoma. Current Opinion in Oncology, 2013, 25, 145-151.	1.1	20
1163	High-throughput digital PCR in a low-cost and practical format introduction. Reviews in Medical Microbiology, 2013, 24, 89-93.	0.4	4
1164	The MEK1/2 Inhibitor AS703026 Circumvents Resistance to the BRAF Inhibitor PLX4032 in Human Malignant Melanoma Cells. American Journal of the Medical Sciences, 2013, 346, 494-498.	0.4	16
1165	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 1767-1774.	0.8	335
1166	Targeted therapies of solid cancers. Current Opinion in Oncology, 2013, 25, 296-304.	1.1	21
1167	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 159-164.	0.6	27
1168	BRAF-targeted therapy and immune responses to melanoma. OncoImmunology, 2013, 2, e24462.	2.1	12
1169	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. OncoImmunology, 2013, 2, e26615.	2.1	97
1170	Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. Oncologist, 2013, 18, 1262-1269.	1.9	13
1171	Ipilimumab-Induced Hepatitis C Viral Suppression. Journal of Clinical Oncology, 2013, 31, e307-e308.	0.8	21
1172	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 1211-1218.	0.8	182
1173	Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clinical Cancer Research, 2013, 19, 3143-3152.	3.2	187

#	Article	IF	Citations
1174	Is there a future for adoptive cell transfer in melanoma patients?. OncoImmunology, 2013, 2, e26098.	2.1	7
1175	Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. Clinical Cancer Research, 2013, 19, 4792-4800.	3.2	330
1176	Editor's snapshot: an unexpected duodenal finding. Gut, 2013, 62, 1590-1590.	6.1	0
1177	Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma. Molecular Cancer Therapeutics, 2013, 12, 901-912.	1.9	52
1178	Long-term survival and outcome of patients originally givenMycobacterium vaccaefor metastatic malignant melanoma. Human Vaccines and Immunotherapeutics, 2013, 9, 2427-2433.	1.4	12
1179	Unintentional Weakness of Cancers: The MEKâ€“ERK Pathway as a Double-Edged Sword. Molecular Cancer Research, 2013, 11, 1125-1128.	1.5	2
1180	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 2013, 12, 1332-1342.	1.9	71
1181	Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity. Cancer Research, 2013, 73, 4050-4060.	0.4	116
1182	Successful Treatment With Vemurafenib in BRAF V600Kâ€“Positive Cerebral Melanoma Metastasis. JAMA Dermatology, 2013, 149, 642.	2.0	7
1183	Brainstem Ganglioglioma Successfully Treated With Vemurafenib. Journal of Clinical Oncology, 2013, 31, e159-e160.	0.8	120
1184	P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma. Journal of the National Cancer Institute, 2013, 105, 606-607.	3.0	73
1185	Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit. Oncologist, 2013, 18, 1315-1320.	1.9	20
1186	Identification of a Novel ComplexBRAFMutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma. JAMA Dermatology, 2013, 149, 1403.	2.0	20
1187	Vemurafenib and Radiosensitization. JAMA Dermatology, 2013, 149, 855.	2.0	83
1188	BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors. Molecular Cancer Therapeutics, 2013, 12, 2950-2961.	1.9	18
1189	Taming the Wild-Types: Targeting PAK1 in Melanomas That Lack BRAF Mutations. Journal of the National Cancer Institute, 2013, 105, 591-592.	3.0	4
1190	Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Research, 2013, 73, 7043-7055.	0.4	102
1191	Another Option in Our KIT of Effective Therapies for Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 3173-3175.	0.8	22

#	Article	IF	Citations
1192	Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary. Journal of Clinical Oncology, 2013, 31, e237-e239.	0.8	31
1193	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2013, 19, 4868-4878.	3.2	167
1194	Cancer Drugs in the United States: Justum Pretiumâ€"The Just Price. Journal of Clinical Oncology, 2013, 31, 3600-3604.	0.8	276
1195	Conjunctival Melanomas Harbor BRAF and NRAS Mutationsâ€"Response. Clinical Cancer Research, 2013, 19, 6331-6332.	3.2	19
1196	Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Annals of Oncology, 2013, 24, 1112-1119.	0.6	62
1197	The FBXO4 Tumor Suppressor Functions as a Barrier to Braf^{V600E}-Dependent Metastatic Melanoma. Molecular and Cellular Biology, 2013, 33, 4422-4433.	1.1	32
1198	Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery, 2013, 3, 52-67.	7.7	104
1199	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. Clinical Cancer Research, 2013, 19, 4931-4940.	3.2	21
1200	From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical Focus, 2013, 34, E2.	1.0	59
1201	Cell-Based Therapeutics: The Next Pillar of Medicine. Science Translational Medicine, 2013, 5, 179ps7.	5.8	337
1202	Vemurafenib Potently Induces Endoplasmic Reticulum Stressâ€"Mediated Apoptosis in BRAFV600E Melanoma Cells. Science Signaling, 2013, 6, ra7.	1.6	114
1203	New treatment approaches in melanoma: current research and clinical prospects. Therapeutic Advances in Medical Oncology, 2013, 5, 73-80.	1.4	19
1204	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Therapeutic Advances in Medical Oncology, 2013, 5, 105-118.	1.4	45
1205	Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth. Clinical Cancer Research, 2013, 19, 4383-4391.	3.2	33
1206	Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine. Journal of Leukemia (Los Angeles, Calif), 2013, 01, 1000124.	0.1	21
1207	Methodological assessment of HCC literature. Annals of Oncology, 2013, 24, 6-14.	0.6	1
1208	BRAF in Melanoma: Current Strategies and Future Directions. Clinical Cancer Research, 2013, 19, 4326-4334.	3.2	76
1209	BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults. Journal of Clinical Oncology, 2013, 31, e233-e236.	0.8	67

#	Article	IF	Citations
1210	BRAFV600E mutation in adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 1105-1106.	0.6	4
1211	Vemurafenib As Neoadjuvant Treatment for Unresectable Regional Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, e251-e253.	0.8	33
1212	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Therapeutic Advances in Medical Oncology, 2013, 5, 278-285.	1.4	26
1213	Vemurafenib-Induced Cardiac Tamponade: A Rare But Potentially Life-Threatening Complication. Journal of Clinical Oncology, 2013, 31, e364-e366.	0.8	12
1214	American Society of Clinical Oncology 2013 Top Five List in Oncology. Journal of Clinical Oncology, 2013, 31, 4362-4370.	0.8	126
1215	Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment. Clinical Cancer Research, 2013, 19, 480-490.	3.2	105
1216	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research, 2013, 19, 2257-2264.	3.2	136
1217	An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance. Cancer Discovery, 2013, 3, 260-263.	7.7	37
1218	Novel cancer therapies: treatments driven by tumour biology. Postgraduate Medical Journal, 2013, 89, 652-658.	0.9	16
1219	Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. Melanoma Research, 2013, 23, 21-26.	0.6	11
1220	Hepatic resection for metastatic melanoma in The Netherlands. Melanoma Research, 2013, 23, 27-32.	0.6	11
1221	Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma. Melanoma Research, 2013, 23, 152-158.	0.6	2
1222	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 351-353.	0.6	7
1223	Clinicopathological relevance of BRAF mutations in human cancer. Pathology, 2013, 45, 346-356.	0.3	131
1224	Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Annals of Oncology, 2013, 24, 2158-2165.	0.6	14
1225	Survivin promotion of melanoma metastasis requires upregulation of Î± 5 integrin. Carcinogenesis, 2013, 34, 2137-2144.	1.3	36
1226	The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Frontiers in Oncology, 2013, 3, 228.	1.3	95
1227	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Frontiers in Immunology, 2013, 4, 363.	2.2	70

#	Article	IF	Citations
1228	Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo. Pharmaceuticals, 2013, 6, 1429-1450.	1.7	40
1229	Isolated pancreatic metastasis from malignant melanoma: Is pancreatectomy worthwile?. Journal of Surgical Technique and Case Report, 2013, 5, 82.	0.2	7
1230	Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S9565.	0.6	8
1231	Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaF^{V600E} Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 655-664.	1.3	158
1232	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine, 2013, 5, 196ra98.	5.8	124
1233	Immunotherapy in the management of melanoma: current status. ImmunoTargets and Therapy, 2013, 2, 1.	2.7	3
1234	Eruptive Squamous Cell Carcinomas after Vemurafenib Therapy. Journal of Cutaneous Medicine and Surgery, 2013, 17, 419-422.	0.6	14
1235	Ipilimumab: A First-in-Classâ€‰â€‰T-Cell Potentiator for Metastatic Melanoma. Journal of Skin Cancer, 2013, 2013, 1-8.	0.5	15
1236	Melanoma: From Melanocyte to Genetic Alterations and Clinical Options. Scientifica, 2013, 2013, 1-22.	0.6	80
1237	Latest Approved Therapies for Metastatic Melanoma: What Comes Next?. Journal of Skin Cancer, 2013, 2013, 1-10.	0.5	26
1238	Melanoma-Targeted Chemothermotherapy andIn SituPeptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles. Journal of Skin Cancer, 2013, 2013, 1-12.	0.5	13
1239	A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine, 2013, 2013, 1-3.	0.2	7
1240	Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting. Frontiers in Oncology, 2013, 3, 205.	1.3	3
1241	Comparison of ThreeBRAFMutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. Korean Journal of Pathology, 2013, 47, 348.	1.2	10
1242	No human virus sequences detected by nextâ€generation sequencing in benign verrucous skin tumors occurring in <scp>BRAF</scp>â€inhibitorâ€treated patients. Experimental Dermatology, 2013, 22, 725-729.	1.4	24
1243	There is a world beyond protein mutations: the role of nonâ€coding <scp>RNA</scp>s in melanomagenesis. Experimental Dermatology, 2013, 22, 303-306.	1.4	4
1244	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. Clinical Pharmacology and Therapeutics, 2013, 95, 24-31.	2.3	75
1245	Genotyping by Induced FÃ¶rster Resonance Energy Transfer (iFRET) Mechanism and Simultaneous Mutation Scanning. Human Mutation, 2013, 34, n/a-n/a.	1.1	2

#	Article	IF	Citations
1246	The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort. British Journal of Dermatology, 2013, 169, 1049-1055.	1.4	97
1247	Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. British Journal of Dermatology, 2013, 169, 934-938.	1.4	32
1248	Vemurafenib-Associated Pancreatitis: Case Report. Pharmacotherapy, 2013, 33, e43-e44.	1.2	13
1249	Malignant Melanoma in Pigmented Skin: Does the Current Interventional Model Fit a Different Clinical, Histologic, and Molecular Entity?. Dermatologic Surgery, 2013, 39, 1291-1303.	0.4	12
1250	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell and Melanoma Research, 2013, 26, 646-653.	1.5	39
1251	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatologic Therapy, 2013, 26, 135-148.	0.8	43
1252	Case of interdigital pilonidal sinus in a dog groomer. Journal of Dermatology, 2013, 40, 1051-1052.	0.6	7
1253	The current and future role of sequence-based analysis in prostate cancer treatment. Personalized Medicine, 2013, 10, 257-273.	0.8	0
1254	Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. Australasian Journal of Dermatology, 2013, 54, 163-172.	0.4	13
1255	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
1256	Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy. British Journal of Dermatology, 2013, 168, 1230-1235.	1.4	19
1257	<scp>DNA</scp> repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell and Melanoma Research, 2013, 26, 805-816.	1.5	22
1258	A costly revolution for a subgroup of patients with metastatic melanoma. British Journal of Dermatology, 2013, 168, 467-470.	1.4	3
1259	Surgical Management of the Patient with Metastatic Melanoma to the Heart. Journal of Cardiac Surgery, 2013, 28, 124-128.	0.3	7
1260	Mutations of theBRAFgene in human cancer, by DaviesetÂal. (Nature2002; 417: 949-54). Clinical and Experimental Dermatology, 2013, 38, 222-223.	0.6	55
1261	Paradoxical oncogenesis: are all <scp>BRAF</scp> inhibitors equal?. Pigment Cell and Melanoma Research, 2013, 26, 611-615.	1.5	44
1262	That which does not kill me makes me stronger; combining <scp>ERK</scp>1/2 pathway inhibitors and <scp>BH</scp>3 mimetics to kill tumour cells and prevent acquired resistance. British Journal of Pharmacology, 2013, 169, 1708-1722.	2.7	19
1263	Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Medicine, 2013, 2, 899-906.	1.3	256

#	Article	IF	Citations
1265	Impact of <scp>MET</scp> expression on outcome in <scp>BRAF</scp>^{V600E/K} advanced melanoma. Histopathology, 2013, 63, 351-361.	1.6	14
1266	Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 2013, 169, 1310-1313.	1.4	41
1267	Second primary melanomas on treatment with vemurafenib: reply from the authors. British Journal of Dermatology, 2013, 168, 888-889.	1.4	2
1268	Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2013, 2, 76-85.	1.3	126
1269	Malignancies of the eyelid: a review of primary and metastatic cancers. International Journal of Dermatology, 2013, 52, 903-926.	0.5	9
1270	Concerns regardingBRAFtesting algorithm: reply from authors. British Journal of Dermatology, 2013, 169, 1168-1170.	1.4	0
1271	Overcoming melanoma drug resistance through metabolic targeting?. Pigment Cell and Melanoma Research, 2013, 26, 793-795.	1.5	0
1272	Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma. Journal of Dermatology, 2013, 40, 1050-1051.	0.6	2
1273	Vemurafenib: an unusual <scp>UVA</scp>â€induced photosensitivity. Experimental Dermatology, 2013, 22, 297-298.	1.4	76
1274	Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases. British Journal of Dermatology, 2013, 169, 172-176.	1.4	23
1275	Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. Journal of Cutaneous Pathology, 2013, 40, 667-669.	0.7	33
1276	Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma. Dermatologic Surgery, 2013, 39, 981-987.	0.4	13
1277	Inhibition of CXCR4â€“CXCL12 chemotaxis in melanoma by AMD11070. British Journal of Cancer, 2013, 108, 1634-1640.	2.9	55
1278	Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. Journal of Clinical Oncology, 2013, 31, e220-e222.	0.8	70
1279	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 2013, 4, 1508.	5.8	67
1280	Rapid response of biallelic <scp>BRAF</scp><scp>V</scp>600<scp>E</scp> mutated hairy cell leukaemia to low dose vemurafenib. British Journal of Haematology, 2013, 161, 150-153.	1.2	60
1281	Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery, 2013, 3, 862-869.	7.7	202
1282	Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. Journal of Clinical Oncology, 2013, 31, e300-e303.	0.8	67

#	Article	IF	Citations
1283	Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. Journal of Clinical Oncology, 2013, 31, e341-e344.	0.8	98
1284	Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation. Journal of Clinical Oncology, 2013, 31, e351-e352.	0.8	60
1285	MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells. Cancer Research, 2013, 73, 4039-4049.	0.4	40
1286	Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3149-3164.	1.8	265
1287	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma. Molecular Therapy, 2013, 21, 1456-1463.	3.7	88
1288	Vemurafenib enhances MHC induction inBRAF^{V600E}homozygous melanoma cells. OncoImmunology, 2013, 2, e22890.	2.1	127
1289	Treatment patterns and outcomes in patients with advanced melanoma in France. Current Medical Research and Opinion, 2013, 29, 1297-1305.	0.9	10
1290	The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology, 2013, 6, 381-395.	1.4	33
1291	Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. OncoImmunology, 2013, 2, e24320.	2.1	40
1292	The immunomodulatory effects of bevacizumab on systemic immunity in patients withÂmetastatic melanoma. OncoImmunology, 2013, 2, e24436.	2.1	37
1294	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Molecular Cancer Therapeutics, 2013, 12, 2367-2377.	1.9	53
1295	The mutational landscape of phosphorylation signaling in cancer. Scientific Reports, 2013, 3, 2651.	1.6	149
1296	Phenformin enhances the therapeutic benefit of BRAF ^{V600E} inhibition in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18226-18231.	3.3	197
1297	Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Journal of Medical Economics, 2013, 16, 202-212.	1.0	44
1298	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death and Disease, 2013, 4, e914-e914.	2.7	55
1299	Regulatory agency struggles under the weight of genomic data. Nature Medicine, 2013, 19, 385-385.	15.2	2
1300	KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. British Journal of Cancer, 2013, 109, 559-564.	2.9	118
1301	Adoptive T-cell transfer in melanoma. Immunotherapy, 2013, 5, 79-90.	1.0	21

#	Article	IF	Citations
1302	Rare mutations in non-small-cell lung cancer. Future Oncology, 2013, 9, 699-711.	1.1	23
1303	<scp>BRAF</scp> mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and metaâ€analysis. Colorectal Disease, 2013, 15, e711-8.	0.7	96
1304	Vemurafenib for Leptomeningeal Melanomatosis. Journal of Clinical Oncology, 2013, 31, e173-e174.	0.8	49
1305	Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers. The Enzymes, 2013, 34 Pt. B, 67-106.	0.7	8
1306	Conformation-Specific Inhibitors of Raf Kinases. The Enzymes, 2013, 34 Pt. B, 41-66.	0.7	3
1307	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
1308	Overcoming Resistance to MAPK Pathway Inhibitors. Journal of the National Cancer Institute, 2013, 105, 9-10.	3.0	10
1309	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 373-379.	0.8	199
1310	Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. Oncologist, 2013, 18, 314-322.	1.9	192
1311	Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clinical Cancer Research, 2013, 19, 1009-1020.	3.2	134
1312	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	3.0	51
1313	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 2013, 133, 509-517.	0.3	156
1314	Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncology, 2013, 9, 1161-1170.	1.1	24
1315	Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Annals of Oncology, 2013, 24, 1691-1697.	0.6	172
1316	Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biology and Therapy, 2013, 14, 146-154.	1.5	18
1317	A moving target: challenges in treating BRAF-mutant colorectal cancer. Colorectal Cancer, 2013, 2, 197-204.	0.8	0
1318	Melanoma treatment: where are we now and whatâ€™s on the horizon?. Clinical Practice (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
1320	Malignes Melanom S3-Leitlinie â€œDiagnostik, Therapie und Nachsorge des Melanomsâ€• JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-126.	0.4	9

#	Article	IF	Citations
1321	Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€• JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.4	122
1322	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, 121, 1495-1500.	0.6	479
1323	Saving orphans: BRAF targeting of histiocytosis. Blood, 2013, 121, 1487-1488.	0.6	9
1324	Advances in the treatment of late stage melanoma. BMJ, The, 2013, 346, f1265-f1265.	3.0	6
1325	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
1326	Melanoma Mutagenesis and Aberrant Cell Signaling. Cancer Control, 2013, 20, 261-281.	0.7	29
1327	New Targeted Therapies in Melanoma. Cancer Control, 2013, 20, 282-288.	0.7	11
1328	Novel Treatments for Melanoma Brain Metastases. Cancer Control, 2013, 20, 298-306.	0.7	14
1329	Vemurafenib-Induced Pulmonary Injury. Onkologie, 2013, 36, 685-686.	1.1	7
1330	Molecular Profiling for Breast Cancer: A Comprehensive Review. Biomarkers in Cancer, 2013, 5, BIC.S9455.	3.6	152
1331	A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Scientific Reports, 2013, 3, 1659.	1.6	36
1332	Malignant melanoma rather than malignant cutaneous melanoma?. European Journal of Gastroenterology and Hepatology, 2013, 25, 503-506.	0.8	3
1333	Update in Hematology and Oncology: Evidence Published in 2012. Annals of Internal Medicine, 2013, 158, 755.	2.0	0
1334	Vemurafenib-Induced Eccrine Squamous Syringometaplasia. Dermatology, 2013, 226, 362-364.	0.9	9
1335	Vemurafenib Treatment ofBRAFV600E-Mutated Malignant Peripheral Nerve Sheath Tumor. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1466-1470.	2.3	23
1336	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	0.9	4
1337	IdentifyingBRAFandKITmutations in melanoma. Expert Review of Dermatology, 2013, 8, 171-176.	0.3	1
1338	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. JAMA Dermatology, 2013, 149, 322.	2.0	32

#	Article	IF	Citations
1339	Patient Derived Cell Culture and Isolation of CD133⁺ Putative Cancer Stem Cells from Melanoma. Journal of Visualized Experiments, 2013, , e50200.	0.2	16
1340	Predicting Disease Progression After Regional Therapy for In-Transit Melanoma. JAMA Surgery, 2013, 148, 493.	2.2	10
1342	Comparison and validation of genomic predictors for anticancer drug sensitivity. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 597-602.	2.2	70
1343	Mutation analysis in malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 2-10.	0.4	2
1344	Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. American Journal of Dermatopathology, 2013, 35, 125-128.	0.3	5
1345	What does the future hold for uveal melanoma, a historically untreatable disease?. Clinical Investigation, 2013, 3, 1097-1099.	0.0	0
1346	ToBRAFor Not toBRAF: Is That Even a Question Anymore?. Journal of Neuropathology and Experimental Neurology, 2013, 72, 2-7.	0.9	98
1347	Current Advances in Therapy for Metastatic Melanoma. Current Cancer Therapy Reviews, 2013, 9, 8-23.	0.2	0
1348	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology, 2013, 37, 61-65.	2.1	289
1349	S2k Kurzleitlinie - Plattenepithelkarzinom der Haut. JDDG - Journal of the German Society of Dermatology, 2013, 11, 39-47.	0.4	16
1350	Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation. American Journal of Surgical Pathology, 2013, 37, 685-698.	2.1	229
1351	S3â€Guideline â€œDiagnosis, therapy and followâ€up of melanomaâ€•â€“ short version. JDDG - Journal of the German Society of Dermatology, 2013, 11, 563-602.	0.4	63
1352	Mutationsanalysen im malignen Melanom. JDDG - Journal of the German Society of Dermatology, 2013, 11, 2-11.	0.4	11
1353	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. Clinical Cancer Research, 2013, 19, 4347-4358.	3.2	81
1355	Managing Malignant Melanoma. Plastic and Reconstructive Surgery, 2013, 132, 446e-460e.	0.7	53
1356	Brief S2k guidelines â€“ Cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2013, 11, 37-45.	0.4	50
1357	XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anti-Cancer Drugs, 2013, 24, 181-188.	0.7	46
1358	Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions. American Journal of Surgical Pathology, 2013, 37, 413-420.	2.1	99

#	Article	IF	Citations
1359	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013, 123, 2257-2267.	3.9	124
1360	Evolutionary dynamics of cancer in response to targeted combination therapy. ELife, 2013, 2, e00747.	2.8	516
1361	Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. European Journal of Dermatology, 2013, 23, 118-118.	0.3	14
1362	Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis. Biomedical Reports, 2013, 1, 365-368.	0.9	13
1363	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica, 2013, 98, 635-639.	1.7	75
1365	Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles. International Journal of Oncology, 2013, 43, 919-926.	1.4	6
1366	Progress in the Management of Melanoma in 2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 645-648.	2.3	17
1367	Melanoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 395-407.	2.3	134
1369	New and emerging treatment options for biliary tract cancer. OncoTargets and Therapy, 2013, 6, 1545.	1.0	17
1370	Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. Cancer Imaging, 2013, 13, 306-313.	1.2	35
1371	Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Management and Research, 2013, 5, 243.	0.9	17
1372	Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. International Journal of Nanomedicine, 2013, 9, 43.	3.3	12
1373	Molecular targeted therapies in metastatic melanoma. Pharmacogenomics and Personalized Medicine, 2013, 6, 49.	0.4	24
1374	Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma. International Journal of Biological Sciences, 2013, 9, 303-312.	2.6	27
1375	Synchronous BRAFV600E and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. OncoTargets and Therapy, 2013, 6, 1649.	1.0	11
1376	Melanoma â€" Epidemiology, Genetics and Risk Factors. , 2013, , .		2
1377	Inhibitory Effect of Melanoma Differentiation Associated Gene-7/Interleukin-24 on Invasion In Vitro of Human Melanoma Cancer Cells. Journal of Korean Medical Science, 2013, 28, 833.	1.1	9
1378	Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient. Case Reports in Oncology, 2013, 6, 285-288.	0.3	4

#	Article	IF	Citations
1379	Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib. PLoS ONE, 2013, 8, e53733.	1.1	49
1380	RASopathic Skin Eruptions during Vemurafenib Therapy. PLoS ONE, 2013, 8, e58721.	1.1	72
1381	A Synergetic Screening Approach with Companion Effector for Combination Therapy: Application to Retinoblastoma. PLoS ONE, 2013, 8, e59156.	1.1	19
1382	Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines. PLoS ONE, 2013, 8, e60339.	1.1	6
1383	NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo. PLoS ONE, 2013, 8, e69064.	1.1	42
1384	Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis. PLoS ONE, 2013, 8, e69604.	1.1	94
1385	Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing. PLoS ONE, 2013, 8, e70826.	1.1	97
1386	Global Phosphotyrosine Proteomics Identifies PKCÎ´ as a Marker of Responsiveness to Src Inhibition in Colorectal Cancer. PLoS ONE, 2013, 8, e80207.	1.1	15
1387	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. PLoS ONE, 2013, 8, e81624.	1.1	54
1388	Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma. PLoS ONE, 2013, 8, e57160.	1.1	53
1389	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Frontiers in Pharmacology, 2013, 4, 3.	1.6	20
1390	Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology, 2013, 4, 57.	1.6	165
1391	Genetics of melanoma. Frontiers in Genetics, 2012, 3, 330.	1.1	27
1392	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology, 2013, 3, 54.	1.3	27
1393	Drug-Diagnostics Co-Development in Oncology. Frontiers in Oncology, 2013, 3, 315.	1.3	17
1394	Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine. Journal of Oncology, 2013, 2013, 1-12.	0.6	34
1395	Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmacogenomics and Personalized Medicine, 2013, 6, 113.	0.4	16
1396	Signal Transduction in Human Cutaneous Melanoma and Target Drugs. Current Cancer Drug Targets, 2013, 13, 843-866.	0.8	56

#	Article	IF	Citations
1397	The Menace of Melanoma: A Photodynamic Approach to Adjunctive Cancer Therapy. , 0, , .		6
1398	Acquired Resistance to Targeted MAPK Inhibition in Melanoma. , 2013, , .		0
1399	Drug resistance: as complex and diverse as the disease itself. , 0, , 921-928.		0
1400	Ras. , 0, , 258-271.		0
1401	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0
1402	BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget, 2013, 4, 310-315.	0.8	140
1403	Histiocytoses. , 2013, , 685-712.		0
1404	Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse. European Journal of Dermatology, 2013, 23, 702-703.	0.3	0
1405	Management of Brain Metastasis in Melanoma Patients. , 0, , .		0
1406	Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment. , 0, , .		0
1407	Current Therapies and New Pharmacologic Targets for Metastatic Melanoma. , 2013, , .		1
1408	Targeted Therapies in Melanoma: Successes and Pitfalls. , 0, , .		1
1409	Treating Metastatic Melanoma in 2014: What Just Happened and What Is Next?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 16-19.	1.8	1
1410	Frontline Approach to Metastatic BRAF-Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e412-e421.	1.8	4
1411	Conjunctival Melanoma and BRAF Inhibitor Therapy. Journal of Clinical & Experimental Ophthalmology, 2014, 05, .	0.1	26
1412	Early Phase Trial Designs and Endpoints for Targeted Therapies in Rare Genotype Subsets. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e107-e110.	1.8	3
1413	BRAF inhibitorâ€“associated ERK activation drives development of chronic lymphocytic leukemia. Journal of Clinical Investigation, 2014, 124, 5074-5084.	3.9	56
1414	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Management and Research, 2014, 6, 279.	0.9	23

#	Article	IF	Citations
1415	Benign Melanocytic Lesions and Melanoma. , 2014, , 1182-1192.		0
1416	Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PLoS ONE, 2014, 9, e85004.	1.1	67
1417	Survival According to BRAF-V600 Tumor Mutations â€“ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194.	1.1	42
1418	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. PLoS ONE, 2014, 9, e89218.	1.1	18
1419	Store-Operated Ca2+ Entry (SOCE) Regulates Melanoma Proliferation and Cell Migration. PLoS ONE, 2014, 9, e89292.	1.1	130
1420	Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFÎ²) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. PLoS ONE, 2014, 9, e90353.	1.1	328
1421	Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors. PLoS ONE, 2014, 9, e93676.	1.1	32
1422	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e95219.	1.1	140
1423	A Natural Bacterial-Derived Product, the Metalloprotease Arazyme, Inhibits Metastatic Murine Melanoma by Inducing MMP-8 Cross-Reactive Antibodies. PLoS ONE, 2014, 9, e96141.	1.1	17
1424	Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS ONE, 2014, 9, e107255.	1.1	35
1425	Clonal Architectures and Driver Mutations in Metastatic Melanomas. PLoS ONE, 2014, 9, e111153.	1.1	69
1427	Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma. Journal of Managed Care Pharmacy, 2014, 20, 346-356.	2.2	57
1429	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug, Healthcare and Patient Safety, 2014, 6, 77.	1.0	32
1430	Bilateral Panuveitis in a Patient on Vemurafenib BRAF Inhibitor Therapy for Stage IV Melanoma. European Journal of Ophthalmology, 2014, 24, 629-632.	0.7	13
1431	Role of HGFâ€“MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines, 2014, 2, 345-358.	1.4	30
1432	Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Switzerland), 2014, 2, 60-73.	1.0	7
1433	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	2.2	127
1434	Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer. Journal of Personalized Medicine, 2014, 4, 402-411.	1.1	0

#	Article	IF	Citations
1435	A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma. Journal of Personalized Medicine, 2014, 4, 448-458.	1.1	5
1436	BRAF mutation in hairy cell leukemia. Oncology Reviews, 2014, 8, 253.	0.8	12
1437	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2014, 8, 775.	2.0	32
1438	Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Design, Development and Therapy, 2014, 8, 255.	2.0	26
1439	Cutaneous melanoma: new advances in treatment. Anais Brasileiros De Dermatologia, 2014, 89, 301-310.	0.5	28
1440	Profile of selumetinib and its potential in the treatment of melanoma. OncoTargets and Therapy, 2014, 7, 1631.	1.0	15
1441	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. Oncology Reports, 2014, 32, 808-814.	1.2	6
1443	Systematic Review: Surgery for Patients with Metastatic Melanoma during Active Treatment with Ipilimumab. American Surgeon, 2014, 80, 805-810.	0.4	7
1444	An incidental finding of a nodal recurrence of cutaneous malignant melanoma after a 45-year disease-free period. BMJ Case Reports, 2014, 2014, bcr2014204289-bcr2014204289.	0.2	3
1445	Pediatric Melanoma: The Whole (Genome) Story. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e432-e435.	1.8	21
1449	Management of Vulvar and Vaginal Melanomas: Current and Future Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e277-e281.	1.8	45
1450	Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69.	1.8	38
1451	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E748-57.	3.3	90
1452	AACR Cancer Progress Report 2014. Clinical Cancer Research, 2014, 20, S1-S112.	3.2	48
1453	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. Personalized Medicine, 2014, 11, 545-558.	0.8	8
1454	Efficacy of solubilized vemurafenib administered via nasogastric tube. Future Oncology, 2014, 10, 165-170.	1.1	7
1455	FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. Clinical Cancer Research, 2014, 20, 4994-5000.	3.2	164
1456	Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?. Personalized Medicine, 2014, 11, 381-393.	0.8	2

#	Article	IF	Citations
1457	Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica, 2014, 44, 352-368.	0.5	22
1458	Personalized Cancer Therapy. , 2014, , 671-824.		1
1459	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy, 2014, 14, 663-686.	1.4	17
1460	Cancer In Silico Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. Molecular Cancer Therapeutics, 2014, 13, 3230-3240.	1.9	21
1461	Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. Future Oncology, 2014, 10, 1559-1570.	1.1	17
1462	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. Expert Review of Molecular Diagnostics, 2014, 14, 439-452.	1.5	69
1463	Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. British Journal of Dermatology, 2014, 171, 1529-1532.	1.4	25
1465	Personalized medicine for chronic, complex diseases: chronic obstructive pulmonary disease as an example. Personalized Medicine, 2014, 11, 669-679.	0.8	9
1466	Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression. Cancer Research, 2014, 74, 2499-2509.	0.4	43
1467	The Minority Report: Targeting the Rare Oncogenes in NSCLC. Current Treatment Options in Oncology, 2014, 15, 644-657.	1.3	12
1468	Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations. Memo - Magazine of European Medical Oncology, 2014, 7, 181-186.	0.3	1
1469	RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 2014, 14, 808.	1.1	35
1470	Prospects for MEK inhibitors for treating cancer. Expert Opinion on Drug Safety, 2014, 13, 483-495.	1.0	17
1471	Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. Cancer Biology and Therapy, 2014, 15, 826-831.	1.5	24
1472	The clinical response to vemurafenib in a patient with a rare BRAF V600DK601del mutation-positive melanoma. BMC Cancer, 2014, 14, 727.	1.1	19
1473	Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 661-672.	1.4	61
1475	Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging, 2014, 14, 30.	1.2	16
1476	Dabrafenib for the treatment ofBRAFV600-positive melanoma: a safety evaluation. Expert Opinion on Drug Safety, 2014, 13, 1249-1258.	1.0	15

#	Article	IF	Citations
1477	To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 2014, 134, 1200-1201.	0.3	0
1478	Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. British Journal of Cancer, 2014, 111, 640-645.	2.9	99
1479	Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. British Journal of Cancer, 2014, 111, 1249-1254.	2.9	66
1480	Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. Journal of Investigative Dermatology, 2014, 134, 1468-1470.	0.3	37
1481	Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1679-1680.	2.9	1
1482	Molecular pathology of cutaneous melanoma. Melanoma Management, 2014, 1, 151-164.	0.1	4
1483	Successes and Limitations of Targeted Cancer Therapy in Melanoma. Progress in Tumor Research, 2014, 41, 78-88.	0.1	4
1484	Activities of multiple cancer-related pathways are associated withBRAFmutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle, 2014, 13, 208-219.	1.3	31
1485	Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncology, 2014, 10, 429-442.	1.1	14
1486	External quality assessment ofBRAFmolecular analysis in melanoma. Journal of Clinical Pathology, 2014, 67, 120-124.	1.0	12
1487	Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib. JDDG - Journal of the German Society of Dermatology, 2014, 12, 151-154.	0.4	0
1488	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Modern Pathology, 2014, 27, 1028-1034.	2.9	96
1489	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	2.9	18
1490	Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 2014, 33, 4756-4766.	2.6	29
1491	A Cancer Theory Kerfuffle Can Lead to New Lines of Research. Journal of the National Cancer Institute, 2014, 107, dju405-dju405.	3.0	66
1492	Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. Cell Death and Differentiation, 2014, 21, 507-520.	5.0	37
1493	Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Therapeutic Advances in Medical Oncology, 2014, 6, 262-266.	1.4	36
1494	Clinically relevant cancer biomarkers and pharmacogenetic assays. Journal of Oncology Pharmacy Practice, 2014, 20, 65-72.	0.5	12

#	Article	IF	Citations
1495	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. Cancer Investigation, 2014, 32, 144-149.	0.6	90
1496	ERBB3 is required for metastasis formation of melanoma cells. Oncogenesis, 2014, 3, e110-e110.	2.1	37
1497	Targeting molecular addictions in cancer. British Journal of Cancer, 2014, 111, 2033-2038.	2.9	35
1498	The role of systemic and targeted therapies in brain metastases. Expert Review of Anticancer Therapy, 2014, 14, 93-103.	1.1	6
1499	The immune escape in melanoma: role of the impaired dendritic cell function. Expert Review of Clinical Immunology, 2014, 10, 1395-1404.	1.3	56
1500	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. Immunotherapy, 2014, 6, 1177-1186.	1.0	6
1501	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature Communications, 2014, 5, 3116.	5.8	521
1502	Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics, 2014, 15, 1771-1790.	0.6	66
1503	Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. Postgraduate Medical Journal, 2014, 90, 228-235.	0.9	4
1504	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death and Disease, 2014, 5, e1434-e1434.	2.7	20
1505	Immunohistochemical detection of the <scp>BRAF V600E</scp> mutation in melanoma patients with monoclonal antibody <scp>VE1</scp>. Pathology International, 2014, 64, 601-606.	0.6	8
1507	In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways. International Journal of Molecular Sciences, 2014, 15, 8773-8794.	1.8	25
1508	Localized insulin-dependent amyloidosis with scar-tissue formation. Journal of the American Academy of Dermatology, 2014, 71, e160-e162.	0.6	6
1509	Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Reports in Oncological Medicine, 2014, 2014, 1-6.	0.2	35
1510	High Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor Vemurafenib. Acta Dermato-Venereologica, 2014, 94, 517-520.	0.6	23
1511	Vemurafenib. Recent Results in Cancer Research, 2014, 201, 215-225.	1.8	30
1512	Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Frontiers in Oncology, 2014, 4, 123.	1.3	147
1513	Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy. Journal of the National Cancer Institute, 2014, 106, .	3.0	38

#	Article	IF	Citations
1514	Vaccines against Cancer. , 2014, , .		0
1515	CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecologic Oncology, 2014, 135, 149-155.	0.6	52
1516	Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of ErdheimÃ¢â‚¬â€œChester Disease. Frontiers in Immunology, 2014, 5, 281.	2.2	40
1517	Resistance to dual blockade of the kinases PI3K and mTOR in KRAS -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Science Signaling, 2014, 7, ra107.	1.6	30
1518	The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Nonâ€“Small Cell Lung Cancer Model Mice. Molecular Cancer Therapeutics, 2014, 13, 329-340.	1.9	58
1519	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 2014, 4, 94-109.	7.7	782
1520	Presence of Human Polyomavirus 6 in Mutation-Specific BRAF Inhibitorâ€“Induced Epithelial Proliferations. JAMA Dermatology, 2014, 150, 1180.	2.0	51
1521	Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas. JAMA Dermatology, 2014, 150, 1306.	2.0	142
1522	Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Molecular and Cellular Proteomics, 2014, 13, 1844-1854.	2.5	52
1523	A Multiplex Technology Platform for the Rapid Analysis of Clinically Actionable Genetic Alterations and Validation for BRAF p.V600E Detection in 1549 Cytologic and Histologic Specimens. Archives of Pathology and Laboratory Medicine, 2014, 138, 371-378.	1.2	11
1524	Melanoma of the oral cavity: pathogenesis, dermoscopy, clinical features, staging and management. Journal of Dermatological Case Reports, 2014, 8, 60-6.	1.1	28
1525	BRAF and beyond: Tailoring strategies for the individual melanoma patient. Journal of Carcinogenesis, 2014, 13, 1.	2.5	19
1526	Cutaneous Adverse Events during Vemurafenib Therapy. Journal of Cutaneous Medicine and Surgery, 2014, 18, 223-228.	0.6	10
1527	â€˜Druggableâ€™ alterations detected by Ion Torrent in metastatic colorectal cancer patients. Oncology Letters, 2014, 7, 1761-1766.	0.8	10
1528	Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Expert Review of Clinical Immunology, 2014, 10, 1107-1123.	1.3	2
1529	Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience, 2014, 8, 479.	0.6	44
1530	Detection ofBRAFp.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	1.2	57
1531	The MEK inhibitor trametinib for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2014, 2, 1341-1349.	0.5	0

#	Article	IF	Citations
1533	Parallel InÂVivo and InÂVitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386.	2.9	34
1534	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Laboratory Investigation, 2014, 94, 13-30.	1.7	63
1535	Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment. Frontiers in Oncology, 2014, 4, 142.	1.3	49
1536	Treating advanced melanoma: current insights and opportunities. Cancer Management and Research, 2014, 6, 349.	0.9	33
1537	Primary malignant melanoma of the breast: A case report and review of the literature. Oncology Letters, 2014, 8, 238-240.	0.8	19
1538	Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. International Journal of Oncology, 2014, 45, 1167-1174.	1.4	26
1539	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy, 2014, 26, 193-201.	0.7	17
1540	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.1	1
1541	Pyogenic Granuloma as a Cutaneous Adverse Effect of Vemurafenib. New England Journal of Medicine, 2014, 371, 1265-1267.	13.9	20
1542	New treatments for metastatic melanoma. Cmaj, 2014, 186, 754-760.	0.9	9
1543	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. Science Signaling, 2014, 7, ra30.	1.6	113
1546	Molecular Pathology of Skin Neoplasms of the Head and Neck. Archives of Pathology and Laboratory Medicine, 2014, 138, 759-787.	1.2	50
1547	The biggest challenges currently facing companion diagnostic advancement. Expert Review of Molecular Diagnostics, 2014, 14, 27-35.	1.5	5
1548	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. OncoImmunology, 2014, 3, e954956.	2.1	19
1549	Application of Genomic Principles to Pharmacotherapy of Cancer. American Journal of Pharmaceutical Education, 2014, 78, 55.	0.7	10
1550	Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. Pharmacogenomics, 2014, 15, 1943-1946.	0.6	5
1551	An evidence-based medicine model for rare and often neglected neoplastic conditions. Journal of Neurosurgery: Spine, 2014, 21, 704-710.	0.9	21
1552	Breakthrough therapies in melanoma. Future Oncology, 2014, 10, 781-784.	1.1	0

#	Article	IF	Citations
1553	Lupus erythematosusâ€“like skin eruption after vemurafenib therapy. Journal of the American Academy of Dermatology, 2014, 71, e159-e160.	0.6	7
1554	Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. Journal of the American Academy of Dermatology, 2014, 71, e205-e206.	0.6	13
1555	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
1557	Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases. Drug Metabolism and Disposition, 2014, 42, 1292-1300.	1.7	89
1558	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. Journal of Clinical Pharmacology, 2014, 54, 368-374.	1.0	41
1559	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Communications, 2014, 5, 5712.	5.8	503
1560	Motor function and survival following radiotherapy alone for metastatic epidural spinal cord compression in melanoma patients. Journal of Dermatology, 2014, 41, 1082-1086.	0.6	3
1561	Dilemmas in the compassionate supply of investigational cancer drugs. Internal Medicine Journal, 2014, 44, 841-845.	0.5	19
1562	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Research, 2014, 74, 4845-4852.	0.4	148
1563	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biology, 2014, 4, 140030.	1.5	11
1564	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australasian Journal of Dermatology, 2014, 55, 250-254.	0.4	60
1565	Targeting RASâ€“ERK signalling in cancer: promises and challenges. Nature Reviews Drug Discovery, 2014, 13, 928-942.	21.5	887
1566	Rapid Evolution of Combination Therapy in Melanoma. New England Journal of Medicine, 2014, 371, 1929-1930.	13.9	10
1567	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. Molecular Cancer Therapeutics, 2014, 13, 3210-3218.	1.9	21
1568	Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. Molecular Cancer Research, 2014, 12, 979-986.	1.5	92
1569	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. Journal of Surgical Oncology, 2014, 109, 405-409.	0.8	23
1571	The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation. Molecular Cancer Therapeutics, 2014, 13, 2253-2263.	1.9	126
1572	Vemurafenib significantly decreases glomerular filtration rate. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 978-979.	1.3	24

#	Article	IF	Citations
1573	Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 2014, 25, 1437-1441.	0.6	117
1574	Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. Annals of Oncology, 2014, 25, 917-918.	0.6	5
1575	Metastatic melanoma to the upper aerodigestive tract. Laryngoscope, 2014, 124, 1143-1149.	1.1	17
1576	Pediatric Brainstem Gangliogliomas Show <scp>BRAF^{V600E}</scp> Mutation in a High Percentage of Cases. Brain Pathology, 2014, 24, 173-183.	2.1	52
1577	Exploiting the curative potential of adoptive Tâ€cell therapy for cancer. Immunological Reviews, 2014, 257, 56-71.	2.8	422
1578	Nano-Oncologicals. Advances in Delivery Science and Technology, 2014, , .	0.4	7
1579	Case of vemurafenibâ€induced Sweet's syndrome. Journal of Dermatology, 2014, 41, 817-820.	0.6	35
1580	On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Annals of Oncology, 2014, 25, 2086-2091.	0.6	72
1581	<scp>BRAF V</scp>600<scp>E</scp> expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathology and Applied Neurobiology, 2014, 40, 337-344.	1.8	47
1582	Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2230-2232.	13.9	43
1583	Targeted therapy in melanoma: the era of personalized medicine. Diagnostic Histopathology, 2014, 20, 425-430.	0.2	1
1584	Loss of <scp>CDKN</scp>2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <scp>CDK</scp>4/6 inhibitor <scp>PD</scp>0332991 in melanoma cell lines. Pigment Cell and Melanoma Research, 2014, 27, 590-600.	1.5	165
1585	Isolated limb perfusion for inâ€transit melanoma metastases: Melphalan or TNFâ€melphalan perfusion?. Journal of Surgical Oncology, 2014, 109, 338-347.	0.8	26
1586	Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK. Molecular Cancer Therapeutics, 2014, 13, 221-229.	1.9	27
1587	Novel function for the p38â€MK2 signaling pathway in circulating CD1c+ (BDCAâ€1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances ILâ€12 whilst suppressing ILâ€10. International Journal of Cancer, 2014, 134, 575-586.	2.3	15
1588	Diseaseâ€specific mutations in mature lymphoid neoplasms: Recent advances. Cancer Science, 2014, 105, 623-629.	1.7	14
1589	XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection. International Journal of Cancer, 2014, 134, 1495-1503.	2.3	20
1590	Squamoproliferative skin lesion during braf inhibitors:one size does not fit all. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 389-391.	1.3	1

#	Article	IF	Citations
1591	Inhibition of mutant <scp>BRAF</scp> splice variant signaling by nextâ€generation, selective <scp>RAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2014, 27, 479-484.	1.5	43
1592	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. Cancer Discovery, 2014, 4, 1377-1386.	7.7	76
1593	Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. British Journal of Dermatology, 2014, 170, 20-30.	1.4	61
1594	Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma. British Journal of Dermatology, 2014, 170, 220-222.	1.4	20
1595	Inhibition of autophagy enhances the effects of the <scp>AKT</scp> inhibitor <scp>MK</scp>â€2206 when combined with paclitaxel and carboplatin in <scp>BRAF</scp> wildâ€type melanoma. Pigment Cell and Melanoma Research, 2014, 27, 465-478.	1.5	50
1596	Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British Journal of Cancer, 2014, 111, 477-485.	2.9	97
1597	High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 53-57.	0.7	14
1598	Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF. Oncogene, 2014, 33, 5397-5404.	2.6	27
1599	Amorphous Solid Dispersions. Advances in Delivery Science and Technology, 2014, , .	0.4	78
1600	Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. International Journal of Dermatology, 2014, 53, e499-506.	0.5	5
1601	Podoplanin expression in cancerâ€associated fibroblasts predicts aggressive behavior in melanoma. Journal of Cutaneous Pathology, 2014, 41, 561-567.	0.7	38
1602	Multiple murine BRaf^{V600E} melanoma cell lines with sensitivity to PLX4032. Pigment Cell and Melanoma Research, 2014, 27, 495-501.	1.5	71
1604	Molecular profiling of sinonasal undifferentiated carcinoma. Head and Neck, 2014, 36, 15-21.	0.9	26
1605	Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nature Medicine, 2014, 20, 1231-1232.	15.2	5
1606	Wholeâ€exome sequencing of pancreatic neoplasms with acinar differentiation. Journal of Pathology, 2014, 232, 428-435.	2.1	151
1607	Efficacy of a general practitioner training campaign for early detection of melanoma in France. British Journal of Dermatology, 2014, 170, 123-129.	1.4	25
1608	Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. British Journal of Dermatology, 2014, 170, 997-999.	1.4	28
1609	Intralesional immunotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 320-326.	0.8	54

#	Article	IF	Citations
1610	Pathobiological properties of the ubiquitin ligase <scp>N</scp>edd4<scp>L</scp> in melanoma. International Journal of Experimental Pathology, 2014, 95, 24-28.	0.6	23
1611	Validation of the <scp>VE1</scp> immunostain for the <scp>BRAF</scp><scp>V600E</scp> mutation in melanoma. Journal of Cutaneous Pathology, 2014, 41, 724-732.	0.7	49
1612	The use of vemurafenib in <scp>A</scp>ustralian patients with unresectable or metastatic melanoma containing the <scp>V</scp>600 <scp>BRAF</scp> gene mutation. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 1-15.	0.7	4
1613	Major therapeutic developments and current challenges in advanced melanoma. British Journal of Dermatology, 2014, 170, 36-44.	1.4	20
1614	Quality assurance for care of melanoma patients based on guidelineâ€derived quality indicators and certification. JDDG - Journal of the German Society of Dermatology, 2014, 12, 139-147.	0.4	15
1615	Vemurafenib in pediatric patients with <scp>BRAFV</scp>600E mutated highâ€grade gliomas. Pediatric Blood and Cancer, 2014, 61, 1101-1103.	0.8	125
1616	Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide ¹³¹I-BA52. Journal of Nuclear Medicine, 2014, 55, 9-14.	2.8	48
1617	Evolving role of tumor antigens for future melanoma therapies. Future Oncology, 2014, 10, 1457-1468.	1.1	15
1618	A randomized, openâ€label clinical trial of tasisulam sodium versus paclitaxel as secondâ€line treatment in patients with metastatic melanoma. Cancer, 2014, 120, 2016-2024.	2.0	19
1619	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. PLoS ONE, 2014, 9, e112025.	1.1	15
1620	Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib. JAMA Ophthalmology, 2014, 132, 1421.	1.4	50
1621	Novel Approaches in Melanoma Prevention and Therapy. Cancer Treatment and Research, 2014, 159, 443-455.	0.2	36
1622	Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?. Expert Opinion on Pharmacotherapy, 2014, 15, 589-592.	0.9	23
1623	Clinical Pharmacogenetics. Cancer Drug Discovery and Development, 2014, , 803-821.	0.2	0
1624	Dabrafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2014, 15, 1043-1050.	0.9	4
1625	MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma. Molecular Cancer Therapeutics, 2014, 13, 1599-1610.	1.9	21
1626	Distribution of Subsequent Primary Invasive Melanomas Following a First Primary Invasive or In Situ Melanoma in Queensland, Australia, 1982-2010. JAMA Dermatology, 2014, 150, 526.	2.0	66
1627	Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines. Molecular Cancer Therapeutics, 2014, 13, 297-306.	1.9	11

#	Article	IF	Citations
1628	â€œTRIMingâ€•the Patient Population to Increase the Benefit of mTOR Inhibition. Journal of the National Cancer Institute, 2014, 106, .	3.0	2
1629	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1Î± and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.4	161
1630	Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience. Oncologist, 2014, 19, 631-636.	1.9	159
1631	Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Familial Cancer, 2014, 13, 645-649.	0.9	18
1632	New Options for the Adjuvant Treatment of Cutaneous Melanoma?. Current Oncology Reports, 2014, 16, 409.	1.8	7
1633	Melanoma 2014â€”an update. Memo - Magazine of European Medical Oncology, 2014, 7, 249-251.	0.3	0
1634	Mutational profiling of kinases in glioblastoma. BMC Cancer, 2014, 14, 718.	1.1	50
1635	Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma. BMC Cancer, 2014, 14, 967.	1.1	6
1636	Melanoma: the role of surgery in the era of new therapies. Journal of Translational Medicine, 2014, 12, 195.	1.8	4
1637	Conjonctival melanoma metastatic to the breast: a case report. BMC Research Notes, 2014, 7, 621.	0.6	4
1638	Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. Journal of Translational Medicine, 2014, 12, 262.	1.8	21
1639	Strategies for modern biomarker and drug development in oncology. Journal of Hematology and Oncology, 2014, 7, 70.	6.9	98
1640	Selective inhibitors of nuclear export (SINE)â€“ a novel class of anti-cancer agents. Journal of Hematology and Oncology, 2014, 7, 78.	6.9	111
1641	Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biology, 2014, 15, 461.	3.8	23
1642	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. Genome Biology, 2014, 15, 489.	3.8	54
1643	BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma. Cancer Immunology Research, 2014, 2, 1044-1050.	1.6	57
1645	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. American Journal of Dermatopathology, 2014, 36, 557-561.	0.3	17
1646	Sentinel node followed by completion lymph node dissection versus nodal observation. Melanoma Research, 2014, 24, 291-294.	0.6	25

#	Article	IF	Citations
1647	A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. Melanoma Research, 2014, 24, 144-149.	0.6	6
1648	Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Research, 2014, 24, 496-500.	0.6	16
1649	The role of systemic therapies in the management of melanoma brain metastases. Current Opinion in Oncology, 2014, 26, 222-229.	1.1	19
1650	Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology, 2014, 46, 509-517.	0.3	69
1651	Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	2.1	66
1652	Where to start with systemic melanoma therapy?. Melanoma Management, 2014, 1, 15-18.	0.1	0
1653	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research, 2014, 74, 2238-2245.	0.4	28
1654	Panniculitis in Patients Treated With BRAF Inhibitors. American Journal of Dermatopathology, 2014, 36, 493-497.	0.3	52
1655	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. Journal of Thoracic Oncology, 2014, 9, 1669-1674.	0.5	106
1656	Hepatic yttrium-90 radioembolization for metastatic melanoma. Melanoma Research, 2014, 24, 244-251.	0.6	23
1657	Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. Melanoma Research, 2014, 24, 501-503.	0.6	11
1658	Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 2014, 24, 468-474.	0.6	42
1659	Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. Melanoma Research, 2014, 24, 322-331.	0.6	5
1660	Low Incidence of Oncogenic EGFR, HRAS, and KRAS Mutations in Seborrheic Keratosis. American Journal of Dermatopathology, 2014, 36, 635-642.	0.3	17
1661	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. Cancer Journal (Sudbury, Mass), 2014, 20, 18-24.	1.0	43
1662	The treatment of melanoma brain metastases before the advent of targeted therapies. Melanoma Research, 2014, 24, 61-67.	0.6	22
1663	Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Research, 2014, 74, 4122-4132.	0.4	45
1664	Vemurafenib in the French temporary authorization for use metastatic melanoma cohort. Melanoma Research, 2014, 24, 75-82.	0.6	20

#	Article	IF	Citations
1665	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas. International Journal of Gynecological Cancer, 2014, 24, S117-S122.	1.2	67
1666	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. Melanoma Research, 2014, 24, 40-46.	0.6	67
1667	BRAF alterations in brain tumours. Current Opinion in Neurology, 2014, 27, 689-696.	1.8	34
1668	Current Systemic Therapies for Melanoma. Dermatologic Surgery, 2014, 40, 948-963.	0.4	29
1669	A Phase I Trial of Bortezomib and Interferon-a-2b in Metastatic Melanoma. Journal of Immunotherapy, 2014, 37, 55-62.	1.2	14
1670	RETINAL TOXICITIES OF CANCER THERAPY DRUGS. Retina, 2014, 34, 1261-1280.	1.0	57
1671	Prognostic Factors for Overall Survival After Radiosurgery for Brain Metastases From Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 580-584.	0.6	18
1672	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Research, 2014, 24, 504-508.	0.6	70
1673	Management of melanomas of the gynaecological tract. Current Opinion in Oncology, 2014, 26, 508-513.	1.1	19
1674	Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Research, 2014, 24, 207-218.	0.6	15
1675	Implementing precision medicine initiatives in the clinic. Current Opinion in Oncology, 2014, 26, 340-346.	1.1	17
1676	Hepatic resection for metastatic melanoma. Melanoma Research, 2014, 24, 1-10.	0.6	11
1677	Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Research, 2014, 24, 448-453.	0.6	14
1678	Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. Melanoma Research, 2014, 24, 349-353.	0.6	34
1680	Ipilimumab for advanced melanoma. Melanoma Research, 2014, 24, 577-583.	0.6	38
1681	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.3	19
1682	Persistent postoperative pain and sensory changes following lymph node excision in melanoma patients. Melanoma Research, 2014, 24, 93-98.	0.6	19
1683	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT	1.0	17

#	Article	IF	Citations
1684	Isolated hepatic perfusion for patients with liver metastases. Therapeutic Advances in Medical Oncology, 2014, 6, 180-194.	1.4	14
1685	Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells. Journal of Biological Chemistry, 2014, 289, 27714-27726.	1.6	44
1686	Improving the quality of â€˜personalized medicineâ€™ research and practice: through an ethical lens. Personalized Medicine, 2014, 11, 413-423.	0.8	9
1687	Management of conjunctival malignant melanoma: a review and update. Expert Review of Ophthalmology, 2014, 9, 185-204.	0.3	116
1689	New RAF kinase inhibitors in cancer therapy. Expert Opinion on Pharmacotherapy, 2014, 15, 1235-1245.	0.9	13
1690	Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma. Current Oncology, 2014, 21, 151.	0.9	36
1691	Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model. Molecular Cancer Therapeutics, 2014, 13, 823-832.	1.9	27
1692	WNT5A-mediated Â-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis, 2014, 35, 784-794.	1.3	42
1693	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors. Cancer Research, 2014, 74, 7079-7089.	0.4	90
1694	Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variantâ€“Expressing Melanoma. Molecular Cancer Research, 2014, 12, 795-802.	1.5	20
1695	Vemurafenib in Brafv600 Mutated Metastatic Melanoma (Mm): a Subanalysis of the Italian Population of a Global Safety Study. Annals of Oncology, 2014, 25, iv384.	0.6	4
1696	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research, 2014, 74, 2340-2350.	0.4	266
1697	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research, 2014, 2, 643-654.	1.6	226
1698	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. PLoS ONE, 2014, 9, e101286.	1.1	42
1699	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. Breast Cancer Research and Treatment, 2014, 148, 197-209.	1.1	6
1701	Perforated intestinal metastasis while taking the <scp>BRAF</scp> inhibitor, vemurafanib. ANZ Journal of Surgery, 2014, 84, 891-891.	0.3	1
1702	Ointment in the Anterior Chamber. JAMA Ophthalmology, 2014, 132, 1425.	1.4	1
1703	Computational identification of multi-omic correlates of anticancer therapeutic response. BMC Genomics, 2014, 15, S2.	1.2	33

#	Article	IF	Citations
1704	Unintended Consequences of Expensive Cancer Therapeuticsâ€"The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225.	1.2	263
1705	Drug development: A chance of survival. Nature, 2014, 515, S118-S120.	13.7	8
1706	Characterization of S628N. JAMA Dermatology, 2014, 150, 1345.	2.0	6
1707	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery, 2014, 4, 69-79.	7.7	141
1708	Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383.	1.3	38
1709	67-kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance. Journal of Biological Chemistry, 2014, 289, 32671-32681.	1.6	60
1710	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	1.6	100
1711	Modeling Melanoma In Vitro and In Vivo. Healthcare (Switzerland), 2014, 2, 27-46.	1.0	90
1712	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. Biochemistry Research International, 2014, 2014, 1-9.	1.5	18
1713	BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT. Acta Medica Medianae, 2014, , 39-41.	0.0	0
1714	Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy. Frontiers in Oncology, 2014, 4, 141.	1.3	24
1715	Drug-Diagnostics Co-Development in Oncology. Frontiers in Oncology, 2014, 4, 208.	1.3	4
1716	Treatment Patterns in Patients with Metastatic Melanoma: A Retrospective Analysis. Journal of Skin Cancer, 2014, 2014, 1-7.	0.5	16
1717	<scp>ROCK</scp>1 is a potential combinatorial drug target for <scp>BRAF</scp> mutant melanoma. Molecular Systems Biology, 2014, 10, 772.	3.2	48
1718	Bespoke treatment: Drivers beware!. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 378-380.	0.7	1
1719	MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition. Cancer Discovery, 2014, 4, 61-68.	7.7	419
1720	Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma. Oncology Research and Treatment, 2014, 37, 757-760.	0.8	33
1721	Adverse events of targeted therapies. Current Opinion in Oncology, 2014, 26, 395-402.	1.1	13

#	Article	IF	Citations
1722	Basal Cell Carcinosarcoma With PTCH1 Mutations in Both Epithelial and Sarcomatoid Primary Tumor Components and in the Sarcomatoid Metastasis. American Journal of Surgical Pathology, 2014, 38, 138-142.	2.1	18
1723	Colorectal malignant polyps: the surveillance dilemma. ANZ Journal of Surgery, 2014, 84, 891-892.	0.3	0
1724	Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. International Journal of Dermatology, 2014, 53, 1428-1433.	0.5	3
1725	Vertical inhibition of the <scp>MAPK</scp> pathway enhances therapeutic responses in <scp>NRAS</scp>â€mutant melanoma. Pigment Cell and Melanoma Research, 2014, 27, 1154-1158.	1.5	47
1726	Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses. Science Translational Medicine, 2014, 6, 249ra111.	5.8	285
1727	Melanoma: Clinical Features and Genomic Insights. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015388-a015388.	2.9	42
1728	Cutaneous melanoma. Lancet, The, 2014, 383, 816-827.	6.3	465
1729	MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene, 2014, 33, 1850-1861.	2.6	92
1730	Biomarkers in Oncology and Nephrology. , 2014, , 21-38.		5
1731	A personalized view on cancer immunotherapy. Cancer Letters, 2014, 352, 113-125.	3.2	63
1733	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, The, 2014, 15, 297-304.	5.1	55
1734	Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRAF/WTNRAS melanoma cells to vemurafenib. European Journal of Cancer, 2014, 50, 1310-1320.	1.3	19
1736	Melanotic and non-melanotic malignancies of the face and external ear â€“ A review of current treatment concepts and future options. Cancer Treatment Reviews, 2014, 40, 819-837.	3.4	38
1737	Nevus melanocÃ‡tico atÃ‡pico amelanÃ³tico inducido por vemurafenib. Actas Dermo-sifiliogrÃ¡ficas, 2014, 105, 726-727.	0.2	1
1738	Cutaneous melanoma: Medical specialists' opinions onÂfollow-up and sentinel lymph node biopsy. European Journal of Surgical Oncology, 2014, 40, 1276-1283.	0.5	8
1739	Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma. Journal of the American Academy of Dermatology, 2014, 70, e39-e41.	0.6	4
1740	Resistance to Raf inhibition in cancer. Drug Discovery Today: Technologies, 2014, 11, 27-32.	4.0	31
1741	Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. American Journal of Surgery, 2014, 207, 549-554.	0.9	33

#	Article	IF	Citations
1742	The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. Current Opinion in Genetics and Development, 2014, 24, 114-119.	1.5	29
1743	RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Letters, 2014, 348, 61-70.	3.2	37
1744	Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical Bacillus Calmetteâ€“GuÃ©rin therapy. Pathology Research and Practice, 2014, 210, 123-126.	1.0	8
1745	Targeted Therapies for Cutaneous Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 491-505.	0.9	11
1746	Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment, 2014, 25, 401-408.	1.1	59
1747	Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochemical Pharmacology, 2014, 87, 150-161.	2.0	271
1748	Atlas of Geriatric Dermatology. , 2014, , .		2
1749	Intracranial Stereotactic Radiosurgery in High Risk Patients with Metastases from Radioresistant Primary Tumors. Tumors of the Central Nervous System, 2014, , 163-172.	0.1	0
1750	Tumors of the Central Nervous System, Volume 11. Tumors of the Central Nervous System, 2014, , .	0.1	0
1752	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. Journal of Investigative Dermatology, 2014, 134, 452-460.	0.3	20
1753	Personalized Health Care (PHC) in Cancer. , 2014, , 23-49.		0
1754	Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Targeted Oncology, 2014, 9, 63-71.	1.7	46
1755	Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Strahlentherapie Und Onkologie, 2014, 190, 229-232.	1.0	34
1756	Targeted Therapies in Brain Metastases. Current Treatment Options in Neurology, 2014, 16, 276.	0.7	42
1757	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations. BMC Cancer, 2014, 14, 13.	1.1	220
1758	BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy. Molecular Diagnosis and Therapy, 2014, 18, 285-91.	1.6	8
1759	Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. Medical Oncology, 2014, 31, 813.	1.2	7
1760	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. Molecular Diagnosis and Therapy, 2014, 18, 273-284.	1.6	132

#	Article	IF	Citations
1761	A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 103-111.	1.1	45
1762	Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. Annals of Surgical Oncology, 2014, 21, 292-299.	0.7	28
1763	Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumor Biology, 2014, 35, 2983-2988.	0.8	16
1764	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. Journal of the National Cancer Institute, 2014, 106, djt435-djt435.	3.0	64
1765	Emerging insights into resistance to BRAF inhibitors in melanoma. Biochemical Pharmacology, 2014, 87, 381-389.	2.0	70
1766	Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63, 844-855.	6.1	1,180
1767	Wholeâ€genome Sequencing of an Aggressive BRAF Wildâ€type Papillary Thyroid Cancer Identified EML4â€“ALK Translocation as a Therapeutic Target. World Journal of Surgery, 2014, 38, 1296-1305.	0.8	54
1768	The chemosensitivity of testicular germ cell tumors. Cellular Oncology (Dordrecht), 2014, 37, 79-94.	2.1	34
1769	Adoptive Immunotherapy for Cancer or Viruses. Annual Review of Immunology, 2014, 32, 189-225.	9.5	240
1770	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	13.7	702
1771	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. Molecular Diagnosis and Therapy, 2014, 18, 409-418.	1.6	34
1772	Recent progress in the identification of BRAF inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 2014, 72, 170-205.	2.6	55
1773	Establishing benchmarks and metrics for disruptive technologies, inappropriate and obsolete tests in the clinical laboratory. Clinica Chimica Acta, 2014, 427, 131-136.	0.5	19
1774	BRAF â€" A new player in hematological neoplasms. Blood Cells, Molecules, and Diseases, 2014, 53, 77-83.	0.6	26
1775	MEK in cancer and cancer therapy. , 2014, 141, 160-171.		200
1776	Erdheimâ€“Chester Disease. Current Rheumatology Reports, 2014, 16, 412.	2.1	110
1777	Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets. Clinical Pharmacokinetics, 2014, 53, 305-325.	1.6	190
1778	Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. Tumor Biology, 2014, 35, 5727-5733.	0.8	24

#	Article	IF	Citations
1779	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunology, Immunotherapy, 2014, 63, 247-257.	2.0	472
1780	The GIST of Targeted Therapy for Malignant Melanoma. Annals of Surgical Oncology, 2014, 21, 2059-2067.	0.7	17
1783	MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma. Tumor Biology, 2014, 35, 2537-2548.	0.8	24
1784	NRAS mutations in primary and metastatic melanomas of Japanese patients. International Journal of Clinical Oncology, 2014, 19, 544-548.	1.0	26
1785	BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation. Molecular Cancer Research, 2014, 12, 447-463.	1.5	46
1786	Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. Molecular Oncology, 2014, 8, 830-839.	2.1	44
1787	Precision treatment for cancer: Role of prognostic and predictive markers. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 30-45.	2.7	25
1788	On the TRAIL to Overcome BRAF-Inhibitor Resistance. Journal of Investigative Dermatology, 2014, 134, 315-318.	0.3	7
1789	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. Cell, 2014, 156, 986-1001.	13.5	149
1790	Epistatic interactions and drug response. Journal of Pathology, 2014, 232, 255-263.	2.1	24
1791	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. Clinical Cancer Research, 2014, 20, 1965-1977.	3.2	447
1792	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology, 2014, 32, 479-484.	9.4	495
1793	Principles and methods of integrative genomic analyses in cancer. Nature Reviews Cancer, 2014, 14, 299-313.	12.8	337
1794	The challenge of intratumour heterogeneity in precision medicine. Journal of Internal Medicine, 2014, 276, 41-51.	2.7	66
1795	Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAFâ€“MEKâ€“ERK Pathway in Cancer. Clinical Cancer Research, 2014, 20, 2516-2522.	3.2	108
1796	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. Clinical Cancer Research, 2014, 20, 2264-2275.	3.2	60
1797	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 2014, 120, 1695-1701.	2.0	195
1798	Deregulation of cell signaling in cancer. FEBS Letters, 2014, 588, 2558-2570.	1.3	103

#	Article	IF	Citations
1801	Diminished WNT â†' Î²-catenin â†' c-MYC signaling is a barrier for malignant progression of BRAF^{V600E}-induced lung tumors. Genes and Development, 2014, 28, 561-575.	2.7	75
1803	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics, 2014, 16, 343-349.	1.2	44
1804	Management of regional metastatic disease in head and neck cutaneous malignancy. 2. Cutaneous malignant melanoma. British Journal of Oral and Maxillofacial Surgery, 2014, 52, 301-307.	0.4	11
1805	Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials, 2014, 35, 4310-4318.	5.7	57
1806	Neck dissection for oral mucosal melanoma: Caution of nodular lesion. Oral Oncology, 2014, 50, 319-324.	0.8	36
1807	The scope of nanoparticle therapies for future metastatic melanoma treatment. Lancet Oncology, The, 2014, 15, e22-e32.	5.1	75
1809	Molecular Testing in Cancer. , 2014, , .		2
1810	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clinical Cancer Research, 2014, 20, 2424-2432.	3.2	323
1811	Mouse tumour models to guide drug development and identify resistance mechanisms. Journal of Pathology, 2014, 232, 103-111.	2.1	28
1812	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
1813	Targeting B-RAF. , 2014, , 529-563.		1
1814	Update on the Biology and Treatment Options for Hairy Cell Leukemia. Current Treatment Options in Oncology, 2014, 15, 187-209.	1.3	27
1815	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	7.7	73
1816	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4
1817	Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. Cancer Cell, 2014, 25, 697-710.	7.7	238
1819	Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib. Journal of Medicinal Chemistry, 2014, 57, 2692-2703.	2.9	33
1820	Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine. Molecular Cancer Therapeutics, 2014, 13, 1679-1689.	1.9	44
1821	Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era. Clinical Pharmacology and Therapeutics, 2014, 95, 269-280.	2.3	62

#	Article	IF	Citations
1822	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. Journal of Pathology, 2014, 232, 274-282.	2.1	48
1823	Harnessing Massively Parallel Sequencing in Personalized Head and Neck Oncology. Journal of Dental Research, 2014, 93, 437-444.	2.5	15
1824	A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 29-32.	1.4	19
1825	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. International Journal of Dermatology, 2014, 53, 376-384.	0.5	62
1826	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Annals of Oncology, 2014, 25, 968-974.	0.6	68
1827	Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition. Molecular Cancer Therapeutics, 2014, 13, 1894-1906.	1.9	35
1828	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	4.2	346
1829	DNA Sequencing of Cancer: What Have We Learned?. Annual Review of Medicine, 2014, 65, 63-79.	5.0	41
1830	Interaction of Immune and Cancer Cells. , 2014, , .		0
1831	BRAF inhibitors in cancer therapy. , 2014, 142, 176-182.		87
1832	Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma. Methods in Molecular Biology, 2014, 1102, 163-174.	0.4	14
1833	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	1.8	9
1834	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. Journal of Molecular Diagnostics, 2014, 16, 56-67.	1.2	234
1835	Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. Critical Reviews in Oncology/Hematology, 2014, 90, 152-164.	2.0	49
1836	Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treatment Reviews, 2014, 40, 205-214.	3.4	75
1837	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 2014, 50, 406-410.	1.3	26
1838	Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. Lab on A Chip, 2014, 14, 24-31.	3.1	29
1839	Advances in Nutrition and Cancer. Cancer Treatment and Research, 2014, , .	0.2	11

#	Article	IF	Citations
1840	Lip Cancer. , 2014, , .		2
1841	Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies. Pharmacogenomics Journal, 2014, 14, 1-5.	0.9	12
1842	Developing an institutional cancer biorepository for personalized medicine. Clinical Biochemistry, 2014, 47, 293-299.	0.8	13
1843	Targeted therapy-induced diarrhea: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 165-179.	2.0	47
1844	Biomarker enrichment strategies: matching trial design to biomarker credentials. Nature Reviews Clinical Oncology, 2014, 11, 81-90.	12.5	147
1845	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	9.4	408
1846	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	4.0	255
1847	The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance. , 2014, 142, 316-338.		174
1848	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta, 2014, 429, 168-174.	0.5	20
1849	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational New Drugs, 2014, 32, 178-187.	1.2	302
1850	From proteomes to complexomes in the era of systems biology. Proteomics, 2014, 14, 24-41.	1.3	35
1851	Towards defining biomarkers indicating resistances to targeted therapies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 909-916.	1.1	9
1852	Resistance to RAF Inhibitors Revisited. Journal of Investigative Dermatology, 2014, 134, 319-325.	0.3	62
1853	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 2014, 4, 80-93.	7.7	836
1854	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 57-63.	1.3	162
1855	Assaying for BRAF V600E in Tissue and Blood in Melanoma. Methods in Molecular Biology, 2014, 1102, 117-136.	0.4	5
1856	A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. Oncologist, 2014, 19, 453-458.	1.9	53
1857	Section IV: Nonâ€“small cell lung cancer and malignant melanoma. Current Problems in Cancer, 2014, 38, 180-198.	1.0	2

#	Article	IF	Citations
1858	Section I: Integrating laboratory medicine with tissue specimens. Current Problems in Cancer, 2014, 38, 144-158.	1.0	4
1859	Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib. Molecular Pharmaceutics, 2014, 11, 4199-4207.	2.3	43
1860	Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. British Journal of Surgery, 2014, 101, 811-819.	0.1	19
1861	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. Journal of Immunology, 2014, 192, 2505-2513.	0.4	69
1862	Progression of <scp>KRAS</scp> mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Internal Medicine Journal, 2014, 44, 597-600.	0.5	19
1863	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science, 2014, 346, 945-949.	6.0	328
1864	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF^{V600}-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. Journal of Clinical Oncology, 2014, 32, 3697-3704.	0.8	173
1865	Genomewide <scp>RNA</scp>i screen identifies protein kinase <scp>C</scp>Î² and new members of mitogenâ€activated protein kinase pathway as regulators of melanoma cell growth and metastasis. Pigment Cell and Melanoma Research, 2014, 27, 418-430.	1.5	12
1866	Progress towards personalized medicine for ameloblastoma. Journal of Pathology, 2014, 232, 488-491.	2.1	23
1867	Successful management of lifeâ€threatening disseminated intravascular coagulopathy due to metastatic melanoma. Internal Medicine Journal, 2014, 44, 207-208.	0.5	3
1868	Recent developments in the medical and surgical treatment of melanoma. Ca-A Cancer Journal for Clinicians, 2014, 64, 171-185.	157.7	56
1869	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. British Journal of Dermatology, 2014, 170, 87-95.	1.4	11
1870	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. Journal of the American Academy of Dermatology, 2014, 71, 1102-1109.e1.	0.6	67
1871	Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer and Metastasis Reviews, 2014, 33, 1109-1124.	2.7	72
1872	Current management of advanced melanoma: a transformed landscape. ANZ Journal of Surgery, 2014, 84, 612-617.	0.3	13
1873	High frequency of <scp>BRAF</scp><scp>V600E</scp> mutations in ameloblastoma. Journal of Pathology, 2014, 232, 492-498.	2.1	240
1874	Isolated limb perfusion with melphalan for melanoma. Journal of Surgical Oncology, 2014, 109, 332-337.	0.8	36
1875	Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting. Stem Cells, 2014, 32, 1373-1379.	1.4	27

#	Article	IF	Citations
1876	Histopathologic characteristics of therapyâ€associated cutaneous neoplasms with vemurafenib, a selective <scp>BRAF</scp> kinase inhibitor, used in the treatment of melanoma. Journal of Cutaneous Pathology, 2014, 41, 568-575.	0.7	13
1877	Clinical implications of distinct metastasizing preferences of different melanoma subtypes. European Journal of Dermatology, 2014, 24, 236-241.	0.3	15
1878	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 2014, 371, 1867-1876.	13.9	1,824
1879	Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15964-15968.	3.3	100
1880	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations. Clinical Cancer Research, 2014, 20, 5527-5536.	3.2	145
1881	Application of genotype-guided cancer therapy in solid tumors. Pharmacogenomics, 2014, 15, 79-93.	0.6	21
1882	Isolated hepatic perfusion for metastatic melanoma. Journal of Surgical Oncology, 2014, 109, 383-388.	0.8	9
1883	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanomaâ€"An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Journal of Clinical Oncology, 2014, 32, 3771-3778.	0.8	99
1884	Building high-resolution synthetic lethal networks: a â€˜Google mapâ€™ of the cancer cell. Trends in Molecular Medicine, 2014, 20, 704-715.	3.5	26
1885	Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Annals of Oncology, 2014, 25, 959-967.	0.6	53
1886	Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy. Journal of Investigative Dermatology, 2014, 134, 1351-1358.	0.3	56
1887	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. Cancer Research, 2014, 74, 7298-7308.	0.4	96
1888	HCC therapiesâ€"lessons learned. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 447-452.	8.2	128
1889	Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy. Cancer Research, 2014, 74, 5937-5941.	0.4	183
1890	Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine. Human Pathology, 2014, 45, 2240-2246.	1.1	0
1891	Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Human Pathology, 2014, 45, 2281-2293.	1.1	53
1893	Physicians' Attitudes About Multiplex Tumor Genomic Testing. Journal of Clinical Oncology, 2014, 32, 1317-1323.	0.8	203
1894	A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression. Thyroid, 2014, 24, 1241-1250.	2.4	24

#	Article	IF	Citations
1895	Personalizing prostate cancer therapy: the way forward. Drug Discovery Today, 2014, 19, 1483-1487.	3.2	7
1896	Vemurafenibâ€induced interface dermatitis manifesting as radiationâ€recall and a keratosis pilarisâ€like eruption. Journal of Cutaneous Pathology, 2014, 41, 539-543.	0.7	13
1897	An Amelanotic Dysplastic Melanocytic Nevus Induced by Vemurafenib. Actas Dermo-sifiliogrÃ¡ficas, 2014, 105, 726-727.	0.2	0
1898	The dream and reality of histology agnostic cancer clinical trials. Molecular Oncology, 2014, 8, 1057-1063.	2.1	28
1899	Investigating the metastatic niche in melanoma: a new therapeutic opportunity?. Future Oncology, 2014, 10, 699-701.	1.1	3
1900	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1472-1479.	0.8	31
1901	Controversies in the Management of Advanced Melanoma. Annals of Pharmacotherapy, 2014, 48, 1456-1468.	0.9	10
1902	Dabrafenib Therapy for Advanced Melanoma. Annals of Pharmacotherapy, 2014, 48, 519-529.	0.9	31
1903	Characterization of Vemurafenib Phototoxicity in a Mouse Model. Toxicological Sciences, 2014, 137, 259-267.	1.4	19
1904	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. Molecular Cancer Therapeutics, 2014, 13, 2793-2804.	1.9	80
1905	Molecular Diagnostics for Dermatology. , 2014, , .		2
1906	Optimizing the treatment of BRAF mutant melanoma. Genome Medicine, 2014, 6, 30.	3.6	0
1907	Advancing clinical oncology through genome biology and technology. Genome Biology, 2014, 15, 427.	3.8	9
1908	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. European Journal of Dermatology, 2014, 24, 265-267.	0.3	10
1909	Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes. Personalized Medicine, 2014, 11, 705-719.	0.8	8
1910	Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged. Cancer Cell, 2014, 26, 603-604.	7.7	49
1911	Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations. Cancer Research, 2014, 74, 7181-7184.	0.4	53
1912	Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. Clinical Cancer Research, 2014, 20, 2072-2079.	3.2	341

#	Article	IF	Citations
1913	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cellular Oncology (Dordrecht), 2014, 37, 353-361.	2.1	43
1915	Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. Journal of Proteome Research, 2014, 13, 1315-1326.	1.8	9
1916	MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. Cancer Immunology Research, 2014, 2, 351-360.	1.6	122
1917	MÃ©tastase sous-cutanÃ©e jugale de mÃ©lanome malin. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2014, 131, 176-178.	0.0	0
1918	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	6.3	1,588
1919	Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology, 2014, 8, 1132-1139.	2.1	153
1920	Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy. Experimental and Molecular Pathology, 2014, 97, 315-320.	0.9	23
1921	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	7.7	242
1922	Theranostics of Malignant Melanoma with ⁶⁴CuCl₂. Journal of Nuclear Medicine, 2014, 55, 812-817.	2.8	85
1923	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	1.9	94
1924	Radionuclide imaging of drug delivery for patient selection in targeted therapy. Expert Opinion on Drug Delivery, 2014, 11, 175-185.	2.4	7
1925	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews Cancer, 2014, 14, 455-467.	12.8	683
1926	NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma. Lancet Oncology, The, 2014, 15, 1056-1057.	5.1	6
1927	PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of⁶⁸Ga- and⁶⁴Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates. Journal of Nuclear Medicine, 2014, 55, 1856-1863.	2.8	46
1928	Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. British Journal of Dermatology, 2014, 170, 136-143.	1.4	23
1929	Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib. American Journal of Ophthalmology, 2014, 158, 831-837.e2.	1.7	81
1930	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	13.9	1,572
1931	Optimal Management of Skin Cancer in Immunosuppressed Patients. American Journal of Clinical Dermatology, 2014, 15, 339-356.	3.3	38

#	Article	IF	Citations
1932	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?. Cancer Immunology, Immunotherapy, 2014, 63, 1081-1091.	2.0	48
1933	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Molecular Oncology, 2014, 8, 1140-1158.	2.1	47
1934	Adjuvant Interferon in Melanoma: Is Duration of Therapy Important?. Journal of Clinical Oncology, 2014, 32, 171-173.	0.8	6
1935	A new look at drugs targeting malignant melanomaâ€"An application for mass spectrometry imaging. Proteomics, 2014, 14, 1963-1970.	1.3	28
1936	Translating Genomics for Precision Cancer Medicine. Annual Review of Genomics and Human Genetics, 2014, 15, 395-415.	2.5	63
1937	The Antiproliferative Response of Indole-3-Carbinol in Human Melanoma Cells Is Triggered by an Interaction with NEDD4-1 and Disruption of Wild-Type PTEN Degradation. Molecular Cancer Research, 2014, 12, 1621-1634.	1.5	62
1938	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280.	0.8	354
1939	Questioning Patient Subgroups for Benefit Assessment: Challenging the German Gemeinsamer Bundesausschuss Approach. Value in Health, 2014, 17, 307-309.	0.1	13
1940	â€œRAFâ€•neighborhood: Proteinâ€“protein interaction in the Raf/Mek/Erk pathway. FEBS Letters, 2014, 588, 2398-2406.	1.3	89
1941	Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. International Immunopharmacology, 2014, 22, 167-175.	1.7	8
1942	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy, 2014, 14, 955-967.	1.4	20
1943	Cutaneous reactions to chemotherapeutic drugs andÂtargeted therapy for cancer. Journal of the American Academy of Dermatology, 2014, 71, 217.e1-217.e11.	0.6	89
1944	Progression-free survival as an end-point in solid tumours â€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	1.3	32
1945	Science and Mechanism of Action of Targeted Therapies in Cancer Treatment. Seminars in Oncology Nursing, 2014, 30, 139-146.	0.7	8
1946	RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 2014, 40, 974-979.	3.4	21
1948	Protein Kinase CÎ´ Is a Therapeutic Target in Malignant Melanoma with NRAS Mutation. ACS Chemical Biology, 2014, 9, 1003-1014.	1.6	26
1949	New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. Clinical Cancer Research, 2014, 20, 4425-4435.	3.2	33
1950	Management of melanoma. British Medical Bulletin, 2014, 111, 149-162.	2.7	61

#	Article	IF	Citations
1951	Cancer of Unknown Primary Site. New England Journal of Medicine, 2014, 371, 757-765.	13.9	217
1952	Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine, 2014, 211, 1503-1523.	4.2	683
1953	BRAF Mutation Testing in Solid Tumors. Journal of Molecular Diagnostics, 2014, 16, 481-485.	1.2	6
1954	Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR. Analytical and Bioanalytical Chemistry, 2014, 406, 5513-5520.	1.9	29
1955	MYC through miR-17-92 Suppresses Specific Target Genes to Maintain Survival, Autonomous Proliferation, and a Neoplastic State. Cancer Cell, 2014, 26, 262-272.	7.7	155
1956	Targeted Therapy in Older Patients With Solid Tumors. Journal of Clinical Oncology, 2014, 32, 2635-2646.	0.8	36
1957	Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncology, The, 2014, 15, e371-e381.	5.1	130
1958	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. Lancet Oncology, The, 2014, 15, 954-965.	5.1	225
1959	Combined inhibition of BRAF and MEK in melanoma patients. Lancet Oncology, The, 2014, 15, 908-910.	5.1	6
1960	Emerging approaches to target tumor metabolism. Current Opinion in Pharmacology, 2014, 17, 22-29.	1.7	18
1961	Successes, toxicities and challenges in solid tumours. Nature Reviews Clinical Oncology, 2014, 11, 627-628.	12.5	23
1962	Melanocytic Lesions. , 2014, , .		2
1963	Oncogenic KRAS signalling in pancreatic cancer. British Journal of Cancer, 2014, 111, 817-822.	2.9	423
1964	Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Review of Clinical Immunology, 2014, 10, 915-926.	1.3	22
1965	The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition. Cancer, 2014, 120, 3142-3153.	2.0	65
1966	Hairy cell leukemia: a â€˜hair-raisingâ€™ update. Expert Review of Hematology, 2014, 7, 659-669.	1.0	3
1967	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research, 2014, 20, 4827-4836.	3.2	186
1968	Comparative evaluation of the new FDA approved THxIDâ„¢-BRAF test with high resolution melting and sanger sequencing. BMC Cancer, 2014, 14, 519.	1.1	20

#	Article	IF	Citations
1969	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Molecular Cancer, 2014, 13, 154.	7.9	2
1970	Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Molecular Cancer, 2014, 13, 194.	7.9	90
1971	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. BMC Medicine, 2014, 12, 140.	2.3	36
1972	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. Journal of Translational Medicine, 2014, 12, 216.	1.8	43
1973	Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. , 2014, 2, 27.		7
1974	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2014, 32, 3659-3666.	0.8	72
1975	A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature Chemical Biology, 2014, 10, 853-860.	3.9	187
1976	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. Journal of Clinical Oncology, 2014, 32, 816-823.	0.8	20
1977	Surgical Treatment Options for Stage IV Melanoma. Surgical Clinics of North America, 2014, 94, 1075-1089.	0.5	10
1978	Drug therapies in dermatology. Clinical Medicine, 2014, 14, 47-53.	0.8	7
1979	Next-generation sequencing technologies: breaking the sound barrier of human genetics. Mutagenesis, 2014, 29, 303-310.	1.0	106
1980	Finding chemical drugs for genetic diseases. Drug Discovery Today, 2014, 19, 1836-1840.	3.2	20
1981	Recent advances in personalized lung cancer medicine. Personalized Medicine, 2014, 11, 309-321.	0.8	22
1982	Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Cancer Causes and Control, 2014, 25, 1379-1386.	0.8	22
1984	Integration of genomic information in the clinical management of HCC. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 831-842.	1.0	19
1986	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine, 2014, 92, 709-722.	1.7	75
1987	Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy. Journal of Molecular Medicine, 2014, 92, 723-733.	1.7	4
1988	The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. European Journal of Clinical Pharmacology, 2014, 70, 983-990.	0.8	0

#	Article	IF	Citations
1989	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	2.0	253
1990	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 675-683.	2.0	230
1991	Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 77-84.	1.1	29
1992	VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 637-643.	1.4	23
1994	Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses. Cancer and Metastasis Reviews, 2014, 33, 737-745.	2.7	10
1995	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 2014, 111, 292-299.	2.9	93
1996	Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. , 2014, 2, 9.		14
1997	Hypoxia in Melanoma: Using Optical Spectroscopy and EF5 to Assess Tumor Oxygenation Before and During Regional Chemotherapy for Melanoma. Annals of Surgical Oncology, 2014, 21, 1435-1440.	0.7	8
1998	Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site. Annals of Surgical Oncology, 2014, 21, 4317-4323.	0.7	23
1999	A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests. Expert Review of Molecular Diagnostics, 2014, 14, 517-524.	1.5	22
2000	Stem Cells in Cancer: Should We Believe or Not?. , 2014, , .		2
2001	Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer, 2014, 120, 781-789.	2.0	79
2002	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. Human Molecular Genetics, 2014, 23, 1527-1537.	1.4	19
2003	Updates on histiocytic disorders. Pediatric Blood and Cancer, 2014, 61, 1329-1335.	0.8	80
2004	Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges. Journal of Clinical Oncology, 2014, 32, 2248-2254.	0.8	184
2005	The novel PI3 kinase inhibitor, BAY 80â€6946, impairs melanoma growth in vivo and in vitro. Experimental Dermatology, 2014, 23, 579-584.	1.4	13
2006	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RASâ€“RAF Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	3.2	60
2007	Clinical Atlas of Skin Tumors. , 2014, , .		7

#	Article	IF	Citations
2008	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. Cancer Discovery, 2014, 4, 816-827.	7.7	448
2009	What Is the Role of Chemotherapy in the Treatment of Melanoma?. Current Treatment Options in Oncology, 2014, 15, 321-335.	1.3	20
2010	Managing The Skin Toxicities From New Melanoma Drugs. Current Treatment Options in Oncology, 2014, 15, 281-301.	1.3	17
2011	Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2014, 16, 362-373.	1.2	7
2013	A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer, 2014, 14, 398.	1.1	21
2014	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 2014, 14, 423.	1.1	48
2015	Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. BMC Research Notes, 2014, 7, 187.	0.6	9
2016	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology, 2014, 25, 1428-1436.	0.6	45
2017	Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. British Journal of Cancer, 2014, 110, 2489-2495.	2.9	39
2018	Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 2014, 20, 2035-2043.	3.2	135
2019	Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors. Clinical Cancer Research, 2014, 20, 1074-1080.	3.2	47
2020	Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlentherapie Und Onkologie, 2014, 190, 1169-1172.	1.0	31
2021	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research, 2014, 20, 3328-3337.	3.2	33
2022	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. European Journal of Cancer, 2014, 50, 2668-2676.	1.3	67
2023	Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in Therapy, 2014, 31, 945-960.	1.3	35
2024	From Cancer Genomics to Precision Oncologyâ€"Tissueâ€™s Still an Issue. Cell, 2014, 157, 1509-1514.	13.5	26
2025	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 1382-1389.	1.9	104
2026	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 164-171.	1.0	108

#	Article	IF	Citations
2027	Melanoma: immune checkpoint blockade story gets better. Lancet, The, 2014, 384, 1078-1079.	6.3	10
2028	Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence. Journal of Clinical Oncology, 2014, 32, 185-190.	0.8	43
2029	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. Journal of Molecular Diagnostics, 2014, 16, 660-672.	1.2	70
2030	Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends in Biochemical Sciences, 2014, 39, 465-474.	3.7	134
2031	Annexin A1 in primary tumors promotes melanoma dissemination. Clinical and Experimental Metastasis, 2014, 31, 749-760.	1.7	45
2032	Tilting the Balance of Dose Modification for Oral Anticancer Drugs?. Journal of Clinical Oncology, 2014, 32, 1537-1539.	0.8	10
2033	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. Cancer Treatment Reviews, 2014, 40, 1192-1198.	3.4	51
2034	Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients. Cancer, 2014, 120, 2158-2163.	2.0	53
2035	Change or die: Targeting adaptive signaling to kinase inhibition in cancer cells. Biochemical Pharmacology, 2014, 91, 417-425.	2.0	8
2036	Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors. Cell Reports, 2014, 8, 1037-1048.	2.9	69
2037	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, The, 2014, 15, 323-332.	5.1	890
2038	Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors. Cancer Discovery, 2014, 4, 773-780.	7.7	203
2039	A two-stage patient enrichment adaptive design in phase II oncology trials. Contemporary Clinical Trials, 2014, 37, 148-154.	0.8	11
2040	Commentary: Molecular testing in melanoma. Journal of the American Academy of Dermatology, 2014, 70, 863-870.	0.6	4
2041	Melanoma de mucosa intraoral: Â¿enfermedad local o sistÃ©mica?. Revista EspaÃ±ola De CirugÃa Oral Y Maxilofacial, 2014, 36, 15-20.	0.0	1
2043	RÃ1e de la TEP/TDM dans la prise en charge du mÃ©lanome. Medecine Nucleaire, 2014, 38, 216-220.	0.2	0
2044	Biased and unbiased strategies to identify biologically active small molecules. Bioorganic and Medicinal Chemistry, 2014, 22, 4474-4489.	1.4	13
2045	Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. Human Pathology, 2014, 45, 1315-1326.	1.1	41

#	Article	IF	Citations
2046	BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Practical Radiation Oncology, 2014, 4, e213-e216.	1.1	6
2047	PFS as a surrogate for overall survival in metastatic melanoma. Lancet Oncology, The, 2014, 15, 246-248.	5.1	2
2048	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncology, The, 2014, 15, 620-630.	5.1	96
2049	NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tractâ€"A study of 24 cases from the Netherlands. Gynecologic Oncology, 2014, 134, 10-14.	0.6	35
2050	Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib. Canadian Journal of Ophthalmology, 2014, 49, e49-e52.	0.4	1
2051	DÃ©veloppement brutal dâ€™une maladie de Dupuytren sous vÃ©murafÃ©nib, inhibiteur de BRAF. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 441-442.	0.0	0
2052	A 20-Year Experience of Hepatic Resection for Melanoma: Is There an Expanding Role?. Journal of the American College of Surgeons, 2014, 219, 62-68.	0.2	41
2053	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncology, The, 2014, 15, 436-444.	5.1	242
2054	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. Journal of Pediatrics, 2014, 164, 376-382.e2.	0.9	47
2055	Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review. European Journal of Surgical Oncology, 2014, 40, 1062-1071.	0.5	18
2056	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. Cancer Epidemiology, 2014, 38, 93-99.	0.8	20
2057	Melanoma as a model for precision medicine in oncology. Lancet Oncology, The, 2014, 15, 251-253.	5.1	6
2058	Erdheim-Chester Disease: Characteristics and Management. Mayo Clinic Proceedings, 2014, 89, 985-996.	1.4	75
2059	Community experience of vemurafenib for BRAFV600 melanoma. Lancet Oncology, The, 2014, 15, 369-370.	5.1	3
2060	COXâ€2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology, 2014, 8, 250-260.	2.1	37
2061	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 2014, 8, 544-554.	2.1	98
2063	Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Life Sciences, 2014, 104, 38-46.	2.0	17
2064	BRAF inhibitors: From the laboratory to clinical trials. Critical Reviews in Oncology/Hematology, 2014, 90, 220-232.	2.0	35

#	Article	IF	Citations
2065	Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 2014, 50, 611-621.	1.3	254
2066	Updates of reactive oxygen species in melanoma etiology and progression. Archives of Biochemistry and Biophysics, 2014, 563, 51-55.	1.4	85
2067	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunology Research, 2014, 2, 410-422.	1.6	322
2068	Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. Clinical Cancer Research, 2014, 20, 2257-2263.	3.2	79
2069	Advances in the Management of Low-Grade Gliomas. Current Oncology Reports, 2014, 16, 398.	1.8	36
2070	Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. Journal of the American Academy of Dermatology, 2014, 71, 229-236.	0.6	38
2072	Treatments for Noncutaneous Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 507-521.	0.9	12
2073	Precision Medicine in Oncology Standard of Care. Seminars in Oncology Nursing, 2014, 30, 100-108.	0.7	1
2074	RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells. Journal of Investigative Dermatology, 2014, 134, 430-440.	0.3	33
2075	A Review of Novel Therapies for Melanoma. American Journal of Clinical Dermatology, 2014, 15, 323-337.	3.3	55
2076	Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 523-536.	0.9	23
2077	Surgical Management of Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 455-470.	0.9	14
2078	Melanoma Adjuvant Therapy. Hematology/Oncology Clinics of North America, 2014, 28, 471-489.	0.9	13
2079	Understanding the Biology of Melanoma and Therapeutic Implications. Hematology/Oncology Clinics of North America, 2014, 28, 437-453.	0.9	33
2080	Drug resistance to targeted therapies: DÃ©jÃ vu all over again. Molecular Oncology, 2014, 8, 1067-1083.	2.1	187
2081	State of Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 415-435.	0.9	32
2082	Drug-Induced Photosensitivity. Dermatologic Clinics, 2014, 32, 363-368.	1.0	50
2083	Malignant melanoma of the gastro-intestinal tract: A case series. International Journal of Surgery, 2014, 12, 523-527.	1.1	24

#	Article	IF	Citations
2084	Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 1-12.	0.9	7
2085	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	1.3	149
2086	Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. Mayo Clinic Proceedings, 2014, 89, 504-519.	1.4	77
2087	Oncogenes in melanoma: An update. European Journal of Cell Biology, 2014, 93, 1-10.	1.6	51
2088	Hypodermal metastasis of malignant melanoma to the cheek. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2014, 131, 189-191.	0.4	0
2089	Update on primary mucosal melanoma. Journal of the American Academy of Dermatology, 2014, 71, 366-375.	0.6	131
2090	Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib. Joint Bone Spine, 2014, 81, 373-374.	0.8	4
2091	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharmaceutica Sinica B, 2014, 4, 105-111.	5.7	48
2092	Melanoma metastasis: new concepts and evolving paradigms. Oncogene, 2014, 33, 2413-2422.	2.6	120
2093	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene, 2014, 33, 1590-1600.	2.6	76
2094	Targeted therapy for melanoma: rational combinatorial approaches. Oncogene, 2014, 33, 1-9.	2.6	85
2095	Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-Î± signaling. Oncogene, 2014, 33, 1700-1712.	2.6	41
2098	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. Journal of Extracellular Vesicles, 2014, 3, 25657.	5.5	29
2099	Targeting ER stressâ€“induced autophagy overcomes BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2014, 124, 1406-1417.	3.9	352
2100	Changing Histopathological Diagnostics by Genome-Based Tumor Classification. Genes, 2014, 5, 444-459.	1.0	12
2101	The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). Journal of Personalized Medicine, 2014, 4, 52-64.	1.1	12
2103	Melanoma, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 621-629.	2.3	61
2104	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). International Journal of Oncology, 2014, 45, 929-949.	1.4	34

#	Article	IF	Citations
2105	Genetics and epigenetics of gliomas. Swiss Medical Weekly, 2014, 144, w14018.	0.8	7
2106	Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. Oncology Letters, 2014, 8, 47-54.	0.8	34
2107	Biomarkers and Personalized Sorafenib Therapy. Liver Cancer, 2014, 3, 399-404.	4.2	19
2108	Educational programmes for primary prevention of skin cancer. The Cochrane Library, 2014, , .	1.5	4
2111	Subcutaneous metastases from melanoma: a discussion of clinical experience. Melanoma Management, 2014, 1, 31-40.	0.1	2
2112	The role of chemotherapy in the modern management of melanoma. Melanoma Management, 2014, 1, 173-184.	0.1	8
2114	Consequences of feedback in signal transduction for targeted therapies. Biochemical Society Transactions, 2014, 42, 770-775.	1.6	15
2115	Advances in targeted therapy for melanoma: a focus on MEK inhibition. Clinical Investigation, 2014, 4, 903-913.	0.0	0
2116	Brutonâ€™s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood, 2014, 123, 1207-1213.	0.6	176
2117	Boldly Targeting Kinases without mutations. Blood, 2014, 123, 1119-1121.	0.6	6
2118	Clinical electrochemotherapy for advanced superficial melanoma. , 2014, , 35-53.		2
2121	Melanoma of the gallbladder: appropriate surgical management and review of the literature. Clinical Case Reports (discontinued), 2014, 2, 313-318.	0.2	20
2122	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3â€² untranslated region of TRIT1. Molecular Therapy - Oncolytics, 2014, 1, 14009.	2.0	2
2125	BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. Cancer Control, 2014, 21, 221-230.	0.7	80
2126	BRAFV600E-Mutant Melanoma Presenting With Cardiac Involvement. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 611-615.	2.3	2
2127	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1629-1649.	2.3	18
2128	Emerging targeted therapies for melanoma treatment (Review). International Journal of Oncology, 2014, 45, 516-524.	1.4	39
2129	Advances in molecular profiling of malignant melanoma: ready for clinical practice?. Melanoma Management, 2014, 1, 3-6.	0.1	0

#	Article	IF	Citations
2130	BRAF V600 mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Research, 2014, 24, 415-418.	0.6	22
2131	Leitlinienbasierte QualitÃtsindikatoren und Zertifizierung als Grundlage fÃ¼r die QualitÃtssicherung der Versorgung von Patienten mit Melanom. JDDG - Journal of the German Society of Dermatology, 2014, 12, 139-147.	0.4	8
2132	Management of â€˜pan-negativeâ€™ melanoma: current and emerging strategies. Melanoma Management, 2014, 1, 87-90.	0.1	0
2133	Resistance to Vemurafenib Can Be Reversible After Treatment Interruption. Medicine (United States), 2014, 93, e157.	0.4	20
2134	Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. Annals of Surgery, 2014, 259, 1215-1222.	2.1	46
2135	Foudroyant metastasierendes, Vemurafenibtherapieresistentes malignes Melanom mit einer seltenen BRAF-Alteration. JDDG - Journal of the German Society of Dermatology, 2014, 12, 151-154.	0.4	2
2136	The biological and clinical challenge of liver cancer heterogeneity. Hepatic Oncology, 2014, 1, 349-353.	4.2	34
2137	Cancer pharmacogenomics, adoption by oncologists and patient benefit. Personalized Medicine, 2014, 11, 143-153.	0.8	14
2138	Vemurafenib-induced nonautoimmune haemolytic anaemia. Melanoma Research, 2014, 24, 418-419.	0.6	2
2139	Combination therapies in advanced melanoma. Melanoma Management, 2014, 1, 47-56.	0.1	2
2140	Adjuvant radiation for patients with melanoma. Lancet Oncology, The, 2015, 16, 1003-1004.	5.1	1
2141	BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens. Pathology, 2015, 47, 349-354.	0.3	7
2142	Income-associated discrepancies in melanoma survival. Cancer Treatment Communications, 2015, 4, 143-147.	0.4	4
2143	Cardiac metastatic melanoma: Imaging diagnostic clues. Journal of Cardiology Cases, 2015, 12, 33-36.	0.2	2
2144	Cutaneous melanoma and the new drugs. CirugÃa Y Cirujanos (English Edition), 2015, 83, 175-180.	0.0	1
2145	BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer. Journal of Clinical Oncology, 2015, 33, e101-e103.	0.8	12
2146	Predicting the outcome of melanoma: can we tell the future of a patientâ€™s melanoma?. Melanoma Management, 2015, 2, 217-224.	0.1	5
2147	Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma. Experimental Hematology and Oncology, 2015, 5, 9.	2.0	1

#	Article	IF	Citations
2148	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology, 2015, 10, 1451-1457.	0.5	141
2149	Neurocutaneous Manifestations of Genetic Mosaicism. Journal of Pediatric Genetics, 2015, 04, 144-153.	0.3	8
2150	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 382-388.	0.6	7
2151	Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 75-82.	0.1	2
2152	Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia. International Journal of Oncology, 2015, 47, 81-90.	1.4	14
2153	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Therapeutic Advances in Medical Oncology, 2015, 7, 170-180.	1.4	105
2154	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. Molecular Pharmaceutics, 2015, 12, 3924-3934.	2.3	18
2155	The Forecast Is Bright: Recent Advances in Melanoma Treatment / Perspectives prometteuses: RÃ©centes percÃ©es dans le traitement des mÃ©lanomes. Journal of Cutaneous Medicine and Surgery, 2015, 19, 435-439.	0.6	0
2156	Multi-center evaluation of the novel fully-automated PCR-based Idyllaâ„¢ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Experimental and Molecular Pathology, 2015, 99, 485-491.	0.9	44
2157	Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Cancer Medicine, 2015, 4, 392-403.	1.3	8
2158	Comprehensive mutation profiling by nextâ€generation sequencing of effusion fluids from patients with highâ€grade serous ovarian carcinoma. Cancer Cytopathology, 2015, 123, 289-297.	1.4	25
2159	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GMâ€CSF: <scp>R</scp>esults in vitro, in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	2.3	41
2160	Costâ€effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. Journal of Surgical Oncology, 2015, 111, 423-430.	0.8	13
2161	Phase I/<scp>II</scp> study of vemurafenib in patients with unresectable or recurrent melanoma with <scp>BRAF^V</scp>⁶⁰⁰ mutations. Journal of Dermatology, 2015, 42, 661-666.	0.6	14
2162	Australasian College of Dermatologists Abstracts Presented at the 48th Annual Scientific Meeting 16-19 May 2015 Adelaide, South Australia. Australasian Journal of Dermatology, 2015, 56, 1-87.	0.4	14
2163	Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 504-507.	0.7	12
2164	BRAF^V^{600E} mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. British Journal of Haematology, 2015, 170, 282-285.	1.2	7
2165	Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists. European Journal of Cancer Care, 2015, 24, 867-872.	0.7	6

#	Article	IF	Citations
2166	Patterns of practice in oncology: is progress reaching our practice?. European Journal of Cancer Care, 2015, 24, 768-770.	0.7	0
2167	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46
2168	Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. European Journal of Dermatology, 2015, 25, 392-403.	0.3	12
2169	Intra-tumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas. Experimental and Therapeutic Medicine, 2015, 9, 1719-1722.	0.8	7
2170	Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol. The Cochrane Library, 0, , .	1.5	19
2171	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. Annals of Surgery, 2015, 262, 456-464.	2.1	26
2173	Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Scientific Reports, 2015, 5, 18592.	1.6	27
2179	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood, 2015, 125, 1207-1216.	0.6	82
2180	Intraâ€•and interâ€tumor heterogeneity in a vemurafenibâ€resistant melanoma patient and derived xenografts. EMBO Molecular Medicine, 2015, 7, 1104-1118.	3.3	129
2181	Do we understand the personalized medicine paradigm?. EMBO Reports, 2015, 16, 133-136.	2.0	19
2182	Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive. European Journal of Dermatology, 2015, 25, 452-456.	0.3	19
2183	ç”²çŠ¶è…ºç™Œã•æ,ªæ€§é»'è‰²è…«ã«å¯¾ã™ã‚‹æ–°ã•—ã•„å^†åæ¨™çš„è–¬. Journal of Otolaryngology of Japan, 2015, 118, 1366-1367.	0.1	0
2184	Hairy Cell Leukemia with Systemic Lymphadenopathy: Detection of BRAF Mutations in Both Lymph Node and Peripheral Blood Specimens. Internal Medicine, 2015, 54, 1397-1402.	0.3	4
2185	FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology, 2015, 47, 557-563.	0.3	25
2186	BRAF p.Val600Glu (V600E) mutation detection in thyroid fine needle aspiration cell block samples: a feasibility study. Pathology, 2015, 47, 432-438.	0.3	13
2187	Synthetic lethality and chemoresistance in cancer. , 0, , 65-82.		0
2189	Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discovery, 2015, 1, 15030.	3.1	56
2190	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. Clinical Journal of Oncology Nursing, 2015, 19, 709-717.	0.3	17

#	Article	IF	Citations
2191	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomarker Insights, 2015, 10s3, BMI.S22436.	1.0	7
2192	Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth and Metastasis, 2015, 8s1, CGM.S21214.	3.5	74
2193	Novel melanoma therapy. Experimental Hematology and Oncology, 2015, 5, 23.	2.0	8
2194	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Research, 2015, 25, 486-495.	0.6	73
2195	Integrating first-line treatment options into clinical practice. Melanoma Research, 2015, 25, 461-469.	0.6	25
2196	SEOM guidelines for the management of Malignant Melanoma 2015. Clinical and Translational Oncology, 2015, 17, 1030-1035.	1.2	11
2199	Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. Medicina (Lithuania), 2015, 51, 133-145.	0.8	12
2200	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
2201	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist, 2015, 20, 1312-1319.	1.9	70
2203	Primary pulmonary melanoma: a report of two cases. World Journal of Surgical Oncology, 2015, 13, 274.	0.8	9
2204	Postâ€operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of preâ€operative treatment and elective indication. Journal of Surgical Oncology, 2015, 111, 980-984.	0.8	24
2205	Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis. Molecular Carcinogenesis, 2015, 54, 1328-1339.	1.3	29
2206	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naÃ¯ve advanced prostate cancer treated with primary androgen deprivation therapy. Prostate, 2015, 75, 1499-1509.	1.2	11
2207	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research, 2015, 25, 239-245.	0.6	23
2208	Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment. British Journal of Dermatology, 2015, 173, 1365-1366.	1.4	4
2209	Vemurafenibâ€Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma. Pediatric Dermatology, 2015, 32, 153-154.	0.5	23
2210	Ipilimumab for the treatment of melanoma. Melanoma Management, 2015, 2, 33-39.	0.1	2
2211	Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?. Melanoma Management, 2015, 2, 5-8.	0.1	0

#	Article	IF	Citations
2212	Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review. Journal of Laryngology and Otology, 2015, 129, 1046-1052.	0.4	6
2213	Lâ€™Ã©mergence de la thÃ©rapeutique de prÃ©cision. Healthcare Management Forum, 2015, 28, S40-S46.	0.6	0
2214	Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis. BMC Cancer, 2015, 15, 758.	1.1	63
2215	Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. BMC Cancer, 2015, 15, 732.	1.1	7
2216	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer, 2015, 15, 779.	1.1	92
2217	Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer, 2015, 15, 892.	1.1	52
2218	Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report. BMC Clinical Pathology, 2015, 15, 15.	1.8	8
2219	Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts. Journal of Translational Medicine, 2015, 13, 191.	1.8	10
2220	Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. Journal of Translational Medicine, 2015, 13, 210.	1.8	97
2221	NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagnostic Pathology, 2015, 10, 121.	0.9	32
2222	Miliary pattern of brain metastases â€“ a case report of a hyperacute onset in a patient with malignant melanoma documented by magnetic resonance imaging. Radiation Oncology, 2015, 10, 148.	1.2	4
2223	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clinical Epigenetics, 2015, 7, 58.	1.8	19
2224	Dupuytrenâ€™s contractures associated with the BRAF inhibitor vemurafenib: a case report. Journal of Medical Case Reports, 2015, 9, 158.	0.4	3
2225	Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing. Cell and Bioscience, 2015, 5, 70.	2.1	4
2226	Towards pathwayâ€centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clinical and Translational Medicine, 2015, 4, 66.	1.7	2
2227	Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma. Annals of Surgery, 2015, 261, 368-377.	2.1	15
2228	Treatment for metastatic melanoma: a new and evolving era. International Journal of Clinical Practice, 2015, 69, 273-280.	0.8	2
2229	Erythema nodosumâ€like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1797-1806.	1.3	55

#	Article	IF	Citations
2230	The broadâ€spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of <scp>BRAF</scp>â€mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell and Melanoma Research, 2015, 28, 417-430.	1.5	13
2231	<scp>PTEN</scp> regulates <scp>IGF</scp>â€1Râ€mediated therapy resistance in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 572-589.	1.5	22
2232	Recent advances in diagnosis and treatment of hairy cell leukemia. International Journal of Hematologic Oncology, 2015, 4, 191-200.	0.7	0
2233	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Management, 2015, 2, 241-254.	0.1	10
2234	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Management, 2015, 2, 209-215.	0.1	7
2235	Establishing a translational genomics infrastructure in pediatric cancer: the GREAT KIDS experience. Personalized Medicine, 2015, 12, 221-229.	0.8	2
2236	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights, 2015, 10s3, BMI.S22430.	1.0	29
2237	Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 314-318.	0.7	4
2238	Diagnostic Molecular Cytopathology â€•a further decade of progress. Cytopathology, 2015, 26, 269-270.	0.4	15
2239	Ultrasound-guided core needle biopsy of superficial lymph nodes. Melanoma Research, 2015, 25, 519-527.	0.6	19
2240	Primary Cutaneous Small/Medium CD4+ T-Cell Lymphoma Occurring During Treatment With Vemurafenib for Advanced Melanoma. American Journal of Dermatopathology, 2015, 37, 440-443.	0.3	8
2241	BRAF Inhibitorâ€“Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma. American Journal of Dermatopathology, 2015, 37, 795-798.	0.3	31
2242	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4
2243	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer, 2015, 121, 4007-4015.	2.0	56
2244	Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancerâ€”Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Molecular Cancer Research, 2015, 13, 993-1002.	1.5	117
2245	Understanding patient and provider perceptions and expectations of genomic medicine. Journal of Surgical Oncology, 2015, 111, 9-17.	0.8	27
2246	Translating predictive biomarkers within oncology clinical development programs. Biomarkers in Medicine, 2015, 9, 851-862.	0.6	1
2247	BRAF-mutated colorectal cancer: clinical implications for a distinct subset of the disease. Colorectal Cancer, 2015, 4, 125-133.	0.8	1

#	Article	IF	Citations
2248	Dabrafenib and its use in the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 199-208.	0.1	21
2249	Cooperative induction of apoptosis in <scp>NRAS</scp> mutant melanoma by inhibition of <scp>MEK</scp> and <scp>ROCK</scp>. Pigment Cell and Melanoma Research, 2015, 28, 307-317.	1.5	41
2250	Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Veterinary and Comparative Oncology, 2015, 13, 288-304.	0.8	58
2251	Systemic therapy of metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1237.	0.4	12
2252	Suppressor of cytokine signallingâ€1 induces significant preclinical antitumor effect in malignant melanoma cells. Experimental Dermatology, 2015, 24, 864-871.	1.4	14
2253	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Research, 2015, 25, 550-554.	0.6	39
2254	Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. Ophthalmic Plastic and Reconstructive Surgery, 2015, 31, e112-e115.	0.4	15
2255	Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology, 2015, 111, 962-968.	0.8	19
2256	Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. Melanoma Research, 2015, 25, 246-251.	0.6	7
2257	Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma Research, 2015, 25, 427-431.	0.6	14
2258	BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Research, 2015, 25, 559-563.	0.6	33
2259	Systemtherapie des metastasierten malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1238.	0.4	7
2260	Molecular Subsetting of Interferon Pathways in SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2015, 67, 2437-2446.	2.9	115
2261	Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts. Molecular Cancer Therapeutics, 2015, 14, 757-768.	1.9	27
2262	An approach to confirmatory testing of subpopulations in clinical trials. Biometrical Journal, 2015, 57, 897-913.	0.6	4
2263	Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of ¹⁸Fâ€FDGâ€PET and ¹⁸Fâ€FLTâ€PET. Contrast Media and Molecular Imaging, 2015, 10, 203-210.	0.4	7
2264	Clinicopathologic features associated with efficacy and longâ€term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	2.0	40
2265	Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. American Journal of Dermatopathology, 2015, 37, e96-e99.	0.3	18

#	Article	IF	Citations
2266	Tumorâ€targeted and immuneâ€targeted monoclonal antibodies: Going from passive to active immunotherapy. Pediatric Blood and Cancer, 2015, 62, 1317-1325.	0.8	13
2267	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?. Melanoma Management, 2015, 2, 15-19.	0.1	4
2268	Genetic variants in Hippo pathway genesYAP1,TEAD1andTEAD4are associated with melanoma-specific survival. International Journal of Cancer, 2015, 137, 638-645.	2.3	48
2269	Cutaneous toxicities associated with vemurafenib therapy in 107 patients withBRAFV600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. British Journal of Dermatology, 2015, 173, 1024-1031.	1.4	36
2270	Growth and hormonal profiling in children with congenital melanocytic naevi. British Journal of Dermatology, 2015, 173, 1366-1367.	1.4	0
2271	Use of clinical nextâ€generation sequencing to identify melanomas harboring <scp>SMARCB1</scp> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317.	0.7	11
2272	Prognostic Factors Influencing the Outcome of 64 Consecutive Patients Undergoing Surgery for Metastatic Melanoma of the Spine. Neurosurgery, 2015, 77, 386-393.	0.6	18
2273	B-type proto-oncogene-mutated tumors of colon cancer. Current Opinion in Oncology, 2015, 27, 276-281.	1.1	1
2274	Cancer genomics. Current Opinion in Oncology, 2015, 27, 250-257.	1.1	14
2275	BRAF mutation screening in melanoma. Melanoma Research, 2015, 25, 328-334.	0.6	9
2276	Complete remission of metastatic melanoma upon BRAF inhibitor treatment â€“ what happens after discontinuation?. Melanoma Research, 2015, 25, 362-366.	0.6	27
2277	The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma. Melanoma Research, 2015, 25, 470-478.	0.6	8
2278	Pluripotent stem cell applications for regenerative medicine. Current Opinion in Organ Transplantation, 2015, 20, 663-670.	0.8	45
2279	Gastrointestinal toxicities from targeted therapies. Current Opinion in Supportive and Palliative Care, 2015, 9, 163-167.	0.5	7
2280	Lowâ€concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogenâ€activated protein kinase pathway activation. Journal of Dermatology, 2015, 42, 881-888.	0.6	9
2281	Improving Clinical Trial Efficiency: Thinking outside the Box. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e141-e147.	1.8	57
2282	VerzÃ¶gert auftretende Paraplegie nach Vollremission unter 2 Zyklen Ipilimumab bei metastasiertem Melanom. Karger Kompass Dermatologie, 2015, 3, 94-97.	0.0	0
2283	Increased Treatment-Related Toxicity Subsequent to an Antiâ€“PD-1 Agent. Current Oncology, 2015, 22, 320-322.	0.9	6

#	Article	IF	Citations
2284	Classification of clinical outcomes using high-throughput informatics: Part 1 â€“ nonparametric method reviews. Model Assisted Statistics and Applications, 2015, 10, 3-23.	0.2	8
2285	The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitors. Oncotarget, 2015, 6, 15250-15264.	0.8	29
2286	Advances in the Treatment of Hairy Cell Leukemia. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	0
2287	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
2288	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer Management and Research, 2015, 7, 93.	0.9	10
2289	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. Journal of Cancer, 2015, 6, 1320-1330.	1.2	6
2290	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. Immune Network, 2015, 15, 58.	1.6	11
2291	Comparative Aspects of BRAF Mutations in Canine Cancers. Veterinary Sciences, 2015, 2, 231-245.	0.6	25
2292	BRAF mutation as a biomarker in colorectal cancer. Advances in Genomics and Genetics, 0, , 347.	0.8	3
2293	Epidemiology of Melanoma in the South of Brazil: study of a city in the Vale do ItajaÃ-from 1999 to 2013. Anais Brasileiros De Dermatologia, 2015, 90, 185-189.	0.5	10
2294	Vemurafenib and cutaneous adverse events - report of five cases. Anais Brasileiros De Dermatologia, 2015, 90, 242-246.	0.5	3
2295	The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Wspolczesna Onkologia, 2015, 4, 280-283.	0.7	3
2296	Treating melanoma in adolescents and young adults: challenges and solutions. Clinical Oncology in Adolescents and Young Adults, 2015, , 75.	0.8	2
2297	BRAF G596R mutation in a slow-progressing melanoma. Pathology and Laboratory Medicine International, 2015, , 63.	0.2	0
2298	Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma. International Journal of Nanomedicine, 2015, 10, 3131.	3.3	14
2299	Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. OncoTargets and Therapy, 2015, 8, 1043.	1.0	10
2300	Targeted Therapy for MAPK Alterations in Pediatric Gliomas. Brain Disorders & Therapy, 2015, s2, .	0.1	6
2301	New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy, 2015, 8, 2535.	1.0	16

#	Article	IF	Citations
2302	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. Medical Journal of Australia, 2015, 202, 115-116.	0.8	2
2303	mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget, 2015, 6, 39702-39713.	0.8	29
2304	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e535-e542.	1.8	8
2305	Comparison of Molecular Testing Methods for Detecting BRAF V600 Mutations in Melanoma Specimens with Challenging Attributes. Journal of Molecular Biomarkers & Diagnosis, 2015, 06, .	0.4	0
2306	Circulating Cell-Free Tumour DNA in the Management of Cancer. International Journal of Molecular Sciences, 2015, 16, 14122-14142.	1.8	104
2307	Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001â€“2008 Hospitalization Records. International Journal of Environmental Research and Public Health, 2015, 12, 9102-9118.	1.2	7
2308	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. Processes, 2015, 3, 235-256.	1.3	8
2309	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Frontiers in Genetics, 2015, 6, 341.	1.1	9
2310	Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma. Frontiers in Oncology, 2015, 5, 95.	1.3	26
2311	Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Frontiers in Oncology, 2015, 5, 135.	1.3	52
2312	Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. Frontiers in Oncology, 2015, 5, 161.	1.3	25
2313			

#	Article	IF	Citations
2320	Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2015, 10, e0133562.	1.1	91
2321	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS ONE, 2015, 10, e0134346.	1.1	72
2322	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLoS ONE, 2015, 10, e0138210.	1.1	9
2323	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLoS ONE, 2015, 10, e0139438.	1.1	27
2324	Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. PLoS ONE, 2015, 10, e0144170.	1.1	84
2325	MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Design, Development and Therapy, 2016, 10, 43.	2.0	22
2326	Adjuvant Therapy of Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 2015, 1, 54-62.	0.5	55
2327	Identification of the Interaction Network of Hub Genes for Melanoma Treated with Vemurafenib Based on Microarray Data. Tumori, 2015, 101, 368-374.	0.6	5
2328	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International, 2015, 2015, 1-16.	0.9	111
2329	Targeted Therapies Compared to Dacarbazine for Treatment of BRAF^{V600E}Metastatic Melanoma: A Cost-Effectiveness Analysis. Journal of Skin Cancer, 2015, 2015, 1-8.	0.5	17
2330	Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	14
2331	The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. Cancers, 2015, 7, 2094-2109.	1.7	19
2332	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.0	3
2333	Surgery and Staging of Melanoma. , 2015, , .		0
2334	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	0.8	57
2336	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. Clinical Cancer Drugs, 2015, 2, 16-28.	0.3	0
2337	Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83.	1.8	344
2338	Achievements and Challenges of Molecular Targeted Therapy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 177-186.	1.8	37

#	Article	IF	Citations
2339	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget, 2015, 6, 2496-2508.	0.8	16
2340	Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. Current Molecular Pharmacology, 2015, 7, 33-43.	0.7	3
2341	Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget, 2015, 6, 4968-4975.	0.8	44
2342	Implications and benefits of the NICE appraisal of pembrolizumab. British Journal of Health Care Management, 2015, 21, 506-508.	0.1	0
2343	Can Redirected T Cells Outsmart Aggressive Melanoma? The Promise and Challenge of Adoptive Cell Therapy. , 0, , .		0
2344	Toxicities of New Drugs for Melanoma Treatment and their Management. , 0, , .		0
2345	RAGE and Its Ligands in Melanoma. , 0, , .		0
2346	Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Research, 2015, 25, 75-79.	0.6	27
2347	CO2 Laser Treatment for Regional Cutaneous Malignant Melanoma Metastases. Dermatologic Surgery, 2015, 41, 78-82.	0.4	12
2348	The Evolving Molecular Genetics of Low-grade Glioma. Advances in Anatomic Pathology, 2015, 22, 94-101.	2.4	89
2349	Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma. Scientific Reports, 2015, 5, 7857.	1.6	89
2350	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology, 2015, 42, 387-401.	0.8	24
2351	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E536-45.	3.3	121
2352	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.3	46
2353	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Molecular Therapy, 2015, 23, 931-942.	3.7	44
2354	Radiosensitization by BRAF inhibitor therapyâ€"mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 2015, 26, 1238-1244.	0.6	101
2355	Personalized Therapies for Cancer Treatment. , 2015, , 317-346.		0
2356	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer, 2015, 51, 1435-1443.	1.3	61

#	Article	IF	Citations
2357	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology, 2015, 11, 997-1009.	1.1	2
2358	Getting the Whole Picture: Lymphangitic Carcinomatosis. American Journal of Medicine, 2015, 128, 837-840.	0.6	13
2360	Exploratory use of docetaxel loaded acid-prepared mesoporous spheres for the treatment of malignant melanoma. Cancer Nanotechnology, 2015, 6, 1.	1.9	1
2361	BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. Expert Opinion on Pharmacotherapy, 2015, 16, 1285-1297.	0.9	24
2362	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	0.8	1,988
2363	Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells. Journal of Investigative Dermatology, 2015, 135, 842-850.	0.3	30
2364	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	12.5	456
2365	Multiscale analysis of the murine intestine for modeling human diseases. Integrative Biology (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	6
2366	Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Pharmacoeconomics, 2015, 33, 1269-1279.	1.7	13
2367	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 96, 156-166.	2.0	61
2368	Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma. Molecular Cell, 2015, 59, 75-88.	4.5	166
2369	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 2015, 7, 107-121.	1.4	8
2370	The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Annals of Oncology, 2015, 26, 1980-1987.	0.6	88
2371	RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotes apoptosis of human melanoma cells. Journal of Dermatological Science, 2015, 79, 57-63.	1.0	18
2372	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	13.9	6,773
2375	AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation. Chemico-Biological Interactions, 2015, 236, 9-18.	1.7	12
2376	Desmoplastic infantile astrocytoma with multiple intracranial and intraspinal localizations at presentation. Child's Nervous System, 2015, 31, 959-964.	0.6	12
2377	Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 996-1015.	2.2	5

#	Article	IF	Citations
2378	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. Journal of Neuro-Oncology, 2015, 123, 75-84.	1.4	8
2379	Prioritizing therapeutic targets using patient-derived xenograft models. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 223-234.	3.3	29
2380	Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. European Journal of Cancer, 2015, 51, 642-652.	1.3	30
2381	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	0.6	39
2382	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. Expert Opinion on Therapeutic Targets, 2015, 19, 733-745.	1.5	22
2383	Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncology, 2015, 11, 579-589.	1.1	16
2384	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. Future Oncology, 2015, 11, 591-606.	1.1	16
2385	Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Research, 2015, 75, 1668-1674.	0.4	40
2386	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients. Clinical Cancer Research, 2015, 21, 98-105.	3.2	60
2387	Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clinical Cancer Research, 2015, 21, 2624-2634.	3.2	25
2388	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Molecular Cancer Therapeutics, 2015, 14, 1236-1246.	1.9	36
2389	Novel therapeutic options for relapsed hairy cell leukemia. Leukemia and Lymphoma, 2015, 56, 2264-2272.	0.6	13
2390	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Molecular Therapy, 2015, 23, 845-856.	3.7	11
2391	Personalized Therapy of Cancer. , 2015, , 199-381.		1
2392	Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncology, 2015, 1, 359.	3.4	164
2393	The relationship between hand hygiene and health care-associated infection: it’s complicated. Infection and Drug Resistance, 2015, 8, 7.	1.1	39
2394	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Molecular Cancer Therapeutics, 2015, 14, 1680-1692.	1.9	32
2395	The Mybâ€“p300 Interaction Is a Novel Molecular Pharmacologic Target. Molecular Cancer Therapeutics, 2015, 14, 1273-1275.	1.9	10

#	Article	IF	Citations
2396	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0
2397	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. Clinical Cancer Research, 2015, 21, 2424-2435.	3.2	29
2398	Emerging clinical applications of selected biomarkers in melanoma. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 35.	0.8	18
2399	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. Current Colorectal Cancer Reports, 2015, 11, 303-310.	1.0	0
2400	Is chemotherapy still an option in the treatment of melanoma?. Annals of Oncology, 2015, 26, 2203-2204.	0.6	1
2401	A singleâ€dose mass balance and metaboliteâ€profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research and Perspectives, 2015, 3, e00113.	1.1	24
2402	Complete Cytologic Remission of V600E BRAF-Mutant Melanomaâ€“Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. Journal of Clinical Oncology, 2015, 33, e109-e111.	0.8	31
2403	Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e122-e124.	0.8	101
2404	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e133-e134.	0.8	10
2405	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v126-v132.	0.6	308
2406	Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiology and Oncology, 2015, 49, 71-74.	0.6	28
2407	Talimogene laherparepvec in the treatment of melanoma. Expert Opinion on Biological Therapy, 2015, 15, 1517-1530.	1.4	8
2408	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	2.1	51
2409	Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer, 2015, 51, 2785-2791.	1.3	53
2410	BRAF inhibitor therapy in HCL. Best Practice and Research in Clinical Haematology, 2015, 28, 246-252.	0.7	13
2412	Treatment Individualization in Colorectal Cancer. Current Colorectal Cancer Reports, 2015, 11, 335-344.	1.0	17
2413	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. Melanoma Management, 2015, 2, 353-366.	0.1	1
2414	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia Research, 2015, 39, 1270-1277.	0.4	11

#	Article	IF	Citations
2415	Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. Karger Kompass Dermatologie, 2015, 3, 65-72.	0.0	0
2416	Is there a role for targeted medical therapies in patients with craniopharyngiomas?. Future Oncology, 2015, 11, 3221-3223.	1.1	4
2417	Langerhans cell histiocytosis: a comprehensive review. Pathology, 2015, 47, 294-301.	0.3	67
2418	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma. Journal of Investigative Medicine High Impact Case Reports, 2015, 3, 232470961560372.	0.3	4
2419	BRAF Alterations as Therapeutic Targets in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1396-1403.	0.5	76
2420	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. Ophthalmology, 2015, 122, 1907-1916.	2.5	69
2421	Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 2015, 25, 177-180.	0.3	18
2422	Intratumoral talimogene laherparepvec therapy in melanoma. Melanoma Management, 2015, 2, 297-300.	0.1	2
2423	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic Advances in Medical Oncology, 2015, 7, 181-191.	1.4	20
2424	Les inhibiteurs de tyrosine kinase. Actualites Pharmaceutiques, 2015, 54, 22-27.	0.0	0
2425	Progress in targeting RAF kinases for cancer therapy. Personalized Medicine, 2015, 12, 183-186.	0.8	1
2426	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	1.3	269
2427	Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report. Melanoma Management, 2015, 2, 115-120.	0.1	4
2428	EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model. Journal of Pharmacological Sciences, 2015, 129, 65-71.	1.1	13
2431	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports, 2015, 11, 1458-1473.	2.9	55
2432	Delayed presentation of a metastatic choroidal melanoma to the liver: The latency of an elective metastatic localization. International Journal of Surgery Case Reports, 2015, 15, 26-29.	0.2	1
2433	RASopathic alopecia: Hair changes associated with vemurafenib therapy. Journal of the American Academy of Dermatology, 2015, 72, 738-741.	0.6	22
2434	Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer & Metabolism, 2015, 3, 11.	2.4	139

#	Article	IF	Citations
2435	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 206-219.	2.0	22
2436	Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation. Dermatology, 2015, 231, 378-384.	0.9	45
2437	Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Review of Anticancer Therapy, 2015, 15, 101-108.	1.1	27
2438	Cutaneous adverse effects of <scp>BRAF</scp> inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 61-68.	1.3	31
2440	Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncology, The, 2015, 16, e43-e52.	5.1	72
2441	Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: A review of the current literature. Gynecologic Oncology, 2015, 136, 143-157.	0.6	85
2442	BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Hormones and Cancer, 2015, 6, 21-36.	4.9	54
2443	<scp>KRAS</scp> and <scp>BRAF</scp> mutations in anal carcinoma. Apmis, 2015, 123, 53-59.	0.9	20
2444	Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. American Journal of Health-System Pharmacy, 2015, 72, 101-110.	0.5	14
2445	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	0.8	64
2446	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer, 2015, 51, 271-281.	1.3	108
2447	Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochemical Pharmacology, 2015, 93, 290-304.	2.0	49
2448	Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. Expert Review of Clinical Pharmacology, 2015, 8, 25-33.	1.3	8
2449	Mucosal Melanoma: An Update. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 96-103.	0.2	2
2450	Exploring a cascade Heckâ€“Suzuki reaction based route to kinase inhibitors using design of experiments. Organic and Biomolecular Chemistry, 2015, 13, 3382-3392.	1.5	21
2451	MGMT promoter methylation is associated with temozolomide response and prolonged progressionâ€free survival in disseminated cutaneous melanoma. International Journal of Cancer, 2015, 136, 2844-2853.	2.3	45
2452	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAF^{V600E}-Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	0.8	238
2454	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	2.1	97

#	Article	IF	Citations
2455	Prognostic and predictive values of oncogenic BRAF, NRAS, câ€KIT and MITF in cutaneous and mucous melanoma. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1530-1538.	1.3	34
2456	Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain. Seminars in Oncology, 2015, 42, 459-465.	0.8	20
2457	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. European Journal of Cancer, 2015, 51, 359-366.	1.3	21
2458	Immunomodulation of Selective Naive T Cell Functions by p110Î´ Inactivation Improves the Outcome of Mismatched Cell Transplantation. Cell Reports, 2015, 10, 702-710.	2.9	12
2459	Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Reports, 2015, 16, 280-296.	2.0	200
2460	Towards the taxonomy of human disease. Nature Reviews Drug Discovery, 2015, 14, 75-76.	21.5	46
2462	<scp>CTLA</scp>â€4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Medicine, 2015, 4, 661-672.	1.3	100
2463	25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations. Molecular Pharmacology, 2015, 87, 766-775.	1.0	130
2464	The metabolic state of cancer stem cellsâ€"a valid target for cancer therapy?. Free Radical Biology and Medicine, 2015, 79, 264-268.	1.3	27
2465	The role of the PI3K pathway in colorectal cancer. Critical Reviews in Oncology/Hematology, 2015, 94, 18-30.	2.0	96
2466	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell, 2015, 27, 85-96.	7.7	188
2467	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 2015, 21, 1652-1664.	3.2	106
2468	Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer. BioDrugs, 2015, 29, 15-30.	2.2	18
2469	Ten things you should know about protein kinases: <scp>IUPHAR R</scp>eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	2.7	270
2470	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology, 2015, 26, 415-421.	0.6	78
2471	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. , 2015, 149, 139-149.		27
2472	BRAF and MEK inhibition in melanoma. Expert Opinion on Drug Safety, 2015, 14, 559-570.	1.0	67
2473	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. Cancer Discovery, 2015, 5, 274-287.	7.7	107

#	Article	IF	Citations
2474	Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cellular Oncology (Dordrecht), 2015, 38, 39-48.	2.1	8
2475	Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 1313-1320.	3.2	240
2476	Individualized Medicine. Advances in Predictive, Preventive and Personalised Medicine, 2015, , .	0.6	8
2477	Reference Databases for Disease Associations. , 2015, , 191-216.		0
2478	Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 769-794.	1.7	94
2479	Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology, 2015, 72, 221-236.	0.6	150
2480	RAS Mutations in Benign Epithelial Tumors Associated with BRAF Inhibitor Treatment of Melanoma. Journal of Investigative Dermatology, 2015, 135, 636-639.	0.3	6
2481	Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3.		0
2482	Nivolumab in Previously Untreated Melanoma withoutBRAFMutation. New England Journal of Medicine, 2015, 372, 320-330.	13.9	4,795
2483	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer, 2015, 51, 327-339.	1.3	63
2484	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology, 2015, 22, 2135-2142.	0.7	126
2485	Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Physical Biology, 2015, 12, 016008.	0.8	39
2486	Adaptive stress signaling in targeted cancer therapy resistance. Oncogene, 2015, 34, 5599-5606.	2.6	57
2487	Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy. Cell, 2015, 160, 977-989.	13.5	295
2488	Long-term Follow-up for Melanoma Patients. Surgical Oncology Clinics of North America, 2015, 24, 359-377.	0.6	32
2489	Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor Î² by the monoclonal antibody fresolimumab (GC1008). Cancer Immunology, Immunotherapy, 2015, 64, 437-446.	2.0	104
2492	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine, 2015, 10, 219-246.	1.0	11
2493	Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumor Biology, 2015, 36, 1003-1013.	0.8	37

#	Article	IF	Citations
2494	BRAF V600E mutation-specific antibody: A review. Seminars in Diagnostic Pathology, 2015, 32, 400-408.	1.0	116
2495	Review of low-grade gliomas in childrenâ€"evolving molecular era and therapeutic insights. Child's Nervous System, 2015, 31, 643-652.	0.6	10
2496	Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis, 2015, 30, 205-211.	1.0	46
2497	Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52Âweeks. British Journal of Dermatology, 2015, 172, 239-243.	1.4	43
2498	Overview of Predictive Biomarkers and Integration of IHC into Molecular Pathology. , 2015, , 91-104.		1
2499	The Cancer Genomics Resource List 2014. Archives of Pathology and Laboratory Medicine, 2015, 139, 989-1008.	1.2	18
2501	Radiotherapy for cutaneous melanoma: current and future applications. Future Oncology, 2015, 11, 525-534.	1.1	25
2503	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€"Mediated Metastatic Melanoma Phenotype. Cancer Discovery, 2015, 5, 264-273.	7.7	82
2504	Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation. Leukemia and Lymphoma, 2015, 56, 2690-2698.	0.6	6
2505	Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Therapeutic Advances in Medical Oncology, 2015, 7, 122-136.	1.4	267
2507	The histiocytosis Erdheimâ€"Chester disease is an inflammatory myeloid neoplasm. Expert Review of Clinical Immunology, 2015, 11, 1033-1042.	1.3	38
2508	MEK inhibitors beyond monotherapy: current and future development. Current Opinion in Pharmacology, 2015, 23, 61-67.	1.7	17
2509	New molecular therapies for hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S80-S85.	0.7	30
2510	¹⁸F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. American Journal of Roentgenology, 2015, 205, 259-270.	1.0	57
2511	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
2513	Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. European Journal of Cancer, 2015, 51, 1596-1602.	1.3	9
2514	Melanoma: Advances in Targeted Therapy and Molecular Markers. Annals of Surgical Oncology, 2015, 22, 3451-3458.	0.7	15
2515	Nuclear factor of activated T cells in cancer development and treatment. Cancer Letters, 2015, 361, 174-184.	3.2	86

#	Article	IF	Citations
2516	Targeted Therapies in Melanoma: Translational Research at Its Finest. Journal of Investigative Dermatology, 2015, 135, 1929-1933.	0.3	12
2517	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics, 2015, 47, 996-1002.	9.4	348
2518	Brave-ish New Worldâ€"Whatâ€™s Needed to Make Precision Oncology a Practical Reality. JAMA Oncology, 2015, 1, 879.	3.4	6
2519	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2015, 51, 2086-2094.	1.3	45
2520	Hematological Effects, Serum, and Pulmonary Cytokine Profiles in a Melanoma Mouse Model Treated with GK1. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 247-254.	0.7	5
2521	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. British Journal of Cancer, 2015, 112, 1326-1331.	2.9	30
2522	Fate and Plasticity of the Epidermis in Response to Congenital Activation of BRAF. Journal of Investigative Dermatology, 2015, 135, 481-489.	0.3	1
2523	Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncology, 2015, 1, 380.	3.4	66
2524	A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*. Molecular and Cellular Proteomics, 2015, 14, 1599-1615.	2.5	94
2525	Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma. Journal of Molecular Diagnostics, 2015, 17, 616-622.	1.2	2
2528	c-Myc modulation: a key role in melanoma drug response. Cancer Biology and Therapy, 2015, 16, 1375-1386.	1.5	7
2529	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	2.1	102
2530	The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biology, 2015, 48, 66-77.	1.5	19
2531	Cytotoxic and DNAâ€targeted therapy in urothelial cancer: Have we squeezed the lemon enough?. Cancer, 2015, 121, 179-187.	2.0	12
2532	The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Molecular Cancer Research, 2015, 13, 1265-1273.	1.5	72
2533	Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1927-34.	1.4	10
2534	Successes and setbacks of early investigational drugs for melanoma. Expert Opinion on Investigational Drugs, 2015, 24, 993-997.	1.9	4
2535	Phenotype Switching in Melanoma: Implications for Progression and Therapy. Frontiers in Oncology, 2015, 5, 31.	1.3	138

#	Article	IF	Citations
2536	Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Frontiers in Oncology, 2015, 5, 54.	1.3	87
2537	Increased BRAF copy number in lung adenocarcinoma. Oncology Letters, 2015, 9, 709-712.	0.8	6
2538	Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, 1873-1877.	0.8	9
2539	A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Annals of Oncology, 2015, 26, 573-582.	0.6	19
2540	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
2541	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Management, 2015, 2, 133-147.	0.1	3
2542	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma. JAMA Oncology, 2015, 1, 433.	3.4	201
2543	Prognostic and Predictive Biomarkers for Castration Resistant Prostate Cancer. Biomarkers in Disease, 2015, , 447-480.	0.0	1
2544	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. Journal of the American Academy of Dermatology, 2015, 73, 491-499.e2.	0.6	14
2545	The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma. Journal of Investigative Dermatology, 2015, 135, 1368-1376.	0.3	24
2546	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	0.6	980
2547	Use of vemurafenib in anaplastic thyroid carcinoma: a case report. Cancer Biology and Therapy, 2015, 16, 1430-1433.	1.5	42
2548	Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model. Free Radical Biology and Medicine, 2015, 87, 193-203.	1.3	25
2549	Trametinib in metastatic melanoma. Expert Review of Anticancer Therapy, 2015, 15, 749-760.	1.1	8
2550	Costâ€“effectiveness of therapies for melanoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 229-242.	0.7	9
2551	Clinical Management of Multiple Melanoma Brain Metastases. JAMA Oncology, 2015, 1, 668.	3.4	70
2553	Understanding next generation sequencing in oncology: A guide for oncologists. Critical Reviews in Oncology/Hematology, 2015, 96, 463-474.	2.0	38
2554	Intra- and Inter-Tumoral Homogeneity of BRAF V600E Mutations in Melanoma Tumors. Journal of Investigative Dermatology, 2015, 135, 3078-3085.	0.3	46

#	Article	IF	Citations
2555	Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956.	0.5	0
2556	Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Current Medical Research and Opinion, 2015, 31, 1561-1572.	0.9	26
2557	Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chemical Biology, 2015, 10, 2099-2107.	1.6	52
2558	Metastatic Melanoma â€“ A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	0.6	186
2559	The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Internal Medicine, 2015, 175, 1389.	2.6	287
2560	General Aspects of Cancer Chemotherapy. , 2015, , 1-22.		5
2561	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Seminars in Oncology, 2015, 42, 601-616.	0.8	139
2562	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treatment Reviews, 2015, 41, 660-670.	3.4	51
2563	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	3.0	78
2564	Targeted therapies in advanced differentiated thyroid cancer. Cancer Treatment Reviews, 2015, 41, 690-698.	3.4	61
2565	Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis. Modern Pathology, 2015, 28, 895-903.	2.9	15
2566	The rise in metastasectomy across cancer types over the past decade. Cancer, 2015, 121, 747-757.	2.0	127
2567	Genomic alterations in lung adenocarcinoma. Lancet Oncology, The, 2015, 16, e342-e351.	5.1	302
2568	KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer. Journal of Molecular Endocrinology, 2015, 54, 115-124.	1.1	9
2569	Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy. PLoS Computational Biology, 2015, 11, e1004142.	1.5	100
2570	Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment. Frontiers in Immunology, 2015, 6, 46.	2.2	69
2571	Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology, 2015, 17, 1051-1063.	0.6	178
2572	Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 2015, 125, 1780-1789.	3.9	364

#	Article	IF	Citations
2573	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods, 2015, 83, 118-127.	1.9	33
2574	The Burgeoning Field of Ablatogenomics. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 258-260.	2.1	7
2575	VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 155-168.	1.4	20
2576	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology and Therapy, 2015, 16, 662-670.	1.5	27
2577	Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Letters, 2015, 361, 86-96.	3.2	45
2578	The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discovery, 2015, 5, 475-487.	7.7	501
2579	Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. Journal of the American Academy of Dermatology, 2015, 72, 1036-1046.e2.	0.6	83
2580	Erdheim-Chester disease. European Journal of Internal Medicine, 2015, 26, 223-229.	1.0	123
2581	Efectos secundarios cutÃ¡neos de los nuevos fÃ¡rmacos antineoplÃ¡sicos. Piel, 2015, 30, 510-517.	0.0	1
2582	Toxicidad cutÃ¡nea de los inhibidores del BRAF y del MEK. Piel, 2015, 30, 309-315.	0.0	1
2583	Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors. Journal of the American Academy of Dermatology, 2015, 72, 741-743.	0.6	3
2584	Tumour and patient factors in renal cell carcinomaâ€"towards personalized therapy. Nature Reviews Urology, 2015, 12, 253-262.	1.9	22
2585	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€"Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	3.2	120
2586	Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opinion on Investigational Drugs, 2015, 24, 781-794.	1.9	4
2587	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	1.3	71
2590	Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. Cancer Immunology, Immunotherapy, 2015, 64, 349-355.	2.0	12
2591	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunology, Immunotherapy, 2015, 64, 381-388.	2.0	70
2592	Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society. Esophagus, 2015, 12, 158-169.	1.0	18

#	Article	IF	Citations
2593	A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 225-232.	1.2	40
2594	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Investigational New Drugs, 2015, 33, 664-670.	1.2	3
2595	LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. Journal of Neuro-Oncology, 2015, 122, 121-126.	1.4	62
2596	Anaplastic ganglioglioma: a report of three cases and review of the literature. Journal of Neuro-Oncology, 2015, 123, 171-177.	1.4	34
2597	Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology, 2015, 16, 15.	1.3	110
2598	The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy. Medical Oncology, 2015, 32, 440.	1.2	6
2599	Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2015, 372, 2521-2532.	13.9	4,838
2600	Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. Journal of Neurosurgery, 2015, 123, 395-401.	0.9	64
2601	On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Molecular Cancer Therapeutics, 2015, 14, 1488-1494.	1.9	82
2602	Melanoma Treatments: Advances and Mechanisms. Journal of Cellular Physiology, 2015, 230, 2626-2633.	2.0	40
2603	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 2015, 372, 2006-2017.	13.9	2,489
2604	Regulation of RAF protein kinases in ERK signalling. Nature Reviews Molecular Cell Biology, 2015, 16, 281-298.	16.1	506
2605	Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. Journal of Translational Medicine, 2015, 13, O1.	1.8	2
2606	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer, 2015, 15, 61.	1.1	25
2607	MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma. Molecular Cancer, 2015, 14, 68.	7.9	67
2608	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. Journal of Translational Medicine, 2015, 13, 26.	1.8	34
2609	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. European Journal of Dermatology, 2015, 25, 36-44.	0.3	35
2610	Application of biomarkers in oncology clinical trials. Clinical Investigation, 2015, 5, 61-74.	0.0	1

#	Article	IF	Citations
2611	Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treatment Reviews, 2015, 41, 401-411.	3.4	40
2612	Ganglion sentinelle et mÃ©lanome. Medecine Nucleaire, 2015, 39, 339-347.	0.2	0
2613	Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Cellular and Molecular Life Sciences, 2015, 72, 3731-3746.	2.4	38
2614	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	1.9	57
2615	Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells. Journal of Medicinal Chemistry, 2015, 58, 4165-4179.	2.9	72
2616	Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. Journal of Investigative Dermatology, 2015, 135, 2155-2161.	0.3	38
2617	Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer, 2015, 15, 356.	1.1	48
2618	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. Molecular Cancer Research, 2015, 13, 670-680.	1.5	22
2619	Biomarkers as Prognostic, Predictive, and Surrogate Endpoints. Current Clinical Pathology, 2015, , 31-41.	0.0	2
2620	Annotation of Sequence Variants in Cancer Samples. Journal of Molecular Diagnostics, 2015, 17, 339-351.	1.2	9
2621	BRAF V600E mutations: a series of case reports in patients with nonâ€“small cell lung cancer. Cancer Genetics, 2015, 208, 351-354.	0.2	9
2622	Design and activity of AP endonuclease-1 inhibitors. Journal of Chemical Biology, 2015, 8, 79-93.	2.2	26
2623	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Annals of Oncology, 2015, 26, 1830-1837.	0.6	43
2624	PARP inhibitors: the journey from research hypothesis to clinical approval. Personalized Medicine, 2015, 12, 139-154.	0.8	2
2625	Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. American Journal of Roentgenology, 2015, 204, 919-932.	1.0	10
2627	Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects. Brain Pathology, 2015, 25, 209-226.	2.1	88
2628	Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discovery, 2015, 5, 410-423.	7.7	181
2629	Targeted agents for cancer treatment during pregnancy. Cancer Treatment Reviews, 2015, 41, 301-309.	3.4	84

#	Article	IF	Citations
2630	Current Staging and Prognostic Factors in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 215-227.	0.6	51
2631	Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 349-356.	1.2	27
2632	Textbook of Personalized Medicine. , 2015, , .		27
2633	Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 2015, 520, 368-372.	13.7	389
2634	Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 829-848.	3.9	503
2635	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Annals of Oncology, 2015, 26, 1791-1798.	0.6	68
2636	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
2637	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Molecular Cancer Therapeutics, 2015, 14, 1354-1364.	1.9	33
2638	New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 2015, 33, e52-e56.	0.8	28
2639	The emerging molecular machinery and therapeutic targets of metastasis. Trends in Pharmacological Sciences, 2015, 36, 349-359.	4.0	52
2640	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research, 2015, 21, 2167-2176.	3.2	16
2641	Targeting precision medicine toxicity: recent developments. Therapeutic Advances in Drug Safety, 2015, 6, 4-14.	1.0	4
2642	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research, 2015, 21, 2892-2897.	3.2	31
2643	Activation of Î²2-adrenergic receptor by (R,Râ€²)-4â€²-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cellular Signalling, 2015, 27, 997-1007.	1.7	21
2644	Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin Î²1/FAK Signaling. Cancer Cell, 2015, 27, 574-588.	7.7	485
2645	Evaluation of ⁶⁸Ga- and ¹⁷⁷Lu-DOTA-PEG₄-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. Molecular Pharmaceutics, 2015, 12, 1929-1938.	2.3	39
2646	The Long and Winding Road. Journal of Clinical Oncology, 2015, 33, 229-231.	0.8	0
2647	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417

#	Article	IF	Citations
2648	BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro. Journal of Immunotherapy, 2015, 38, 12-23.	1.2	32
2649	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Research, 2015, 25, 68-74.	0.6	11
2650	Surgical management of metastatic melanoma in the era of targeted systemic therapies. Melanoma Research, 2015, 25, 1-8.	0.6	5
2651	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nature Reviews Clinical Oncology, 2015, 12, 319-334.	12.5	489
2652	Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations. Seminars in Diagnostic Pathology, 2015, 32, 381-391.	1.0	4
2653	Translating genomic discoveries to the clinic in pediatric oncology. Current Opinion in Pediatrics, 2015, 27, 34-43.	1.0	29
2654	Vemurafenib beyond progression in a patient with metastatic melanoma. Anti-Cancer Drugs, 2015, 26, 464-468.	0.7	2
2655	Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 61-67.	0.6	36
2656	Cross-cultural development of a quality-of-life measure for patients with melanoma. Melanoma Research, 2015, 25, 47-58.	0.6	16
2657	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Melanoma Research, 2015, 25, 180-183.	0.6	13
2658	BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Research, 2015, 25, 9-14.	0.6	43
2659	BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal, 2015, 5, e299-e299.	2.8	36
2660	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	1.2	1,566
2661	Treatment Algorithms in Stage IV Melanoma. American Journal of Therapeutics, 2015, 22, 61-67.	0.5	9
2662	BRAF VE1 Immunoreactivity Patterns in Epithelioid Glioblastomas Positive for BRAF V600E Mutation. American Journal of Surgical Pathology, 2015, 39, 528-540.	2.1	56
2663	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	2.1	25
2664	Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	4
2665	Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma. Therapeutic Drug Monitoring, 2015, 37, 132-136.	1.0	8

#	Article	IF	Citations
2666	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. American Journal of Therapeutics, 2015, 22, 44-53.	0.5	11
2667	Biomarker development in the context of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 295-301.	0.8	20
2668	In silico identification of novel kinase inhibitors by targeting B-Rafv660e from natural products database. Journal of Molecular Modeling, 2015, 21, 102.	0.8	6
2669	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 2015, 161, 205-214.	13.5	1,872
2670	Trametinib in the treatment of melanoma. Expert Opinion on Biological Therapy, 2015, 15, 735-747.	1.4	23
2671	Oncolytic Virus Immunotherapy for Melanoma. Current Treatment Options in Oncology, 2015, 16, 326.	1.3	40
2672	PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncology, 2015, 11, 1083-1091.	1.1	19
2674	Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit. Carcinogenesis, 2015, 36, 937-945.	1.3	19
2675	Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Translational Oncology, 2015, 8, 1-9.	1.7	23
2676	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncology, The, 2015, 16, 1389-1398.	5.1	206
2677	MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nature Reviews Cancer, 2015, 15, 577-592.	12.8	461
2678	Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. Cancer Research, 2015, 75, 4573-4581.	0.4	23
2679	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
2680	Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update. Archives of Pathology and Laboratory Medicine, 2015, 139, 1211-1214.	1.2	95
2681	Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib. JAMA Oncology, 2015, 1, 1133.	3.4	75
2682	Targeted therapy in cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1113-1132.	1.1	139
2683	Mutational Analysis of BRAF Inhibitorâ€“Associated Squamoproliferative Lesions. Journal of Molecular Diagnostics, 2015, 17, 644-651.	1.2	9
2684	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naÃ¯ve patients with metastatic melanoma. Annals of Oncology, 2015, 26, 2267-2274.	0.6	67

#	Article	IF	Citations
2685	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
2686	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600â€“Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	0.8	430
2687	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biology and Therapy, 2021, 22, 513-526.	1.5	24
2688	Biobanking for Personalized Medicine. Advances in Experimental Medicine and Biology, 2015, 864, 55-68.	0.8	41
2689	The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing. Journal of Photochemistry and Photobiology B: Biology, 2015, 151, 233-238.	1.7	20
2690	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. American Journal of Clinical Pathology, 2015, 144, 620-628.	0.4	43
2691	Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?. Cellular and Molecular Life Sciences, 2015, 72, 3589-3598.	2.4	2
2692	Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology/Hematology, 2015, 96, 385-398.	2.0	51
2693	Dabrafenib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 1075-1084.	0.5	0
2694	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatology and Therapy, 2015, 5, 151-169.	1.4	19
2695	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology, 2015, 26, 2173-2179.	0.6	74
2696	Targeting RAS -mutant Cancers: Is ERK the Key?. Trends in Cancer, 2015, 1, 183-198.	3.8	104
2697	Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance. Lab on A Chip, 2015, 15, 4614-4624.	3.1	23
2698	Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterology, 2015, 15, 63.	0.8	85
2699	Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology, 2015, 42, 896-908.	0.8	36
2700	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanomaâ€”challenges in management. International Journal of Colorectal Disease, 2015, 30, 1595-1602.	1.0	5
2701	What role could organoids play in the personalization of cancer treatment?. Pharmacogenomics, 2015, 16, 1523-1526.	0.6	11
2702	Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews Cancer, 2015, 15, 747-756.	12.8	466

#	Article	IF	Citations
2703	A river model to map convergent cancer evolution and guide therapy in RCC. Nature Reviews Urology, 2015, 12, 706-712.	1.9	49
2704	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naÃ¯ve patient melanomas. Clinical Epigenetics, 2015, 7, 59.	1.8	49
2705	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. Current Colorectal Cancer Reports, 2015, 11, 317-325.	1.0	0
2706	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. Cancer Biology and Therapy, 2015, 16, 1128-1135.	1.5	26
2707	Failures in Phase III: Causes and Consequences. Clinical Cancer Research, 2015, 21, 4552-4560.	3.2	70
2708	The emergence of precision therapeutics. Healthcare Management Forum, 2015, 28, S33-S39.	0.6	6
2709	Personalized Medicine: Four Perspectives of Tailored Medicine. Statistics in Biopharmaceutical Research, 2015, 7, 214-229.	0.6	44
2710	Next-generation sequencing and empowering personalised cancer medicine. Drug Discovery Today, 2015, 20, 1470-1475.	3.2	22
2711	Interferons and the Immunogenic Effects of Cancer Therapy. Trends in Immunology, 2015, 36, 725-737.	2.9	107
2712	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology, 2015, 42, 775-787.	0.8	6
2713	STAP-2 Protein Expression in B16F10 Melanoma Cells Positively Regulates Protein Levels of Tyrosinase, Which Determines Organs to Infiltrate in the Body. Journal of Biological Chemistry, 2015, 290, 17462-17473.	1.6	10
2714	Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015, 47, 1408-1410.	9.4	90
2715	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. Journal of Neuro-Oncology, 2015, 125, 411-418.	1.4	14
2716	<scp>ER</scp> stressâ€induced autophagy in melanoma. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 811-816.	0.9	21
2717	Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development. Advances in Experimental Medicine and Biology, 2015, 867, 81-90.	0.8	7
2718	Virologic and genetic evaluation of vemurafenib-induced skin cancers. Cutaneous and Ocular Toxicology, 2015, 34, 251-253.	0.5	5
2719	Tumorâ€infiltrating lymphocytes for the treatment of metastatic cancer. Molecular Oncology, 2015, 9, 1918-1935.	2.1	104
2721	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Nonâ€“V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Molecular Cancer Therapeutics, 2015, 14, 1962-1971.	1.9	25

#	Article	IF	Citations
2722	Vemurafenib inBRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	1.1	6
2723	Drug compound characterization by mass spectrometry imaging in cancer tissue. Archives of Pharmacal Research, 2015, 38, 1718-1727.	2.7	22
2724	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Molecular Cancer Therapeutics, 2015, 14, 2187-2197.	1.9	57
2725	Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature. Dermatology, 2015, 230, 1-4.	0.9	23
2726	Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. Dermatology, 2015, 231, 127-133.	0.9	10
2727	Systematic analysis of <scp>BRAF^V</scp>^{600E} melanomas reveals a role for <scp>JNK</scp>/câ€jun pathway in adaptive resistance to drugâ€induced apoptosis. Molecular Systems Biology, 2015, 11, 797.	3.2	84
2728	Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil. British Journal of Dermatology, 2015, 172, 1135-1136.	1.4	7
2729	<scp>BRAF</scp> inhibitorsâ€induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 392-393.	1.3	12
2730	<scp>W</scp>nt5<scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 184-195.	1.5	77
2731	Detailed imaging and genetic analysis reveal a secondary <scp>BRAF^L</scp>^{505H} resistance mutation and extensive intrapatient heterogeneity in metastatic <scp>BRAF</scp> mutant melanoma patients treated with vemurafenib. Pigment Cell and Melanoma Research, 2015, 28, 318-323.	1.5	20
2732	Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 121-123.	0.7	17
2733	The future of targeted therapies for brain metastases. Future Oncology, 2015, 11, 2315-2327.	1.1	6
2734	Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 2015, 151, 1103.	2.0	139
2735	Hitting the Target in BRAF-Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3990-3992.	0.8	12
2736	Emerging targets for combination therapy in melanomas. FEBS Letters, 2015, 589, 3438-3448.	1.3	21
2737	A molecular insight into the phototoxic reactions observed with vemurafenib, a first-line drug against metastatic melanoma. Photochemical and Photobiological Sciences, 2015, 14, 2119-2127.	1.6	10
2738	Busting robustness: using cancerâ€™s greatest strength to our advantage. Future Oncology, 2015, 11, 73-77.	1.1	7
2739	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncology, The, 2015, 16, e522-e526.	5.1	20

#	Article	IF	Citations
2740	Editorial overview: Cancer: Changing the landscape â€" new pharmacology steering the course towards improved treatment options in cancer. Current Opinion in Pharmacology, 2015, 23, iv-vi.	1.7	0
2741	RAF inhibitors that evade paradoxical MAPK pathway activation. Nature, 2015, 526, 583-586.	13.7	322
2742	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015, 4, e1032492.	2.1	53
2743	Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer, 2015, 15, 400.	1.1	38
2744	Variations of BRAF mutant allele percentage in melanomas. BMC Cancer, 2015, 15, 497.	1.1	36
2745	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs and Aging, 2015, 32, 821-834.	1.3	12
2746	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
2747	YY1 regulates melanoma tumorigenesis through a miR-9â€‰~â€‰RYBP axis. Journal of Experimental and Clinical Cancer Research, 2015, 34, 66.	3.5	54
2748	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy, 2015, 7, 981-997.	1.0	5
2749	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4032-4038.	0.8	583
2750	Role of the Medical Oncologist in the Management of Skin Cancer. Current Dermatology Reports, 2015, 4, 205-212.	1.1	0
2751	Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. Journal of Dermatological Science, 2015, 80, 33-37.	1.0	87
2753	Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. Journal of Proteome Research, 2015, 14, 4179-4193.	1.8	7
2754	Current position of TNF-Î± in melanomagenesis. Tumor Biology, 2015, 36, 6589-6602.	0.8	13
2755	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. Seminars in Cancer Biology, 2015, 35, 125-132.	4.3	20
2756	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	13.9	1,483
2757	Let's Not Put All Our Eggs in One Basket. New England Journal of Medicine, 2015, 373, 691-693.	13.9	14
2758	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	1.6	114

#	Article	IF	Citations
2759	Gauging the Long-Term Benefits of Ipilimumab in Melanoma. Journal of Clinical Oncology, 2015, 33, 1865-1866.	0.8	41
2760	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. OncoImmunology, 2015, 4, e998107.	2.1	65
2761	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist, 2015, 20, 617-618.	1.9	9
2762	Molecular Oncologic Testing of Skin and Adnexa Tumors. , 2015, , 567-618.		0
2763	RÃ1e de la TEP/TDM au 18FDG dans la caractÃ©risation et le suivi thÃ©rapeutique des histiocytoses. Medecine Nucleaire, 2015, 39, 357-370.	0.2	0
2764	A Bayesian adaptive design for biomarker trials with linked treatments. British Journal of Cancer, 2015, 113, 699-705.	2.9	26
2765	An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1307-1320.	1.9	7
2766	The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Medicinal Chemistry, 2015, 7, 269-289.	1.1	60
2767	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology, 2015, 8, 83-87.	0.3	24
2768	Cutaneous Drug Eruptions. , 2015, , .		1
2769	Precision Molecular Pathology of Dermatologic Diseases. Molecular Pathology Library, 2015, , .	0.1	2
2770	Recent progress on MAP kinase pathway inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4047-4056.	1.0	55
2771	Natural Killer cell control ofBRAFV600Emutant melanoma during targeted therapy. OncoImmunology, 2015, 4, e998119.	2.1	5
2772	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of Clinical Oncology, 2015, 33, 3817-3825.	0.8	393
2773	Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opinion on Investigational Drugs, 2015, 24, 1419-1431.	1.9	10
2774	Computational Systems Toxicology. Methods in Pharmacology and Toxicology, 2015, , .	0.1	5
2775	BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases. JAMA Dermatology, 2015, 151, 410.	2.0	27
2776	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2015, 373, 1733-1747.	13.9	281

#	Article	IF	Citations
2777	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	3.2	17
2778	Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cellular Signalling, 2015, 27, 2191-2200.	1.7	3
2779	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	3.2	136
2780	Development of a Center for Personalized Cancer Care at a Regional Cancer Center. Journal of Molecular Diagnostics, 2015, 17, 695-704.	1.2	14
2781	Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology and Therapy, 2015, 16, 1014-1018.	1.5	9
2782	Genetic Testing in the Multidisciplinary Management of Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 779-793.	0.6	3
2783	PhosphoPath: Visualization of Phosphosite-centric Dynamics in Temporal Molecular Networks. Journal of Proteome Research, 2015, 14, 4332-4341.	1.8	56
2784	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. Annals of Oncology, 2015, 26, 1470-1475.	0.6	46
2785	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. Journal of Clinical Oncology, 2015, 33, 2986-2998.	0.8	175
2786	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell, 2015, 28, 384-398.	7.7	243
2787	Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Molecular Cancer Therapeutics, 2015, 14, 2700-2711.	1.9	59
2788	The current management of brain metastasis in melanoma: a focus on riluzole. Expert Review of Neurotherapeutics, 2015, 15, 779-792.	1.4	12
2789	What is the future for cancer clinical trials?. Future Oncology, 2015, 11, 5-7.	1.1	0
2791	Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Research, 2015, 75, 5355-5366.	0.4	33
2792	Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurgical Focus, 2015, 38, E5.	1.0	20
2793	Myositis and metastatic melanoma. Clinical Medicine, 2015, 15, 210.	0.8	2
2794	NecrÃ³lisis epidÃ©rmica tÃ³xica por vemurafenib. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 682-683.	0.2	16
2795	Toxic epidermal necrolysis induced by vemurafenib. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 682-683.	0.2	6

#	Article	IF	Citations
2797	Primary Malignant Melanoma of the Lip: AÂReport of 48 Cases. Journal of Oral and Maxillofacial Surgery, 2015, 73, 2232-2240.	0.5	12
2798	Steroid hormone influence on melanomagenesis. Molecular and Cellular Endocrinology, 2015, 417, 94-102.	1.6	38
2799	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	1.1	43
2800	Detection of BRAF mutations from solid tumors using Tumorplexâ„¢ technology. MethodsX, 2015, 2, 316-322.	0.7	0
2801	MicroRNA-3151 inactivates TP53 in BRAF -mutated human malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6744-51.	3.3	17
2802	Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Seminars in Oncology, 2015, 42, 863-875.	0.8	24
2803	Molecular Pathways: Fatty Acid Synthase. Clinical Cancer Research, 2015, 21, 5434-5438.	3.2	212
2804	Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy. Journal of Oncology Pharmacy Practice, 2015, 21, 293-295.	0.5	8
2805	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 2015, 8, 111-118.	3.1	17
2806	Hairy cell leukemia: Past, present and future. Best Practice and Research in Clinical Haematology, 2015, 28, 269-272.	0.7	12
2807	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Molecular Oncology, 2015, 9, 2054-2062.	2.1	85
2808	Microenvironmental regulation of therapeutic response in cancer. Trends in Cell Biology, 2015, 25, 198-213.	3.6	604
2809	The Quinone Methide Aurin Is a Heat Shock Response Inducer That Causes Proteotoxic Stress and Noxa-dependent Apoptosis in Malignant Melanoma Cells. Journal of Biological Chemistry, 2015, 290, 1623-1638.	1.6	26
2810	Systemic Therapy of Brain Metastases. Current Neurology and Neuroscience Reports, 2015, 15, 518.	2.0	46
2811	New therapeutic options for advanced non-resectable malignant melanoma. Advances in Medical Sciences, 2015, 60, 83-88.	0.9	40
2812	BRAF Targets in Melanoma. Cancer Drug Discovery and Development, 2015, , .	0.2	2
2813	A review of sentinel lymph node biopsy for thin melanoma. Irish Journal of Medical Science, 2015, 184, 119-123.	0.8	11
2814	Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. Pharmacoeconomics, 2015, 33, 367-380.	1.7	19

#	Article	IF	Citations
2816	Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer, 2015, 87, 85-87.	0.9	28
2817	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitorâ€“Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 2015, 135, 532-541.	0.3	79
2818	Role of phosphoproteomics in the development of personalized cancer therapies. Proteomics - Clinical Applications, 2015, 9, 383-395.	0.8	40
2819	Mutations in G protein Î² subunits promote transformation and kinase inhibitor resistance. Nature Medicine, 2015, 21, 71-75.	15.2	106
2820	Clinicopathological characterization of primary oral and sinonasal melanoma in a referral centre in Mexico City: 2000â€“2012. International Journal of Oral and Maxillofacial Surgery, 2015, 44, 427-432.	0.7	6
2821	PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature Reviews Cancer, 2015, 15, 7-24.	12.8	1,083
2822	Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. Journal of Controlled Release, 2015, 198, 10-17.	4.8	35
2823	Optimization of Diarylthiazole Bâ€Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect. ChemMedChem, 2015, 10, 276-295.	1.6	8
2824	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	1.6	24
2825	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine, 2015, 372, 30-39.	13.9	2,240
2826	Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Modern Pathology, 2015, 28, 480-486.	2.9	37
2827	Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews Clinical Oncology, 2015, 12, 197-212.	12.5	162
2829	Abscopal effects of radiation therapy: A clinical review for the radiobiologist. Cancer Letters, 2015, 356, 82-90.	3.2	354
2830	Bridging scales in cancer progression: Mapping genotype to phenotype using neural networks. Seminars in Cancer Biology, 2015, 30, 30-41.	4.3	14
2831	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Medicinal Chemistry Letters, 2015, 6, 47-52.	1.3	14
2832	Nextâ€generation clinical trials: Novel strategies to address theÂchallenge of tumor molecular heterogeneity. Molecular Oncology, 2015, 9, 967-996.	2.1	119
2833	Beyond BRAF: where next for melanoma therapy?. British Journal of Cancer, 2015, 112, 217-226.	2.9	99
2834	Stress Response Pathways in Cancer. , 2015, , .		3

#	Article	IF	Citations
2836	Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunology, Immunotherapy, 2015, 64, 113-121.	2.0	28
2837	Emerging biomarkers in head and neck cancer in the era of genomics. Nature Reviews Clinical Oncology, 2015, 12, 11-26.	12.5	264
2838	Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E77-E81.	1.8	109
2839	Pharmacogenomics and the Resulting Impact on Psoriasis Therapies. Dermatologic Clinics, 2015, 33, 149-160.	1.0	13
2840	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants. Molecular Cancer Therapeutics, 2015, 14, 317-325.	1.9	43
2841	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research, 2015, 75, 181-193.	0.4	76
2842	Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. British Journal of Dermatology, 2015, 172, 1454-1455.	1.4	36
2843	Comparative analysis ofBRAF,NRASandc-KITmutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Experimental Dermatology, 2015, 24, 70-73.	1.4	5
2844	ActualizaciÃ³n en melanoma mucoso. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 96-103.	0.2	12
2845	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene, 2015, 34, 3215-3225.	2.6	130
2846	Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. Clinica Chimica Acta, 2015, 439, 128-136.	0.5	5
2847	Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors. European Journal of Medicinal Chemistry, 2015, 89, 581-596.	2.6	39
2848	Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene, 2015, 34, 2951-2957.	2.6	99
2849	The role of surgeons in building a personalized medicine program. Journal of Surgical Oncology, 2015, 111, 3-8.	0.8	5
2850	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188.	1.7	35
2851	Personalised cancer medicine. International Journal of Cancer, 2015, 137, 262-266.	2.3	277
2852	Immunotherapy in Melanoma. Journal of Pharmacy Practice, 2015, 28, 193-203.	0.5	8
2853	The Targeting of Indoleamine 2,3 Dioxygenase â€Mediated Immune Escape in Cancer. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 19-24.	1.2	30

#	Article	IF	Citations
2854	Metastatic Rhabdoid Meningioma withBRAFV600E Mutation and Good Response to Personalized Therapy: Case Report and Review of the Literature. Pediatric Hematology and Oncology, 2015, 32, 207-211.	0.3	30
2855	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015, 34, 3617-3626.	2.6	211
2856	Subungual desmoplastic malignant melanoma. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 360-362.	1.3	0
2857	Challenges in the use of immunotherapy in metastatic melanoma. BMJ Case Reports, 2016, 2016, bcr2016216681.	0.2	1
2858	miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget, 2016, 7, 53558-53570.	0.8	86
2859	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. Global & Regional Health Technology Assessment, 2016, 3, 9-15.	0.2	1
2860	Healthcare Analytics: From Data to Knowledge to Healthcare Improvement. , 2016, , .		12
2861	FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget, 2016, 7, 55924-55938.	0.8	103
2862	Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Postepy Dermatologii I Alergologii, 2016, 1, 52-56.	0.4	6
2863	Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3. Tumori, 2016, 102, S54-S56.	0.6	4
2865	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	0.8	6
2866	Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403.	1.1	45
2867	Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center. Anais Brasileiros De Dermatologia, 2016, 91, 40-43.	0.5	1
2868	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	3.9	219
2869	Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. OncoTargets and Therapy, 2016, 9, 2725.	1.0	18
2870	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	2.3	340
2871	Gene expression profiling analysis of lung adenocarcinoma. Brazilian Journal of Medical and Biological Research, 2016, 49, .	0.7	32
2872	Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget, 2016, 7, 9707-9717.	0.8	123

#	Article	IF	Citations
2873	Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma. Acta Dermato-Venereologica, 2016, 96, 630-634.	0.6	27
2874	Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests. Journal of Solid Tumors, 2016, 7, 14.	0.1	0
2875	Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. Oncolytic Virotherapy, 2016, Volume 5, 91-98.	6.0	13
2876	Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example. OncoTargets and Therapy, 2016, Volume 9, 5399-5404.	1.0	1
2877	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences, 2016, 17, 2149.	1.8	2
2878	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy, 2016, Volume 9, 7081-7093.	1.0	83
2879	Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib. Molecular Medicine Reports, 2016, 13, 3281-3288.	1.1	18
2880	Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience, 2016, 10, 648.	0.6	29
2881	Pragmatic medicine in solid cancer: a translational alternative to precision medicine. OncoTargets and Therapy, 2016, 9, 1839.	1.0	6
2882	Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature. Clinical Epidemiology, 2016, 8, 109.	1.5	91
2883	The Emerging Epigenetic Landscape in Melanoma. , 0, , .		0
2884	Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget, 2016, 7, 77163-77174.	0.8	73
2885	Management of Melanoma Therapy-Associated Toxicities. , 2016, , 299-319.		1
2886	Quality in the Age of Precision Medicine: The Clinician Perspective. Journal of Oncology Practice, 2016, 12, 839-843.	2.5	8
2887	Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183.		0
2888	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
2889	Patients with Brain Metastases from Melanoma. , 2016, , 185-196.		2
2890	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget, 2016, 7, 71737-71743.	0.8	72

#	Article	IF	Citations
2891	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e505-e514.	1.8	10
2892	B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up. Translational Lung Cancer Research, 2016, 5, 367-369.	1.3	8
2893	Brain Metastases from Melanoma. , 2016, , 65-83.		0
2894	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. World Journal of Gastrointestinal Oncology, 2016, 8, 173.	0.8	28
2895	Beyond RAS and BRAF: a target rich disease that is ripe for picking. Journal of Gastrointestinal Oncology, 2016, 7, 705-712.	0.6	2
2896	Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, 2369-2371.	0.6	3
2897	Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition. Translational Andrology and Urology, 2016, 5, 616-619.	0.6	0
2898	Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation. Case Reports in Oncological Medicine, 2016, 2016, 1-4.	0.2	4
2899	The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology. Journal of Nanotechnology, 2016, 2016, 1-18.	1.5	10
2900	Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatology Research and Practice, 2016, 2016, 1-6.	0.3	53
2901	Challenges and Opportunities of Nanoparticle-Based Theranostics inÂSkinÂCancer. , 2016, , 177-188.		4
2902	Targeted Nanoparticles for Drug Delivery to Melanoma. , 2016, , 203-215.		3
2903	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2
2904	Melanoma and the Unfolded Protein Response. Cancers, 2016, 8, 30.	1.7	32
2905	The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. OncoTargets and Therapy, 2016, 9, 3739.	1.0	9
2907	Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmacogenomics and Personalized Medicine, 2016, Volume 9, 65-77.	0.4	25
2908	BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. OncoTargets and Therapy, 2016, Volume 9, 7149-7159.	1.0	33
2909	An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo, Brazil), 2016, 14, 294-299.	0.3	2

#	Article	IF	Citations
2910	Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313.	0.9	16
2911	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 33.	1.8	84
2912	Estrogen Receptor Î² in Melanoma: From Molecular Insights to Potential Clinical Utility. Frontiers in Endocrinology, 2016, 7, 140.	1.5	57
2913	Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. Frontiers in Nutrition, 2016, 3, 48.	1.6	41
2914	Updates in Therapy for Advanced Melanoma. Cancers, 2016, 8, 17.	1.7	37
2915	Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. International Journal of Molecular Sciences, 2016, 17, 1468.	1.8	45
2916	A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer, 2016, 16, 634.	1.1	32
2917	The principle of safety evaluation in medicinal drug - how can toxicology contribute to drug discovery and development as a multidisciplinary science? -. Journal of Toxicological Sciences, 2016, 41, SP49-SP67.	0.7	7
2918	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS ONE, 2016, 11, e0155217.	1.1	14
2919	FRIZZLED7 Is Required for Tumor Inititation and Metastatic Growth of Melanoma Cells. PLoS ONE, 2016, 11, e0147638.	1.1	22
2920	Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma. PLoS ONE, 2016, 11, e0153576.	1.1	31
2921	Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS ONE, 2016, 11, e0157125.	1.1	8
2922	A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer. PLoS ONE, 2016, 11, e0162407.	1.1	74
2923	Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology, 2016, 5, 458-462.	0.4	23
2924	Biomarker Development in Targeting Cancer Epigenetic. , 2016, , 123-142.		0
2925	Cutaneous melanoma â€“ guidelines for diagnostics and therapy in 2016. Przeglad Dermatologiczny, 2016, 1, 1-18.	0.0	0
2926	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	1.0	7
2928	Clinical Genomics: Challenges and Opportunities. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 97-113.	0.4	12

#	Article	IF	Citations
2929	Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget, 2016, 7, 30453-30460.	0.8	48
2930	Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. , 2016, , 267-297.		11
2931	BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma. Advances in Anatomic Pathology, 2016, 23, 244-271.	2.4	19
2932	BRAF Inhibitor-Induced Panniculitis. Clinical Nuclear Medicine, 2016, 41, e149-e151.	0.7	4
2933	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. British Journal of Dermatology, 2016, 175, 966-978.	1.4	8
2934	Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review. Histopathology, 2016, 69, 535-541.	1.6	9
2935	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	1.2	26
2936	Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Research, 2016, 26, 321-328.	0.6	23
2937	Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Melanoma Research, 2016, 26, 1-11.	0.6	13
2938	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma. Melanoma Research, 2016, 26, 83-87.	0.6	21
2939	MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma. Melanoma Research, 2016, 26, 21-28.	0.6	22
2940	Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Research, 2016, 26, 367-376.	0.6	22
2941	Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Research, 2016, 26, 354-360.	0.6	13
2942	Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery, 2016, 42, S40-S48.	0.4	8
2943	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. Journal of Neuro-Oncology, 2016, 129, 389-393.	1.4	7
2944	Recognizing melanoma. Nurse Practitioner, 2016, 41, 24-29.	0.2	0
2945	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. Current Opinion in Oncology, 2016, 28, 185-191.	1.1	17
2946	Primary Malignant Melanoma of the Esophagus With Unusual Endoscopic Findings. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	7

#	Article	IF	Citations
2947	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. American Journal of Surgical Pathology, 2016, 40, 786-795.	2.1	41
2948	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	31
2949	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	2.1	14
2950	Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 354-356.	0.7	3
2951	Severe diclofenac photoallergy in a patient treated with vemurafenib. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 713-715.	1.3	3
2952	Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer Journal (Sudbury, Mass), 2016, 22, 138-146.	1.0	36
2953	câ€Metâ€mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Molecular Carcinogenesis, 2016, 55, 1678-1687.	1.3	47
2954	New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 419-426.	1.1	30
2955	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	2.9	61
2956	Wnt/Î²-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treatment Reviews, 2016, 49, 1-12.	3.4	85
2957	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€“ Update 2016. European Journal of Cancer, 2016, 63, 201-217.	1.3	330
2958	Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study. Statistics in Biopharmaceutical Research, 2016, 8, 248-257.	0.6	44
2959	Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with knownBRAFmutation status. British Journal of Dermatology, 2016, 174, 823-830.	1.4	26
2960	Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients withBRAF-mutant melanoma. British Journal of Dermatology, 2016, 174, 716-717.	1.4	2
2961	Destabilizing RET in targeted treatment of thyroid cancers. Endocrine Connections, 2016, 5, 10-19.	0.8	6
2962	Allied therapies against BRAF-mutated advanced colon cancer: the right plans to win the battle. Colorectal Cancer, 2016, 5, 53-55.	0.8	1
2963	Getting personal: Head and neck cancer management in the era of genomic medicine. Head and Neck, 2016, 38, E2250-8.	0.9	19
2964	Update on immune therapy in melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 799-808.	0.5	0

#	Article	IF	Citations
2965	Absence of microsatellite instability andBRAF(V600E) mutation in testicular germ cell tumors. Andrology, 2016, 4, 866-872.	1.9	18
2966	End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. British Journal of Dermatology, 2016, 175, 583-592.	1.4	19
2967	Benefits of dermoscopy for skin lesions confusing with tick bite and tick bites confusing with skin lesions. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 715-716.	1.3	2
2968	Precision Oncology Medicine: The Clinical Relevance of Patientâ€Specific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology, 2016, 56, 1484-1499.	1.0	75
2969	A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma. International Journal of Cancer, 2016, 139, 1106-1116.	2.3	14
2970	A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. British Journal of Cancer, 2016, 115, 223-227.	2.9	17
2971	The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resistance Updates, 2016, 28, 28-42.	6.5	24
2972	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
2973	Singleâ€cell profiling approaches to probing tumor heterogeneity. International Journal of Cancer, 2016, 139, 243-255.	2.3	52
2974	Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma Research, 2016, 26, 138-144.	0.6	12
2975	Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma. Melanoma Research, 2016, 26, 254-260.	0.6	24
2976	The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 285-289.	0.7	11
2977	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83.		14
2978	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research, 2016, 26, 157-163.	0.6	16
2979	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. Archives of Pathology and Laboratory Medicine, 2016, 140, 355-357.	1.2	9
2980	Antigenâ€specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. European Journal of Immunology, 2016, 46, 1351-1360.	1.6	31
2981	Melanoma therapy: Check the checkpoints. Journal of Dermatology, 2016, 43, 121-124.	0.6	13
2982	A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact lowâ€grade diffuse astrocytoma. Neuropathology, 2016, 36, 181-186.	0.7	22

#	Article	IF	Citations
2983	Clinicopathological characteristics associated with <scp>BRAF</scp>^{K601E} and <scp>BRAF</scp>^{L597} mutations in melanoma. Pigment Cell and Melanoma Research, 2016, 29, 222-228.	1.5	16
2984	Breaking BRAF(V600E)â€“drug resistance by stressing mitochondria. Pigment Cell and Melanoma Research, 2016, 29, 401-403.	1.5	5
2985	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	2.3	76
2986	The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 795-806.	2.3	19
2987	Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375. Skin Pharmacology and Physiology, 2016, 29, 281-290.	1.1	29
2989	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer, 2016, 5, 221-232.	4.2	44
2990	AACR Cancer Progress Report 2016. Clinical Cancer Research, 2016, 22, S1-S137.	3.2	29
2991	Systems Pharmacology and Pharmacodynamics. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , .	0.2	9
2992	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Translational Oncology, 2016, 9, 557-564.	1.7	16
2993	Functional exploration of colorectal cancer genomes using Drosophila. Nature Communications, 2016, 7, 13615.	5.8	82
2994	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74
2995	AKT1 as the PageRank hub gene is associated with melanoma and its functional annotation is highly related to the estrogen signaling pathway that may regulate the growth of melanoma. Oncology Reports, 2016, 36, 2087-2093.	1.2	9
2996	CRAF R391W is a melanoma driver oncogene. Scientific Reports, 2016, 6, 27454.	1.6	13
2997	Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report. Journal of Medical Case Reports, 2016, 10, 363.	0.4	2
2998	Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. European Journal of Dermatology, 2016, 26, 232-239.	0.3	34
2999	Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. International Journal of Oncology, 2016, 49, 1164-1174.	1.4	52
3000	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiology and Oncology, 2016, 50, 274-279.	0.6	24
3001	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54

#	Article	IF	Citations
3002	Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer, 2016, 16, 668.	1.1	11
3003	BrÃ¨ves de lâ€™AERIO. Oncologie, 2016, 18, 562-566.	0.2	0
3004	hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. Cell Death Discovery, 2016, 2, 16081.	2.0	11
3005	Optimizing combination dabrafenib and trametinib therapy in BRAF mutationâ€positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	0.7	22
3006	<scp>ZEB</scp> 1â€mediated melanoma cell plasticity enhances resistance to <scp>MAPK</scp> inhibitors. EMBO Molecular Medicine, 2016, 8, 1143-1161.	3.3	98
3007	CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncology Letters, 2016, 11, 2424-2428.	0.8	16
3008	Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells. Cancer Science, 2016, 107, 1919-1928.	1.7	14
3009	Advancements in unresectable melanoma: a multidisciplinary perspective. Melanoma Management, 2016, 3, 171-175.	0.1	0
3010	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2016, 1, 379-385.	0.4	5
3011	When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood, 2016, 128, 2381-2387.	0.6	51
3012	Chronic activation of the D156A point mutant of Channelrhodopsin-2 signals apoptotic cell death: the good and the bad. Cell Death and Disease, 2016, 7, e2447-e2447.	2.7	17
3013	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery, 2016, 2, 16028.	3.1	57
3014	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
3015	A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Research, 2016, 26, 604-608.	0.6	17
3016	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. Current Pharmacology Reports, 2016, 2, 309-325.	1.5	18
3018	Dermatologic conditions in the elderly. , 2016, , 477-508.		0
3019	Response to Targeted Therapy inBRAFMutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1203-1207.	2.3	16
3022	Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	6

#	Article	IF	Citations
3023	Genomic Alterationâ€“Driven Clinical Trial Designs in Oncology. Annals of Internal Medicine, 2016, 165, 270.	2.0	40
3024	Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Radiotherapy and Oncology, 2016, 118, 267-271.	0.3	36
3025	Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 270-279.	1.4	17
3026	Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. Cancer Research, 2016, 76, 2990-3002.	0.4	123
3027	Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert Opinion on Pharmacotherapy, 2016, 17, 1031-1038.	0.9	28
3028	From Nevi to Melanoma: Understanding the Basics of Lesions. Physician Assistant Clinics, 2016, 1, 221-231.	0.1	1
3029	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2016, 18, 370-377.	1.2	25
3030	AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. Oncogene, 2016, 35, 5295-5303.	2.6	48
3031	The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. Oncogenesis, 2016, 5, e216-e216.	2.1	24
3032	Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation. Angewandte Chemie, 2016, 128, 995-998.	1.6	0
3033	Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Management, 2016, 3, 149-159.	0.1	1
3034	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. Melanoma Management, 2016, 3, 137-147.	0.1	1
3036	Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity. Biochemical and Biophysical Research Communications, 2016, 470, 137-143.	1.0	0
3037	Positional proteomics in the era of the human proteome project on the doorstep of precision medicine. Biochimie, 2016, 122, 110-118.	1.3	42
3038	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. European Journal of Cancer, 2016, 62, 76-85.	1.3	178
3039	Lymph nodes and the melanoma surgeon: re-defining a long-term relationship. Melanoma Management, 2016, 3, 73-82.	0.1	0
3040	Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. British Journal of Cancer, 2016, 114, 669-679.	2.9	13
3041	What Is New in Melanoma Genetics and Treatment?. Dermatology, 2016, 232, 259-264.	0.9	25

#	Article	IF	Citations
3042	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports, 2016, 18, 42.	1.8	54
3043	Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. BioDrugs, 2016, 30, 307-319.	2.2	7
3044	Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. Journal of Laryngology and Otology, 2016, 130, S133-S141.	0.4	21
3045	Investigational new drugs for brain cancer. Expert Opinion on Investigational Drugs, 2016, 25, 937-956.	1.9	16
3046	Improving patient outcomes to targeted therapies in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 633-641.	1.1	6
3047	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
3048	Therapeutic Application of Pharmacogenomics in Oncology. AAPS Journal, 2016, 18, 819-829.	2.2	7
3050	Genomics of SCC: Tumor Formation, Progression, and Future Therapeutic Implications for High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , 67-102.		1
3051	The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma. Expert Review of Anticancer Therapy, 2016, 16, 705-715.	1.1	8
3052	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701.	0.4	203
3053	The Role of PGC1Î± in Cancer Metabolism and its Therapeutic Implications. Molecular Cancer Therapeutics, 2016, 15, 774-782.	1.9	149
3054	Genomically Driven Tumors and Actionability across Histologies:BRAF-Mutant Cancers as a Paradigm. Molecular Cancer Therapeutics, 2016, 15, 533-547.	1.9	63
3055	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 2016, 37, 462-476.	2.9	232
3056	Specialty pharmacy services for patients receiving oral medications for solid tumors. American Journal of Health-System Pharmacy, 2016, 73, 775-796.	0.5	14
3057	Pembrolizumab for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 867-873.	0.5	10
3058	Computational modeling in melanoma for novel drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 609-621.	2.5	15
3059	New oncogenes drivers in lung cancerâ€"new therapeutic targets. Current Pulmonology Reports, 2016, 5, 49-56.	0.5	0
3060	The Conundrum of Genetic â€œDriversâ€•in Benign Conditions. Journal of the National Cancer Institute, 2016, 108, djw036.	3.0	113

#	Article	IF	Citations
3061	Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. British Journal of Cancer, 2016, 114, 1071-1077.	2.9	155
3062	Combination with Î³-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells. Cancer Letters, 2016, 376, 43-52.	3.2	10
3063	Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples. Molecular Diagnosis and Therapy, 2016, 20, 241-253.	1.6	1
3064	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	1.3	8
3065	Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor. Journal of Dermatological Treatment, 2016, 27, 418-421.	1.1	7
3066	A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. Molecular Cancer Therapeutics, 2016, 15, 1163-1176.	1.9	19
3067	Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF^{V600E} melanoma. OncoImmunology, 2016, 5, e1089381.	2.1	32
3068	PD-1 Blockade in Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1573.	3.8	5
3070	BRAF inhibitors - do we need to worry about kidney injury?. Expert Opinion on Drug Safety, 2016, 15, 579-581.	1.0	9
3071	Targeted therapy in BRAF-mutated lung adenocarcinoma. Lancet Oncology, The, 2016, 17, 550-551.	5.1	1
3072	Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. Molecular and Cellular Oncology, 2016, 3, e1179381.	0.3	4
3073	Surgical Oncology Manual. , 2016, , .		1
3074	Emerging targeted therapies for melanoma. Expert Opinion on Emerging Drugs, 2016, 21, 195-207.	1.0	22
3075	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
3076	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clinical Cancer Research, 2016, 22, 3127-3131.	3.2	80
3077	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. Critical Reviews in Oncology/Hematology, 2016, 101, 32-39.	2.0	15
3078	Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. Journal of Medical Economics, 2016, 19, 900-912.	1.0	30
3079	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clinical Cancer Research, 2016, 22, 2127-2132.	3.2	21

#	Article	IF	Citations
3080	High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , .		5
3081	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines and Immunotherapeutics, 2016, 12, 2219-2231.	1.4	49
3082	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
3083	Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). International Journal of Radiation Oncology Biology Physics, 2016, 95, 632-646.	0.4	132
3084	The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle, 2016, 15, 1462-1470.	1.3	66
3085	Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1581-1589.	1.2	28
3086	Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology, 2016, 48, 113-131.	0.3	145
3088	RAS and RAF mutation status in the selection of patients for anti-EGFR therapy. Colorectal Cancer, 2016, 5, 81-89.	0.8	0
3089	Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Clinical Cancer Research, 2016, 22, 6031-6038.	3.2	16
3090	Zebrafish Melanoma. Advances in Experimental Medicine and Biology, 2016, 916, 439-450.	0.8	10
3091	Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma â€“ Case Series and Review. Klinische Monatsblatter Fur Augenheilkunde, 2016, 233, 540-544.	0.3	43
3092	Genetics of Melanoma. , 2016, , .		3
3093	Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Management, 2016, 3, 33-45.	0.1	28
3094	Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. Current Oncology Reports, 2016, 18, 67.	1.8	10
3095	Synthesis, radiolabelling, and biodistribution studies of triazole derivatives for targeting melanoma. Canadian Journal of Chemistry, 2016, 94, 773-780.	0.6	2
3096	Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis. Biomedicine and Pharmacotherapy, 2016, 83, 1321-1326.	2.5	5
3097	Design, synthesis and biological evaluation of novel benzo-Î±-pyrone containing piperazine derivatives as potential BRAF V600E inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4983-4991.	1.0	7
3098	Alterations in BRAF gene, and enhanced mTOR and MAPK signaling in dysembryoplastic neuroepithelial tumors (DNTs). Epilepsy Research, 2016, 127, 141-151.	0.8	26

#	Article	IF	Citations
3099	Clinical significance of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography in patients with primary malignant melanoma of the esophagus: report of three cases. Esophagus, 2016, 13, 311-316.	1.0	1
3100	Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. OncoImmunology, 2016, 5, e1219826.	2.1	9
3101	Treatment of malignant melanoma with nivolumab and vemurafenib combined with hypofractionated radiation therapy. International Cancer Conference Journal, 2016, 5, 214-218.	0.2	1
3102	Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAF^{V600} mutated melanoma. Melanoma Management, 2016, 3, 207-216.	0.1	21
3103	CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. Tumor Biology, 2016, 37, 13077-13090.	0.8	36
3104	Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. Journal of Clinical Oncology, 2016, 34, 3605-3608.	0.8	72
3105	What questions can a placebo answer?. Monash Bioethics Review, 2016, 34, 23-36.	0.4	9
3106	Actin remodeling confers <scp>BRAF</scp> inhibitor resistance to melanoma cells through <scp>YAP</scp>/<scp>TAZ</scp> activation. EMBO Journal, 2016, 35, 462-478.	3.5	201
3107	Primary malignant melanoma of the esophagus treated by endoscopic submucosal dissection: A case report. Experimental and Therapeutic Medicine, 2016, 12, 1319-1322.	0.8	11
3108	Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology, 2016, 43, 436-445.	0.8	64
3109	Targeted therapy in endometrial cancer: Making progress. Cancer, 2016, 122, 3428-3429.	2.0	1
3110	Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. European Journal of Cancer, 2016, 67, 213-222.	1.3	32
3111	Will we have a new ending for Irvin Yalom's novel? A medical oncologist view. Journal of Oncological Science, 2016, 2, 5-6.	0.1	0
3112	Biomarkers in Melanoma: Lessons from Translational Medicine. Trends in Cancer, 2016, 2, 305-312.	3.8	11
3114	Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC. European Urology Focus, 2016, 2, 465-466.	1.6	1
3118	Vemurafenib-induced pityriasis amiantacea: a case report. Cutaneous and Ocular Toxicology, 2016, 35, 329-331.	0.5	10
3119	Limits to Personalized Cancer Medicine. New England Journal of Medicine, 2016, 375, 1289-1294.	13.9	329
3120	Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials. Expert Review of Precision Medicine and Drug Development, 2016, 1, 419-430.	0.4	1

#	Article	IF	Citations
3121	Immunotherapy of Melanoma. Oncology Research and Treatment, 2016, 39, 369-376.	0.8	14
3122	Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1060-1069.	0.4	109
3123	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opinion on Pharmacotherapy, 2016, 17, 2253-2266.	0.9	26
3124	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	0.9	194
3125	Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Journal of Medical Case Reports, 2016, 10, 158.	0.4	9
3126	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. British Journal of Cancer, 2016, 115, 1280-1284.	2.9	36
3127	Pediatric melanoma. Seminars in Pediatric Surgery, 2016, 25, 290-298.	0.5	25
3128	The future of melanoma therapy: developing new drugs and improving the use of old ones. Future Oncology, 2016, 12, 2531-2534.	1.1	7
3130	Melanoma: Kids are not just little people. Clinics in Dermatology, 2016, 34, 742-748.	0.8	12
3131	Future Perspective of Single-Molecule FRET Biosensors and Intravital FRET Microscopy. Biophysical Journal, 2016, 111, 1103-1111.	0.2	37
3132	MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene. Tumor Biology, 2016, 37, 13941-13950.	0.8	31
3133	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260.	5.1	832
3134	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Seminars in Cell and Developmental Biology, 2016, 58, 108-117.	2.3	10
3135	A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 403-408.	0.7	11
3136	Cancer treatment and survivorship statistics, 2016. Ca-A Cancer Journal for Clinicians, 2016, 66, 271-289.	157.7	4,123
3137	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyteâ€macrophage colonyâ€stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head and Neck, 2016, 38, 1752-1758.	0.9	49
3138	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Investigational New Drugs, 2016, 34, 677-684.	1.2	30
3139	Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker. Clinical Pharmacology and Therapeutics, 2016, 100, 617-625.	2.3	57

#	Article	IF	Citations
3140	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell, 2016, 30, 485-498.	7.7	130
3141	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 489-521.	0.7	3
3142	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. Current Treatment Options in Oncology, 2016, 17, 48.	1.3	36
3143	Patient-derived tumor xenograft models for melanoma drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 895-906.	2.5	20
3144	Realâ€world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the <scp>IMAGE</scp> study. Cancer Medicine, 2016, 5, 1436-1443.	1.3	14
3145	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaâ€analysis of antiâ€CTLAâ€4 and antiâ€PDâ€1 agents trials. Cancer Medicine, 2016, 5, 1481-1491.	1.3	86
3146	Leveraging big data to transform target selection and drug discovery. Clinical Pharmacology and Therapeutics, 2016, 99, 285-297.	2.3	147
3147	Melanoma Regression and Recurrence in Zebrafish. Methods in Molecular Biology, 2016, 1451, 143-153.	0.4	6
3148	Inflammation and Metastasis. , 2016, , .		4
3149	Quantitative changes of melanomaâ€associated antigens as a biomarker for targeted therapy response. Experimental Dermatology, 2016, 25, 727-729.	1.4	1
3150	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
3151	FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome. Journal of Pathology: Clinical Research, 2016, 2, 41-52.	1.3	28
3152	HLA class I downregulation is associated with enhanced NKâ€cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. European Journal of Immunology, 2016, 46, 409-419.	1.6	31
3153	Biomarkers in melanoma. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S104-S112.	0.6	8
3154	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. Melanoma Management, 2016, 3, 231-243.	0.1	4
3155	Epidemiology of cutaneous melanoma in Swedenâ€”Stageâ€specific survival and rate of recurrence. International Journal of Cancer, 2016, 139, 2722-2729.	2.3	49
3156	The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. Journal of Thoracic Oncology, 2016, 11, 1615-1626.	0.5	74
3157	Trends in melanoma in the elderly in Denmark, 1980â€“2012. Acta OncolÃ³gica, 2016, 55, 52-58.	0.8	6

#	Article	IF	Citations
3158	Medicinal attributes of pyrazolo[1,5-a]pyrimidine based scaffold derivatives targeting kinases as anticancer agents. Future Journal of Pharmaceutical Sciences, 2016, 2, 60-70.	1.1	35
3159	B-Raf mutation and papillary thyroid carcinoma patients. Oncology Letters, 2016, 11, 2699-2705.	0.8	9
3160	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine, 2016, 10, 85-100.	2.7	56
3161	Detrimental effects of melanocortinâ€1 receptor (<scp>MC</scp>1R) variants on the clinical outcomes of <scp>BRAF</scp> V600 metastatic melanoma patients treated with <scp>BRAF</scp> inhibitors. Pigment Cell and Melanoma Research, 2016, 29, 679-687.	1.5	8
3162	BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1397-1405.	1.5	17
3163	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. Journal of Cell Communication and Signaling, 2016, 10, 191-196.	1.8	49
3164	Interplay Between Membrane Lipid Peroxidation and Photoproduct Formation in the Ultraviolet A-Induced Phototoxicity of Vemurafenib in Skin Keratinocytes. Toxicological Sciences, 2016, 154, 289-295.	1.4	8
3165	Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. , 2016, , .		1
3166	Sequencing of New and Old Therapies for Metastatic Melanoma. Current Treatment Options in Oncology, 2016, 17, 52.	1.3	7
3167	Revealing the molecular mechanism of different residence times of ERK2 inhibitors via binding free energy calculation and unbinding pathway analysis. Chemometrics and Intelligent Laboratory Systems, 2016, 158, 91-101.	1.8	16
3168	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. Cell Cycle, 2016, 15, 2405-2409.	1.3	11
3169	The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer. Journal of Molecular Diagnostics, 2016, 18, 605-619.	1.2	55
3170	Quantitative Super-Resolution Microscopy for Cancer Biology and Medicine. Series in Cellular and Clinical Imaging, 2016, , 321-350.	0.2	0
3171	Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14283-14288.	3.3	62
3172	The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvateâ€“Lactate Exchange in BRAF-Mutant Human Melanoma Cells. Molecular Cancer Therapeutics, 2016, 15, 2987-2999.	1.9	43
3173	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. Journal of Proteome Research, 2016, 15, 4476-4489.	1.8	16
3174	Does clinical trial participation improve outcomes in patients with ovarian cancer?. ESMO Open, 2016, 1, e000057.	2.0	9
3176	Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine, 2016, 375, 1054-1067.	13.9	660

#	Article	IF	Citations
3177	Comparing surface properties of melanoma cells using time of flight secondary ions mass spectrometry. Analyst, The, 2016, 141, 6217-6225.	1.7	5
3178	Clinical Prognostic Markers in Stage IIIB Melanoma. Annals of Surgical Oncology, 2016, 23, 4195-4202.	0.7	4
3179	Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opinion on Biological Therapy, 2016, 16, 1491-1499.	1.4	15
3180	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 627-642.	1.5	102
3181	Clinical Perspectives on Targeting Therapies for Personalized Medicine. Advances in Protein Chemistry and Structural Biology, 2016, 102, 79-114.	1.0	6
3182	Zebrafish. Methods in Molecular Biology, 2016, , .	0.4	9
3183	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
3184	Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules. Chemical Reviews, 2016, 116, 9001-9090.	23.0	702
3185	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatric Blood and Cancer, 2016, 63, 1974-1982.	0.8	49
3186	Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma. Orthopaedic Surgery, 2016, 8, 129-138.	0.7	2
3187	Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1272-1282.	5.1	290
3188	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology, 2016, 5, e1238557.	2.1	113
3189	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
3190	Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces. Scientific Reports, 2016, 6, 19709.	1.6	8
3191	Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221.	0.5	12
3192	Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open, 2016, 1, e000078.	2.0	38
3193	Targeted therapy and elderly people: A review. European Journal of Cancer, 2016, 69, 199-215.	1.3	34
3194	BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood, 2016, 128, 1918-1927.	0.6	84

#	Article	IF	Citations
3195	Genome and Skin Cancer. , 2016, , 127-139.		0
3196	The Treatment of Melanoma Brain Metastases. Current Oncology Reports, 2016, 18, 73.	1.8	16
3197	Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13456-13461.	3.3	65
3198	A phase I trial of panobinostat (<scp>LBH</scp>589) in patients with metastatic melanoma. Cancer Medicine, 2016, 5, 3041-3050.	1.3	51
3199	Cancer Drug Discovery. , 2016, , .		6
3200	Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. International Journal of Biochemistry and Cell Biology, 2016, 81, 121-132.	1.2	38
3201	Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular Cancer Therapeutics, 2016, 15, 3015-3027.	1.9	36
3202	A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 2016, 7, 11428.	5.8	136
3203	The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. Diabetes Care, 2016, 39, 1858-1869.	4.3	25
3204	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. Oncology and Therapy, 2016, 4, 239-256.	1.0	8
3206	Molekulare Diagnostik und Techniken. , 2016, , 51-60.		0
3207	Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Scientific Reports, 2016, 6, 22498.	1.6	96
3208	The combination of vemurafenib and cobimetinib in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 1105-1111.	0.5	3
3209	Development and Validation of Molecular Testing on Cytologic Specimens. Essentials in Cytopathology Series, 2016, , 1-15.	0.1	1
3210	From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathologica Communications, 2016, 4, 70.	2.4	115
3211	Recent Development in Methodology for Gene Network Problems and Inferences. , 2016, , 1-29.		0
3212	Anticancer effects of morin-7-sulphate sodium, a flavonoid derivative, in mouse melanoma cells. Biomedicine and Pharmacotherapy, 2016, 84, 909-916.	2.5	27
3213	Brain Metastases From Melanoma: Therapy at the Crossroads. International Journal of Radiation Oncology Biology Physics, 2016, 96, 713-716.	0.4	4

#	Article	IF	Citations
3214	Drug Combinations as the New Standard for Melanoma Treatment. Current Treatment Options in Oncology, 2016, 17, 61.	1.3	16
3215	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
3216	Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Scientific Reports, 2016, 6, 20864.	1.6	46
3217	An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Scientific Reports, 2016, 6, 22120.	1.6	11
3218	Targeting MAPK Signaling in Age-Related Macular Degeneration. Ophthalmology and Eye Diseases, 2016, 8, OED.S32200.	1.2	55
3219	BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. Case Reports in Oncology, 2016, 9, 241-245.	0.3	6
3220	PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM. Molecular Medicine Reports, 2016, 14, 521-528.	1.1	16
3222	Acute visual loss after ipilimumab treatment for metastatic melanoma. , 2016, 4, 66.		59
3223	Groverâ€™s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
3224	Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases. American Journal of Dermatopathology, 2016, 38, 687-689.	0.3	11
3225	Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer, 2016, 16, 889.	1.1	2
3226	How the future of clinical cancer diagnostics can contribute to overcoming race-associated cancer disparities. Expert Review of Molecular Diagnostics, 2016, 16, 1233-1235.	1.5	2
3227	Next-generation sequencing in patients with advanced cancer. Anti-Cancer Drugs, 2016, 27, 899-907.	0.7	3
3228	BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 175-178.	1.0	31
3229	Molecular Triage Trials in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 218-222.	1.0	0
3230	Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients. Melanoma Research, 2016, 26, 487-491.	0.6	7
3231	Systemic vasculitis associated with vemurafenib treatment. Medicine (United States), 2016, 95, e4988.	0.4	9
3232	Estimation of time-shift models with application to survival calibration in health technology assessment. Statistics in Medicine, 2016, 35, 3645-3656.	0.8	0

#	Article	IF	Citations
3233	Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy. Head and Neck, 2016, 38, E1122-9.	0.9	10
3234	Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Research, 2016, 26, 382-386.	0.6	31
3235	Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. British Journal of Dermatology, 2016, 174, 621-624.	1.4	27
3236	Radiological imaging in all stage III melanoma: current practice in the U.K.. British Journal of Dermatology, 2016, 175, 426-428.	1.4	0
3237	Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermatoâ€oncology clinic. International Journal of Dermatology, 2016, 55, 473-478.	0.5	9
3238	A singleâ€institution study examining cutaneous and nonâ€cutaneous melanomas treated with nivolumab. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e227-e229.	1.3	0
3239	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. Cancer Research, 2016, 76, 4765-4774.	0.4	86
3240	Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics, 2016, 15, 743-752.	1.9	144
3242	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	1.9	78
3243	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	1.8	10
3244	Treatment of elderly patients with melanoma. Memo - Magazine of European Medical Oncology, 2016, 9, 13-16.	0.3	0
3245	Talimogene laherparepvec in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 781-788.	0.5	0
3246	Impact of genomic sequencing on precision medicine for clinical oncology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 255-265.	0.4	0
3247	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms. JAMA Oncology, 2016, 2, 1452.	3.4	279
3248	Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma. Colloids and Surfaces B: Biointerfaces, 2016, 146, 188-197.	2.5	72
3249	Precision medicine informatics. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 668-670.	2.2	31
3250	The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. Molecular Cancer Therapeutics, 2016, 15, 1859-1869.	1.9	16
3251	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology, 2016, 5, e1201625.	2.1	21

#	Article	IF	Citations
3252	Radicality of initial surgery for primary malignant melanoma of the vagina. Melanoma Research, 2016, 26, 173-180.	0.6	4
3253	Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival. Melanoma Research, 2016, 26, 312-315.	0.6	23
3254	Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Molecular Cancer Research, 2016, 14, 767-775.	1.5	27
3255	Metastatic Cancer to the Parotid. Advances in Oto-Rhino-Laryngology, 2016, 78, 95-103.	1.6	11
3256	The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Expert Opinion on Drug Discovery, 2016, 11, 907-916.	2.5	111
3257	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. British Journal of Cancer, 2016, 115, 145-155.	2.9	50
3258	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncology, The, 2016, 17, 1037-1039.	5.1	26
3259	Ipilimumab in anti-PD1 refractory metastatic melanoma. Melanoma Research, 2016, 26, 153-156.	0.6	18
3260	Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers. Journal of Medicinal Chemistry, 2016, 59, 6501-6511.	2.9	26
3261	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. British Journal of Radiology, 2016, 89, 20160086.	1.0	2
3263	Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncology, 2016, 5, 175-186.	1.2	11
3264	Scientific Advances Shaping the Future Roles of Oncology Nurses. Seminars in Oncology Nursing, 2016, 32, 87-98.	0.7	13
3265	Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 911-922.	1.5	48
3266	Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin. Dermatologica Sinica, 2016, 34, 88-91.	0.2	5
3267	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine, 2016, 8, 132-149.	2.7	44
3268	Induction Chemotherapy. , 2016, , .		3
3269	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. Journal of Cancer Policy, 2016, 7, 12-22.	0.6	4
3270	BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Research, 2016, 26, 387-394.	0.6	81

#	Article	IF	Citations
3271	Emerging Role of mTOR in the Response to Cancer Therapeutics. Trends in Cancer, 2016, 2, 241-251.	3.8	95
3272	The use of biomarkers in the treatment of non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 25-36.	0.4	2
3273	The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark. BMC Cancer, 2016, 16, 295.	1.1	2
3274	BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. Diagnostic Pathology, 2016, 11, 39.	0.9	12
3275	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
3276	Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. CardioVascular and Interventional Radiology, 2016, 39, 1128-1135.	0.9	27
3277	Can histone proteins promote the growth of melanoma?. Melanoma Management, 2016, 3, 1-4.	0.1	2
3278	Severe rash associated with vemurafenib administration following nivolumab therapy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e84-e86.	1.3	12
3279	Management of Brain Metastases in Patients With Melanoma. Journal of Oncology Practice, 2016, 12, 536-542.	2.5	31
3280	Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 51-63.	3.3	8
3281	Contemporary and potential future molecular diagnosis of melanoma. Expert Review of Molecular Diagnostics, 2016, 16, 975-985.	1.5	3
3282	Primary mucosal melanoma of the head and neck in Denmark, 1982â€“2012: Demographic and clinical aspects. A retrospective DAHANCA study. Acta OncolÃ³gica, 2016, 55, 1001-1008.	0.8	31
3283	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochemical Pharmacology, 2016, 122, 1-9.	2.0	34
3284	Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. Current Opinion in Oncology, 2016, 28, 172-179.	1.1	10
3285	Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nuclear Medicine Communications, 2016, 37, 122-128.	0.5	23
3286	Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. Clinical and Experimental Medicine, 2016, 16, 295-300.	1.9	25
3288	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. British Journal of Cancer, 2016, 114, 256-261.	2.9	256
3289	Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations. Physical Chemistry Chemical Physics, 2016, 18, 5622-5629.	1.3	38

#	Article	IF	Citations
3290	Treatment of Melanoma CNS Metastases. Cancer Treatment and Research, 2016, 167, 263-279.	0.2	6
3291	Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Molecular Oncology, 2016, 10, 450-463.	2.1	79
3292	Patient knowledge and information-seeking about personalized cancer therapy. International Journal of Medical Informatics, 2016, 88, 52-57.	1.6	19
3293	The kinome 'at large' in cancer. Nature Reviews Cancer, 2016, 16, 83-98.	12.8	226
3294	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opinion on Biological Therapy, 2016, 16, 389-396.	1.4	35
3295	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry, 2016, 109, 314-341.	2.6	452
3296	B-Raf Inhibition in the Clinic: Present and Future. Annual Review of Medicine, 2016, 67, 29-43.	5.0	65
3297	Targeted therapy in cancer. Medicine, 2016, 44, 34-38.	0.2	23
3298	BRAF inhibitor therapyâ€“associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Human Pathology, 2016, 50, 79-89.	1.1	18
3299	Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. Clinical and Translational Oncology, 2016, 18, 848-858.	1.2	21
3300	Regulatory T cells in the immunotherapy of melanoma. Tumor Biology, 2016, 37, 77-85.	0.8	17
3301	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. American Journal of Clinical Dermatology, 2016, 17, 1-10.	3.3	8
3302	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
3303	Varying Mutational Alterations in Multiple Primary Melanomas. Journal of Molecular Diagnostics, 2016, 18, 75-83.	1.2	17
3304	Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors ofNRASsignaling pathway. Neuro-Oncology, 2016, 18, 528-537.	0.6	13
3305	Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clinical Cancer Research, 2016, 22, 2377-2385.	3.2	34
3306	Drugâ€“diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics, 2016, 16, 187-204.	1.5	4
3307	Use of vemurafenib in a patient unable to swallow whole. Journal of Oncology Pharmacy Practice, 2016, 22, 733-737.	0.5	6

#	Article	IF	Citations
3308	Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy, 2016, 16, 433-441.	1.4	16
3309	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	2.0	45
3310	Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. Future Oncology, 2016, 12, 25-30.	1.1	4
3311	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology, 2016, 126, 385-393.	1.4	31
3312	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. Practical Radiation Oncology, 2016, 6, 110-113.	1.1	3
3313	Prognostic and predictive biomarkers in melanoma: an update. Expert Review of Molecular Diagnostics, 2016, 16, 223-237.	1.5	23
3314	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist, 2016, 21, 84-94.	1.9	20
3315	Chemotherapy for Melanoma. Cancer Treatment and Research, 2016, 167, 209-229.	0.2	112
3316	Adjuvant Therapy of Melanoma. Cancer Treatment and Research, 2016, 167, 181-208.	0.2	17
3317	Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib. Clinical Cancer Research, 2016, 22, 1341-1347.	3.2	5
3318	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncology, 2016, 12, 751-762.	1.1	18
3319	Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Cancer Research, 2016, 76, 3067-3077.	0.4	75
3320	Vemurafenib and ipilimumab: A promising combination? Results of a case series. OncoImmunology, 2016, 5, e1101207.	2.1	17
3321	Personalised cancer care: promises and challenges of targeted therapy. Journal of the Royal Society of Medicine, 2016, 109, 98-105.	1.1	13
3322	Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. CNS Oncology, 2016, 5, 77-90.	1.2	28
3323	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 497-521.	9.6	37
3324	Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma. Drugs, 2016, 76, 605-615.	4.9	16
3325	Molecular techniques for predicting behaviour inÂmelanocytic neoplasms. Pathology, 2016, 48, 142-146.	0.3	7

#	Article	IF	Citations
3326	Dermoscopy in the era of dermato-oncology: from bed to bench side and retour. Expert Review of Anticancer Therapy, 2016, 16, 531-541.	1.1	10
3327	A cost-effective microdevice bridges microfluidic and conventional in vitro scratch / wound-healing assay for personalized therapy validation. Biochip Journal, 2016, 10, 56-64.	2.5	12
3328	Synthesis of Î±,Î²-Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. Journal of Medicinal Chemistry, 2016, 59, 3549-3561.	2.9	74
3329	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 692-700.	2.2	6
3330	2015 and human cancer: back to overall survival. Future Oncology, 2016, 12, 1751-1754.	1.1	0
3331	New Translational Research in the Medical Management of Orbital Melanoma. Seminars in Ophthalmology, 2016, 31, 53-58.	0.8	4
3332	Adjusting for treatment switching in the <scp>METRIC</scp> study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Medicine, 2016, 5, 806-815.	1.3	38
3333	Next-generation molecular diagnostics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 121-130.	1.0	1
3334	Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. Cancer Treatment Reviews, 2016, 45, 120-128.	3.4	8
3335	Hepatic Perfusion Therapy. Surgical Clinics of North America, 2016, 96, 357-368.	0.5	1
3336	Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation. Angewandte Chemie - International Edition, 2016, 55, 983-986.	7.2	43
3338	Recognizing melanoma. Nurse Practitioner, 2016, 41, 29-30.	0.2	4
3339	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-37.	0.4	4
3340	Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36.	0.4	16
3341	Severe cutaneous adverse reaction associated with vemurafenib: <scp>DRESS</scp>,<scp> AGEP</scp> or overlap reaction?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 178-179.	1.3	29
3342	Germline determinants of clinical outcome of cutaneous melanoma. Pigment Cell and Melanoma Research, 2016, 29, 15-26.	1.5	12
3343	Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib. ACS Chemical Biology, 2016, 11, 1595-1602.	1.6	19
3344	Cobimetinib and vemurafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2016, 17, 1005-1011.	0.9	21

#	Article	IF	Citations
3345	Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature. American Journal of Dermatopathology, 2016, 38, e93-e96.	0.3	22
3346	Dissecting Therapeutic Resistance to ERK Inhibition. Molecular Cancer Therapeutics, 2016, 15, 548-559.	1.9	50
3347	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	3.3	23
3348	The Changing Landscape of Pediatric Low-Grade Gliomas: Clinical Challenges and Emerging Therapies. Neuropediatrics, 2016, 47, 070-083.	0.3	17
3349	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology, 2016, 136, 994-1001.	0.3	27
3350	NRAS mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.1	12
3351	New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. Current Oncology Reports, 2016, 18, 18.	1.8	12
3352	Clostridium novyi-NT in cancer therapy. Genes and Diseases, 2016, 3, 144-152.	1.5	73
3353	Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Reports of Practical Oncology and Radiotherapy, 2016, 21, 271-277.	0.3	15
3354	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology, 2016, 28, 73-80.	2.7	56
3355	Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Cancer Letters, 2016, 382, 118-126.	3.2	15
3356	Experimental treatment of multiple myeloma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 37-51.	0.4	5
3357	Antitumor Activity of BRAF Inhibitor and IFNÎ± Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35
3358	Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. Journal of Neuro-Oncology, 2016, 127, 607-615.	1.4	51
3359	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	2.1	55
3360	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. Targeted Oncology, 2016, 11, 557-563.	1.7	16
3361	Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors. ACS Chemical Biology, 2016, 11, 1245-1254.	1.6	82
3362	Precision oncology: origins, optimism, and potential. Lancet Oncology, The, 2016, 17, e81-e86.	5.1	190

#	Article	IF	Citations
3363	Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines. Cancer Biology and Therapy, 2016, 17, 526-542.	1.5	9
3365	Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. Clinical and Translational Oncology, 2016, 18, 1044-1050.	1.2	0
3366	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology, 2016, 5, e1057673.	2.1	67
3367	DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?. Cancer Discovery, 2016, 6, 130-132.	7.7	44
3368	Keratoacanthoma (KA): An update and review. Journal of the American Academy of Dermatology, 2016, 74, 1220-1233.	0.6	174
3369	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. CKJ: Clinical Kidney Journal, 2016, 9, 245-251.	1.4	64
3370	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAFâ€“CRAF Heterodimerization. Cancer Research, 2016, 76, 1476-1484.	0.4	44
3371	The impact of sequencing on diagnosis and treatment of malignant melanoma. Expert Review of Molecular Diagnostics, 2016, 16, 423-433.	1.5	4
3372	Surgical Management of Melanoma. Cancer Treatment and Research, 2016, 167, 149-179.	0.2	14
3373	Braf V600E mutation in melanoma: translational current scenario. Clinical and Translational Oncology, 2016, 18, 863-871.	1.2	13
3374	Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmology, 2016, 16, 11.	0.6	34
3375	The possibility of clinical sequencing in the management of cancer. Japanese Journal of Clinical Oncology, 2016, 46, 399-406.	0.6	26
3376	Cutaneous manifestations of nontargeted and targeted chemotherapies. Seminars in Oncology, 2016, 43, 419-425.	0.8	23
3377	CancerResourceâ€”updated database of cancer-relevant proteins, mutations and interacting drugs. Nucleic Acids Research, 2016, 44, D932-D937.	6.5	33
3378	Sentinel Lymph Node Biopsy in Thin Cutaneous Melanoma: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2016, 23, 4178-4188.	0.7	91
3379	The Impact of Genomic Profiling for Novel Cancer Therapy â€“ Recent Progress in Non-Small Cell Lung Cancer. Journal of Genetics and Genomics, 2016, 43, 3-10.	1.7	8
3381	Development of immuno-oncology drugs â€” from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
3382	The current state of the art of quantitative phosphoproteomics and its applications to diabetes research. Expert Review of Proteomics, 2016, 13, 421-433.	1.3	26

#	Article	IF	Citations
3383	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.3	19
3384	Selumetinib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 223-231.	0.5	1
3385	Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. Journal of Neuro-Oncology, 2016, 128, 93-100.	1.4	80
3386	Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature Reviews Clinical Oncology, 2016, 13, 209-227.	12.5	177
3388	Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncology, 2016, 12, 95-106.	1.1	15
3389	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery, 2016, 6, 286-299.	7.7	208
3390	Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma. Brain Tumor Pathology, 2016, 33, 137-146.	1.1	35
3391	Personalized Preclinical Trials in BRAF Inhibitorâ€“Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	3.2	108
3392	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134.	1.3	137
3393	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Current Oncology Reports, 2016, 18, 6.	1.8	26
3395	Mutations of the EGFR, K-ras, EML4â€“ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surgery Today, 2016, 46, 1091-1098.	0.7	22
3396	Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. Journal of Molecular Diagnostics, 2016, 18, 190-204.	1.2	33
3397	Opportunities and challenges in combination gene cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 35-40.	6.6	64
3398	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Current Opinion in Immunology, 2016, 39, 30-38.	2.4	23
3399	The rapidly evolving therapies for advanced melanomaâ€”Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/Hematology, 2016, 99, 91-99.	2.0	87
3400	Response of metastatic glioma to vemurafenib. Neuro-Oncology Practice, 2016, 3, 268-271.	1.0	14
3401	Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). Advances in Experimental Medicine and Biology, 2016, 890, 203-222.	0.8	28
3402	Emerging Biomarkers in Personalized Therapy of Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 890, 25-36.	0.8	16

#	Article	IF	Citations
3403	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 48-56.	1.4	240
3404	Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of Oncology, 2016, 27, 434-441.	0.6	213
3406	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discovery, 2016, 6, 300-315.	7.7	134
3407	Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discovery, 2016, 6, 14-16.	7.7	14
3408	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 482-488.	3.3	37
3409	Principles of Melanoma Staging. Cancer Treatment and Research, 2016, 167, 131-148.	0.2	29
3410	MicroRNA-125b suppresses the epithelialâ€“mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumor Biology, 2016, 37, 5941-5949.	0.8	36
3411	Targeted Therapy for Melanoma. Cancer Treatment and Research, 2016, 167, 251-262.	0.2	75
3412	Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treatment and Research, 2016, 167, 295-320.	0.2	89
3413	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Annals of Oncology, 2016, 27, 373-378.	0.6	50
3414	Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Letters, 2016, 370, 332-344.	3.2	79
3415	Is the NCI MATCH trial a match for gynecologic oncology?. Gynecologic Oncology, 2016, 140, 161-166.	0.6	19
3416	Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia, 2016, 30, 937-946.	3.3	52
3417	Novel Treatments in Development for Melanoma. Cancer Treatment and Research, 2016, 167, 371-416.	0.2	15
3418	Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 251-259.	1.3	18
3419	Clinical Cases in Skin of Color. , 2016, , .		0
3420	Tumor microenvironment and cancer therapy resistance. Cancer Letters, 2016, 380, 205-215.	3.2	246
3421	Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 291-300.	3.2	185

#	Article	IF	Citations
3422	Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2016, 24, 175-183.	3.7	26
3423	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	3.2	188
3424	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research, 2016, 22, 1185-1196.	3.2	89
3425	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	2.3	31
3427	Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?. Blood Reviews, 2016, 30, 73-88.	2.8	23
3428	Sensitivity of plasma BRAF^{mutant} and NRAS^{mutant} cellâ€free DNA assays to detect metastatic melanoma in patients with low RECIST scores and nonâ€RECIST disease progression. Molecular Oncology, 2016, 10, 157-165.	2.1	63
3429	Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene, 2016, 35, 2166-2177.	2.6	49
3430	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research, 2016, 22, 374-382.	3.2	38
3431	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Targeted Oncology, 2016, 11, 149-156.	1.7	1
3432	Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. Targeted Oncology, 2016, 11, 59-69.	1.7	43
3433	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 2016, 18, 128-136.	1.1	83
3434	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene, 2016, 35, 1225-1235.	2.6	70
3435	Opportunities and challenges provided by crosstalk between signalling pathways in cancer. Oncogene, 2016, 35, 1073-1079.	2.6	39
3436	Clinicopathologic characteristics of esophageal primary malignant melanoma. Esophagus, 2016, 13, 17-24.	1.0	2
3437	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut, 2017, 66, 530-540.	6.1	161
3438	Economic burden of toxicities associated with treating metastatic melanoma in eight countries. European Journal of Health Economics, 2017, 18, 49-58.	1.4	37
3439	Gene Expression Profiling of Tumors From Heavily Pretreated Patients With Metastatic Cancer for the Selection of Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 140-145.	0.6	10
3440	BRAFâ€V600 mutational status affects recurrence patterns of melanoma brain metastasis. International Journal of Cancer, 2017, 140, 2716-2727.	2.3	24

#	Article	IF	Citations
3441	Lymphopenia can be a useful biomarker of adverse events related to vemurafenib. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e24-e26.	1.3	2
3442	Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. Oncogene, 2017, 36, 423-428.	2.6	30
3443	Radiotherapy utilization in <scp>BRAF</scp> mutationâ€tested metastatic melanoma in the targeted therapy era. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e117-e123.	0.7	2
3444	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clinical and Translational Oncology, 2017, 19, 119-124.	1.2	23
3446	Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. Oncogene, 2017, 36, 84-96.	2.6	35
3448	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	2.1	10
3449	Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nature Reviews Clinical Oncology, 2017, 14, 57-66.	12.5	239
3450	Discrete cytosolic macromolecular <scp>BRAF</scp> complexes exhibit distinct activities and composition. EMBO Journal, 2017, 36, 646-663.	3.5	52
3451	Bringing 3D tumor models to the clinic â€“ predictive value for personalized medicine. Biotechnology Journal, 2017, 12, 1600295.	1.8	35
3452	Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells. Cancer Research, 2017, 77, 1623-1636.	0.4	13
3453	Pseudokinases: update on their functions and evaluation as new drug targets. Future Medicinal Chemistry, 2017, 9, 245-265.	1.1	71
3454	Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells. Journal of Cancer Research and Clinical Oncology, 2017, 143, 639-648.	1.2	7
3455	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer, 2017, 116, 432-440.	2.9	59
3456	Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. Pathology Research and Practice, 2017, 213, 522-530.	1.0	4
3457	Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. Journal of Dermatological Treatment, 2017, 28, 549-553.	1.1	6
3458	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Journal of Hematology and Oncology, 2017, 10, 3.	6.9	47
3459	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 6-16.	0.2	14
3460	Pembrolizumabâ€™s non-cross resistance mechanism of action successfully overthrown ipilimumab. Critical Reviews in Oncology/Hematology, 2017, 111, 1-6.	2.0	8

#	Article	IF	Citations
3461	P21â€activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. Molecular Carcinogenesis, 2017, 56, 1515-1525.	1.3	29
3463	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
3464	Genomic insights in gynecologic cancer. Current Problems in Cancer, 2017, 41, 8-36.	1.0	13
3466	Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia, 2017, 19, 17-27.	2.3	14
3467	Evolving health care through personal genomics. Nature Reviews Genetics, 2017, 18, 259-267.	7.7	98
3468	Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch. Clinical and Translational Science, 2017, 10, 84-92.	1.5	92
3469	Clinicopathologic characteristics and outcomes of Chinese patients with nonâ€smallâ€cell lung cancer and <scp>BRAF</scp> mutation. Cancer Medicine, 2017, 6, 555-562.	1.3	46
3470	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Medicine, 2017, 9, 4.	3.6	170
3471	Micro<scp>RNA</scp>â€125a promotes resistance to <scp>BRAF</scp> inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell and Melanoma Research, 2017, 30, 328-338.	1.5	34
3472	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. Cancer Treatment Reviews, 2017, 54, 34-42.	3.4	46
3473	Tumor-TargetingSalmonella typhimuriumA1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. Journal of Cellular Biochemistry, 2017, 118, 2314-2319.	1.2	53
3474	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene, 2017, 36, 3334-3345.	2.6	83
3475	Antiproliferative Effects of 1Î±-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Scientific Reports, 2017, 7, 40370.	1.6	20
3476	Recent advances of pyrrolopyridines derivatives: a patent and literature review. Expert Opinion on Therapeutic Patents, 2017, 27, 591-606.	2.4	7
3477	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene, 2017, 36, 3252-3262.	2.6	25
3478	The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis, 2017, 6, e291-e291.	2.1	53
3479	BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. British Journal of Dermatology, 2017, 177, 914-923.	1.4	29
3480	Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 611-629.	1.4	5

#	Article	IF	Citations
3481	BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. British Journal of Dermatology, 2017, 177, e94-e95.	1.4	11
3482	Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma. Molecular Diagnosis and Therapy, 2017, 21, 209-216.	1.6	8
3483	Predicting evolution. Nature Ecology and Evolution, 2017, 1, 77.	3.4	272
3484	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. Cancer and Metastasis Reviews, 2017, 36, 53-75.	2.7	30
3485	Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. European Journal of Medicinal Chemistry, 2017, 130, 86-106.	2.6	20
3486	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
3487	Nanomedicine as a potent strategy in melanoma tumor microenvironment. Pharmacological Research, 2017, 126, 31-53.	3.1	25
3488	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. American Journal of Clinical Dermatology, 2017, 18, 303-310.	3.3	12
3489	Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Scientific Reports, 2017, 7, 42604.	1.6	41
3490	Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity inKRASwild-type tumors. International Journal of Cancer, 2017, 140, 2331-2343.	2.3	30
3491	Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026781.	2.9	278
3492	Crosstalk signaling in targeted melanoma therapy. Cancer and Metastasis Reviews, 2017, 36, 23-33.	2.7	15
3493	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. Current Treatment Options in Oncology, 2017, 18, 9.	1.3	51
3494	Droplet-Based Digital PCR. Advances in Clinical Chemistry, 2017, 79, 43-91.	1.8	87
3495	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. OncoImmunology, 2017, 6, e1299303.	2.1	20
3496	Mechanisms of Drug Resistance in Melanoma. Handbook of Experimental Pharmacology, 2017, 249, 91-108.	0.9	63
3497	Precision medicine driven by cancer systems biology. Cancer and Metastasis Reviews, 2017, 36, 91-108.	2.7	38
3498	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	5.1	399

#	Article	IF	Citations
3499	Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?. Expert Opinion on Pharmacotherapy, 2017, 18, 487-495.	0.9	7
3500	Beyond the BRAF ^V ^{600E} hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients. British Journal of Dermatology, 2017, 177, 936-944.	1.4	39
3501	Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics, 2017, 14, 284-297.	2.1	471
3502	Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell and Melanoma Research, 2017, 30, 68-71.	1.5	8
3503	Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma. Handbook of Experimental Pharmacology, 2017, 249, 129-143.	0.9	3
3504	Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Current Problems in Cancer, 2017, 41, 182-193.	1.0	75
3505	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 2017, 75, 169-178.	1.3	96
3506	PIK3CAâ€mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. Pigment Cell and Melanoma Research, 2017, 30, 353-367.	1.5	9
3507	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. British Journal of Cancer, 2017, 116, 802-810.	2.9	124
3508	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
3509	AURKA Overexpression Is Driven byÂFOXM1 and MAPK/ERK Activation inÂMelanoma Cells Harboring BRAF orÂNRASÂMutations: Impact on MelanomaÂPrognosis and Therapy. Journal of Investigative Dermatology, 2017, 137, 1297-1310.	0.3	40
3510	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Reports, 2017, 18, 1543-1557.	2.9	95
3511	Isolation and Characterization of a Distinct Subpopulation from the WM115 Cell Line That Resembles In Vitro Properties of Melanoma Cancer Stem Cells. SLAS Discovery, 2017, 22, 484-493.	1.4	4
3512	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Current Oncology Reports, 2017, 19, 17.	1.8	30
3513	Transdermal Gene Delivery by Functional Peptide-Conjugated Cationic Gold Nanoparticle Reverses the Progression and Metastasis of Cutaneous Melanoma. ACS Applied Materials & Interfaces, 2017, 9, 9388-9401.	4.0	91
3514	Tissue-specific tumorigenesis: context matters. Nature Reviews Cancer, 2017, 17, 239-253.	12.8	234
3515	Exome Sequencing Identifies Potentially Druggable Mutations in Nasopharyngeal Carcinoma. Scientific Reports, 2017, 7, 42980.	1.6	27
3516	In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncology Reports, 2017, 37, 1367-1378.	1.2	5

#	Article	IF	Citations
3517	Clinical Pharmacokinetics of Vemurafenib. Clinical Pharmacokinetics, 2017, 56, 1033-1043.	1.6	41
3518	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncology, The, 2017, 18, 464-472.	5.1	139
3519	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer, 2017, 75, 268-279.	1.3	62
3520	A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. ACS Chemical Biology, 2017, 12, 1245-1256.	1.6	19
3521	Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene, 2017, 36, 3842-3851.	2.6	16
3522	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. Journal of Leukocyte Biology, 2017, 102, 381-391.	1.5	50
3523	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88
3524	Key Lessons Learned from Moffittâ€™s Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist, 2017, 22, 144-151.	1.9	74
3525	High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncology Reports, 2017, 37, 785-792.	1.2	64
3526	Mucosal melanoma of the head and neck. Critical Reviews in Oncology/Hematology, 2017, 112, 136-152.	2.0	125
3527	Mutational profiling of acral melanomas in Korean populations. Experimental Dermatology, 2017, 26, 883-888.	1.4	23
3528	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-ÎºB Pathway in Melanoma. Clinical Cancer Research, 2017, 23, 4831-4842.	3.2	33
3529	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine, 2017, 18, 56-61.	2.7	83
3530	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1069-1077.	0.4	58
3531	Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. Scientific Reports, 2017, 7, 46244.	1.6	19
3534	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2980-2992.	1.1	25
3535	Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis. Journal of Surgical Research, 2017, 215, 114-124.	0.8	7
3536	Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clinical Epigenetics, 2017, 9, 34.	1.8	129

#	Article	IF	Citations
3538	Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury. Cancer Chemotherapy and Pharmacology, 2017, 79, 1043-1049.	1.1	17
3539	Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. Oncology Research and Treatment, 2017, 40, 174-183.	0.8	14
3540	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncology, 2017, 6, 139-151.	1.2	12
3541	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. American Journal of Clinical Dermatology, 2017, 18, 597-611.	3.3	11
3542	Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. Journal of Nuclear Medicine, 2017, 58, 689-696.	2.8	15
3543	PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. Melanoma Research, 2017, 27, 251-257.	0.6	16
3544	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology, 2017, 283, 314-340.	3.6	19
3545	BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response. Melanoma Research, 2017, 27, 281-287.	0.6	25
3546	Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. British Journal of Cancer, 2017, 116, 1564-1571.	2.9	40
3547	Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. British Medical Bulletin, 2017, 121, 107-119.	2.7	19
3548	Open-label, multicentre safety study of vemurafenib inÂ3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European Journal of Cancer, 2017, 79, 176-184.	1.3	31
3549	Targeting PI3K Signaling in Combination Cancer Therapy. Trends in Cancer, 2017, 3, 454-469.	3.8	124
3550	RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. Nature Communications, 2017, 8, 15262.	5.8	38
3551	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs, 2017, 22, 191-200.	1.0	3
3552	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
3554	Immunotherapy in advanced melanoma: a network meta-analysis. Immunotherapy, 2017, 9, 471-479.	1.0	9
3555	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology, 2017, 6, e1321184.	2.1	23
3556	Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890.		0

#	Article	IF	Citations
3557	Biologics in patients with skin diseases. Journal of Allergy and Clinical Immunology, 2017, 139, 1423-1430.	1.5	28
3558	A systematic review and network metaâ€analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Medicine, 2017, 6, 1143-1153.	1.3	60
3559	MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. Current Topics in Microbiology and Immunology, 2017, 407, 117-151.	0.7	25
3560	Clinicopathologic features and immunohistochemical spectrum of 11 cases of epithelioid malignant peripheral nerve sheath tumors, including INI1/SMARCB1 results and BRAF V600E analysis. Apmis, 2017, 125, 679-689.	0.9	25
3561	Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIÎ± and Akt pathway inhibitor, and evaluation of its anti-melanoma activity. European Journal of Medicinal Chemistry, 2017, 135, 282-295.	2.6	17
3562	Rational design of non-resistant targeted cancer therapies. Scientific Reports, 2017, 7, 46632.	1.6	11
3563	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	13.9	1,786
3564	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Annals of Oncology, 2017, 28, 1380-1387.	0.6	134
3565	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. Journal of Experimental Medicine, 2017, 214, 1691-1710.	4.2	71
3566	MITF suppression by CH5552074 inhibits cell growth in melanoma cells. Cancer Chemotherapy and Pharmacology, 2017, 79, 1187-1193.	1.1	10
3567	BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. Journal of Clinical Pathology, 2017, 70, 935-940.	1.0	16
3568	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	7.7	49
3569	Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. CNS Oncology, 2017, 6, 5-9.	1.2	35
3570	BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. Pathology, 2017, 49, 55-61.	0.3	38
3571	<scp>DEK</scp> oncogene is overexpressed during melanoma progression. Pigment Cell and Melanoma Research, 2017, 30, 194-202.	1.5	19
3572	Melanoma Brain Metastases. Cancer Journal (Sudbury, Mass), 2017, 23, 68-74.	1.0	44
3573	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5339-5348.	3.2	142
3574	Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. Clinical Cancer Research, 2017, 23, 5547-5560.	3.2	40

#	Article	IF	Citations
3575	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. Journal of Immunotherapy, 2017, 40, 31-35.	1.2	85
3576	Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. European Journal of Cancer, 2017, 81, 106-115.	1.3	43
3577	Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Oncologist, 2017, 22, 786-796.	1.9	95
3578	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist, 2017, 22, 963-971.	1.9	145
3579	Somatic driver mutations in melanoma. Cancer, 2017, 123, 2104-2117.	2.0	96
3580	Advances in potential targeted therapies for Erdheim-Chester disease. Expert Opinion on Orphan Drugs, 0, , 1-8.	0.5	5
3581	Biomarkers as Adjuncts to Clinical Trials. , 2017, , 391-400.		0
3583	Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma. Targeted Oncology, 2017, 12, 365-371.	1.7	15
3584	MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine and Growth Factor Reviews, 2017, 36, 39-48.	3.2	26
3585	Interleukin-2. , 2017, , 323-334.		0
3586	B-Raf. , 2017, , 673-681.		0
3588	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. Cell Cycle, 2017, 16, 1288-1294.	1.3	37
3589	S3â€Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms â€“ Update 2015/2016, Kurzversion 2.0. JDDG - Journal of the German Society of Dermatology, 2017, 15, e1-e41.	0.4	29
3590	The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma. Molecular Cancer Therapeutics, 2017, 16, 1002-1009.	1.9	50
3591	Ethical considerations of neuro-oncology trial design in the era of precision medicine. Journal of Neuro-Oncology, 2017, 134, 1-7.	1.4	6
3592	Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy. Medical Oncology, 2017, 34, 129.	1.2	6
3593	Clinical research in small genomically stratified patient populations. European Journal of Cancer, 2017, 80, 73-82.	1.3	2
3594	Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response. ACS Applied Materials & Interfaces, 2017, 9, 21673-21687.	4.0	53

#	Article	IF	Citations
3595	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib. Cancer Immunology Research, 2017, 5, 582-593.	1.6	17
3596	Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo. European Journal of Dermatology, 2017, 27, 177-178.	0.3	1
3597	Usefulness of 11 C-methionine-PET for predicting the efficacy of carbon ion radiation therapy for head and neck mucosal malignant melanoma. International Journal of Oral and Maxillofacial Surgery, 2017, 46, 1220-1228.	0.7	7
3598	Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research, 2017, 23, 5238-5245.	3.2	32
3599	Ubiquitination in melanoma pathogenesis and treatment. Cancer Medicine, 2017, 6, 1362-1377.	1.3	24
3600	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer, 2017, 123, 2118-2129.	2.0	121
3601	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	2.0	24
3602	BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5631-5638.	3.2	56
3603	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (United States), 2017, 96, e6931.	0.4	3
3604	Genetic and epigenetic markers in colorectal cancer screening: recent advances. Expert Review of Molecular Diagnostics, 2017, 17, 665-685.	1.5	22
3605	Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. Clinical Journal of Gastroenterology, 2017, 10, 336-341.	0.4	8
3606	A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Cancer Letters, 2017, 402, 61-70.	3.2	51
3607	A review of binimetinib for the treatment of mutant cutaneous melanoma. Future Oncology, 2017, 13, 1755-1766.	1.1	35
3608	ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Molecular Cancer, 2017, 16, 102.	7.9	108
3609	Regarding â€œOncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapiesâ€• Oncologist, 2017, 22, 757-758.	1.9	2
3610	Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2087-2094.	1.2	13
3611	Metastatic melanoma moves on: translational science in the era of personalized medicine. Cancer and Metastasis Reviews, 2017, 36, 7-21.	2.7	16
3612	Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. Immunotherapy, 2017, 9, 375-378.	1.0	5

#	Article	IF	Citations
3613	Vitamin C at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations. Molecular Carcinogenesis, 2017, 56, 1965-1976.	1.3	33
3614	Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology, 2017, 14, 463-482.	12.5	945
3615	Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Zeitschrift Fur Gastroenterologie, 2017, 55, 575-581.	0.2	25
3616	Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of Oncology, 2017, 28, 946-957.	0.6	20
3617	Controversies in Intrapatient Melanoma BRAFV600E Mutation Status. American Journal of Dermatopathology, 2017, 39, 291-295.	0.3	6
3618	Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. American Journal of Dermatopathology, 2017, 39, 1-13.	0.3	10
3619	Arrhythmias in a patient with metastatic melanoma treated with targeted therapy and implantable cardioverter defibrillator. British Journal of Dermatology, 2017, 177, 584-587.	1.4	3
3620	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
3621	Research progress in advanced melanoma. Cancer Letters, 2017, 397, 120-126.	3.2	34
3622	Do the Side Effects of BRAF Inhibitors Mimic RASopathies?. Journal of Investigative Dermatology, 2017, 137, 805-809.	0.3	8
3623	Â¿CÃ³mo debe realizarse el seguimiento de los pacientes tratados con vemurafenib?. Piel, 2017, 32, 123-125.	0.0	0
3624	Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discovery, 2017, 7, 462-477.	7.7	735
3625	Immunotherapy in malignant melanoma: recent approaches and new perspectives. Melanoma Management, 2017, 4, 39-48.	0.1	7
3626	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. Drugs, 2017, 77, 713-719.	4.9	33
3627	Acral lentiginous melanoma versus other melanoma: A singleâ€center analysis in Japan. Journal of Dermatology, 2017, 44, 932-938.	0.6	45
3628	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	3.5	55
3629	Individual Biomarkers Using Molecular Personalized Medicine Approaches. Orl, 2017, 79, 7-13.	0.6	6
3630	Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas. Cancer Chemotherapy and Pharmacology, 2017, 79, 971-983.	1.1	10

#	Article	IF	Citations
3631	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	1.7	120
3632	Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1035-1046.	1.7	7
3633	Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. International Journal of Dermatology, 2017, 56, 792-794.	0.5	4
3634	Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 281-293.	1.4	16
3635	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Journal of Neuro-Oncology, 2017, 134, 541-549.	1.4	109
3636	Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKI2 inhibition. Redox Biology, 2017, 11, 562-576.	3.9	32
3637	Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients. Neoplasia, 2017, 19, 255-260.	2.3	35
3641	Sequencing brain metastases and opportunities for targeted therapies. Pharmacogenomics, 2017, 18, 585-594.	0.6	8
3642	Mechanisms of Resistance to Immune Checkpoint Antibodies. Handbook of Experimental Pharmacology, 2017, 249, 109-128.	0.9	26
3643	Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews, 2017, 55, 136-149.	3.4	36
3644	Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. Organic and Biomolecular Chemistry, 2017, 15, 3455-3465.	1.5	14
3645	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1312-1318.	3.3	23
3646	Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. Advances in Therapy, 2017, 34, 495-512.	1.3	5
3647	Clinical and therapeutic implications of <scp>BRAF</scp> mutation heterogeneity in metastatic melanoma. Pigment Cell and Melanoma Research, 2017, 30, 233-242.	1.5	16
3648	Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event. British Journal of Dermatology, 2017, 176, 1645-1648.	1.4	23
3649	Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. Pathology and Oncology Research, 2017, 23, 181-188.	0.9	4
3650	Subungual fibro-osseous pseudotumour of the digit: a rare occurrence. International Journal of Dermatology, 2017, 56, e11-e13.	0.5	3
3651	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 939-946.	0.7	41

#	Article	IF	Citations
3652	Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, e211-e213.	1.1	8
3653	Systemic therapy of brain metastases: nonâ€“small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology, 2017, 19, i1-i24.	0.6	171
3654	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
3655	Introduction to the special issue of European Journal of Surgical Oncology: New roads in melanoma management. European Journal of Surgical Oncology, 2017, 43, 513-516.	0.5	4
3656	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 46-58.	1.4	27
3657	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
3658	Advancing Techniques and Insights in Circulating Tumor Cell (CTC) Research. Cancer Drug Discovery and Development, 2017, , 71-94.	0.2	2
3659	The Cancer Secretome. Cancer Drug Discovery and Development, 2017, , 95-120.	0.2	0
3660	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 75-102.	9.6	30
3661	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 2017, 72, 156-165.	1.3	77
3662	An Overview of the Changing Landscape of Treatment forÂAdvanced Melanoma. Pharmacotherapy, 2017, 37, 319-333.	1.2	33
3663	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. Clinical Cancer Research, 2017, 23, 351-362.	3.2	52
3664	Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Laboratory Investigation, 2017, 97, 166-175.	1.7	37
3665	A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?. International Journal of Rheumatic Diseases, 2017, 20, 398-401.	0.9	8
3666	Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Supportive Care in Cancer, 2017, 25, 237-244.	1.0	23
3667	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research, 2017, 117, 20-31.	3.1	78
3668	Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncology, 2017, 6, 291-296.	1.2	58
3669	Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics, 2017, 18, 1525-1539.	0.6	21

#	Article	IF	Citations
3670	Tests to assist in the staging of cutaneous melanoma: a generic protocol. The Cochrane Library, 2017, , .	1.5	1
3671	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4952-4955.	1.0	5
3672	RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nature Communications, 2017, 8, 1211.	5.8	65
3673	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	5.8	123
3674	Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Scientific Reports, 2017, 7, 12277.	1.6	21
3675	Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicleâ€“Associated PDGFRÎ². Neoplasia, 2017, 19, 932-940.	2.3	50
3676	Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nature Communications, 2017, 8, 1186.	5.8	78
3677	Trapping Cancers as They Adapt to Survive. Cancer Discovery, 2017, 7, 1216-1217.	7.7	3
3678	Genetic homogeneity of adult Langerhans cell histiocytosis lesions: Insights from BRAFV600E mutations in adult populations. Oncology Letters, 2017, 14, 4449-4454.	0.8	13
3679	Degradation of AMPKâ€Î±1 sensitizes BRAF inhibitorâ€resistant melanoma cells to arginine deprivation. Molecular Oncology, 2017, 11, 1806-1825.	2.1	19
3680	Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. Advances in Radiation Oncology, 2017, 2, 572-580.	0.6	63
3681	Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. Clinical and Translational Radiation Oncology, 2017, 6, 25-30.	0.9	5
3682	001 INCOME-ASSOCIATED DISCREPANCIES IN MELANOMA SURVIVAL. Journal of Investigative Dermatology Symposium Proceedings, 2017, 18, S85.	0.8	0
3683	New perspectives for targeting RAF kinase in human cancer. Nature Reviews Cancer, 2017, 17, 676-691.	12.8	285
3684	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology, 2017, 89, 1915-1922.	1.5	82
3685	Statistical Challenges with the Advances in Cancer Therapies. , 2017, , 11-20.		0
3686	Phase III Clinical Trial Designs Incorporating Predictive Biomarkers: An Overview. , 2017, , 85-103.		0
3687	Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. Cancer Research, 2017, 77, 6240-6252.	0.4	98

#	Article	IF	Citations
3689	Molecular Testing of Colorectal Cancer in the Modern Era. Surgical Pathology Clinics, 2017, 10, 1009-1020.	0.7	4
3690	Recent advances in malignant melanoma. Internal Medicine Journal, 2017, 47, 1114-1121.	0.5	40
3691	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Research, 2017, 77, 6313-6320.	0.4	22
3692	Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Molecular Cancer Therapeutics, 2017, 16, 2351-2363.	1.9	166
3693	Rescue of cell cycle progression in BRAFV600E inhibitorâ€“resistant human melanoma by a chromatin modifier. Tumor Biology, 2017, 39, 1010428317721621.	0.8	5
3694	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
3695	Qualityâ€ofâ€life outcomes in patients with advanced melanoma: A review of the literature. Pigment Cell and Melanoma Research, 2017, 30, 511-520.	1.5	16
3696	Nanotechnology as a Delivery Tool for Precision Cancer Therapies. AAPS Journal, 2017, 19, 1632-1642.	2.2	9
3697	The renaissance of antiâ€neoplastic immunity from tumor cell demise. Immunological Reviews, 2017, 280, 194-206.	2.8	53
3698	Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492.	157.7	1,662
3700	Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. Transplantation Proceedings, 2017, 49, 1551-1554.	0.3	24
3701	High frequency of brain metastases after adjuvant therapy for highâ€risk melanoma. Cancer Medicine, 2017, 6, 2576-2585.	1.3	27
3702	Molecular Tumor Boards: current practice and future needs. Annals of Oncology, 2017, 28, 3070-3075.	0.6	112
3703	An architecture for genomics analysis in a clinical setting using Galaxy and Docker. GigaScience, 2017, 6, 1-9.	3.3	10
3704	Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH. Cancer Letters, 2017, 408, 43-54.	3.2	36
3705	Survival of patients with advanced metastatic melanoma: the impact of novel therapiesâ€“update 2017. European Journal of Cancer, 2017, 83, 247-257.	1.3	236
3706	BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics. American Journal of Surgical Pathology, 2017, 41, 1532-1541.	2.1	49
3707	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. BMJ Open, 2017, 7, e014880.	0.8	18

#	Article	IF	Citations
3708	Bioinformatics Meets Biomedicine: OncoFinder, a Quantitative Approach for Interrogating Molecular Pathways Using Gene Expression Data. Methods in Molecular Biology, 2017, 1613, 53-83.	0.4	62
3709	Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. Analytical Chemistry, 2017, 89, 10592-10600.	3.2	30
3710	Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Current Opinion in Oncology, 2017, 29, 484-492.	1.1	58
3711	MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor. Cancer Letters, 2017, 409, 116-124.	3.2	23
3712	MEK inhibition and immune responses in advanced melanoma. OncoImmunology, 2017, 6, e1335843.	2.1	15
3713	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treatment Reviews, 2017, 60, 109-119.	3.4	45
3714	Overcoming key biological barriers to cancer drug delivery and efficacy. Journal of Controlled Release, 2017, 267, 15-30.	4.8	92
3715	Histiocitosis sistÃ©micas. EMC - Tratado De Medicina, 2017, 21, 1-4.	0.0	0
3716	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology, 2017, 93, 164-176.	0.9	6
3717	Precision Oncology: The Road Ahead. Trends in Molecular Medicine, 2017, 23, 874-898.	3.5	131
3718	Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. Ocular Oncology and Pathology, 2017, 3, 133-141.	0.5	44
3719	Misregulation of Histone Methylation Regulators in Cancer. Cancer Drug Discovery and Development, 2017, , 221-248.	0.2	2
3720	Radiosensitization by BRAF inhibitors. JDDG - Journal of the German Society of Dermatology, 2017, 15, 703-708.	0.4	3
3721	Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australasian Journal of Dermatology, 2017, 58, 292-298.	0.4	9
3722	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	7.7	158
3723	Insights from zebrafish on human pigment cell disease and treatment. Developmental Dynamics, 2017, 246, 889-896.	0.8	26
3724	Approaches to identify kinase dependencies in cancer signalling networks. FEBS Letters, 2017, 591, 2577-2592.	1.3	11
3725	Single-Subject Studies in Translational Nutrition Research. Annual Review of Nutrition, 2017, 37, 395-422.	4.3	64

#	Article	IF	Citations
3726	A firstâ€inâ€human phase I, multicenter, openâ€label, doseâ€escalation study of the oral RAF/VEGFRâ€2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. Cancer Medicine, 2017, 6, 1904-1914.	1.3	24
3727	Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. Expert Review of Anticancer Therapy, 2017, 17, 939-949.	1.1	6
3728	Radiosensibilisierung durch BRAF Inhibitoren. JDDG - Journal of the German Society of Dermatology, 2017, 15, 703-708.	0.4	3
3729	A new horizon for sepsis: Personalised medicine: Hype or hope?. European Journal of Molecular and Clinical Medicine, 2017, 3, 289.	0.5	0
3730	Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. Melanoma Research, 2017, 27, 351-357.	0.6	14
3731	Precision Medicine and PET/Computed Tomography in Melanoma. PET Clinics, 2017, 12, 449-458.	1.5	11
3733	Liquid Biopsy in Cancer Patients. Current Clinical Pathology, 2017, , .	0.0	6
3734	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. Pharmacogenomics, 2017, 18, 1299-1304.	0.6	4
3735	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	2.3	49
3736	Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. Radiographics, 2017, 37, 1461-1482.	1.4	21
3737	Integrating Models to Quantify Environment-Mediated Drug Resistance. Cancer Research, 2017, 77, 5409-5418.	0.4	27
3738	MALT1 promotes melanoma progression through JNK/c-Jun signaling. Oncogenesis, 2017, 6, e365-e365.	2.1	25
3739	Isothermal Point Mutation Detection: Toward a First-Pass Screening Strategy for Multidrug-Resistant Tuberculosis. Analytical Chemistry, 2017, 89, 9017-9022.	3.2	27
3741	Target and Agent Prioritization for the Childrenâ€™s Oncology Groupâ€”National Cancer Institute Pediatric MATCH Trial. Journal of the National Cancer Institute, 2017, 109, .	3.0	85
3742	Critical role of gliomaâ€associated oncogene homolog 1 in maintaining invasive and mesenchymalâ€like properties of melanoma cells. Cancer Science, 2017, 108, 1602-1611.	1.7	16
3743	Liquid Biopsies in Malignant Melanoma: From Bench to Bedside. Current Clinical Pathology, 2017, , 161-193.	0.0	0
3744	Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Letters, 2017, 406, 1-11.	3.2	46
3745	Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. Journal of Thoracic Oncology, 2017, 12, 1503-1511.	0.5	49

#	Article	IF	Citations
3746	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology, 2017, 28, 2581-2587.	0.6	201
3748	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. Cancer Immunology Research, 2017, 5, 790-803.	1.6	38
3749	Review of Targeted Therapies for Periocular Tumors. International Ophthalmology Clinics, 2017, 57, 153-168.	0.3	3
3750	Novel Targeted Therapies for Metastatic Melanoma. Cancer Journal (Sudbury, Mass), 2017, 23, 54-58.	1.0	19
3751	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. Cancer Journal (Sudbury, Mass), 2017, 23, 63-67.	1.0	8
3752	Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors. Melanoma Research, 2017, 27, 68-71.	0.6	2
3753	Current status and future direction in the management of malignant melanoma. Melanoma Research, 2017, 27, 403-410.	0.6	50
3754	Editorial: Tissue Acquisition in Clinical Trialsâ€"Essential for Progress. Journal of the National Cancer Institute, 2017, 109, .	3.0	0
3755	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology, 2017, 93, 249-258.	0.9	19
3756	Development of <scp>RET</scp> mutant cutaneous angiosarcoma during <scp>BRAF</scp> inhibitor therapy. Journal of Cutaneous Pathology, 2017, 44, 1053-1056.	0.7	4
3757	Inference for multimarker adaptive enrichment trials. Statistics in Medicine, 2017, 36, 4083-4093.	0.8	15
3758	Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal. Melanoma Research, 2017, 27, 159-163.	0.6	2
3759	Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Oncogene, 2017, 36, 6581-6591.	2.6	31
3760	Advances in the Management of Melanoma. Current Dermatology Reports, 2017, 6, 288-296.	1.1	1
3762	Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Scientific Reports, 2017, 7, 16517.	1.6	51
3763	The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases. Medicine (United States), 2017, 96, e8404.	0.4	17
3764	Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining â€œActionabilityâ€•of a Molecular Lesion and Patient Management Support. Molecular Cancer Therapeutics, 2017, 16, 2645-2655.	1.9	59
3765	MELK Promotes Melanoma Growth by Stimulating the NF-Î°B Pathway. Cell Reports, 2017, 21, 2829-2841.	2.9	61

#	Article	IF	Citations
3766	Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10947-E10955.	3.3	58
3767	A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens. Pathology, 2017, 49, 776-783.	0.3	3
3768	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
3769	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Molecular Cell, 2017, 68, 731-744.e9.	4.5	90
3770	Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 512-518.	0.4	31
3771	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. Journal of the Egyptian National Cancer Institute, 2017, 29, 171-176.	0.6	0
3772	New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. Scientific Reports, 2017, 7, 15126.	1.6	7
3773	Genetics of Hepatocellular Carcinoma: Risk Stratification, Clinical Outcome, and Implications for Therapy. Digestive Disease Interventions, 2017, 01, 055-065.	0.3	2
3774	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Research, 2017, 27, 585-590.	0.6	21
3775	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Research, 2017, 27, 545-557.	0.6	6
3776	Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. Oral Oncology, 2017, 74, 62-67.	0.8	23
3777	Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. European Journal of Cancer, 2017, 82, 25-26.	1.3	2
3778	Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes. Archives of Gynecology and Obstetrics, 2017, 296, 397-404.	0.8	6
3779	A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochemical Pharmacology, 2017, 142, 39-45.	2.0	9
3780	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 621-630.	0.2	5
3781	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist, 2017, 22, 823-833.	1.9	69
3782	Perioperative BRAF inhibitors in locally advanced stage III melanoma. Journal of Surgical Oncology, 2017, 116, 856-861.	0.8	11
3784	Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research, 2017, 123, 95-102.	3.1	52

#	Article	IF	Citations
3785	The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). International Journal of Molecular Medicine, 2017, 40, 271-280.	1.8	814
3786	The new paradigm of systemic therapies for metastatic melanoma. Journal of the American Academy of Dermatology, 2017, 77, 356-368.	0.6	34
3787	MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. Cell Death Discovery, 2017, 3, 17028.	2.0	36
3788	The role for chemotherapy in the modern management of melanoma. Melanoma Management, 2017, 4, 125-136.	0.1	26
3789	A retrospective clinical analysis of 5 cases of vaginal melanoma. Molecular and Clinical Oncology, 2017, 6, 373-376.	0.4	10
3790	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98
3792	Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer. Life Sciences, 2017, 183, 37-44.	2.0	10
3793	Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. Npj Systems Biology and Applications, 2017, 3, 14.	1.4	45
3794	Imaging characteristics of cardiac metastases in patients with malignant melanoma. Cancer Imaging, 2017, 17, 19.	1.2	12
3796	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. Cancer Research, 2017, 77, 4684-4696.	0.4	80
3797	BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. Molecular Cancer Research, 2017, 15, 1431-1444.	1.5	18
3798	Proteasome beta-4 subunit contributes to the development of melanoma and is regulated by miR-148b. Tumor Biology, 2017, 39, 101042831770576.	0.8	8
3799	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics, 2017, 18, 934.	1.2	62
3800	Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Medicine, 2017, 9, 37.	3.6	52
3801	Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 2017, 5, 17.	2.8	11
3802	The Evolution of Oncology Companion Diagnostics from Signal Transduction to Immuno-Oncology. Trends in Pharmacological Sciences, 2017, 38, 41-54.	4.0	21
3803	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cellular and Molecular Life Sciences, 2017, 74, 1457-1474.	2.4	77
3804	Technical and US regulatory issues in triaging material for the molecular laboratory. Cancer Cytopathology, 2017, 125, 83-90.	1.4	4

#	Article	IF	Citations
3805	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Annals of Oncology, 2017, 28, 34-43.	0.6	198
3806	Resisting Resistance. Annual Review of Cancer Biology, 2017, 1, 203-221.	2.3	45
3807	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Journal of Neuro-Oncology, 2017, 131, 495-505.	1.4	29
3808	Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. MedChemComm, 2017, 8, 88-95.	3.5	4
3809	Reduced expression of the <scp>ATP</scp>2A2 gene in vemurafenibâ€induced keratoacanthomaâ€like papules in a melanoma patient. International Journal of Dermatology, 2017, 56, e33-e35.	0.5	2
3810	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
3811	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). Seminars in Cancer Biology, 2017, 45, 36-49.	4.3	11
3812	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends in Pharmacological Sciences, 2017, 38, 25-40.	4.0	87
3813	The biology of beta human papillomaviruses. Virus Research, 2017, 231, 128-138.	1.1	112
3814	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
3815	Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology, 2017, 43, 604-611.	0.5	216
3816	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation, 2017, 97, 176-186.	1.7	14
3817	Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. JAMA Oncology, 2017, 3, 366.	3.4	68
3818	The evolving clinical management of cerebral metastases. European Journal of Surgical Oncology, 2017, 43, 1173-1185.	0.5	11
3819	Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 2017, 43, 581-593.	0.5	45
3820	(Neo)adjuvant systemic therapy for melanoma. European Journal of Surgical Oncology, 2017, 43, 534-543.	0.5	52
3821	Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Medicinal Research Reviews, 2017, 37, 98-148.	5.0	92
3822	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	0.9	62

#	Article	IF	Citations
3823	Epidemiology of Melanoma. , 2017, , 591-611.		2
3824	Nivolumab therapy before vemurafenib administration induces a severe skin rash. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e169-e171.	1.3	18
3825	Management Controversies in Head and Neck Melanoma. JAMA Facial Plastic Surgery, 2017, 19, 53-62.	2.2	19
3826	Transient receptor potential cation 3 channel regulates melanoma proliferation and migration. Journal of Physiological Sciences, 2017, 67, 497-505.	0.9	28
3827	Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. Hematological Oncology, 2017, 35, 890-893.	0.8	40
3828	A case of occipital neuralgia in a vemurafenib-treated melanoma patient. International Journal of Dermatology, 2017, 56, e10-e11.	0.5	1
3829	Symptom prevalence in patients with advanced skin cancer. Journal of Dermatology, 2017, 44, 123-126.	0.6	6
3830	ZIC5 Drives Melanoma Aggressiveness by PDGFD-Mediated Activation of FAK and STAT3. Cancer Research, 2017, 77, 366-377.	0.4	34
3831	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 6-16.	0.2	31
3832	Cobimetinib. Annals of Pharmacotherapy, 2017, 51, 146-153.	0.9	35
3833	Synthetic Lethality in Cancer Therapeutics. Annual Review of Cancer Biology, 2017, 1, 141-161.	2.3	36
3834	An acneiform eruption exhibiting locus minoris resistentiae after wholeâ€brain radiation and vemurafenib therapy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e209-e210.	1.3	2
3835	High-Grade Gliomas. Pediatric Oncology, 2017, , 37-50.	0.5	0
3836	Sequence analysis of <scp>RAS</scp> and <scp>RAF</scp> mutation hot spots in canine carcinoma. Veterinary and Comparative Oncology, 2017, 15, 1598-1605.	0.8	18
3837	Clinical Pharmacokinetics of Vemurafenib in BRAFâ€Mutated Melanoma Patients. Journal of Clinical Pharmacology, 2017, 57, 125-128.	1.0	14
3838	Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence. Dermatologic Clinics, 2017, 35, 85-93.	1.0	17
3839	Metastatic pathways in patients with cutaneous melanoma. Pigment Cell and Melanoma Research, 2017, 30, 13-27.	1.5	38
3840	Improvement of overall survival in stage IV melanoma patients during 2011â€“2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). Journal of Cancer Research and Clinical Oncology, 2017, 143, 533-540.	1.2	41

#	Article	IF	Citations
3841	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. Brain Tumor Pathology, 2017, 34, 8-19.	1.1	22
3842	Metastasectomy in cutaneous melanoma. European Journal of Surgical Oncology, 2017, 43, 572-580.	0.5	18
3843	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Cancer Research, 2017, 77, 557-565.	0.4	10
3844	Determination of A Novel Selective B-RafV600E Inhibitor (LXK4) in Dog Plasma by HPLCâ€“MS/MS and its Application in a Pharmacokinetic Study. Chromatographia, 2017, 80, 71-76.	0.7	0
3845	Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote antiâ€melanoma immune response. International Journal of Cancer, 2017, 140, 747-755.	2.3	25
3846	The presentation and outcomes of mucosal melanoma in 695 patients. International Forum of Allergy and Rhinology, 2017, 7, 99-105.	1.5	46
3847	Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib. Journal of Cutaneous Medicine and Surgery, 2017, 21, 54-59.	0.6	10
3848	Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Human Pathology, 2017, 59, 48-54.	1.1	8
3849	The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. Journal of Investigative Dermatology, 2017, 137, 261-264.	0.3	9
3850	miRâ€106bâ€5p promotes cell cycle progression of malignant melanoma by targeting PTEN. Oncology Reports, 2018, 39, 331-337.	1.2	12
3851	Targeted therapy of brain metastases: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 781-796.	1.4	46
3852	The rise of the genome and personalised medicine. Clinical Medicine, 2017, 17, 545-551.	0.8	88
3853	Melanoma cutÃ¡neo cervicofacial. EMC - OtorrinolaringologÃa, 2017, 46, 1-9.	0.0	0
3854	Melanomi cutanei cervicofacciali. EMC - Otorinolaringoiatria, 2017, 16, 1-9.	0.0	0
3855	Restoring Radioiodine Uptake in BRAF V600Eâ€Mutated Papillary Thyroid Cancer. Journal of the Endocrine Society, 2017, 1, 285-287.	0.1	20
3857	MAPK Pathwayâ€Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. Clinical Journal of Oncology Nursing, 2017, 21, 699-709.	0.3	15
3858	Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations. Oncology Letters, 2018, 15, 635-641.	0.8	7
3859	Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options. Case Reports in Oncology, 2017, 9, 543-546.	0.3	12

#	Article	IF	Citations
3860	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. World Neurosurgery, 2017, 105, 184-190.	0.7	13
3862	MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. BMC Cancer, 2017, 17, 750.	1.1	23
3863	Matrix Metalloproteinases in Melanoma with and without Regression. , 2017, , .		0
3864	Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget, 2017, 8, 57654-57669.	0.8	99
3865	Eleven Month Progressionâ€“Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600Eâ€“Mutated Glioblastoma WHO Grade 4. JCO Precision Oncology, 2017, 1, 1-5.	1.5	5
3866	Primary malignant melanoma of the cervix: Report of 14 cases and review of literature. Oncotarget, 2017, 8, 73162-73167.	0.8	22
3867	Overcoming resistance to BRAF inhibitors. Annals of Translational Medicine, 2017, 5, 387-387.	0.7	109
3868	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget, 2017, 8, 15894-15911.	0.8	84
3869	Critical aspects to achieve a high-quality melanoma clinic. Current Opinion in Oncology, 2017, 29, 145-150.	1.1	5
3870	Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-12.	1.5	1
3871	BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Advances, 2017, 1, 2147-2160.	2.5	5
3872	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 325-339.	0.8	52
3873	Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging. Theranostics, 2017, 7, 1257-1265.	4.6	16
3874	Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. Oncotarget, 2017, 8, 35761-35775.	0.8	23
3875	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1389-1399.	0.8	23
3876	Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2017, 18, 752.	1.8	86
3877	Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors. Acta Dermato-Venereologica, 2017, 97, 258-260.	0.6	9
3878	Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies. Molecules, 2017, 22, 542.	1.7	7

#	Article	IF	Citations
3879	The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment. Molecules, 2017, 22, 1411.	1.7	23
3881	Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b] indole Derivatives as Broad-Spectrum Potent Anticancer Agents. Drug Designing: Open Access, 2017, 06, .	0.2	11
3882	Cancer as a Paradigm for Translational and Clinical Biomedical Research. , 2017, , 587-607.		0
3883	Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. International Journal of Molecular Sciences, 2017, 18, 585.	1.8	28
3884	Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. International Journal of Molecular Sciences, 2017, 18, 715.	1.8	37
3885	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. Frontiers in Immunology, 2017, 8, 1215.	2.2	80
3886	Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways. Frontiers in Microbiology, 2017, 8, 2426.	1.5	23
3887	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Frontiers in Oncology, 2017, 7, 230.	1.3	43
3888	Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	1.9	128
3889	Management of the cutaneous adverse effects of antimelanoma therapy. Melanoma Management, 2017, 4, 187-202.	0.1	5
3890	Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma. Case Reports in Oncological Medicine, 2017, 2017, 1-4.	0.2	2
3891	Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis. OncoTargets and Therapy, 2017, Volume 10, 5391-5403.	1.0	12
3892	Melanoma: tumor microenvironment and new treatments. Anais Brasileiros De Dermatologia, 2017, 92, 156-166.	0.5	35
3893	BRAF^{V600} mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. OncoTargets and Therapy, 2017, Volume 10, 965-971.	1.0	28
3894	Therapeutic and Prognostic Applications. , 0, , 287-295.		0
3895	Therapy of Melanoma. , 2017, , 91-142.		0
3896	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Management and Research, 2017, Volume 9, 433-442.	0.9	15
3897	Molecular Pathology and Testing in Melanocytic Tumors. , 2017, , 321-337.		1

#	Article	IF	Citations
3899	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. PLoS ONE, 2017, 12, e0177830.	1.1	17
3901	Population Approach to Precision Medicine. , 2017, , 115-128.		0
3902	Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients. Case Reports in Oncology, 2017, 10, 290-295.	0.3	6
3903	Addressing the challenges of applying precision oncology. Npj Precision Oncology, 2017, 1, 28.	2.3	43
3905	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer, 2017, 17, 649.	1.1	12
3906	Social inequality, scientific inequality, and the future of mental illness. Philosophy, Ethics, and Humanities in Medicine, 2017, 12, 10.	0.7	13
3907	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. BMC Research Notes, 2017, 10, 320.	0.6	7
3908	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
3909	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surgical Case Reports, 2017, 3, 94.	0.2	14
3910	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatology, 2017, 17, 9.	2.1	19
3911	Epigenetic signature of differentially methylated genes in cutaneous melanoma. Applied Cancer Research, 2017, 37, .	1.0	1
3912	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. European Journal of Dermatology, 2017, 27, 482-486.	0.3	10
3913	A case of keratoacanthoma in a patient receiving sorafenib for the treatment of hepatocellular carcinoma, which showed spontaneous disappearance after discontinuing sorafenib. Acta Hepatologica Japonica, 2017, 58, 248-254.	0.0	1
3914	The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine, 2017, 5, 388-388.	0.7	54
3915	MicroRNAs in melanoma development and resistance to target therapy. Oncotarget, 2017, 8, 22262-22278.	0.8	89
3916	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget, 2017, 8, 78174-78192.	0.8	75
3917	Metastatic Hepatic Angiosarcoma and BRAF Inhibitor Therapy. Journal of Clinical Epigenetics, 2017, 03, .	0.3	0
3918	Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. Oncotarget, 2017, 8, 102033-102045.	0.8	25

#	Article	IF	Citations
3919	Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. World Journal of Gastroenterology, 2017, 23, 7945-7951.	1.4	54
3920	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy, 2017, Volume 6, 11-18.	6.0	32
3921	First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets and Therapy, 2017, Volume 6, 1-10.	2.7	26
3922	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. Journal of Cancer, 2017, 8, 2713-2719.	1.2	16
3923	Management of intracranial melanomas in the era of precision medicine. Oncotarget, 2017, 8, 89326-89347.	0.8	16
3924	Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion. Journal of Gastrointestinal Oncology, 2017, 8, E32-E38.	0.6	25
3925	Circulating tumor cells and CDX models as a tool for preclinical drug development. Translational Lung Cancer Research, 2017, 6, 397-408.	1.3	68
3926	Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2017, 1, 49-56.	0.2	36
3927	Access to Oncology Drugs in Brazil: Juggling Innovation and Sustainability in Developing Countries. Medicine Access Point of Care, 2017, 1, maapoc.0000004.	1.0	2
3928	Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Oncotarget, 2017, 8, 596-609.	0.8	26
3929	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 674-683.	1.8	18
3930	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	1.5	51
3931	Clinical Trials in the Genomic Era. Journal of Clinical Oncology, 2017, 35, 1011-1017.	0.8	14
3932	Genomics of Hairy Cell Leukemia. Journal of Clinical Oncology, 2017, 35, 1002-1010.	0.8	64
3933	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. Journal of Oncology Practice, 2017, 13, e653-e665.	2.5	31
3934	Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies. JCO Precision Oncology, 2017, 1, 1-13.	1.5	18
3935	Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. Journal of Clinical Oncology, 2017, 35, 3153-3159.	0.8	20
3936	Patient-Derived Xenografting of Human Melanoma. , 2017, , 341-363.		0

#	Article	IF	Citations
3937	Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 210-215.	1.8	25
3938	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	0.8	174
3939	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences, 2017, 1, 429-445.	1.1	45
3940	BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma, 2017, 64, 626-632.	0.7	38
3941	Molecular Tests for the Choice of Cancer Therapy. Current Pharmaceutical Design, 2017, 23, 4794-4806.	0.9	10
3942	Targeting Melanoma with Cancer-Killing Viruses. The Open Virology Journal, 2017, 11, 28-47.	1.8	8
3943	Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. JAMA Dermatology, 2018, 154, 589.	2.0	9
3944	BRIMâ€P: A phase I, openâ€label, multicenter, doseâ€escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutationâ€positive melanoma. Pediatric Blood and Cancer, 2018, 65, e26947.	0.8	29
3945	6-(2-Morpholinoethyl)-thiazolo[3,2-a]pyrimidin-5-one: A novel scaffold for the synthesis of potential PI3kÎ± inhibitors. Egyptian Journal of Basic and Applied Sciences, 2018, 5, 183-189.	0.2	2
3946	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	5.1	183
3947	Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report. International Journal of Surgery Case Reports, 2018, 44, 135-138.	0.2	4
3949	Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Letters, 2018, 421, 152-160.	3.2	31
3950	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
3951	Personalized cancer therapyâ€"leveraging a knowledge base for clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a001578.	0.5	50
3952	Identification of 4â€arylâ€1Hâ€pyrrole[2,3â€b]pyridine derivatives for the development of new Bâ€Raf inhibitors. Chemical Biology and Drug Design, 2018, 92, 1382-1386.	1.5	3
3953	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. Melanoma Research, 2018, 28, 195-203.	0.6	17
3954	Targeting <scp>CDK</scp> 2 overcomes melanoma resistance against <scp>BRAF</scp> and Hsp90 inhibitors. Molecular Systems Biology, 2018, 14, e7858.	3.2	53
3956	ERK5 is activated by oncogenic BRAF and promotes melanoma growth. Oncogene, 2018, 37, 2601-2614.	2.6	50

#	Article	IF	Citations
3957	Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with <scp>BRAF</scp> V600 mutationâ€positive advanced cutaneous melanoma. Journal of Dermatology, 2018, 45, 397-407.	0.6	22
3958	BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. Drugs, 2018, 78, 549-566.	4.9	95
3959	A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2315-2328.	1.8	18
3960	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	31
3961	Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours. Clinical Nuclear Medicine, 2018, 43, 333-334.	0.7	1
3962	Novel Trial Design in Sepsis. , 2018, , 217-230.		0
3963	Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. Clinical Cancer Research, 2018, 24, 5516-5524.	3.2	55
3964	Multidisciplinary Approach in the Management of Primary Malignant Melanoma of the Uterine Cervix: Diagnostic and Management Challenges. Journal of Gynecologic Surgery, 2018, 34, 209-213.	0.0	2
3965	Primary and Metastatic Melanoma With NTRK Fusions. American Journal of Surgical Pathology, 2018, 42, 1052-1058.	2.1	72
3966	The Polysaccharide Extracted from <i>Umbilicaria esculenta</i> Inhibits Proliferation of Melanoma Cells through ROS-Activated Mitochondrial Apoptosis Pathway. Biological and Pharmaceutical Bulletin, 2018, 41, 57-64.	0.6	18
3967	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Targeted Oncology, 2018, 13, 363-370.	1.7	4
3968	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF^{V600} Mutationâ€“Positive Metastatic Malignancy. Journal of Clinical Pharmacology, 2018, 58, 1067-1073.	1.0	11
3969	Characterising the phenotypic evolution of circulating tumour cells during treatment. Nature Communications, 2018, 9, 1482.	5.8	86
3970	Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncology, 2018, 4, 1093.	3.4	274
3971	Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. Nature Reviews Clinical Oncology, 2018, 15, 443-458.	12.5	56
3972	Concurrent BRAF/MEK Inhibitors in BRAF V600â€“Mutant High-Grade Primary Brain Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 343-347.	2.3	46
3973	Melanoma: What do all the mutations mean?. Cancer, 2018, 124, 3490-3499.	2.0	131
3974	A new era of proactive melanoma therapy: hit hard, hit early. British Journal of Dermatology, 2018, 178, 817-820.	1.4	7

#	Article	IF	Citations
3975	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-27.	0.1	1
3976	Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafV600E and VEGFR-2. Bioorganic and Medicinal Chemistry, 2018, 26, 2381-2391.	1.4	13
3977	Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 2372-2380.	1.4	11
3978	<scp>RAS</scp>opathic comedoneâ€like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins <scp>MADISH</scp>. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1368-1372.	1.3	5
3979	Concordance of somatic mutational profile in multiple primary melanomas. Pigment Cell and Melanoma Research, 2018, 31, 592-603.	1.5	1
3980	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
3981	BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 1332-1340.	1.9	21
3982	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocrine Reviews, 2018, 39, 154-191.	8.9	45
3983	Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathology, 2018, 126, 406-413.	1.4	33
3984	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393
3985	Handbook of Sepsis. , 2018, , .		10
3986	Systemic therapy for brain metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.0	23
3988	Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway. Cell Death and Disease, 2018, 9, 260.	2.7	59
3989	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2467-2472.	3.3	131
3990	Long-term survival with modern therapeutic agents against metastatic melanomaâ€"vemurafenib and ipilimumab in a daily life setting. Medical Oncology, 2018, 35, 24.	1.2	13
3991	Targeted cancer therapies. Journal of the American Dental Association, 2018, 149, 100-111.	0.7	12
3992	The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coordination Chemistry Reviews, 2018, 360, 17-33.	9.5	94
3994	Overview of metastatic disease of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 3-23.	1.0	28

#	Article	IF	Citations
3995	RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma. Cancer Research, 2018, 78, 2191-2204.	0.4	47
3996	Targeting insulinâ€like growth factor 2 mRNAâ€binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF^{V600E} inhibitors. Molecular Carcinogenesis, 2018, 57, 678-683.	1.3	26
3997	Antitumor Potential of S-Nitrosothiol-Containing Polymeric Nanoparticles against Melanoma. Molecular Pharmaceutics, 2018, 15, 1160-1168.	2.3	25
3998	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. Cancer Immunology Research, 2018, 6, 255-266.	1.6	158
3999	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1423172.	2.1	25
4000	Cancer Systems Biology. Methods in Molecular Biology, 2018, , .	0.4	8
4001	Impact of genomics on the surgical management of melanoma. British Journal of Surgery, 2018, 105, e31-e47.	0.1	3
4002	The role of nivolumab in melanoma. Future Oncology, 2018, 14, 1241-1252.	1.1	12
4003	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
4004	An Easy-to-Use Prognostic Model for Survival Estimation for Patients with Symptomatic Long Bone Metastases. Journal of Bone and Joint Surgery - Series A, 2018, 100, 196-204.	1.4	60
4005	Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis. Journal of Dermatological Science, 2018, 90, 211-213.	1.0	10
4006	Effects of PHA-665752 and vemurafenib combination treatment on inÃ¯Â¿Â½vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations. Oncology Letters, 2018, 15, 3904-3910.	0.8	9
4008	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	5.1	486
4009	Bioinformatics Approaches to Predict Drug Responses from Genomic Sequencing. Methods in Molecular Biology, 2018, 1711, 277-296.	0.4	12
4010	Pediatric patients with cutaneous melanoma: A European study. Pediatric Blood and Cancer, 2018, 65, e26974.	0.8	26
4011	Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. Melanoma Research, 2018, 28, 126-133.	0.6	31
4012	Development of encorafenib for BRAF-mutated advanced melanoma. Current Opinion in Oncology, 2018, 30, 125-133.	1.1	122
4013	A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma. British Journal of Dermatology, 2018, 178, 1-4.	1.4	5

#	Article	IF	Citations
4014	BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 709-713.	0.6	43
4015	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
4016	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery, 2018, 8, 184-195.	7.7	283
4017	Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma. Cancer Medicine, 2018, 7, 95-104.	1.3	16
4018	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treatment Reviews, 2018, 63, 135-143.	3.4	56
4019	Postdiagnosis aspirin use and overall survival in patients with melanoma. Journal of the American Academy of Dermatology, 2018, 78, 949-956.e1.	0.6	9
4020	Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas. Journal of Dermatological Science, 2018, 90, 13-20.	1.0	3
4021	Cancer Drugs Approved Based on Biomarkers and Not Tumor Typeâ€"FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncology, 2018, 4, 157.	3.4	114
4022	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. Journal of Pathology, 2018, 244, 512-524.	2.1	144
4023	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer, 2018, 142, 2139-2152.	2.3	56
4024	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Melanoma Research, 2018, 28, 96-104.	0.6	41
4025	Application of nextâ€generation sequencing to improve cancer management: A review of the clinical effectiveness and costâ€effectiveness. Clinical Genetics, 2018, 93, 533-544.	1.0	63
4026	Update on adjuvant melanoma therapy. Current Opinion in Oncology, 2018, 30, 118-124.	1.1	12
4027	Diagnosis and management of metastatic neoplasms with unknown primary. Seminars in Diagnostic Pathology, 2018, 35, 199-206.	1.0	46
4028	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Journal of Immunotherapy, 2018, 41, 86-95.	1.2	28
4029	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
4030	BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene, 2018, 37, 1576-1593.	2.6	37
4031	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. Scientific Reports, 2018, 8, 653.	1.6	13

#	Article	IF	Citations
4033	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178
4034	Genomics Studies in Hepatocellular Carcinoma via Next-Generation Sequencing. Molecular Pathology Library, 2018, , 49-68.	0.1	1
4035	Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions. Pigment Cell and Melanoma Research, 2018, 31, 496-508.	1.5	21
4037	ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nature Communications, 2018, 9, 28.	5.8	60
4038	Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles. Molecular Pharmaceutics, 2018, 15, 536-547.	2.3	10
4039	Patient-specific devices and population-level evidence: evaluating therapeutic interventions with inherent variation. Medicine, Health Care and Philosophy, 2018, 21, 335-345.	0.9	5
4040	The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology, 2018, 29, 30-35.	0.6	118
4041	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. BMC Cancer, 2018, 18, 389.	1.1	10
4042	Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. BMC Systems Biology, 2018, 12, 33.	3.0	25
4043	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer, 2018, 18, 307.	1.1	18
4044	Relevance of a molecular tumour board (MTB) for patientsâ€™ enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	2.0	37
4045	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ¹⁸Fâ€<scp>FDG</scp> injection. Medical Physics, 2018, 45, 2179-2185.	1.6	8
4046	Melanoma of the lower genital tract: Prognostic factors and treatment modalities. Gynecologic Oncology, 2018, 150, 180-189.	0.6	57
4047	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Cancer Treatment Reviews, 2018, 66, 82-94.	3.4	112
4048	Modification, Biological Evaluation and <scp>SAR</scp> Studies of Novel 1Hâ€Pyrazol Derivatives Containing N,Nâ€²â€Disubstituted Urea Moiety as Potential Antiâ€melanoma Agents. Chemistry and Biodiversity, 2018, 15, e1700504.	1.0	5
4049	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
4050	Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 552-562.	5.7	294
4051	Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661876761.	1.0	64

#	Article	IF	Citations
4052	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia, 2018, 20, 467-477.	2.3	13
4053	Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 2018, 52, 1071-1080.	1.4	281
4055	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene, 2018, 37, 3183-3199.	2.6	317
4056	Kernelized rank learning for personalized drug recommendation. Bioinformatics, 2018, 34, 2808-2816.	1.8	44
4057	Aberrations and clinical significance of BRAF in malignant melanoma. Medicine (United States), 2018, 97, e9509.	0.4	15
4058	Treatment Sequencing in Advanced BRAF-Mutant Melanoma Patients: Current Practice in the United States. Journal of Pharmacy Technology, 2018, 34, 17-23.	0.5	5
4059	A Nonquiescent â€œldlingâ€•Population State in Drug-Treated, BRAF-Mutated Melanoma. Biophysical Journal, 2018, 114, 1499-1511.	0.2	34
4060	Analytical Chemistry in the Regulatory Science of Medical Devices. Annual Review of Analytical Chemistry, 2018, 11, 307-327.	2.8	5
4061	Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature. Pathology Research and Practice, 2018, 214, 679-685.	1.0	22
4062	Cellular origin of glioblastoma and its implication in precision therapy. Cellular and Molecular Immunology, 2018, 15, 737-739.	4.8	52
4063	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 603-615.	5.1	751
4064	Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. OncoImmunology, 2018, 7, e1450127.	2.1	22
4065	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. European Journal of Cancer, 2018, 94, 179-186.	1.3	82
4066	Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Research, 2018, 28, 250-255.	0.6	17
4067	Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2018, 40, 616-619.	0.3	1
4068	NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Advanced Drug Delivery Reviews, 2018, 125, 78-93.	6.6	89
4069	Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer. Scientific Reports, 2018, 8, 4470.	1.6	32
4070	AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene, 2018, 37, 3275-3289.	2.6	82

#	Article	IF	Citations
4071	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. European Journal of Health Economics, 2018, 19, 1163-1172.	1.4	25
4072	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 90-94.	0.6	8
4073	Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 249-253.	1.5	18
4074	The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. Journal of Cellular Physiology, 2018, 233, 2162-2169.	2.0	49
4075	Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis. Journal of Dermatological Treatment, 2018, 29, 314-321.	1.1	11
4076	Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report. Ocular Immunology and Inflammation, 2018, 26, 783-785.	1.0	15
4077	Functional interplay between secreted ligands and receptors in melanoma. Seminars in Cell and Developmental Biology, 2018, 78, 73-84.	2.3	16
4078	Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. Clinical and Translational Oncology, 2018, 20, 169-175.	1.2	15
4079	Genetic study of the <scp>BRAF</scp> gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. Journal of Oral Pathology and Medicine, 2018, 47, 86-90.	1.4	23
4080	The Autophagy Receptor Adaptor p62 is Upâ€regulated by <scp>UVA</scp> Radiation in Melanocytes and in Melanoma Cells. Photochemistry and Photobiology, 2018, 94, 432-437.	1.3	25
4081	Epidemiology of skin cancer in the mature patient. Clinics in Dermatology, 2018, 36, 167-176.	0.8	89
4082	Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. Journal of the National Cancer Institute, 2018, 110, 290-303.	3.0	32
4083	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600â€“Mutant Solid Tumors. Clinical Cancer Research, 2018, 24, 22-32.	3.2	30
4084	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene, 2018, 37, 821-832.	2.6	55
4085	Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations. Journal of the American Academy of Dermatology, 2018, 78, 579-590.e4.	0.6	48
4086	Combination therapy strategies for improving PDâ€1 blockade efficacy: a new era in cancer immunotherapy. Journal of Internal Medicine, 2018, 283, 110-120.	2.7	162
4087	Melanoma maligno con mutaciÃ³n BRAF: terapia diana. Piel, 2018, 33, 295-299.	0.0	2
4088	Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 587-594.	1.3	9

#	Article	IF	Citations
4089	Where Did It Start? Subcutaneous Metastatic Melanoma. American Journal of Medicine, 2018, 131, 41-44.	0.6	0
4090	Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. Melanoma Research, 2018, 28, 56-60.	0.6	25
4091	miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. Cellular Signalling, 2018, 42, 30-43.	1.7	25
4092	Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature. Neurosurgical Review, 2018, 41, 333-339.	1.2	27
4093	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery, 2018, 8, 37-48.	7.7	248
4094	Management of Toxicities of Targeted Therapies. , 2018, , 490-500.e3.		2
4095	Clinical Trial Methodology in Lung Cancer. , 2018, , 620-627.e2.		1
4096	Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. Cancer Biology and Therapy, 2018, 19, 53-62.	1.5	12
4097	Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist, 2018, 23, 128-134.	1.9	34
4098	Targeted drug delivery to melanoma. Advanced Drug Delivery Reviews, 2018, 127, 208-221.	6.6	99
4099	Definitions and statistical properties of master protocols for personalized medicine in oncology. Journal of Biopharmaceutical Statistics, 2018, 28, 217-228.	0.4	27
4100	Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. Clinical Cancer Research, 2018, 24, 994-1001.	3.2	10
4101	Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study. Investigational New Drugs, 2018, 36, 259-268.	1.2	8
4102	The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy. Journal of Investigative Dermatology, 2018, 138, 159-170.	0.3	11
4103	A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers. International Journal of Cancer, 2018, 142, 156-164.	2.3	2
4104	Neurological Complications of Targeted Therapies. , 2018, , 311-333.		2
4105	Efforts to Develop KRAS Inhibitors. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031864.	2.9	27
4106	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature Reviews Clinical Oncology, 2018, 15, 151-167.	12.5	247

#	Article	IF	Citations
4107	Physician interpretation of genomic test results and treatment selection. Cancer, 2018, 124, 966-972.	2.0	10
4108	Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma. Clinical Neurology and Neurosurgery, 2018, 164, 32-38.	0.6	17
4109	Evolution of early phase clinical trials in oncology. Journal of Molecular Medicine, 2018, 96, 31-38.	1.7	13
4110	Expression signatures of early-stage and advanced medaka melanomas. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2018, 208, 20-28.	1.3	11
4111	Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies. , 2018, , .		9
4112	MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2018, 27, 17-30.	1.9	63
4113	miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Research, 2018, 78, 1017-1030.	0.4	140
4114	Medical bioinformatics in melanoma. Current Opinion in Oncology, 2018, 30, 113-117.	1.1	13
4115	Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma. European Journal of Cancer, 2018, 90, 149-152.	1.3	4
4116	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. Melanoma Research, 2018, 28, 143-146.	0.6	4
4117	Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clinical and Experimental Dermatology, 2018, 43, 117-123.	0.6	28
4118	Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 325-332.	1.1	11
4119	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Molecular Cancer Research, 2018, 16, 378-389.	1.5	99
4120	Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne, 2018, 56, 122-126.	0.3	6
4121	Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. European Journal of Cancer, 2018, 89, 90-101.	1.3	19
4122	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
4123	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. Cell Cycle, 2018, 17, 356-361.	1.3	40
4124	CAR-T cells and combination therapies: Whatâ€™s next in the immunotherapy revolution?. Pharmacological Research, 2018, 129, 194-203.	3.1	33

#	Article	IF	Citations
4125	Advancing cancer drug development through precision medicine and innovative designs. Journal of Biopharmaceutical Statistics, 2018, 28, 229-244.	0.4	1
4126	HDAC inhibitors restore BRAFâ€inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 2018, 142, 1926-1937.	2.3	48
4127	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. Journal of Neuro-Oncology, 2018, 137, 67-75.	1.4	17
4129	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 299-310.	2.0	48
4130	Surgical and Anatomic Considerations of Malignancies Affecting the Groin: Consideration for Melanoma. , 2018, , 63-74.		0
4131	Dabrafenib inhibits the growth of BRAFâ€WT cancers through CDK16 and NEK9 inhibition. Molecular Oncology, 2018, 12, 74-88.	2.1	30
4132	A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib. Lung Cancer, 2018, 116, 96-98.	0.9	1
4133	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncology, 2018, 4, 126.	3.4	8
4134	Recent advances in melanoma research via â€œomicsâ€•platforms. Journal of Proteomics, 2018, 188, 152-166.	1.2	13
4135	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern Pathology, 2018, 31, 24-38.	2.9	324
4136	The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. Pharmacological Research, 2018, 135, 265-267.	3.1	6
4137	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology, 2018, 19, 303-317.	3.3	78
4138	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research, 2018, 129, 414-423.	3.1	31
4139	Revisiting Expectations in an Era of Precision Oncology. Oncologist, 2018, 23, 386-388.	1.9	23
4140	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine, 2018, 69, 319-331.	5.0	61
4141	SEOM clinical guideline for the management of malignant melanoma (2017). Clinical and Translational Oncology, 2018, 20, 69-74.	1.2	16
4142	Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013â€“2016. Melanoma Research, 2018, 28, 52-55.	0.6	6
4143	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs, 2018, 36, 103-113.	1.2	19

#	Article	IF	Citations
4144	Concordance in <scp>BRAF</scp> V600E status over time in malignant melanoma and corresponding metastases. Histopathology, 2018, 72, 814-825.	1.6	10
4145	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Molecular Cancer Therapeutics, 2018, 17, 84-95.	1.9	22
4146	Cytotoxicity mechanisms in melanoma cells and UPLC-QTOF/MS2 chemical characterization of two Brazilian stingless bee propolis: Uncommon presence of piperidinic alkaloids. Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 502-511.	1.4	37
4147	Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 46-53.	0.6	2
4148	Rescue Surgery in a Patient With Metastatic Melanoma and BRAF V600E Mutation. CirugÃa EspaÃ±ola (English Edition), 2018, 96, 665-666.	0.1	0
4149	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	3
4150	Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in BRAF V600E Colorectal Cancer. JCO Precision Oncology, 2018, 2018, 1-4.	1.5	5
4151	Direct costs associated with adverse events of systemic therapies for advanced melanoma. Medicine (United States), 2018, 97, e11736.	0.4	19
4152	PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	8
4153	Long-Term Outcomes in Patients With BRAF V600â€“Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology, 2018, 36, 667-673.	0.8	196
4154	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	98
4155	Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration. JCO Precision Oncology, 2018, 2, 1.	1.5	5
4156	Antiâ€‘cancer effects of a novel Panâ€‘RAF inhibitor in a hepatocellular carcinoma cell line. Molecular Medicine Reports, 2018, 17, 6185-6193.	1.1	5
4157	Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 759-762.	1.8	13
4158	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390.	0.8	431
4159	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	0.8	362
4160	Duration of Antiâ€“Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?. Journal of Clinical Oncology, 2018, 36, 1649-1653.	0.8	4
4161	Malignant melanoma: Claims and controversies. Journal of Patient Safety and Risk Management, 2018, 23, 243-249.	0.4	0

#	Article	IF	Citations
4162	Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 20-25.	1.8	35
4163	Mechanisms of Drug Resistance in Cancer Therapy. Handbook of Experimental Pharmacology, 2018, , .	0.9	1
4164	Automated phosphopeptide enrichment from minute quantities of frozen malignant melanoma tissue. PLoS ONE, 2018, 13, e0208562.	1.1	15
4166	Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma. Melanoma Management, 2018, 5, MMT08.	0.1	2
4167	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. Scientifica, 2018, 2018, 1-7.	0.6	14
4168	Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma. Journal of Cancer, 2018, 9, 4665-4676.	1.2	20
4169	DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem. BMJ Case Reports, 2018, 2018, bcr-2018-224379.	0.2	15
4170	Survey of various methods for diagnostic signatures for cutaneous melanoma from genetic and imaging data. International Journal of Business Intelligence and Data Mining, 2018, 13, 40.	0.2	0
4171	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precision Oncology, 2018, 2, 1-16.	1.5	41
4173	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
4174	Elevated Levels of BRAF^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precision Oncology, 2018, 2, 1-17.	1.5	3
4175	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology, 2018, 2, 1-18.	1.5	4
4176	BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. JCO Precision Oncology, 2018, 2, 1-6.	1.5	6
4177	Access to Cancer Precision Medicines in Switzerland: A Comparative Analysis (USA and EU) and Health Policy Implications. Public Health Genomics, 2018, 21, 238-243.	0.6	1
4178	BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2018, 2, 1-14.	1.5	19
4179	Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. The Cochrane Library, 2018, 12, CD013190.	1.5	41
4180	Factors associated with immunotherapy selection in patients with advanced melanoma. Immunotherapy, 2018, 10, 1361-1369.	1.0	2
4181	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. Anticancer Research, 2018, 38, 6393-6397.	0.5	3

#	Article	IF	Citations
4182	Counteracting Resistance to BRAF V600E Mutation in Melanoma Using Dietary Polyphenols. , 2018, , 185-193.		0
4183	Multifunctional Nanoparticle Approach forÂTargeting Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2018, 19, S89-S90.	0.8	0
4184	Radiogenomics. Medical Physics, 2018, 45, e1111-e1122.	1.6	37
4185	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature Communications, 2018, 9, 4775.	5.8	70
4187	Global view of a drug-sensitivity gene network. Oncotarget, 2018, 9, 3254-3266.	0.8	3
4188	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. Current Treatment Options in Oncology, 2018, 19, 70.	1.3	17
4189	⁶⁸ Ga-DOTA-GGNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine, 2018, 10, .	5.8	30
4190	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma. PLoS ONE, 2018, 13, e0206942.	1.1	35
4191	Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells. Anticancer Research, 2018, 38, 6195-6200.	0.5	4
4192	BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. Cell Reports, 2018, 25, 1501-1510.e3.	2.9	34
4193	Lessons in practicing cancer genomics and precision medicine. Expert Review of Precision Medicine and Drug Development, 2018, 3, 287-298.	0.4	0
4194	Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder. OncoTargets and Therapy, 2018, Volume 11, 8723-8728.	1.0	7
4195	Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. Analytical Cellular Pathology, 2018, 2018, 1-7.	0.7	11
4196	Anorectal mucosal melanoma. Oncotarget, 2018, 9, 8785-8800.	0.8	68
4197	Tratamiento quirÃºrgico de rescate en paciente con melanoma metastÃ¡sico con mutaciÃ³n BRAF V600E. CirugÃa EspaÃ±ola, 2018, 96, 665-666.	0.1	0
4198	Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget, 2018, 9, 6174-6187.	0.8	28
4199	Targeted Next-Generation Sequencing in Head and Neck Cancer. , 2018, , 37-50.		0
4200	Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Scientific Reports, 2018, 8, 17914.	1.6	65

#	Article	IF	Citations
4201	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer, 2018, 18, 1274.	1.1	31
4202	How theBRAFV600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterology Research and Practice, 2018, 2018, 1-14.	0.7	34
4203	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. OncoTargets and Therapy, 2018, Volume 11, 9081-9089.	1.0	41
4204	Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability. OncoTargets and Therapy, 2018, Volume 11, 8293-8299.	1.0	6
4205	The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities. International Journal of Molecular Sciences, 2018, 19, 3929.	1.8	14
4206	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. Journal of Clinical Investigation, 2018, 128, 1442-1457.	3.9	30
4207	Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Research, 2018, 28, 536-546.	0.6	20
4208	Recurrent copy number alterations in young women with breast cancer. Oncotarget, 2018, 9, 11541-11558.	0.8	12
4209	In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data. High-Throughput, 2018, 7, 37.	4.4	15
4210	BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). Oncology Reports, 2018, 40, 3-15.	1.2	57
4211	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell, 2018, 34, 922-938.e7.	7.7	63
4212	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Molecular Cancer, 2018, 17, 145.	7.9	54
4213	Low-Grade Gliomas. , 2018, , 223-250.		0
4214	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	9.4	145
4215	A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 1249-1270.	1.1	164
4216	The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia, 2018, 20, 1121-1134.	2.3	32
4217	Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP. Molecular Cancer Therapeutics, 2018, 17, 2543-2550.	1.9	52
4218	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treatment Reviews, 2018, 71, 8-18.	3.4	58

#	Article	IF	Citations
4219	A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth. Cell Chemical Biology, 2018, 25, 1485-1494.e5.	2.5	20
4220	Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma. PLoS ONE, 2018, 13, e0204930.	1.1	0
4221	Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Annals of Surgical Oncology, 2018, 25, 3960-3965.	0.7	67
4222	Effect Sizes of Somatic Mutations in Cancer. Journal of the National Cancer Institute, 2018, 110, 1171-1177.	3.0	71
4223	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy, 2018, Volume 11, 7095-7107.	1.0	187
4225	Computational Approaches to Prioritize Cancer Driver Missense Mutations. International Journal of Molecular Sciences, 2018, 19, 2113.	1.8	20
4226	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiology, 2018, 57, 80-84.	0.8	7
4227	Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium. Archives of Public Health, 2018, 76, 49.	1.0	11
4228	Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget, 2018, 9, 25808-25825.	0.8	64
4229	Cladribine treatment for Erdheimâ€“Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. Journal of Clinical and Experimental Hematopathology: JCEH, 2018, 58, 161-165.	0.3	7
4230	Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics. Melanoma Research, 2018, 28, 527-535.	0.6	1
4231	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. Targeted Oncology, 2018, 13, 541-544.	1.7	7
4232	Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. Annales De Dermatologie Et De Venereologie, 2018, 145, 649-658.	0.5	3
4233	Pathologie molÃ©culaire des mÃ©lanomes : applications pratiques. Revue Francophone Des Laboratoires, 2018, 2018, 34-39.	0.0	1
4234	Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. American Journal of Clinical Dermatology, 2018, 19, 31-39.	3.3	208
4235	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. BMC Medical Informatics and Decision Making, 2018, 18, 89.	1.5	18
4236	Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival. Frontiers in Genetics, 2018, 9, 421.	1.1	38
4237	Targeted Therapy in Advanced Melanoma. , 2018, , 1-20.		0

#	Article	IF	Citations
4238	A Platform for Comprehensive Genomic Profiling in Human Cancers and Pharmacogenomics Therapy Selection. Methods in Molecular Biology, 2018, 1825, 413-424.	0.4	0
4239	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. Future Medicinal Chemistry, 2018, 10, 2445-2455.	1.1	7
4240	Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs in Context, 2018, 7, 1-11.	1.0	20
4241	8 Surgical Implications of Systemic Therapy for Skin Cancer. , 2018, , .		0
4242	Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. Expert Review of Proteomics, 2018, 15, 701-708.	1.3	8
4243	Apatinib mesylate tablet in the treatment of advanced malignant melanoma. OncoTargets and Therapy, 2018, Volume 11, 5333-5338.	1.0	9
4244	Sequential treatment approaches inÂ the management of BRAF wild-type advanced melanoma: a costâ€“effectiveness analysis. Immunotherapy, 2018, 10, 1241-1252.	1.0	19
4245	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	5.8	80
4246	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy, 2018, 67, 1833-1844.	2.0	52
4247	Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma. Kaohsiung Journal of Medical Sciences, 2018, 34, 535-536.	0.8	1
4248	Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of hilar and mediastinal lymph node metastases of melanoma. Turk Patoloji Dergisi, 2018, 35, 92-101.	0.1	1
4249	Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. Frontiers in Oncology, 2018, 8, 328.	1.3	12
4250	Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trials. ICSA Book Series in Statistics, 2018, , 23-52.	0.0	0
4251	UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. Cancer Research, 2018, 78, 6462-6472.	0.4	56
4252	Translational Research and Genomics Driven Trials in Thyroid Cancer. , 2018, , 319-338.		0
4253	Drug and chemical induced photosensitivity from a clinical perspective. Photochemical and Photobiological Sciences, 2018, 17, 1885-1903.	1.6	33
4254	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genetics, 2018, 14, e1007589.	1.5	56
4255	Costs associated with adverse events for systemic therapies in metastatic melanoma. Journal of Comparative Effectiveness Research, 2018, 7, 867-879.	0.6	1

#	Article	IF	Citations
4256	S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib. Cellular Physiology and Biochemistry, 2018, 49, 1184-1203.	1.1	18
4257	Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine. Biomolecules, 2018, 8, 21.	1.8	60
4258	Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 2018, 158, 144-166.	2.6	31
4259	Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trials Communications, 2018, 12, 1-8.	0.5	81
4260	MEK inhibitors for the treatment of NRAS mutant melanoma. Drug Design, Development and Therapy, 2018, Volume 12, 2553-2565.	2.0	37
4261	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 2018, 41, 343-349.	1.2	9
4262	Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. Biochemical and Biophysical Research Communications, 2018, 503, 3086-3092.	1.0	27
4263	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. Cancer Treatment Reviews, 2018, 70, 144-153.	3.4	27
4264	Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy. Bioscience Reports, 2018, 38, .	1.1	28
4265	Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science, 2018, 361, .	6.0	118
4266	Can Early Clinical Trials Help Deliver More Precise Cancer Care?. , 2018, , 115-128.		0
4267	Personalized Medicine. , 2018, , 659-673.		0
4268	ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. Clinical Cancer Research, 2018, 24, 4044-4055.	3.2	36
4269	<scp>MEK</scp>1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and <scp>ABT</scp>â€737 under conditions that mimic the chronic lymphocytic leukaemia (<scp>CLL</scp>) tumour microenvironment. British Journal of Haematology, 2018, 182, 360-372.	1.2	23
4270	Oncogenic PKC-Î¹ activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-Î¹ and PKC-Î¶ specific inhibitors. Cell Adhesion and Migration, 2018, 12, 1-17.	1.1	21
4272	Advances in the systemic treatment of melanoma brain metastases. Annals of Oncology, 2018, 29, 1509-1520.	0.6	31
4273	Histiocytoid Sweetâ€™s syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma. Melanoma Research, 2018, 28, 256-257.	0.6	9
4274	Cutaneous toxicities of new treatments for melanoma. Clinical and Translational Oncology, 2018, 20, 1373-1384.	1.2	24

#	Article	IF	Citations
4275	Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 210-228.	2.6	32
4276	A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell, 2018, 33, 801-815.	7.7	181
4277	AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. British Journal of Cancer, 2018, 118, 1453-1463.	2.9	13
4278	Translational â€“omics: Future potential and current challenges in precision medicine. Methods, 2018, 151, 3-11.	1.9	22
4279	A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma. Clinical Oncology, 2018, 30, 609-617.	0.6	16
4280	Resource utilization and disaggregated cost analysis for initial treatment of melanoma. Journal of Cancer Policy, 2018, 16, 63-69.	0.6	4
4281	Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47.	1.4	11
4282	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. Medical Oncology, 2018, 35, 110.	1.2	6
4283	IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. Cancer Letters, 2018, 433, 147-155.	3.2	27
4284	Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. , 2018, , 323-332.		4
4285	Diagnosis and Management of Acral Lentiginous Melanoma. Current Treatment Options in Oncology, 2018, 19, 42.	1.3	44
4286	Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. Advances in Clinical Chemistry, 2018, 83, 53-72.	1.8	22
4287	The Prediction of Drug-Disease Correlation Based on Gene Expression Data. BioMed Research International, 2018, 2018, 1-6.	0.9	9
4288	Predictive Value of Epigenetic Signatures. , 2018, , 275-311.		0
4289	A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 1892-1908.	2.5	13
4290	New developments in brain metastases. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878550.	1.5	25
4291	Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanomaâ€”Reply. JAMA Oncology, 2018, 4, 1136.	3.4	1
4292	Chaos synchronization and Nelder-Mead search for parameter estimation in nonlinear pharmacological systems: Estimating tumor antigenicity in a model of immunotherapy. Progress in Biophysics and Molecular Biology, 2018, 139, 23-30.	1.4	5

#	Article	IF	Citations
4293	Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction. Cancer Science, 2018, 109, 2757-2766.	1.7	60
4294	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. Annals of Internal Medicine, 2018, 169, 233.	2.0	20
4295	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600â€“Mutated Metastatic Melanoma. JAMA Oncology, 2018, 4, 1382.	3.4	65
4296	Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer. Clinical Cancer Research, 2018, 24, 4271-4281.	3.2	45
4297	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
4298	Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. Biomaterials, 2018, 182, 1-12.	5.7	54
4299	Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays in Biochemistry, 2018, 62, 583-593.	2.1	25
4300	BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncology Letters, 2018, 16, 2402-2408.	0.8	13
4301	Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics, 2018, 14, 105.	1.4	15
4303	Targeting signal-transducer-and-activator-of-transcription 3Âsensitizes human cutaneous melanoma cells to BRAF inhibitor. Cancer Biomarkers, 2018, 23, 67-77.	0.8	8
4304	Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). Cancers, 2018, 10, 157.	1.7	39
4305	Malignant Melanoma: Diagnostic and Management Update. Plastic and Reconstructive Surgery, 2018, 142, 202e-216e.	0.7	45
4306	Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract. Oncology Letters, 2018, 16, 2675-2681.	0.8	7
4307	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. Molecular Cancer, 2018, 17, 106.	7.9	46
4308	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
4309	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
4310	Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines. BMC Cancer, 2018, 18, 675.	1.1	23
4311	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. International Journal of Oncology, 2018, 53, 1149-1159.	1.4	12

#	Article	IF	Citations
4312	Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biology and Therapy, 2018, 19, 871-874.	1.5	18
4313	Melanoma treatment in review. ImmunoTargets and Therapy, 2018, Volume 7, 35-49.	2.7	483
4314	Overview of precision oncology trials: challenges and opportunities. Expert Review of Clinical Pharmacology, 2018, 11, 797-804.	1.3	31
4315	Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. Acta Dermato-Venereologica, 2018, 98, 44-49.	0.6	20
4316	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers, 2018, 10, 35.	1.7	19
4317	Vemurafenib. Recent Results in Cancer Research, 2018, 211, 77-89.	1.8	52
4318	Heterogeneity and phenotypic stratification in acute respiratory distress syndrome. Lancet Respiratory Medicine,the, 2018, 6, 651-653.	5.2	26
4319	Primary Solitary Intracranial Malignant Melanoma: A Systematic Review of Literature. World Neurosurgery, 2018, 117, 386-393.	0.7	19
4320	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFÎ²1 Axis. Clinical Cancer Research, 2018, 24, 6078-6097.	3.2	43
4321	Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. Journal of Cancer, 2018, 9, 1267-1276.	1.2	7
4322	The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cellâ€“Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth. Frontiers in Oncology, 2018, 8, 8.	1.3	28
4323	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. Frontiers in Oncology, 2018, 8, 185.	1.3	60
4324	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. Frontiers in Oncology, 2018, 8, 202.	1.3	35
4325	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology, 2018, 8, 226.	1.3	56
4326	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. Targeted Oncology, 2018, 13, 423-436.	1.7	5
4327	Pelvic lymph node dissection in metastatic melanoma to the groin should not be abandoned yet. European Journal of Surgical Oncology, 2018, 44, 1779-1785.	0.5	5
4328	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 2018, 18, 726.	1.1	77
4329	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	1.7	21

#	Article	IF	Citations
4330	The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. Cancer Prevention Research, 2018, 11, 607-620.	0.7	8
4331	The Emerging Therapeutic Landscape of Advanced Melanoma. Current Pharmaceutical Design, 2018, 24, 549-558.	0.9	16
4332	Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. International Journal of Molecular Sciences, 2018, 19, 394.	1.8	78
4333	Non-Metastatic Cutaneous Melanoma Induces Chronodisruption in Central and Peripheral Circadian Clocks. International Journal of Molecular Sciences, 2018, 19, 1065.	1.8	33
4334	Extracting Fitness Relationships and Oncogenic Patterns among Driver Genes in Cancer. Molecules, 2018, 23, 39.	1.7	0
4335	Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. BMC Cancer, 2018, 18, 705.	1.1	23
4337	BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. Journal of Investigative Dermatology, 2018, 138, 2489-2491.	0.3	5
4338	Patterns of genomic evolution in advanced melanoma. Nature Communications, 2018, 9, 2665.	5.8	62
4339	Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Fullâ€Length Protein. ChemBioChem, 2018, 19, 1988-1997.	1.3	32
4340	Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. ELife, 2018, 7, .	2.8	474
4341	Emerging findings into molecular mechanism of brain metastasis. Cancer Medicine, 2018, 7, 3820-3833.	1.3	34
4342	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research, 2018, 6, 1039-1045.	1.6	60
4343	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Clinical and Experimental Metastasis, 2018, 35, 503-520.	1.7	9
4344	The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Scientific Reports, 2018, 8, 10902.	1.6	19
4345	Results of the UK NEQAS for Molecular Genetics reference sample analysis. Journal of Clinical Pathology, 2018, 71, 989-994.	1.0	5
4346	(Arg)9-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 138.	3.5	16
4348	Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature. BMC Medical Research Methodology, 2018, 18, 10.	1.4	5
4349	Vemurafenib in Chinese patients with BRAFV600 mutationâ€“positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer, 2018, 18, 520.	1.1	10

#	Article	IF	Citations
4350	Liquid biomarkers in melanoma: detection and discovery. Molecular Cancer, 2018, 17, 8.	7.9	74
4351	Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Molecular Cancer, 2018, 17, 55.	7.9	75
4352	Clinical trial cytology: Use of onâ€site evaluation of small biopsy and FNA samples for clinical trials and biomarker research studies. Cancer Cytopathology, 2018, 126, .	1.4	11
4353	Deep learning of mutation-gene-drug relations from the literature. BMC Bioinformatics, 2018, 19, 21.	1.2	43
4355	Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation. Scientific Reports, 2018, 8, 11519.	1.6	37
4356	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
4357	Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. Journal of Oncology, 2018, 2018, 1-13.	0.6	3
4358	Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 967-974.	2.3	29
4359	Synthetic Lethality: From Research to Precision Cancer Nanomedicine. Current Cancer Drug Targets, 2018, 18, 337-346.	0.8	17
4360	Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. Journal of Neurosurgery, 2018, 129, 27-34.	0.9	35
4361	CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells. Scientific Reports, 2018, 8, 11893.	1.6	20
4362	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs, 2018, 78, 1197-1209.	4.9	34
4364	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opinion on Orphan Drugs, 2018, 6, 545-551.	0.5	6
4365	BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Wspolczesna Onkologia, 2018, 2018, 68-72.	0.7	38
4366	A catalogue of somatic NRF2 gain-of-function mutations in cancer. Scientific Reports, 2018, 8, 12846.	1.6	92
4367	Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Oncotarget, 2018, 9, 24248-24259.	0.8	30
4368	Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer, 2018, 18, 812.	1.1	17
4369	Characterization and Outcomes of Disease Progression in 52 Patients Treated with <i>BRAF</i>-V600 + MEK Inhibitors for Advanced Melanoma. Dermatology, 2018, 234, 92-98.	0.9	5

#	Article	IF	Citations
4370	Dabrafenibâ€“trametinib combination in â€˜field-practiceâ€™: an Italian experience. Future Oncology, 2018, 14, 2045-2052.	1.1	3
4371	Melanoma treatment: from conventional to nanotechnology. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2283-2302.	1.2	128
4372	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
4373	Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. Cancer Management and Research, 2018, Volume 10, 2289-2301.	0.9	24
4374	PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5766-E5775.	3.3	17
4375	History of Melanoma. , 2018, , 1-13.		1
4376	Management of Melanoma Locoregional Recurrence. , 2018, , 351-359.		1
4377	Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481.		1
4378	Adjuvant Therapy of Melanoma. , 2018, , 483-498.		0
4379	Sulfonamide Drug Allergy. Current Allergy and Asthma Reports, 2018, 18, 38.	2.4	25
4380	Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Journal of Hepatology, 2018, 69, 826-839.	1.8	89
4381	Multispectroscopic and molecular modeling studies on the interaction of copper-ibuprofenate complex with bovine serum albumin (BSA). Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 203, 510-521.	2.0	33
4382	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. Journal of Experimental Medicine, 2018, 215, 1913-1928.	4.2	41
4383	Precision Medicine in Head and Neck Cancer: Myth or Reality?. Clinical Medicine Insights: Oncology, 2018, 12, 117955491877958.	0.6	18
4384	Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy. PLoS ONE, 2018, 13, e0192525.	1.1	20
4385	In vitro models of melanoma. , 2018, , 57-75.		1
4386	Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2. PLoS ONE, 2018, 13, e0191419.	1.1	55
4387	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood, 2018, 132, 587-597.	0.6	335

#	Article	IF	Citations
4388	A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. Cancer Discovery, 2018, 8, 1130-1141.	7.7	56
4389	GDA, a web-based tool for Genomics and Drugs integrated analysis. Nucleic Acids Research, 2018, 46, W148-W156.	6.5	9
4390	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 645-670.	0.1	0
4391	KRAS: Reasons for optimism in lung cancer. European Journal of Cancer, 2018, 99, 20-27.	1.3	43
4392	Molecular pathway activation â€“ New type of biomarkers for tumor morphology and personalized selection of target drugs. Seminars in Cancer Biology, 2018, 53, 110-124.	4.3	101
4393	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. Journal of Neuro-Oncology, 2018, 140, 55-62.	1.4	25
4394	Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 2018, 558, 605-609.	13.7	177
4395	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43
4396	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. , 2019, , 25-60.		2
4397	Fibroblast Growth Factor Receptor Inhibitors: Enhancing Therapeutic Strategies for Solid Tumors. , 2019, , 101-121.		0
4398	Cutaneous <scp>pH</scp> landscape as a facilitator of melanoma initiation and progression. Acta Physiologica, 2019, 225, e13105.	1.8	11
4399	Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Acta Pharmacologica Sinica, 2019, 40, 268-278.	2.8	12
4400	BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. Neurosurgery, 2019, 84, 868-880.	0.6	32
4401	Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. Supportive Care in Cancer, 2019, 27, 219-227.	1.0	5
4402	BRAF^{V600E} mutation: A promising target in colorectal neuroendocrine carcinoma. International Journal of Cancer, 2019, 144, 1379-1390.	2.3	33
4403	Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. Clinical Pharmacokinetics, 2019, 58, 451-467.	1.6	72
4404	MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. Journal of Cellular Physiology, 2019, 234, 2152-2168.	2.0	54
4405	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	0.5	20

#	Article	IF	Citations
4406	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. Health Information and Libraries Journal, 2019, 36, 318-340.	1.3	3
4407	Exercise Behaviors and Fatigue in Patients Receiving Immunotherapy for Advanced Melanoma: A Cross-Sectional Survey via Social Media. Integrative Cancer Therapies, 2019, 18, 153473541986443.	0.8	14
4408	Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. PLoS ONE, 2019, 14, e0219566.	1.1	22
4409	Targeted Therapy in Advanced Melanoma. , 2019, , 667-686.		0
4410	Adjuvant Therapy. , 2019, , 717-741.		0
4411	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
4412	Molecular Genetics of Melanocytic Neoplasia. , 2019, , 123-145.		1
4413	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
4414	Circadian Rhythms and Personalized Melanoma Therapy. Europeanization and Globalization, 2019, , 327-340.	0.1	0
4415	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open, 2019, 2, e198890.	2.8	96
4416	Impact of depth of response on survival in patients treated with cobimetinibâ€‰Â±â€‰vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. British Journal of Cancer, 2019, 121, 522-528.	2.9	20
4417	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. , 2019, 7, 251513551986223.	1.4	28
4418	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers, 2019, 11, 1176.	1.7	20
4419	Immunohistochemical analysis of Bclâ€2, nuclear S100A4, MITF and Ki67 for risk stratification of earlyâ€stage melanoma â€“ A combined IHC score for melanoma risk stratification. JDDG - Journal of the German Society of Dermatology, 2019, 17, 800-808.	0.4	12
4420	Personalized Medicine in Healthcare Systems. Europeanization and Globalization, 2019, , .	0.1	2
4421	Current state of melanoma diagnosis and treatment. Cancer Biology and Therapy, 2019, 20, 1366-1379.	1.5	462
4422	Efficacy of Vemurafenib in Patients With Nonâ€“Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	1.5	31
4423	Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study. Translational Lung Cancer Research, 2019, 8, 258-267.	1.3	17

#	Article	IF	Citations
4424	Systemic Therapies for Advanced Melanoma. Dermatologic Clinics, 2019, 37, 409-423.	1.0	42
4425	A patent review of RAF kinase inhibitors (2010â€“2018). Expert Opinion on Therapeutic Patents, 2019, 29, 675-688.	2.4	13
4426	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	1.4	21
4427	Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. Cancer Research, 2019, 79, 5074-5087.	0.4	13
4428	Targeting Oncogenic BRAF: Past, Present, and Future. Cancers, 2019, 11, 1197.	1.7	143
4429	Biophysical and Biochemical Characteristics as Complementary Indicators of Melanoma Progression. Analytical Chemistry, 2019, 91, 9885-9892.	3.2	17
4430	Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. Experimental Hematology and Oncology, 2019, 8, 14.	2.0	10
4431	Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. Bioorganic Chemistry, 2019, 91, 103125.	2.0	9
4432	Predicting drug activity against cancer cells by random forest models based on minimal genomic information and chemical properties. PLoS ONE, 2019, 14, e0219774.	1.1	75
4433	Surgery for gastrointestinal metastases of malignant melanoma â€" a retrospective exploratory study. World Journal of Surgical Oncology, 2019, 17, 123.	0.8	8
4435	An Integrated Microfluidics Approach for Personalized Cancer Drug Sensitivity and Resistance Assay. Advanced Biology, 2019, 3, 1900001.	3.0	6
4436	The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and metaâ€anâ€alysis. Cancer, 2019, 125, 3776-3789.	2.0	48
4437	A patent review of BRAF inhibitors: 2013-2018. Expert Opinion on Therapeutic Patents, 2019, 29, 595-603.	2.4	8
4438	SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. Scientific Reports, 2019, 9, 10369.	1.6	33
4439	Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma. Metallomics, 2019, 11, 1430-1440.	1.0	39
4440	Importance of genetic screens in precision oncology. ESMO Open, 2019, 4, e000505.	2.0	10
4441	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
4442	Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. Journal of Controlled Release, 2019, 309, 158-172.	4.8	3

#	Article	IF	Citations
4443	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. British Journal of Cancer, 2019, 121, 434-442.	2.9	54
4444	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	1.8	18
4445	Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy. Journal of Radiation Research, 2019, 60, 803-811.	0.8	9
4446	Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition. , 2019, 60, 2764.		24
4447	Thymoquinone Enhances the Effect of Gamma Knife in B16-F10 Melanoma Through Inhibition of Phosphorylated STAT3. World Neurosurgery, 2019, 128, e570-e581.	0.7	12
4448	Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. Current Oncology Reports, 2019, 21, 72.	1.8	29
4449	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. Advanced Drug Delivery Reviews, 2019, 141, 104-124.	6.6	14
4450	Targeted therapy for malignant melanoma. Current Opinion in Pharmacology, 2019, 46, 116-121.	1.7	19
4451	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
4452	Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2437-2448.	2.7	19
4453	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	3.2	107
4454	Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies. Journal of Surgical Oncology, 2019, 120, 540-549.	0.8	10
4455	Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Research, 2019, 29, 725-738.	5.7	661
4456	Pitfalls in molecular diagnostics. Seminars in Diagnostic Pathology, 2019, 36, 342-354.	1.0	10
4457	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Annals of Surgical Oncology, 2019, 26, 4621-4630.	0.7	10
4458	Analysis of the survival of patients receiving systemic treatment for melanoma of the skin: a retrospective population study with patients treated in Poland in 2011â€“2015. Postepy Dermatologii I Alergologii, 2019, 36, 438-441.	0.4	2
4459	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clinical Cancer Research, 2019, 25, 6852-6867.	3.2	74
4460	Melanoma Growth Analysis in Blood Serum and Tissue Using Xenograft Model with Response to Cold Atmospheric Plasma Activated Medium. Applied Sciences (Switzerland), 2019, 9, 4227.	1.3	26

#	Article	IF	Citations
4461	Treatment of metastatic malignant melanoma during pregnancy with a BRAF kinase inhibitor: A case report. Case Reports in Women's Health, 2019, 24, e00142.	0.2	9
4462	Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA. Diagnostics, 2019, 9, 117.	1.3	6
4463	Expression of CMV protein pp65 in cutaneous malignant melanoma. PLoS ONE, 2019, 14, e0223854.	1.1	1
4464	Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. Journal of Clinical Neuroscience, 2019, 70, 157-163.	0.8	3
4465	Molecular Biology of Pituitary Adenomas. Neurosurgery Clinics of North America, 2019, 30, 391-400.	0.8	13
4466	Precision medicine and companion diagnostics in drug development. , 2019, , 75-96.		0
4467	Molecular harvesting with electroporation for tissue profiling. Scientific Reports, 2019, 9, 15750.	1.6	9
4468	Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. BMC Cancer, 2019, 19, 1025.	1.1	7
4469	Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets. European Journal of Cancer, 2019, 121, 202-209.	1.3	11
4470	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 2019, 123, 58-71.	1.3	45
4471	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Review of Clinical Pharmacology, 2019, 12, 1107-1119.	1.3	11
4472	miR- 26a Sensitizes Melanoma Cells To Dabrafenib Via Targeting HMGB1-Dependent Autophagy Pathways . Drug Design, Development and Therapy, 2019, Volume 13, 3717-3726.	2.0	16
4473	The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy. Anticancer Research, 2019, 39, 6241-6247.	0.5	3
4474	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
4475	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 2019, 48, 178-190.	2.7	66
4476	The Landscape of Atypical and Eukaryotic Protein Kinases. Trends in Pharmacological Sciences, 2019, 40, 818-832.	4.0	87
4477	Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocrine Reviews, 2019, 40, 1573-1604.	8.9	196
4478	Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. PLoS ONE, 2019, 14, e0224267.	1.1	26

#	Article	IF	Citations
4479	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	1.8	15
4480	Novel Immunotherapy Combinations. Current Oncology Reports, 2019, 21, 96.	1.8	12
4481	Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized Î±-Melanocyte-Stimulating Hormone Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 597-603.	0.7	11
4482	Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. The Cochrane Library, 2019, 7, CD012806.	1.5	22
4483	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. Nature Communications, 2019, 10, 5143.	5.8	15
4485	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	1.7	47
4488	Structure-based Method for Predicting Deleterious Missense SNPs. , 2019, 2019, .		2
4489	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control, 2019, 26, 107327481987054.	0.7	16
4490	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clinical Cancer Research, 2019, 25, 7202-7217.	3.2	29
4491	Intracardiac melanoma metastases on ¹⁸F-FDG PET-CTâ€"a case report and review of literature with imaging features. BJR|case Reports, 2019, 5, 20180118.	0.1	0
4492	Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers. Frontiers in Medicine, 2019, 6, 194.	1.2	18
4493	Advances in the therapy of BRAF^{V600E} metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2019, 19, 823-829.	1.1	5
4494	Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations . OncoTargets and Therapy, 2019, Volume 12, 6045-6052.	1.0	6
4495	YY1 cooperates with TFEB to regulate autophagy and lysosomal biogenesis in melanoma. Molecular Carcinogenesis, 2019, 58, 2149-2160.	1.3	29
4496	Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. European Journal of Pharmacology, 2019, 862, 172621.	1.7	65
4497	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 2019, 11, 1262.	1.7	99
4498	Are Regulatory Age Limits in Pediatric Melanoma Justified?. Current Therapeutic Research, 2019, 90, 113-118.	0.5	3
4499	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10

#	Article	IF	Citations
4500	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology, 2019, 30, 1821-1830.	0.6	99
4501	Incidence and risk of developing photosensitivity with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2019, 81, 1009-1011.	0.6	7
4502	Transperineal abdominoperineal resection for anorectal melanoma: A case report. International Journal of Surgery Case Reports, 2019, 61, 214-217.	0.2	1
4503	The Role of MET in Melanoma and Melanocytic Lesions. American Journal of Pathology, 2019, 189, 2138-2148.	1.9	21
4504	Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts. Molecular Cancer Therapeutics, 2019, 18, 2421-2432.	1.9	2
4505	Determining patient preferences and willingness to pay related to scar length and appearance after skin cancer treatment on the face and trunk: A multicenter discrete choice experiment. Journal of the American Academy of Dermatology, 2019, 81, 1011-1013.	0.6	12
4506	Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries. PLoS ONE, 2019, 14, e0222904.	1.1	8
4507	90-gene signature assay for tissue origin diagnosis of brain metastases. Journal of Translational Medicine, 2019, 17, 331.	1.8	12
4508	ASO Author Reflections: Survival for Stage III Melanomaâ€"Where Do We Stand in the Current Landscape of Melanoma Therapies?. Annals of Surgical Oncology, 2019, 26, 4631-4632.	0.7	0
4509	BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis. Pathology Research and Practice, 2019, 215, 152671.	1.0	8
4510	Cytogenetics and Cytogenomics Evaluation in Cancer. International Journal of Molecular Sciences, 2019, 20, 4711.	1.8	14
4511	Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. Cancers, 2019, 11, 1480.	1.7	31
4512	Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. Pathology Research and Practice, 2019, 215, 152617.	1.0	14
4513	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes and Development, 2019, 33, 1295-1318.	2.7	203
4514	An integrated multi-molecular sensor for simultaneous BRAFV600E protein and DNA single point mutation detection in circulating tumour cells. Lab on A Chip, 2019, 19, 738-748.	3.1	16
4515	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology, 2019, 83, 693-704.	1.1	21
4516	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
4517	Illuminating the dark phosphoproteome. Science Signaling, 2019, 12, .	1.6	219

#	Article	IF	Citations
4518	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. Melanoma Research, 2019, 29, 301-310.	0.6	7
4519	Spatio-Genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma. Journal of Theoretical Biology, 2019, 466, 84-105.	0.8	12
4520	High response rates for Tâ€VEC in early metastatic melanoma (stage IIIB/Câ€IVM1a). International Journal of Cancer, 2019, 145, 974-978.	2.3	67
4521	Immune therapy of melanoma: Overview of therapeutic vaccines. Journal of Cellular Physiology, 2019, 234, 14612-14621.	2.0	25
4522	Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients. Cancer Genetics, 2019, 231-232, 46-53.	0.2	6
4523	Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell, 2019, 176, 1113-1127.e16.	13.5	74
4524	Understanding the Anti-Tumor Properties Mediated by the Synthetic Peptide GK-1. , 2019, , .		0
4525	Complete response with fluorouracil and irinotecan with a BRAF^{V600E} and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report. OncoTargets and Therapy, 2019, Volume 12, 443-447.	1.0	10
4526	Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine, 2019, 25, 185-197.	3.5	118
4527	Targeted Therapy and Immunotherapy for Melanoma in Japan. Current Treatment Options in Oncology, 2019, 20, 7.	1.3	79
4528	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. Journal of the American College of Surgeons, 2019, 228, 644-649.	0.2	65
4529	Detection ofBRAFV600EMutation in Melanoma Patients by Digital PCR of Circulating DNA. Genetic Testing and Molecular Biomarkers, 2019, 23, 241-245.	0.3	19
4530	JACKS: joint analysis of CRISPR/Cas9 knockout screens. Genome Research, 2019, 29, 464-471.	2.4	64
4531	Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. Journal of Experimental and Clinical Cancer Research, 2019, 38, 48.	3.5	38
4532	Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. Future Oncology, 2019, 15, 967-977.	1.1	10
4533	The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy, 2019, 7, 1-32.	1.0	19
4534	Capsaicin induces apoptosis and autophagy in human melanoma cells. Oncology Letters, 2019, 17, 4827-4834.	0.8	22
4535	Epithelioid glioblastoma presenting as aphasia in a young adult with ovarian cancer: A case report. Clinical Case Reports (discontinued), 2019, 7, 821-825.	0.2	4

#	Article	IF	Citations
4536	Data challenges for evaluating new treatments. Cancer, 2019, 125, 2528-2531.	2.0	0
4537	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4
4538	Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenibâ€resistant BRAF^{V600E} mutation bearing metastatic melanoma cells. Molecular Carcinogenesis, 2019, 58, 1680-1690.	1.3	16
4539	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health, 2019, 22, 777-784.	0.1	14
4540	Management of metastatic cutaneous melanoma: updates in clinical practice. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985166.	1.4	29
4541	A systematic analysis of genomics-based modeling approaches for prediction of drug response to cytotoxic chemotherapies. BMC Medical Genomics, 2019, 12, 87.	0.7	10
4542	Mechanisms of immunogenicity in colorectal cancer. British Journal of Surgery, 2019, 106, 1283-1297.	0.1	32
4543	Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research, 2019, 178, 137-169.	0.2	9
4544	High Prevalence of BRAF V600E Mutations in Langerhans Cell Histiocytosis of Head and Neck in Chinese Patients. International Journal of Surgical Pathology, 2019, 27, 836-843.	0.4	5
4545	Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report. SAGE Open Medical Case Reports, 2019, 7, 2050313X1984735.	0.2	3
4546	Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. Annals of Surgical Oncology, 2019, 26, 4610-4618.	0.7	20
4547	PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 462.	1.3	41
4548	The molecular clock in the skin, its functionality, and how it is disrupted in cutaneous melanoma: a new pharmacological target?. Cellular and Molecular Life Sciences, 2019, 76, 3801-3826.	2.4	28
4549	HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research, 2019, 25, 5686-5701.	3.2	75
4550	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma. IScience, 2019, 16, 453-467.	1.9	14
4551	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. Journal of Experimental Medicine, 2019, 216, 2150-2169.	4.2	85
4552	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open, 2019, 4, e000491.	2.0	140
4553	m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nature Communications, 2019, 10, 2782.	5.8	468

#	Article	IF	Citations
4554	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nature Medicine, 2019, 25, 929-935.	15.2	188
4555	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nature Medicine, 2019, 25, 936-940.	15.2	246
4556	Pharmacodynamic Evaluation: Dermatology. , 2019, , 1-17.		0
4557	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. American Journal of Clinical Dermatology, 2019, 20, 817-827.	3.3	29
4558	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutationâ€"positive metastatic melanoma treated with vemurafenib Â± cobimetinib. European Journal of Cancer, 2019, 116, 45-55.	1.3	9
4559	Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630.	1.8	308
4560	AKT and ERK dual inhibitors: The way forward?. Cancer Letters, 2019, 459, 30-40.	3.2	144
4561	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990.	2.2	86
4562	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Medicine, 2019, 45, 988-997.	3.9	18
4563	Diagnostic and therapeutic approach for neurocutaneous melanosis in a young adult. NeurologÃa (English Edition), 2019, 34, 336-338.	0.2	0
4565	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. PLoS ONE, 2019, 14, e0217399.	1.1	12
4566	Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance. PLoS Computational Biology, 2019, 15, e1007034.	1.5	41
4567	Brain Metastases and Leptomeningeal Metastases. , 2019, , 377-386.		0
4568	Cancer treatment and survivorship statistics, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 363-385.	157.7	3,303
4569	New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematological Oncology, 2019, 37, 30-37.	0.8	22
4570	Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Research Notes, 2019, 12, 296.	0.6	6
4571	Targeting ERK beyond the boundaries of the kinase active site in melanoma. Molecular Carcinogenesis, 2019, 58, 1551-1570.	1.3	26
4572	SnapshotDx Quiz: June 2019. Journal of Investigative Dermatology, 2019, 139, e59-e64.	0.3	0

#	Article	IF	Citations
4573	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	5.8	21
4574	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheimâ€“Chester Disease,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 707 T Oncology Reports, 2019, 21, 62.	1.8	48
4575	Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L.. Molecules, 2019, 24, 1725.	1.7	15
4576	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. Current Treatment Options in Oncology, 2019, 20, 49.	1.3	6
4577	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e721-e723.	0.9	7
4578	Translating Nanomedicine to Comparative Oncologyâ€"the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 671-681.	1.3	7
4579	Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 564-571.	1.8	42
4580	A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology, 2019, 12, 951-958.	1.7	7
4581	SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. Cancers, 2019, 11, 673.	1.7	22
4582	Translation of cancer immunotherapy from the bench to the bedside. Advances in Cancer Research, 2019, 143, 1-62.	1.9	28
4583	Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells. Cancers, 2019, 11, 659.	1.7	43
4584	The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.		0
4585	Polymerase Chain Reaction. , 2019, , 111-133.		1
4586	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. Experimental and Molecular Pathology, 2019, 110, 104260.	0.9	8
4587	Endobronchial, laryngeal and mediastinal melanoma: a rare constellation of metastatic disease. BMJ Case Reports, 2019, 12, e228957.	0.2	1
4588	Deciphering the universe of genetic context-dependencies using mouse models of cancer. Current Opinion in Genetics and Development, 2019, 54, 97-104.	1.5	3
4589	Clinical Validation of a Cell-Free DNA Gene Panel. Journal of Molecular Diagnostics, 2019, 21, 632-645.	1.2	15
4590	Changes in populationâ€level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. Cancer, 2019, 125, 2656-2665.	2.0	15

#	Article	IF	Citations
4591	DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. Translational Oncology, 2019, 12, 932-950.	1.7	13
4592	Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study. Journal of Skin Cancer, 2019, 2019, 1-6.	0.5	3
4593	Targeted Therapies for Brain Metastases. Progress in Neurological Surgery, 2019, 34, 125-137.	1.3	14
4594	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. BMC Cancer, 2019, 19, 403.	1.1	21
4595	A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells. BMC Cancer, 2019, 19, 402.	1.1	41
4596	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 48.	2.8	24
4597	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
4598	BRAF status as a predictive factor for response in isolated limb perfusion. International Journal of Hyperthermia, 2019, 36, 510-514.	1.1	2
4599	Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma. Cells, 2019, 8, 350.	1.8	26
4600	Separating Response of Tumor and non-Tumor Cells to Drug In Vitro by Quantifying a Mutation. Anticancer Research, 2019, 39, 1777-1783.	0.5	1
4601	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine, 2019, 25, 751-758.	15.2	362
4602	Acute Respiratory Distress Syndrome Phenotypes. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 019-030.	0.8	83
4603	Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Molecular Pharmacology, 2019, 96, 36-46.	1.0	22
4604	Repurposing the Electron Transfer Reactant Phenazine Methosulfate (PMS) for the Apoptotic Elimination of Malignant Melanoma Cells through Induction of Lethal Oxidative and Mitochondriotoxic Stress. Cancers, 2019, 11, 590.	1.7	17
4605	Basket Trials for Intractable Cancer. Frontiers in Oncology, 2019, 9, 229.	1.3	22
4606	Precision Oncology in Sarcomas: Divide and Conquer. JCO Precision Oncology, 2019, 3, 1-16.	1.5	14
4607	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Research, 2019, 79, 2947-2961.	0.4	59
4608	Quantitative Interrogation of the Human Kinome Perturbed by Two BRAF Inhibitors. Journal of Proteome Research, 2019, 18, 2624-2631.	1.8	12

#	Article	IF	Citations
4609	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. PLoS ONE, 2019, 14, e0209134.	1.1	16
4610	Multiple antigen-engineered DC vaccines with or without IFNÎ± to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
4611	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease, 2019, 10, 342.	2.7	125
4612	Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-Î± dependent PDK-1 signaling pathway. Redox Biology, 2019, 25, 101197.	3.9	15
4613	Translating Human Cancer Sequences Into Personalized Porcine Cancer Models. Frontiers in Oncology, 2019, 9, 105.	1.3	10
4614	Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology, 2019, 35, 293-332.	2.4	33
4615	Cancer Treatment in the Genomic Era. Annual Review of Biochemistry, 2019, 88, 247-280.	5.0	24
4616	CD117 immunoexpression in oral and sinonasal mucosal melanoma does not correlate with somatic driver mutations in the <scp>MAPK</scp> pathway. Journal of Oral Pathology and Medicine, 2019, 48, 382-388.	1.4	9
4617	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
4618	DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. Experimental Cell Research, 2019, 379, 48-54.	1.2	27
4619	Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells. Molecular and Cellular Proteomics, 2019, 18, 1096-1109.	2.5	25
4620	Redifferentiation of a BRAF^{K601E}-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. Thyroid, 2019, 29, 735-742.	2.4	35
4621	Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1Râ€“MEK5â€“Erk5 Pathway. Cancer Research, 2019, 79, 2244-2256.	0.4	41
4622	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. Annals of Surgical Oncology, 2019, 26, 3945-3952.	0.7	24
4623	Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology. International Journal of Molecular Sciences, 2019, 20, 1011.	1.8	8
4624	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 2019, 30, 804-814.	0.6	117
4625	CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features. Frontiers in Genetics, 2019, 10, 121.	1.1	6
4626	Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trials. Pharmaceutical Statistics, 2019, 18, 459-475.	0.7	2

#	Article	IF	Citations
4627	Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation. Cell Death and Differentiation, 2019, 26, 2416-2429.	5.0	25
4628	Genomic Features of Exceptional Response in Vemurafenib Â± Cobimetinibâ€“treated Patients with BRAFV600-mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	3.2	32
4629	BRAF Inhibition: Bridge or Boost to T-cell Therapy?. Clinical Cancer Research, 2019, 25, 2682-2684.	3.2	5
4630	Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF^{V600E} A375 Melanoma Cells. Chemical Research in Toxicology, 2019, 32, 645-658.	1.7	5
4631	Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature. Frontiers in Oncology, 2019, 9, 177.	1.3	17
4632	Case Report of Rarely Described Polymorphous Low-Grade Neuroepithelial Tumor of the Young and Comparison with Oligodendroglioma. World Neurosurgery, 2019, 127, 47-51.	0.7	21
4633	Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma. British Journal of Biomedical Science, 2019, 76, 77-82.	1.2	7
4634	BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. Endocrine, 2019, 64, 406-413.	1.1	28
4635	Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Letters, 2019, 451, 79-91.	3.2	22
4636	KRAS G12V Mutation is an Adverse Prognostic Factor of Chinese Gastric Cancer Patients. Journal of Cancer, 2019, 10, 821-828.	1.2	20
4637	Absorbent Microbiopsy Sampling and RNA Extraction for Minimally Invasive, Simultaneous Blood and Skin Analysis. Journal of Visualized Experiments, 2019, , .	0.2	4
4638	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Current Colorectal Cancer Reports, 2019, 15, 53-60.	1.0	4
4639	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Scientific Reports, 2019, 9, 1225.	1.6	16
4640	Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model. PLoS ONE, 2019, 14, e0213095.	1.1	10
4641	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. Clinical Pharmacokinetics, 2019, 58, 1029-1043.	1.6	6
4642	Combination Treatment with the BRAF^{V600E} Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma. Thyroid, 2019, 29, 540-548.	2.4	13
4643	Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in TP53 mutant pancreatic tumors. Future Science OA, 2019, 5, FSO366.	0.9	16
4644	Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with BRAF V600E mutation. BMJ Case Reports, 2019, 12, e228519.	0.2	1

#	Article	IF	Citations
4645	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	0.8	101
4646	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. Scientific Reports, 2019, 9, 5154.	1.6	12
4647	Chorioidale Raumforderung: primÃres Aderhautmelanom oder metastasiertes kutanes Melanom?. Karger Kompass Ophthalmologie, 2019, 5, 19-21.	0.0	0
4648	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opinion on Drug Safety, 2019, 18, 381-392.	1.0	62
4649	Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts. Journal of Translational Medicine, 2019, 17, 1-18.	1.8	1
4650	Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature. Frontiers in Oncology, 2019, 9, 168.	1.3	3
4651	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. , 2019, , 169-185.		1
4652	Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. Drug Metabolism and Disposition, 2019, 47, 616-631.	1.7	10
4653	Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. Paediatric Drugs, 2019, 21, 71-79.	1.3	4
4654	Current Immunotherapy Approaches for Malignant Melanoma. Biochip Journal, 2019, 13, 105-114.	2.5	10
4655	Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clinical Cancer Research, 2019, 25, 4530-4541.	3.2	69
4656	Targeting the ERK Signaling Pathway in Melanoma. International Journal of Molecular Sciences, 2019, 20, 1483.	1.8	116
4657	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600Eâ€“Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	0.8	188
4658	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 2019, 142, 151-168.	3.1	202
4659	Magnolol induces cell death through PI3K/Aktâ€mediated epigenetic modifications boosting treatment of BRAFâ€ and NRASâ€mutant melanoma. Cancer Medicine, 2019, 8, 1186-1196.	1.3	16
4660	Ethics of Innovation in Neurosurgery. , 2019, , .		6
4661	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. Cancer Treatment Reviews, 2019, 74, 43-48.	3.4	38
4662	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. European Journal of Cancer, 2019, 111, 8-11.	1.3	6

#	Article	IF	Citations
4663	Methionine Dependence of Cancer and Aging. Methods in Molecular Biology, 2019, , .	0.4	3
4664	Serum S100B Levels in Melanoma. Methods in Molecular Biology, 2019, 1929, 691-700.	0.4	8
4665	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer Journal, 2019, 9, 15.	2.8	30
4666	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591882029.	1.4	12
4667	Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 56.	3.5	25
4668	Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs. Frontiers in Pharmacology, 2019, 10, 1.	1.6	303
4669	High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. Methods in Molecular Biology, 2019, 1866, 149-161.	0.4	6
4670	Clinical candidates modulating protein-protein interactions: The fragment-based experience. European Journal of Medicinal Chemistry, 2019, 167, 76-95.	2.6	24
4671	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clinical Cancer Research, 2019, 25, 2783-2794.	3.2	25
4672	Cumingianoside A, a Phyto-Triterpenoid Saponin Inhibits Acquired BRAF Inhibitor Resistant Melanoma Growth via Programmed Cell Death. Frontiers in Pharmacology, 2019, 10, 30.	1.6	5
4673	Management of intussusception in patients with melanoma. Journal of Surgical Oncology, 2019, 119, 897-902.	0.8	5
4674	Interleukin-13 receptor Î±2 is a novel marker and potential therapeutic target for human melanoma. Scientific Reports, 2019, 9, 1281.	1.6	33
4675	Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma. PLoS ONE, 2019, 14, e0212801.	1.1	13
4676	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2019, 68, 765-772.	2.0	35
4677	Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 313-322.	3.3	166
4678	Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4583-4591.	3.3	33
4679	BRAF in the cross-hairs. Expert Review of Hematology, 2019, 12, 183-193.	1.0	0
4680	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. Oncologist, 2019, 24, 657-663.	1.9	5

#	Article	IF	Citations
4681	Bixin, an apocarotenoid isolated from Bixa orellana L., sensitizes human melanoma cells to dacarbazine-induced apoptosis through ROS-mediated cytotoxicity. Food and Chemical Toxicology, 2019, 125, 549-561.	1.8	48
4682	Firstâ€line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-14.	0.7	4
4683	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. Molecular Pharmaceutics, 2019, 16, 1694-1702.	2.3	26
4684	Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data. Pigment Cell and Melanoma Research, 2019, 32, 576-583.	1.5	8
4685	How I treat metastatic melanoma. ESMO Open, 2019, 4, e000509.	2.0	2
4686	Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates. , 0, , .		0
4687	Immunotherapy for Melanoma Brain Metastases. Discoveries, 2019, 7, e93.	1.5	4
4688	Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment. Frontiers in Pharmacology, 2019, 10, 1456.	1.6	16
4691	Bayesian Basket Designs for Cancer Clinical Trials. Japanese Journal of Biometrics, 2019, 39, 103-122.	0.0	0
4692	Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology, 2019, 20, 81.	1.3	28
4693	Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69. Biomedicines, 2019, 7, 90.	1.4	30
4694	Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRÎ² Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. Frontiers in Immunology, 2019, 10, 2213.	2.2	9
4695	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	5.8	46
4696	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nature Communications, 2019, 10, 5232.	5.8	17
4697	23 Carcinoma of the Skin of the Head, Face, and Neck. , 2019, , .		0
4698	Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation. JCO Precision Oncology, 2019, 3, 1-9.	1.5	5
4699	Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precision Oncology, 2019, 3, 1-12.	1.5	36
4700	Primary Melanoma: from History to Actual Debates. Current Oncology Reports, 2019, 21, 112.	1.8	8

#	Article	IF	Citations
4701	Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: twoÂcase reports and review of the literature. Journal of Medical Case Reports, 2019, 13, 385.	0.4	12
4702	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology and Oncology, 2019, 12, 145.	6.9	35
4703	OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina, 2019, 39, 1435-1450.	1.0	70
4704	Multi-Platform Omics Analysis for Identification of Molecular Characteristics and Therapeutic Targets of Uveal Melanoma. Scientific Reports, 2019, 9, 19235.	1.6	7
4705	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	1.3	5
4706	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	3.8	16
4708	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. Journal of Cancer, 2019, 10, 6114-6123.	1.2	3
4709	Molecular/Targeted Therapy of Cancer. , 2019, , 251-285.		0
4710	Protein kinase C-Î± is upregulated by IMP1 in melanoma and is linked to poor survival. Melanoma Research, 2019, 29, 539-543.	0.6	9
4711	Multiplatform Molecular Profiling. Cancer Journal (Sudbury, Mass), 2019, 25, 80-80.	1.0	1
4712	Melanoma. Anti-Cancer Drugs, 2019, 30, 543-553.	0.7	1
4713	Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Research, 2019, 29, 626-634.	0.6	15
4714	Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Research, 2019, 29, 522-526.	0.6	12
4715	Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K. American Journal of Dermatopathology, 2019, 41, 733-740.	0.3	4
4716	Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit. International Ophthalmology Clinics, 2019, 59, 13-26.	0.3	9
4717	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer Journal (Sudbury, Mass), 2019, 25, 245-253.	1.0	4
4718	Proteomic identification of a marker signature for <scp>MAPK</scp> i resistance in melanoma. EMBO Journal, 2019, 38, e95874.	3.5	26
4719	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. Oncology Reviews, 2019, 13, 433.	0.8	9

#	Article	IF	Citations
4720	An update on adjuvant systemic therapies in melanoma. Melanoma Management, 2019, 6, MMT28.	0.1	10
4721	Reverse Phase Protein Arrays. Advances in Experimental Medicine and Biology, 2019, , .	0.8	1
4722	BRAF Inhibitorâ€"Associated Granulomatous Dermatitis: A Report of 3 Cases. American Journal of Dermatopathology, 2019, 41, 214-217.	0.3	11
4725	Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency. Melanoma Research, 2019, 29, 99-101.	0.6	7
4726	18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Research, 2019, 29, 178-186.	0.6	43
4727	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. Cancers, 2019, 11, 1940.	1.7	29
4728	Erdheim-Chester Disease: a Concise Review. Current Rheumatology Reports, 2019, 21, 66.	2.1	38
4729	Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage. Melanoma Research, 2019, 29, 134-144.	0.6	12
4730	A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma. Melanoma Research, 2019, 29, 13-18.	0.6	1
4731	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers, 2019, 11, 1972.	1.7	8
4732	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. Cancers, 2019, 11, 1950.	1.7	24
4733	Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis. International Journal of Molecular Sciences, 2019, 20, 6191.	1.8	19
4734	Genome Sequencing during a Patientâ€™s Journey through Cancer. New England Journal of Medicine, 2019, 381, 2145-2156.	13.9	50
4736	Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. Pharmacogenomics, 2019, 20, 1283-1290.	0.6	2
4737	Predicting marker for early progression in unresectable melanoma treated with nivolumab. International Journal of Clinical Oncology, 2019, 24, 323-327.	1.0	17
4738	Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell and Melanoma Research, 2019, 32, 237-247.	1.5	35
4739	Immunomodulators targeting the PDâ€1/PDâ€L1 proteinâ€protein interaction: From antibodies to small molecules. Medicinal Research Reviews, 2019, 39, 265-301.	5.0	128
4740	Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. Molecular Cancer Research, 2019, 17, 199-211.	1.5	44

#	Article	IF	Citations
4741	Chrysin inhibit human melanoma A375.S2 cell migration and invasion via affecting MAPK signaling and NFâ€ºB signaling pathway in vitro. Environmental Toxicology, 2019, 34, 434-442.	2.1	25
4742	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 2019, 107, 175-185.	1.3	13
4743	Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF^{V600} Mutationâ€“Positive Metastatic Malignancy. Clinical Pharmacology in Drug Development, 2019, 8, 837-843.	0.8	6
4744	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy, 2019, 11, 283-295.	1.0	24
4745	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers, 2019, 11, 11.	1.7	46
4746	Dermatology today and tomorrow: from symptom control to targeted therapy. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 3-36.	1.3	31
4747	Indications for the surgical resection of stage IV disease. Journal of Surgical Oncology, 2019, 119, 249-261.	0.8	14
4748	Rational combination of cancer immunotherapy in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 433-447.	1.4	7
4749	Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase. Cancer Letters, 2019, 443, 189-202.	3.2	18
4750	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). Pharmacological Research, 2019, 141, 63-72.	3.1	14
4751	Functional micro<scp>RNA</scp> binding site variants. Molecular Oncology, 2019, 13, 4-8.	2.1	28
4752	Reâ€examining the role of adjuvant radiation therapy. Journal of Surgical Oncology, 2019, 119, 242-248.	0.8	1
4753	Pharmacogenomics: Success and Challenges. , 2019, , 595-606.		0
4754	Oxidative stress generated by irradiation of a zinc(II) phthalocyanine induces a dual apoptotic and necrotic response in melanoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 119-134.	2.2	16
4755	Phenotypes in acute respiratory distress syndrome: moving towards precision medicine. Current Opinion in Critical Care, 2019, 25, 12-20.	1.6	128
4756	<i>BRAF</i> V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens. Acta Cytologica, 2019, 63, 10-16.	0.7	5
4757	Cutaneous Melanomaâ€”A Review in Detection, Staging, and Management. Hematology/Oncology Clinics of North America, 2019, 33, 25-38.	0.9	85
4758	The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene, 2019, 38, 2320-2336.	2.6	32

#	Article	IF	Citations
4759	Updates in adjuvant systemic therapy for melanoma. Journal of Surgical Oncology, 2019, 119, 222-231.	0.8	35
4760	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
4761	Management of inâ€transit melanoma metastases: a review. ANZ Journal of Surgery, 2019, 89, 647-652.	0.3	18
4762	BRAF-Mutant Melanoma. , 2019, , 655-668.		0
4763	BRAF mutation testing in melanoma: results from a German observational multicenter study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 71-78.	1.4	1
4764	High concordance of BRAF mutational status in matched primary and metastatic melanoma. Journal of Cutaneous Pathology, 2019, 46, 117-122.	0.7	10
4765	Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. Cancer Letters, 2019, 442, 453-463.	3.2	33
4766	Updates in Melanoma. Dermatologic Clinics, 2019, 37, 73-82.	1.0	57
4767	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in Bâ€rapidly accelerated fibrosarcomaâ€mutated advanced melanoma. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 686-692.	1.3	17
4768	Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin. Biomedicine and Pharmacotherapy, 2019, 110, 29-36.	2.5	12
4769	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology, 2019, 46, 190-194.	0.7	6
4770	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 446-461.	1.3	15
4771	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	3.2	57
4772	Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting. Advances in Cancer Research, 2019, 141, 43-84.	1.9	114
4773	Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Letters, 2019, 446, 25-37.	3.2	28
4775	The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer. High-Throughput, 2019, 8, 1.	4.4	7
4776	MicroRNAâ€23a inhibits melanoma cell proliferation, migration, and invasion in mice through a negative feedback regulation of sdcbp and the MAPK/ERK signaling pathway. IUBMB Life, 2019, 71, 587-600.	1.5	12
4777	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell International, 2019, 19, 10.	1.8	31

#	Article	IF	Citations
4778	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Review of Clinical Pharmacology, 2019, 12, 259-266.	1.3	44
4779	MAPKâ€Targeted Drug Delivered by a pHâ€Sensitive MSNP Nanocarrier Synergizes with PDâ€1 Blockade in Melanoma without Tâ€Cell Suppression. Advanced Functional Materials, 2019, 29, 1806916.	7.8	34
4780	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	0.8	3
4781	Beating tumour drug resistance: â€œLamarckianâ€•induction in the spotlight. Pigment Cell and Melanoma Research, 2019, 32, 6-8.	1.5	3
4782	Melanoma: Where we are and where we go. Journal of Cellular Physiology, 2019, 234, 3307-3320.	2.0	53
4783	Fibroblast growth factor receptors as treatment targets in clinical oncology. Nature Reviews Clinical Oncology, 2019, 16, 105-122.	12.5	227
4784	Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patientsâ€”real-world data. European Journal of Clinical Pharmacology, 2019, 75, 329-334.	0.8	15
4785	BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. OncoImmunology, 2019, 8, e1512456.	2.1	15
4786	Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250.	0.6	400
4787	MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity inÂMelanoma. Journal of Investigative Dermatology, 2019, 139, 167-176.	0.3	21
4788	Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF^{V600E} mutation. Journal of Cellular Biochemistry, 2019, 120, 5315-5325.	1.2	8
4789	Whatâ€™s New in Dermatopathology: Inflammatory Dermatoses. Advances in Anatomic Pathology, 2019, 26, 40-55.	2.4	2
4790	Beyond the message: advantages of snapshot proteomics with singleâ€cell mass cytometry in solid tumors. FEBS Journal, 2019, 286, 1523-1539.	2.2	26
4791	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. Journal of Surgical Oncology, 2019, 119, 175-186.	0.8	32
4792	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. International Immunopharmacology, 2019, 67, 160-175.	1.7	33
4793	Examining Cellular Responses to Kinase Drug Inhibition Through Phosphoproteome Mapping of Substrates. Methods in Molecular Biology, 2019, 1888, 141-152.	0.4	1
4795	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Molecular Cancer Therapeutics, 2019, 18, 278-288.	1.9	24
4796	A prospective observational safety study of patients with BRAF V 600 â€mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British Journal of Dermatology, 2019, 180, 1254-1255.	1.4	3

#	Article	IF	Citations
4797	NOP14 inhibits melanoma proliferation and metastasis by regulating Wnt/Î²-catenin signaling pathway. Brazilian Journal of Medical and Biological Research, 2019, 52, e7952.	0.7	17
4799	Inhibition of isoprenylation synergizes with <scp>MAPK</scp> blockade to prevent growth in treatmentâ€resistant melanoma, colorectal, and lung cancer. Pigment Cell and Melanoma Research, 2019, 32, 292-302.	1.5	17
4800	Cardiotoxicity after vemurafenib administration. Hellenic Journal of Cardiology, 2019, 60, 256-257.	0.4	4
4801	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Future Oncology, 2019, 15, 459-471.	1.1	27
4802	Cell Model Passportsâ€"a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Research, 2019, 47, D923-D929.	6.5	118
4803	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 166-176.	3.2	14
4804	Stimuli-responsive perallyloxycucurbit[6]uril-based nanoparticles for selective drug delivery in melanoma cells. Materials Chemistry Frontiers, 2019, 3, 199-202.	3.2	17
4805	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica, 2019, 104, 576-586.	1.7	40
4806	Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Pathology and Oncology Research, 2019, 25, 45-50.	0.9	9
4807	Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine. Journal of Proteomics, 2019, 191, 68-79.	1.2	30
4808	Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. Journal of Neurosurgery, 2019, 130, 1299-1303.	0.9	49
4809	Bioinformatics for precision oncology. Briefings in Bioinformatics, 2019, 20, 778-788.	3.2	49
4810	P21 activated kinase signaling in cancer. Seminars in Cancer Biology, 2019, 54, 40-49.	4.3	154
4811	Melanosis neurocutÃ¡nea en paciente adulto joven: abordaje diagnÃ³stico y terapÃ©utico. NeurologÃa, 2019, 34, 336-338.	0.3	3
4812	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wiener Medizinische Wochenschrift, 2019, 169, 314-322.	0.5	5
4813	Detection of cellâ€free circulating <scp> BRAF ^V </scp> ^{600E} by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. British Journal of Dermatology, 2020, 182, 382-389.	1.4	7
4814	The Impact of Genetic Counseling Educational Tools on Patientsâ€™ Knowledge of Molecular Testing Terminology. Journal of Cancer Education, 2020, 35, 864-870.	0.6	8
4815	Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). Seminars in Cell and Developmental Biology, 2020, 98, 192-201.	2.3	30

#	Article	IF	Citations
4816	Development of Acute Vogtâ€“Koyanagiâ€“Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma. Ocular Immunology and Inflammation, 2020, 28, 505-508.	1.0	12
4817	Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells. Investigational New Drugs, 2020, 38, 634-649.	1.2	7
4818	Dermatologic Toxicities of Anticancer Therapy. , 2020, , 621-648.e5.		3
4819	Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. Journal of Medicinal Chemistry, 2020, 63, 2013-2027.	2.9	27
4820	Intracellular Signaling. , 2020, , 24-46.e12.		0
4821	Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. Annals of Surgical Oncology, 2020, 27, 293-300.	0.7	48
4823	Network indirect comparison of 3 BRAFâ€‰+â€‰MEK inhibitors for the treatment of advanced BRAF mutated melanoma. Clinical and Translational Oncology, 2020, 22, 900-907.	1.2	8
4824	Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer. Pharmacogenomics Journal, 2020, 20, 136-158.	0.9	15
4825	Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker. Journal of Cellular Physiology, 2020, 235, 1921-1932.	2.0	77
4826	The role of poloâ€like kinase 3 in the response of BRAFâ€mutant cells to targeted anticancer therapies. Molecular Carcinogenesis, 2020, 59, 5-14.	1.3	6
4827	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020, , .	1.8	11
4828	Clinical Trial Designs in Oncology. , 2020, , 296-307.e2.		3
4829	Basics of Radiation Therapy. , 2020, , 431-460.e3.		4
4830	Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. Journal of Drug Targeting, 2020, 28, 154-165.	2.1	12
4831	Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. Acta OncolÃ³gica, 2020, 59, 4-12.	0.8	9
4832	Therapeutic Targeting of Cancer Cells. , 2020, , 420-430.e2.		0
4833	Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. Value in Health, 2020, 23, 52-60.	0.1	23
4834	NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. European Journal of Medicinal Chemistry, 2020, 186, 111885.	2.6	30

#	Article	IF	Citations
4835	Management of Locoregionally Advanced Melanoma. Surgical Clinics of North America, 2020, 100, 109-125.	0.5	5
4836	Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America, 2020, 100, 175-188.	0.5	40
4837	A TLR7 agonist strengthens T and NK cell function during BRAFâ€targeted therapy in a preclinical melanoma model. International Journal of Cancer, 2020, 146, 1409-1420.	2.3	22
4838	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
4839	Nucleic Acid Detection and Structural Investigations. Methods in Molecular Biology, 2020, , .	0.4	1
4840	Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells. Oncogene, 2020, 39, 1466-1483.	2.6	40
4841	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. Annals of Palliative Medicine, 2020, 9, 4430-4445.	0.5	0
4842	Whatâ€™s new in pediatric melanoma: An update from the APSA cancer committee. Journal of Pediatric Surgery, 2020, 55, 1714-1721.	0.8	10
4843	Precision oncology: A primer for pediatric surgeons from the APSA cancer committee. Journal of Pediatric Surgery, 2020, 55, 1706-1713.	0.8	4
4844	Image Guided Dermatologic Treatments. , 2020, , .		4
4845	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Molecular Cancer Therapeutics, 2020, 19, 460-467.	1.9	60
4846	Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery, 2020, 19, 23-38.	21.5	295
4847	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell and Melanoma Research, 2020, 33, 390-402.	1.5	19
4849	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
4850	Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 126-134.	0.7	6
4851	Qualityâ€ofâ€life assessment in French patients with metastatic melanoma in real life. Cancer, 2020, 126, 611-618.	2.0	12
4852	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. International Journal of Cancer, 2020, 146, 1479-1489.	2.3	20
4853	The mutational landscape of mucosal melanoma. Seminars in Cancer Biology, 2020, 61, 139-148.	4.3	112

#	Article	IF	Citations
4854	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600â€“mutant melanoma. European Journal of Cancer, 2020, 126, 33-44.	1.3	130
4855	Stereotactic body radiation therapy and minimally invasive surgery in the management of spinal metastases: A change in the paradigm. NeurocirugÃa (English Edition), 2020, 31, 119-131.	0.1	2
4856	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€“ Update 2019. European Journal of Cancer, 2020, 126, 159-177.	1.3	154
4857	Precision Medicine in the Treatment of Melanoma. Surgical Oncology Clinics of North America, 2020, 29, 1-13.	0.6	7
4858	Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 29, 35-49.	0.6	23
4859	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. Translational Oncology, 2020, 13, 275-286.	1.7	13
4860	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	0.7	39
4861	Targeted and Untargeted Proteomics Approaches in Biomarker Development. Proteomics, 2020, 20, e1900029.	1.3	83
4862	The â€œARTâ€•of Epigenetics in Melanoma: From histone â€œAlterations, to Resistance and Therapiesâ€• Theranostics, 2020, 10, 1777-1797.	4.6	44
4863	Lung Metastases. , 2020, , 831-845.e6.		3
4865	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. Expert Review of Anticancer Therapy, 2020, 20, 53-62.	1.1	6
4866	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology, 2020, 85, 449-459.	1.1	1
4867	Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy. Molecular Biology Reports, 2020, 47, 1435-1443.	1.0	12
4868	Primary sellar melanocytoma: pathological, clinical and treatment review. Journal of Endocrinological Investigation, 2020, 43, 575-585.	1.8	4
4869	A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 337-351.	1.4	30
4870	Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. British Journal of Cancer, 2020, 122, 506-516.	2.9	16
4871	Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. British Journal of Cancer, 2020, 122, 72-81.	2.9	21
4872	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. Current Opinion in Oncology, 2020, 32, 91-97.	1.1	7

#	Article	IF	Citations
4873	Targeting Mutant KRAS for Immunogenic Cell Death Induction. Trends in Pharmacological Sciences, 2020, 41, 1-3.	4.0	3
4874	Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 115-121.	0.6	18
4875	The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. Melanoma Research, 2020, 30, 107-112.	0.6	6
4876	CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. Melanoma Research, 2020, 30, 14-25.	0.6	16
4877	Development of the Melanoma Concerns Questionnaire (MCQâ€28); refinement of the EORTC QLQâ€MEL38 module. Psycho-Oncology, 2020, 29, 321-330.	1.0	7
4878	Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeqâ„¢ Assay. Molecular Diagnosis and Therapy, 2020, 24, 103-111.	1.6	1
4879	Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018. American Journal of Ophthalmology, 2020, 211, 132-141.	1.7	26
4880	Characterization of glycolysis-related gene expression in malignant melanoma. Pathology Research and Practice, 2020, 216, 152752.	1.0	22
4881	Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. Paediatric Drugs, 2020, 22, 45-54.	1.3	7
4882	Expanding the understanding of the heterogeneous nature of melanoma with bioinformatics and disorder-based proteomics. International Journal of Biological Macromolecules, 2020, 150, 1281-1293.	3.6	4
4883	Partial response in hairy cell leukemia with vemurafenib despite early discontinuation due to agranulocytosis. Anti-Cancer Drugs, 2020, 31, 196-198.	0.7	1
4884	Exploring the Experiences of People Treated With Immunotherapies for Advanced Melanoma and Those Caring for Them: â€œReal-Worldâ€•Data. Cancer Nursing, 2020, 43, E97-E104.	0.7	21
4885	Immunohistochemistry Critical Assay Performance Controls (ICAPC) Reduce Interobserver Variability in the Interpretation of BRAFV600E Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 422-427.	0.6	3
4886	Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. International Journal of Gynecological Pathology, 2020, 39, 587-594.	0.9	18
4887	Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. Cancers, 2020, 12, 28.	1.7	14
4888	Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. American Journal of Clinical Pathology, 2020, 153, 513-523.	0.4	1
4889	Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). JNCI Cancer Spectrum, 2020, 4, pkaa078.	1.4	8
4890	BRAF Alteration in Central and Peripheral Nervous System Tumors. Frontiers in Oncology, 2020, 10, 574974.	1.3	15

#	Article	IF	Citations
4891	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS ONE, 2020, 15, e0239966.	1.1	4
4892	Assessment of Incidence Rate and Risk Factors for Keratoacanthoma Among Residents of Queensland, Australia. JAMA Dermatology, 2020, 156, 1324.	2.0	8
4893	The supramolecular host-guest complexation of Vemurafenib with Î²-cyclodextrin and cucurbit[7]uril as drug photoprotecting systems: A DFT/TD-DFT study. Computational and Theoretical Chemistry, 2020, 1191, 113026.	1.1	8
4894	BRAF-Mutant Metastatic Melanoma Presenting as a Fungating Soft Tissue Mass Suspicious for Sarcoma. Operative Techniques in Orthopaedics, 2020, 30, 100804.	0.2	0
4895	Drug-Induced Uveitis: Part 1. Advances in Ophthalmology and Optometry, 2020, 5, 265-306.	0.3	0
4896	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in Cancer Biology, 2022, 84, 50-59.	4.3	36
4897	Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma. Experimental Cell Research, 2020, 396, 112275.	1.2	22
4898	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers, 2020, 12, 3057.	1.7	50
4899	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 2020, 10, 17687.	1.6	14
4900	Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. Journal of Medical Economics, 2020, 23, 1542-1552.	1.0	9
4901	ADDI: Recommending alternatives for drugâ€“drug interactions with negative health effects. Computers in Biology and Medicine, 2020, 125, 103969.	3.9	9
4902	Management of Malignant Vulval Melanoma: A Retrospective Case Series and Review of the Literature. Journal of Lower Genital Tract Disease, 2020, 24, 272-276.	0.9	5
4903	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Critical Reviews in Oncology/Hematology, 2020, 156, 103119.	2.0	97
4904	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Critical Reviews in Oncology/Hematology, 2020, 156, 103118.	2.0	17
4905	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers, 2020, 12, 2870.	1.7	64
4906	A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. European Journal of Ophthalmology, 2020, , 112067212096204.	0.7	14
4907	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. International Immunopharmacology, 2020, 88, 106971.	1.7	7
4908	Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature. Pathology Research and Practice, 2020, 216, 153146.	1.0	7

#	Article	IF	Citations
4909	Epithelioid glioblastoma with microglia features: potential for novel therapy. Brain Pathology, 2020, 30, 1119-1133.	2.1	9
4910	Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges. Oncogenesis, 2020, 9, 66.	2.1	52
4911	Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience. Leukemia and Lymphoma, 2020, 61, 2568-2583.	0.6	10
4912	Tumor organoids to study gastroesophageal cancer: a primer. Journal of Molecular Cell Biology, 2020, 12, 593-606.	1.5	7
4913	Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEERâ€Medicare analysis. Cancer Medicine, 2020, 9, 6216-6224.	1.3	5
4914	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterology Report, 2020, 8, 192-205.	0.6	59
4915	Perturbation biology links temporal protein changes to drug responses in a melanoma cell line. PLoS Computational Biology, 2020, 16, e1007909.	1.5	15
4916	Optic Pathway Gliomas. , 2020, , 1891-1907.		0
4917	Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews, 2020, 90, 102082.	3.4	15
4918	Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma. Molecular Therapy - Oncolytics, 2020, 18, 100-108.	2.0	12
4919	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. Clinical Cancer Research, 2020, 26, 5102-5112.	3.2	23
4920	An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. Journal of Physical Education and Sports Management, 2020, 6, a005140.	0.5	1
4921	Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016. JAMA Network Open, 2020, 3, e208204.	2.8	10
4922	Rapid BRAF Mutation Testing in Pigmented Melanomas. American Journal of Dermatopathology, 2020, 42, 343-348.	0.3	7
4923	Melanoma Diagnosis and Treatment in the Elderly. Current Geriatrics Reports, 2020, 9, 199-205.	1.1	0
4924	BRAF: A Two-Faced Janus. Cells, 2020, 9, 2549.	1.8	23
4925	Anticancer activity of Momordica cochinchinensis (red gac) aril and the impact of varietal diversity. BMC Complementary Medicine and Therapies, 2020, 20, 365.	1.2	7
4926	The Role of BRAF in Metastatic Colorectal Carcinomaâ€"Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	1.8	8

#	Article	IF	Citations
4927	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	1.8	88
4928	BRAF inhibition protects against hearing loss in mice. Science Advances, 2020, 6, .	4.7	31
4929	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 9034.	1.8	5
4930	Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy. Molecules, 2020, 25, 5693.	1.7	5
4931	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenibâ€‰Â±â€‰cobimetinib: a pooled analysis of four clinical trials. Journal of Translational Medicine, 2020, 18, 294.	1.8	8
4932	Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. Seminars in Cancer Biology, 2022, 84, 3-15.	4.3	12
4933	Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. Journal of Experimental and Clinical Cancer Research, 2020, 39, 239.	3.5	21
4934	SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study. International Journal of Dermatology and Venereology, 2020, 3, 156-165.	0.1	1
4936	3D in vitro cutaneous melanoma models. , 2020, , 287-303.		0
4937	A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia. Nature Medicine, 2020, 26, 1375-1379.	15.2	49
4938	The non-linearity of RAF-MEK signaling in dendritic cells. Cell Cycle, 2020, 19, 2249-2259.	1.3	5
4939	Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. Journal of the Royal College of Surgeons of Edinburgh, 2021, 19, 238-243.	0.8	30
4940	Current State of Target Treatment in BRAF Mutated Melanoma. Frontiers in Molecular Biosciences, 2020, 7, 154.	1.6	82
4941	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers, 2020, 12, 1994.	1.7	26
4942	A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy. Frontiers in Endocrinology, 2020, 11, 471.	1.5	5
4943	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers, 2020, 12, 1727.	1.7	36
4944	Symptomatic acute hypotension associated with high-dose dacarbazine. Melanoma Research, 2020, 30, 426-428.	0.6	1
4945	Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. Cancers, 2020, 12, 2085.	1.7	17

#	Article	IF	Citations
4946	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	1.7	16
4947	Novel [99mTc]-Tricarbonyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake. Molecular Pharmaceutics, 2020, 17, 3581-3588.	2.3	14
4948	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Journal of Clinical Medicine, 2020, 9, 2430.	1.0	10
4949	Subphenotypes in critical care: translation into clinical practice. Lancet Respiratory Medicine,the, 2020, 8, 631-643.	5.2	117
4950	Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer, 2020, 6, 797-810.	3.8	169
4951	A Phase I Study of Dinaciclib in Combination With MKâ€2206 in Patients With Advanced Pancreatic Cancer. Clinical and Translational Science, 2020, 13, 1178-1188.	1.5	23
4952	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert Review of Anticancer Therapy, 2020, 20, 687-701.	1.1	6
4953	Pseudomyxoma Peritonei Originating from Transverse Colon Mucinous Adenocarcinoma: A Case Report and Literature Review. Gastroenterology Research and Practice, 2020, 2020, 1-7.	0.7	1
4954	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 1844-1856.	0.5	83
4955	Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies . Clinical Ophthalmology, 2020, Volume 14, 3137-3152.	0.9	12
4956	Glioneuronal tumors: clinicopathological findings and treatment options. Future Neurology, 2020, 15, .	0.9	7
4957	Synthetic Lethality through the Lens of Medicinal Chemistry. Journal of Medicinal Chemistry, 2020, 63, 14151-14183.	2.9	31
4958	Predicting therapy response by analysis of metastasis founder cells: emerging perspectives for personalized tumor therapy. Expert Review of Precision Medicine and Drug Development, 2020, 5, 413-420.	0.4	1
4959	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers, 2020, 12, 3004.	1.7	3
4960	Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability. Journal of Chemotherapy, 2020, 32, 437-444.	0.7	2
4961	Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells. Cell Systems, 2020, 11, 478-494.e9.	2.9	71
4962	Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. Melanoma Research, 2020, 30, 492-499.	0.6	3
4963	The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Journal of Hematology and Oncology, 2020, 13, 113.	6.9	232

#	Article	IF	Citations
4964	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	1.8	15
4965	HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E. Theranostics, 2020, 10, 9721-9740.	4.6	19
4966	Management of brain metastases according to molecular subtypes. Nature Reviews Neurology, 2020, 16, 557-574.	4.9	104
4967	Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. Frontiers in Molecular Biosciences, 2020, 7, 562798.	1.6	85
4968	Identification, Validation, and Functional Annotations of Genome-Wide Profile Variation between Melanocytic Nevus and Malignant Melanoma. BioMed Research International, 2020, 2020, 1-19.	0.9	7
4969	Mining database for the clinical significance and prognostic value of CBX family in skin cutaneous melanoma. Journal of Clinical Laboratory Analysis, 2020, 34, e23537.	0.9	7
4970	Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. Expert Opinion on Drug Safety, 2020, 19, 1229-1236.	1.0	3
4971	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. Journal of Gastrointestinal Cancer, 2021, 52, 932-939.	0.6	1
4972	Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. Journal of Dermatological Treatment, 2020, , 1-8.	1.1	2
4973	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. Cancers, 2020, 12, 2591.	1.7	8
4975	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. Targeted Oncology, 2020, 15, 567-577.	1.7	14
4976	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Research, 2020, 30, 465-471.	0.6	14
4977	Trends in pediatric skin cancer. Current Opinion in Pediatrics, 2020, 32, 516-523.	1.0	6
4978	Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Research, 2020, 30, 477-483.	0.6	5
4979	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. , 2020, 8, e000275.		11
4980	B-Raf-Mutated Melanoma. , 2020, , .		0
4981	A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base. Chinese Clinical Oncology, 2020, 9, 75-75.	0.4	9
4982	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. Melanoma Management, 2020, 7, MMT43.	0.1	7

#	Article	IF	Citations
4983	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000â€“2016. Cancers, 2020, 12, 2354.	1.7	8
4984	Lipid Metabolism and Resistance to Anticancer Treatment. Biology, 2020, 9, 474.	1.3	57
4985	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. International Journal of Molecular Sciences, 2020, 21, 9730.	1.8	15
4986	BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3065-3071.	0.8	8
4987	Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort. International Journal of Medical Informatics, 2020, 143, 104261.	1.6	3
4988	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 2020, 10, 18878.	1.6	16
4989	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2020, 10, 571135.	1.3	2
4990	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. Therapie, 2020, 75, 183-193.	0.6	0
4991	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23
4992	Targeting PSMD14 inhibits melanoma growth through SMAD3 stabilization. Scientific Reports, 2020, 10, 19214.	1.6	13
4993	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
4994	Molecular Profilingâ€“Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 532403.	1.3	20
4995	Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?. Cancers, 2020, 12, 1101.	1.7	9
4996	Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Research and Treatment, 2020, 181, 679-689.	1.1	30
4997	American Society of Clinical Oncology Policy Statement on Skin Cancer Prevention. JCO Oncology Practice, 2020, 16, 490-499.	1.4	8
4998	The influence of uncertainty and uncertainty tolerance on attitudes and self-efficacy about genomic tumor testing. Psychology, Health and Medicine, 2021, 26, 805-817.	1.3	12
4999	Quest for Clinically Effective RAF Dimer Inhibitors. Journal of Clinical Oncology, 2020, 38, 2197-2200.	0.8	5
5000	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	1.5	62

#	Article	IF	Citations
5001	Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy. Pharmacogenomics, 2020, 21, 637-645.	0.6	26
5002	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF^{V600} Mutationâ€“Positive Malignancies. Clinical Pharmacology in Drug Development, 2020, 9, 651-658.	0.8	3
5003	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670.	3.2	107
5004	Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. Scientific Reports, 2020, 10, 7826.	1.6	14
5005	Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis. Frontiers in Oncology, 2020, 10, 442.	1.3	45
5006	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. Journal of Translational Medicine, 2020, 18, 192.	1.8	7
5007	Review of gynaecological malignant melanomas. The Obstetrician and Gynaecologist, 2020, 22, 199-207.	0.2	0
5008	Tumor-agnostic precision oncology: striving to prioritize internationalization for the management of cancer patients. International Journal of Clinical Oncology, 2020, 25, 995-996.	1.0	0
5009	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 739-753.	1.9	2
5010	Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurgery, 2020, 139, 226-231.	0.7	5
5011	Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nature Communications, 2020, 11, 2345.	5.8	74
5012	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	5.7	23
5013	Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies. Cancers, 2020, 12, 1364.	1.7	19
5014	Role of Surgery in Stage IV Melanoma. Surgical Oncology Clinics of North America, 2020, 29, 485-495.	0.6	8
5015	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	12.5	60
5016	POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation. Cell Death and Disease, 2020, 11, 451.	2.7	15
5017	A brief synopsis on scalp melanoma. Dermatologic Therapy, 2020, 33, e13795.	0.8	6
5018	Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell, 2020, 78, 1002-1018.	4.5	95

#	Article	IF	Citations
5019	Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance. Pharmacological Research, 2020, 159, 104998.	3.1	10
5020	The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma. International Journal of Molecular Sciences, 2020, 21, 4055.	1.8	23
5021	Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. Autoimmunity Reviews, 2020, 19, 102587.	2.5	20
5022	Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics. Biochemical Pharmacology, 2020, 178, 114104.	2.0	15
5023	Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology, 2020, 77, 601-610.	1.6	5
5024	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BrafV600E Melanoma. Cancers, 2020, 12, 1500.	1.7	9
5025	Precision oncology: the intention-to-treat analysis fallacy. European Journal of Cancer, 2020, 133, 25-28.	1.3	4
5026	Case report: Neoadjuvant systemic therapy for melanoma. Annals of Medicine and Surgery, 2020, 55, 177-179.	0.5	2
5027	TERT promoter mutation determines apoptotic and therapeutic responses of BRAF -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15846-15851.	3.3	31
5028	Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Frontiers in Oncology, 2020, 10, 834.	1.3	14
5029	Current status and perspectives of patient-derived rare cancer models. Human Cell, 2020, 33, 919-929.	1.2	15
5030	N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death. Phytomedicine, 2020, 76, 153261.	2.3	45
5031	Treatment options in BRAF-mutant metastatic colorectal cancer. Anti-Cancer Drugs, 2020, 31, 545-557.	0.7	7
5032	Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma. Frontiers in Cell and Developmental Biology, 2020, 8, 486.	1.8	42
5033	Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling. Cancers, 2020, 12, 1588.	1.7	50
5034	HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?. PharmacoEconomics - Open, 2020, 4, 529-539.	0.9	3
5035	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Journal of Clinical Oncology, 2020, 38, 2140-2150.	0.8	68
5036	A Comparative Analysis of Tumors and Plasma Circulating Tumor DNA in 145 Advanced Cancer Patients Annotated by 3 Core Cellular Processes. Cancers, 2020, 12, 701.	1.7	5

#	Article	IF	Citations
5037	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 130, 126-138.	1.3	84
5038	An update on the implications of cyclin D1 in melanomas. Pigment Cell and Melanoma Research, 2020, 33, 788-805.	1.5	34
5039	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. Molecular Oncology, 2020, 14, 933-950.	2.1	29
5040	Decoding the Genomic Report for Radiologists. American Journal of Roentgenology, 2020, 214, 949-961.	1.0	0
5041	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
5042	Metabolic Plasticity in Chemotherapy Resistance. Frontiers in Oncology, 2020, 10, 281.	1.3	106
5043	Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma . OncoTargets and Therapy, 2020, Volume 13, 2289-2298.	1.0	21
5044	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	1.7	2
5045	Discovery of Selective Small Molecule Degraders of BRAF-V600E. Journal of Medicinal Chemistry, 2020, 63, 4069-4080.	2.9	43
5046	The discovery and development of binimetinib for the treatment of melanoma. Expert Opinion on Drug Discovery, 2020, 15, 745-754.	2.5	25
5047	Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. Immunotherapy, 2020, 12, 333-349.	1.0	12
5048	Vorinostat in patients with resistant BRAF^{V600E} mutated advanced melanoma: a proof of concept study. Future Oncology, 2020, 16, 619-629.	1.1	16
5049	MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers. Frontiers in Cell and Developmental Biology, 2020, 8, 145.	1.8	19
5050	Malignant melanoma of the breast: controversies in the diagnosis and therapeutic management of a rare nosologic entity. International Journal of Dermatology, 2020, 59, 1057-1064.	0.5	7
5051	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 4544.	1.8	24
5052	The Role of Neoadjuvant Therapy in Melanoma. Current Oncology Reports, 2020, 22, 80.	1.8	8
5053	Vemurafenibâ€related photosensitivity. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1079-1083.	0.4	0
5054	Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature. Journal of the American Academy of Dermatology, 2020, 83, 1425-1433.	0.6	3

#	Article	IF	Citations
5055	BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. Neoplasia, 2020, 22, 376-389.	2.3	14
5056	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. Oncology and Therapy, 2020, 8, 59-66.	1.0	4
5057	Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis. Archives of Cardiovascular Diseases, 2020, 113, 420-432.	0.7	4
5058	Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. Cancers, 2020, 12, 1650.	1.7	21
5059	BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels. Cancers, 2020, 12, 1661.	1.7	22
5060	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. Frontiers in Oncology, 2020, 10, 1056.	1.3	5
5062	Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3. Melanoma Research, 2020, 30, 325-335.	0.6	3
5063	Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	1.4	31
5064	Integrating Diagnostic Products Into the Drug Development Workflow: Applications for Companion Diagnostics. , 2020, , 359-370.		0
5065	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	7.7	93
5066	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. Tumori, 2020, 106, 241-248.	0.6	13
5067	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. Journal of Translational Medicine, 2020, 18, 99.	1.8	12
5068	Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers, 2020, 12, 482.	1.7	112
5069	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers, 2020, 12, 512.	1.7	15
5071	An overview of binimetinib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2020, 21, 747-754.	0.9	8
5072	Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. BMC Cancer, 2020, 20, 157.	1.1	3
5073	Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. Clinical and Translational Oncology, 2020, 22, 1818-1824.	1.2	7
5074	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice, 2020, 7, 369-375.	1.0	2

#	Article	IF	Citations
5075	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. Journal of the National Cancer Institute, 2020, 112, 875-885.	3.0	20
5076	BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. BMC Cancer, 2020, 20, 129.	1.1	9
5077	Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine, 2020, 12, 17.	3.6	20
5078	RNA expression and risk of venous thromboembolism in lung cancer. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 117-123.	1.0	9
5079	Absolute Bioavailability of Vemurafenib in Patients With BRAF V600 Mutationâ€“Positive Malignancies. Clinical Pharmacology in Drug Development, 2020, 9, 496-504.	0.8	4
5080	A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis. Scientific Reports, 2020, 10, 2485.	1.6	5
5081	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. Trials, 2020, 21, 34.	0.7	19
5082	Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. International Journal of Molecular Sciences, 2020, 21, 1580.	1.8	17
5083	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells, 2020, 9, 417.	1.8	32
5084	Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. High-Throughput, 2020, 9, 4.	4.4	1
5085	Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. Biochemical Pharmacology, 2020, 176, 113855.	2.0	11
5086	Rose Bengalâ€“Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma. Journal of Medicinal Chemistry, 2020, 63, 1328-1336.	2.9	25
5087	Conjunctival Melanoma: Current Treatments and Future Options. American Journal of Clinical Dermatology, 2020, 21, 371-381.	3.3	33
5088	â€œMetastatic Cancer of Unknown Primaryâ€•or â€œPrimary Metastatic Cancerâ€?. Frontiers in Oncology, 2019, 9, 1546.	1.3	35
5089	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	9.6	50
5090	Molecular profiling for precision cancer therapies. Genome Medicine, 2020, 12, 8.	3.6	447
5091	An ultrasensitive colorimetric test for the detection of somatic rare mutations in DNA. Nanoscale, 2020, 12, 2973-2979.	2.8	6
5092	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1799-1807.	1.4	10

#	Article	IF	Citations
5093	Prediction of Drug Efficacy in Colon Cancer Preclinical Models Using a Novel Ranking Method of Gene Expression. Cancers, 2020, 12, 149.	1.7	2
5094	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell, 2020, 37, 85-103.e9.	7.7	91
5095	Identification of drug resistance associated ncRNAs based on comprehensive heterogeneous network. Life Sciences, 2020, 243, 117256.	2.0	4
5096	The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. Expert Review of Anticancer Therapy, 2020, 20, 131-136.	1.1	9
5097	Highly efficient singlet oxygen generation, two-photon photodynamic therapy and melanoma ablation by rationally designed mitochondria-specific near-infrared AIEgens. Chemical Science, 2020, 11, 2494-2503.	3.7	131
5098	PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein. Biochemistry (Moscow), 2020, 85, 108-118.	0.7	6
5099	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	1.8	63
5100	Understanding and information needs of cancer patients regarding treatmentâ€focused genomic testing: A systematic review. Psycho-Oncology, 2020, 29, 632-638.	1.0	13
5101	Regulation of the error-prone DNA polymerase Polζ by oncogenic signaling and its contribution to drug resistance. Science Signaling, 2020, 13, .	1.6	26
5102	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.0	11
5103	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. International Journal of Molecular Sciences, 2020, 21, 2531.	1.8	56
5104	The powerful world of antisense oligonucleotides: From bench to bedside. Wiley Interdisciplinary Reviews RNA, 2020, 11, e1594.	3.2	162
5105	Beta human papillomaviruses infection and skin carcinogenesis. Reviews in Medical Virology, 2020, 30, e2104.	3.9	19
5106	Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. International Journal of Clinical Oncology, 2020, 25, 1234-1241.	1.0	9
5107	Carotenoids from Rhodomonas salina Induce Apoptosis and Sensitize A2058 Melanoma Cells to Chemotherapy. Revista Brasileira De Farmacognosia, 2020, 30, 155-168.	0.6	6
5108	Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF. Bioorganic and Medicinal Chemistry, 2020, 28, 115493.	1.4	12
5109	Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. Scientific Reports, 2020, 10, 5688.	1.6	7
5110	Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab. Nuklearmedizin - NuclearMedicine, 2020, 59, 228-234.	0.3	20

#	Article	IF	Citations
5111	Targeted Therapies: Friends or Foes for Patientâ€™s NK Cell-Mediated Tumor Immune-Surveillance?. Cancers, 2020, 12, 774.	1.7	10
5112	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	3.2	54
5113	Donor-Transmitted Melanoma: Is It Still Bothering Us?. Current Treatment Options in Oncology, 2020, 21, 38.	1.3	2
5114	Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery, 2020, 87, 498-515.	0.6	3
5115	Applications of personalised signalling network models in precision oncology. , 2020, 212, 107555.		14
5116	Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. International Journal of Molecular Sciences, 2020, 21, 2956.	1.8	92
5117	Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clinical Drug Investigation, 2020, 40, 519-527.	1.1	32
5118	An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer. Chemico-Biological Interactions, 2020, 323, 109061.	1.7	6
5119	Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy. IScience, 2020, 23, 101028.	1.9	12
5120	BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 833-844.	0.8	48
5121	Cryopreservation of Viable Human Tissues: Renewable Resource for Viable Tissue, Cell Lines, and Organoid Development. Biopreservation and Biobanking, 2020, 18, 222-227.	0.5	20
5122	Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells. Clinical and Experimental Immunology, 2020, 201, 145-160.	1.1	7
5123	Predictive value of FDGâ€PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2261-2267.	1.3	6
5124	The evidence landscape in precision medicine. Science Translational Medicine, 2020, 12, .	5.8	16
5125	Erdheim-Chester disease. Blood, 2020, 135, 1311-1318.	0.6	99
5126	Metastatic Melanoma Patientâ€“Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research, 2020, 26, 3803-3818.	3.2	21
5127	Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	3.2	17
5128	Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death. Molecular Cancer Therapeutics, 2020, 19, 627-636.	1.9	10

#	Article	IF	Citations
5129	Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma. Journal of Oncology Pharmacy Practice, 2020, 26, 1754-1758.	0.5	2
5130	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers, 2020, 12, 927.	1.7	6
5131	Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open, 2021, 5, 13-22.	0.9	5
5132	Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31.	0.3	193
5133	Genetics and Genomics of Breast Cancer: update and translational perspectives. Seminars in Cancer Biology, 2021, 72, 27-35.	4.3	14
5134	Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steadyâ€State Pharmacokinetics of Vemurafenib in Patients With BRAF V600 Mutationâ€“Positive Malignancies. Clinical Pharmacology in Drug Development, 2021, 10, 39-45.	0.8	3
5135	Pathology of the Conjunctiva, Orbit, Lacrimal Gland, and Intraocular Tumors. , 2021, , 1098-1150.		1
5136	Systemic Anticancer Agents. , 2021, , 405-418.e3.		0
5137	Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study. Journal of the American Academy of Dermatology, 2021, 84, 1554-1561.	0.6	15
5138	Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews, 2021, 121, 3297-3351.	23.0	203
5139	Keratoacanthoma, committed stem cells and neoplastic aberrant infundibulogenesis integral to formulating a conceptual model for an infundibulocystic pathway to squamous cell carcinoma. Journal of Cutaneous Pathology, 2021, 48, 184-191.	0.7	6
5140	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal of Neuro-Oncology, 2021, 152, 15-25.	1.4	15
5141	The meiosis-specific cohesin component stromal antigen 3 promotes cell migration and chemotherapeutic resistance in colorectal cancer. Cancer Letters, 2021, 497, 112-122.	3.2	12
5142	Prevalence of class Iâ€“III BRAF mutations among 114,662 cancer patients in a large genomic database. Experimental Biology and Medicine, 2021, 246, 31-39.	1.1	36
5143	Current Management of Melanoma. Updates in Surgery Series, 2021, , .	0.0	0
5144	Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. European Journal of Medicinal Chemistry, 2021, 212, 113031.	2.6	11
5145	Surgery of metastatic melanoma after systemic therapy â€“ the SUMMIST trial: study protocol for a randomized controlled trial. Acta OncolÃ³gica, 2021, 60, 52-55.	0.8	5
5146	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	3.4	2

#	Article	IF	Citations
5147	Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 2021, 20, 101-124.	21.5	3,154
5148	Molecular Docking Strategy to Design Novel V600E-BRAF Kinase Inhibitors with Prediction of Their Drug-Likeness and Pharmacokinetics ADMET Properties. Chemistry Africa, 2021, 4, 189-205.	1.2	1
5149	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
5150	State of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 1-27.	0.9	4
5151	The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function. Redox Biology, 2021, 38, 101801.	3.9	133
5152	Juniperus indica Bertol. extract synergized with cisplatin against melanoma cells via the suppression of AKT/mTOR and MAPK signaling and induction of cell apoptosis. International Journal of Medical Sciences, 2021, 18, 157-168.	1.1	4
5153	Recent developments in the synthesis of azaindoles from pyridine and pyrrole building blocks. Organic Chemistry Frontiers, 2021, 8, 466-513.	2.3	31
5154	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
5155	CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Research, 2021, 49, D1083-D1093.	6.5	104
5156	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. Cancer Discovery, 2021, 11, 678-695.	7.7	114
5157	Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. Clinical Cancer Research, 2021, 27, 1082-1093.	3.2	20
5158	LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clinical Cancer Research, 2021, 27, 2061-2073.	3.2	39
5159	The prospects of tumor chemosensitivity testing at the single-cell level. Drug Resistance Updates, 2021, 54, 100741.	6.5	4
5160	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology, 2021, 16, 47-57.	1.7	8
5161	Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets. Nucleic Acids Research, 2021, 49, D1365-D1372.	6.5	54
5162	Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56.	0.9	40
5163	Systematic review of BRAF/MEK inhibitorsâ€induced Severe Cutaneous Adverse Reactions (SCARs). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 607-614.	1.3	26
5164	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. Statistics in Biopharmaceutical Research, 2021, 13, 133-146.	0.6	3

#	Article	IF	Citations
5165	Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. Journal of Surgical Oncology, 2021, 123, 104-109.	0.8	3
5166	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. Expert Review of Clinical Pharmacology, 2021, 14, 9-23.	1.3	5
5167	Models of Cancer Drug Discovery and Response to Therapy. , 2021, , 269-276.		0
5168	Chimeric antigen receptor T-cell therapy for melanoma. Expert Review of Clinical Immunology, 2021, 17, 209-223.	1.3	12
5169	Diagnosis of meningeal melanomatosis in a dog using magnetic resonance imaging and cerebrospinal fluid findings. Journal of Veterinary Medical Science, 2021, 83, 94-99.	0.3	1
5170	Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review. Current Problems in Cancer, 2021, 45, 100701.	1.0	10
5171	A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy. Advances in Experimental Medicine and Biology, 2021, 1275, 357-382.	0.8	2
5172	A potential role for metastasis-associated in colon cancer 1 (<i>MACC1</i>) as a pan-cancer prognostic and immunological biomarker. Mathematical Biosciences and Engineering, 2021, 18, 8331-8353.	1.0	5
5173	Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers. PLoS Computational Biology, 2021, 17, e1007900.	1.5	30
5174	The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?. Journal of Intensive Care, 2021, 9, 14.	1.3	13
5175	Malignant Melanoma: From Molecular Characterization to Targeted Therapies. , 2021, , .		0
5176	Vitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032. Journal of Experimental and Clinical Cancer Research, 2021, 40, 34.	3.5	16
5177	Vemurafenib and Cobimetinib. , 2021, , 149-165.		0
5178	Preparation, Drug Treatment, and Immunohistological Analysis of Tri-Culture Spheroid 3D Melanoma-Like Models. Methods in Molecular Biology, 2021, 2265, 173-183.	0.4	3
5179	Systemic Implications of Melanoma. , 2021, , 91-115.		1
5180	Melanin Chemistry. , 2021, , 1-31.		0
5181	Advances in anti-BRAF therapies for lung cancer. Investigational New Drugs, 2021, 39, 879-890.	1.2	22
5182	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers, 2021, 13, 137.	1.7	46

#	Article	IF	Citations
5183	Dabrafenib and Trametinib. , 2021, , 131-147.		0
5184	Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis. Cancer Research and Treatment, 2021, 53, 261-269.	1.3	18
5185	TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, Î²-Catenin, and TRK pathways. Investigational New Drugs, 2021, 39, 724-735.	1.2	12
5186	Melanoom en andere huidtumoren. , 2021, , 515-526.		0
5187	Do Carcinogens Have a Threshold Dose? The Pros and Cons. , 2021, , 1-19.		0
5188	Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals. Biomedicines, 2021, 9, 79.	1.4	10
5189	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. Advances in Experimental Medicine and Biology, 2021, 1301, 7-24.	0.8	1
5190	Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics. Molecular Biotechnology, 2021, 63, 167-183.	1.3	4
5191	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 2021, 124, 1222-1230.	2.9	16
5192	Cell Proliferation Is Strongly Associated with the Treatment Conditions of an ER Stress Inducer New Anti-Melanoma Drug in Melanoma Cell Lines. Biomedicines, 2021, 9, 96.	1.4	5
5193	Developing Novel Anticancer Drugs for Targeted Populations: An Update. Current Pharmaceutical Design, 2021, 27, 250-262.	0.9	3
5194	Expression of chondroitin sulfate proteoglycanÂ4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF. Oncology Reports, 2021, 45, .	1.2	8
5195	Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma. Cancers, 2021, 13, 731.	1.7	12
5196	Pancreatic ductal adenocarcinoma in the era of precision medicine. Seminars in Oncology, 2021, 48, 19-33.	0.8	8
5197	Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PharmacoEconomics - Open, 2021, 5, 143-155.	0.9	17
5198	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	7.7	30
5199	Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion. Expert Opinion on Pharmacotherapy, 2021, 22, 677-684.	0.9	6
5200	Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma. Oncotarget, 2021, 12, 160-172.	0.8	8

#	Article	IF	Citations
5201	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
5202	From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past. Frontiers in Immunology, 2021, 12, 623639.	2.2	22
5203	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clinical Cancer Research, 2021, 27, 2624-2635.	3.2	22
5204	Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Molecular Carcinogenesis, 2021, 60, 201-212.	1.3	15
5205	G-quadruplexes: a promising target for cancer therapy. Molecular Cancer, 2021, 20, 40.	7.9	239
5206	The BH3 mimetic (Â±) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro. Archives of Toxicology, 2021, 95, 1349-1365.	1.9	13
5207	Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology, 2021, 22, 30.	1.3	25
5208	Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell Death and Disease, 2021, 12, 179.	2.7	11
5209	Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 586029.	1.3	4
5211	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. ESMO Open, 2021, 6, 100002.	2.0	12
5212	Current status and future outlook for patientâ€derived cancer models from a rare cancer research perspective. Cancer Science, 2021, 112, 953-961.	1.7	20
5213	Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 2021, 6, 351-370.	23.3	388
5214	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Frontiers in Immunology, 2020, 11, 629722.	2.2	75
5215	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Frontiers in Oncology, 2020, 10, 626129.	1.3	48
5216	Recent Advances in Nanotechnology for the Treatment of Melanoma. Molecules, 2021, 26, 785.	1.7	42
5217	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 2021, 39, 285-294.	0.8	169
5218	CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sciences, 2021, 267, 118969.	2.0	31
5219	Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma. Nutrients, 2021, 13, 686.	1.7	7

#	Article	IF	Citations
5220	Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells. Molecules, 2021, 26, 1867.	1.7	9
5221	Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy. Frontiers in Bioengineering and Biotechnology, 2021, 9, 661214.	2.0	7
5222	Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. Case Reports in Oncology, 2021, 14, 616-621.	0.3	13
5223	Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro. Investigational New Drugs, 2021, 39, 987-1000.	1.2	3
5224	Melanoma cutÃ¡neo. Medicine, 2021, 13, 1493-1505.	0.0	1
5225	Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications. Frontiers in Oncology, 2021, 11, 636681.	1.3	22
5226	MicroRNA-205-5p inhibits skin cancer cell proliferation and increase drug sensitivity by targeting TNFAIP8. Scientific Reports, 2021, 11, 5660.	1.6	4
5227	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. Melanoma Research, 2021, 31, 218-223.	0.6	4
5228	National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?. Cancer, 2021, 127, 2181-2183.	2.0	2
5230	Thinking Differently about Cancer Treatment Regimens. Cancer Discovery, 2021, 11, 1016-1023.	7.7	29
5231	Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial. Leukemia, 2021, 35, 3314-3318.	3.3	24
5232	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 168-179.	0.9	9
5233	Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy. International Cancer Conference Journal, 2021, 10, 254-258.	0.2	3
5234	Targeting Genome Stability in Melanomaâ€"A New Approach to an Old Field. International Journal of Molecular Sciences, 2021, 22, 3485.	1.8	4
5235	A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. Scientific Reports, 2021, 11, 5849.	1.6	4
5236	Targeting FAK in anticancer combination therapies. Nature Reviews Cancer, 2021, 21, 313-324.	12.8	154
5237	Cutaneous melanoma: cost of illness under Brazilian health system perspectives. BMC Health Services Research, 2021, 21, 284.	0.9	6
5238	Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 91.	3.5	24

#	Article	IF	Citations
5240	Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. International Journal of Molecular Sciences, 2021, 22, 3228.	1.8	5
5241	Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis. Scientific Reports, 2021, 11, 5798.	1.6	13
5242	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3940-3955.	2.9	17
5243	BRAF Gene and Melanoma: Back to the Future. International Journal of Molecular Sciences, 2021, 22, 3474.	1.8	40
5244	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. Cancers, 2021, 13, 1430.	1.7	50
5245	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. Cancer Immunology, Immunotherapy, 2021, 70, 3123-3135.	2.0	6
5246	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. Cancers, 2021, 13, 1227.	1.7	9
5247	Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras as Therapeutic Targets for Hepatocellular Carcinoma. Journal of Liver Cancer, 2021, 21, 1-11.	0.3	4
5248	Recent advancements in melanoma management. Internal Medicine Journal, 2021, 51, 327-333.	0.5	4
5249	Emerging strategies for treating metastasis. Nature Cancer, 2021, 2, 258-270.	5.7	71
5250	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. American Journal of Clinical Dermatology, 2021, 22, 301-314.	3.3	18
5251	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics, 2021, 11, 733.	1.3	13
5252	The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAFâ€“MEK1/2â€“ERK1/2 Pathway. Cancer Research, 2021, 81, 3849-3861.	0.4	14
5253	Targeting pan-essential genes in cancer: Challenges and opportunities. Cancer Cell, 2021, 39, 466-479.	7.7	88
5254	Next Generation Sequencing Technology in the Clinic and Its Challenges. Cancers, 2021, 13, 1751.	1.7	17
5255	Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action. PLoS ONE, 2021, 16, e0243336.	1.1	0
5256	Regulation of MAPK ERK1/2 Signaling by Phosphorylation: Implications in Physiological and Pathological Contexts. , 0, , .		1
5257	Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid, 2021, 31, 1451-1462.	2.4	10

#	Article	IF	Citations
5258	CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model. Briefings in Bioinformatics, 2021, 22, .	3.2	5
5259	Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer. BMC Cancer, 2021, 21, 368.	1.1	9
5260	From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers, 2021, 13, 2024.	1.7	5
5261	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. Otolaryngologic Clinics of North America, 2021, 54, 329-342.	0.5	1
5262	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports, 2021, 11, 9043.	1.6	13
5263	Pathway-Directed Therapy in Multiple Myeloma. Cancers, 2021, 13, 1668.	1.7	15
5264	The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Scientific Reports, 2021, 11, 9091.	1.6	20
5265	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097.	1.1	5
5266	Pediatric Melanomaâ€"Diagnosis, Management, and Anticipated Outcomes. Surgical Oncology Clinics of North America, 2021, 30, 373-388.	0.6	2
5267	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. Frontiers in Medicine, 2021, 8, 642380.	1.2	28
5268	Melanoma of the lacrimal drainage system: A systematic review. Head and Neck, 2021, 43, 2240-2252.	0.9	4
5269	The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies. International Journal of Molecular Sciences, 2021, 22, 4166.	1.8	10
5270	Up to your NEK2 in CIN. Oncotarget, 2021, 12, 723-725.	0.8	0
5271	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. Npj Precision Oncology, 2021, 5, 33.	2.3	5
5272	Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Childrenâ€™s Oncology Group (ANZCHOG) Study. Frontiers in Oncology, 2021, 11, 660172.	1.3	1
5273	Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. Journal of Controlled Release, 2021, 332, 194-209.	4.8	25
5274	Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future. Anti-Cancer Drugs, 2021, 32, 593-601.	0.7	3
5276	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A realâ€world study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1371-1379.	0.9	0

#	Article	IF	Citations
5278	LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene, 2021, 40, 3707-3718.	2.6	8
5279	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Frontiers in Immunology, 2021, 12, 661737.	2.2	29
5280	BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma. Cancers, 2021, 13, 2393.	1.7	8
5281	Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. Frontiers in Oncology, 2021, 11, 635488.	1.3	36
5282	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature, 2021, 594, 418-423.	13.7	64
5283	Preclinical models and technologies to advance nanovaccine development. Advanced Drug Delivery Reviews, 2021, 172, 148-182.	6.6	18
5284	Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Survey of Ophthalmology, 2022, 67, 388-410.	1.7	8
5285	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanomaâ€"A Retrospective Multicenter ADOReg Study. Cancers, 2021, 13, 2312.	1.7	11
5286	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Crossâ€sectional and longitudinal analysis using two large national registries. Cancer Medicine, 2021, 10, 3862-3872.	1.3	17
5287	Leptomeningeal disease from melanomaâ€"Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 2021, 148, 395-404.	1.3	16
5288	BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 5744.	1.8	10
5289	Photosensitizing Medications and Skin Cancer: A Comprehensive Review. Cancers, 2021, 13, 2344.	1.7	10
5290	Functional and genetic determinants of mutation rate variability in regulatory elements of cancer genomes. Genome Biology, 2021, 22, 133.	3.8	12
5291	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. Journal of Experimental Pharmacology, 2021, Volume 13, 521-535.	1.5	5
5292	Retrospective evaluation of malignant melanoma patients: A single-center experience. Family Practice and Palliative Care, 0, , 98-104.	0.2	0
5293	Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas. Life, 2021, 11, 424.	1.1	3
5295	Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. Cancer Medicine, 2021, 10, 3155-3164.	1.3	5
5296	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and â€œBrainstormingâ€•Session. , 0, , .		2

#	Article	IF	Citations
5297	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	1.3	2
5298	Manganese-Doped Calcium Silicate Nanowire Composite Hydrogels for Melanoma Treatment and Wound Healing. Research, 2021, 2021, 9780943.	2.8	21
5299	Cancer of Unknown Primary in the Molecular Era. Trends in Cancer, 2021, 7, 465-477.	3.8	35
5300	When the MET receptor kicks in to resist targeted therapies. Oncogene, 2021, 40, 4061-4078.	2.6	13
5301	Retinal toxicities of systemic anticancer drugs. Survey of Ophthalmology, 2022, 67, 97-148.	1.7	16
5302	Actual treatment options for locally advanced and metastatic cutaneous squamous cell carcinoma. Journal of Modern Oncology, 2021, 23, 94-98.	0.1	0
5303	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. Progress in Retinal and Eye Research, 2022, 86, 100971.	7.3	35
5304	Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Ocular Immunology and Inflammation, 2022, 30, 1449-1459.	1.0	7
5305	CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells, 2021, 10, 1334.	1.8	31
5306	Nicotinamide Nâ€methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment Cell and Melanoma Research, 2021, 34, 1039-1048.	1.5	30
5307	Mucosal Melanoma of the Head and Neck: From Diagnosis to Treatment. , 0, , .		0
5308	Effect of melanoma stem cells on melanoma metastasis (Review). Oncology Letters, 2021, 22, 566.	0.8	13
5309	Ocular Safety Profile of BRAF and MEK Inhibitors. Ophthalmology, 2021, 128, 1748-1755.	2.5	17
5310	Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma. International Journal of Molecular Sciences, 2021, 22, 6727.	1.8	11
5311	Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanomaâ€"A Retrospective Single-Institute Study. Cancers, 2021, 13, 3302.	1.7	3
5312	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. Gynecologic Oncology, 2021, 161, 645-652.	0.6	15
5313	The Research on the Treatment of Metastatic Skin Cutaneous Melanoma by Huanglian Jiedu Decoction Based on the Analysis of Immune Infiltration Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-22.	0.5	0
5314	Drug Development in Tissue-Agnostic Indications. Cancers, 2021, 13, 2758.	1.7	8

#	Article	IF	Citations
5315	The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. Molecular Oncology, 2022, 16, 565-593.	2.1	11
5316	Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. International Cancer Conference Journal, 2021, 10, 274-279.	0.2	2
5317	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	3.4	24
5318	Recent Advances in the Treatment of Melanoma. New England Journal of Medicine, 2021, 384, 2229-2240.	13.9	201
5319	Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers, 2021, 13, 2774.	1.7	11
5320	Reâ€thinking therapeutic development for CNS metastatic disease. Experimental Dermatology, 2021, , .	1.4	1
5321	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. Cancers, 2021, 13, 3042.	1.7	3
5322	Oncogenic BRAF, unrestrained by TGFÎ²-receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 2021, 12, 3464.	5.8	33
5323	The role of immunotherapy and molecularâ€targeted therapy in the treatment of melanoma (Review). Oncology Reports, 2021, 46, .	1.2	14
5324	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer, 2021, 68, e28992.	0.8	9
5325	Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells, 2021, 10, 1450.	1.8	27
5326	Cutaneous adverse events in children treated with vemurafenib for refractory BRAF^{V600E} mutated Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2021, 68, e29140.	0.8	6
5327	Natural products targeting cancer cell dependency. Journal of Antibiotics, 2021, 74, 677-686.	1.0	7
5328	Therapeutic implications of menin inhibition in acute leukemias. Leukemia, 2021, 35, 2482-2495.	3.3	76
5329	N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production. Molecular Metabolism, 2021, 48, 101217.	3.0	10
5330	Clinical characteristics and prognosis of acral lentiginous melanoma: a singleâ€center series of 211 cases in China. International Journal of Dermatology, 2021, 60, 1504-1509.	0.5	5
5331	Postgraduate training in Cancer Geneticsâ€"a cross-specialty survey exploring experience of clinicians in Ireland. Irish Journal of Medical Science, 2021, , 1.	0.8	2
5332	Metabolic Reprogramming and Molecular Rewiring in Cancer: Therapeutic Opportunities. Indonesian Biomedical Journal, 2021, 13, 114-39.	0.2	3

#	Article	IF	Citations
5333	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Reports, 2021, 4, e1419.	0.6	4
5334	Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations. Npj Precision Oncology, 2021, 5, 50.	2.3	14
5335	Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival. Cancers, 2021, 13, 2879.	1.7	8
5336	Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism. Current Drug Targets, 2021, 22, 1071-1086.	1.0	5
5337	High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open, 2021, 6, 100133.	2.0	12
5338	Melanoma genomics: a stateâ€ofâ€theâ€art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281.	1.4	12
5339	Progression of melanoma is suppressed by targeting all transforming growth factorâ€Î² isoforms with an Fc chimeric receptor. Oncology Reports, 2021, 46, .	1.2	12
5340	Inhibition of human UDPâ€glucuronosyltransferase enzyme by Dabrafenib: Implications for drugâ€“drug interactions. Biomedical Chromatography, 2021, 35, e5205.	0.8	3
5341	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
5342	BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran. Iranian Journal of Pathology, 2021, 16, 370-375.	0.2	0
5343	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell Reports Medicine, 2021, 2, 100350.	3.3	6
5344	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	3.2	12
5345	Emerging strategies to target RAS signaling in human cancer therapy. Journal of Hematology and Oncology, 2021, 14, 116.	6.9	98
5347	Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics, 2021, 11, 1341.	1.3	55
5348	A chondroitin sulfate proteoglycan 4â€specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model. International Journal of Oncology, 2021, 59, .	1.4	6
5349	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	0.6	23
5350	Recognition, Staging, and Management of Melanoma. Medical Clinics of North America, 2021, 105, 643-661.	1.1	4
5351	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. JCO Oncology Practice, 2021, , OP.21.00140.	1.4	6

#	Article	IF	Citations
5352	Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes. Molecular Oncology, 2021, 15, 3299-3316.	2.1	5
5353	Global Implementation of Precision Oncology. JCO Precision Oncology, 2021, 5, 854-858.	1.5	5
5354	Fragment-based drug design facilitates selective kinase inhibitor discovery. Trends in Pharmacological Sciences, 2021, 42, 551-565.	4.0	22
5355	In Situ Single Cell Proteomics Reveals Circulating Tumor Cell Heterogeneity during Treatment. ACS Nano, 2021, 15, 11231-11243.	7.3	47
5356	Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers, 2021, 13, 3526.	1.7	22
5357	Cannabinoids and their derivatives in struggle against melanoma. Pharmacological Reports, 2021, 73, 1485-1496.	1.5	7
5358	Engineering large-scale chromosomal deletions by CRISPR-Cas9. Nucleic Acids Research, 2021, 49, 12007-12016.	6.5	18
5359	New systemic therapies for cutaneous melanoma: why, who and what. Italian Journal of Dermatology and Venereology, 2021, 156, 344-355.	0.1	2
5360	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Current Problems in Surgery, 2022, 59, 101030.	0.6	4
5361	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. Anti-Cancer Drugs, 2021, 32, 1076-1083.	0.7	2
5362	Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling. International Journal of Molecular Sciences, 2021, 22, 8151.	1.8	7
5363	Biomolecular Condensates and Their Links to Cancer Progression. Trends in Biochemical Sciences, 2021, 46, 535-549.	3.7	51
5364	ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Molecular Cancer Therapeutics, 2021, 20, 1757-1768.	1.9	13
5365	The Role of Glycosylation in Melanoma Progression. Cells, 2021, 10, 2136.	1.8	21
5366	Molecular alterations of low-grade gliomas in young patients: Strategies and platforms for routine evaluation. Neuro-Oncology Practice, 2021, 8, 652-661.	1.0	0
5367	Clinical Application of Next-Generation Sequencing in Recurrent Glioblastoma. Onco, 2021, 1, 38-48.	0.2	1
5368	Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease. JAMA Oncology, 2021, 7, 1220.	3.4	5
5369	Epigenetic instability may alter cell state transitions and anticancer drug resistance. PLoS Computational Biology, 2021, 17, e1009307.	1.5	6

#	Article	IF	Citations
5370	Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. International Journal of Molecular Sciences, 2021, 22, 9151.	1.8	9
5371	Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. International Journal of Hematology, 2021, 114, 725-734.	0.7	17
5372	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	0.8	145
5373	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal of Neuro-Oncology, 2021, 154, 197-203.	1.4	10
5374	The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B. Frontiers in Pharmacology, 2021, 12, 720619.	1.6	4
5375	Glucometerâ€based Ultraâ€sensitive BRAF V600E Mutation Detection Facilitated by Magnetic Nanochains and a Selfâ€made Pointâ€ofâ€care (POC) Device. Electroanalysis, 0, , .	1.5	4
5376	Melanoma medicine in the new millennium. British Journal of Dermatology, 2021, 185, 239-240.	1.4	0
5377	Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1297-1305.	0.4	6
5378	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Frontiers in Oncology, 2021, 11, 720044.	1.3	9
5379	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. Journal of Investigative Dermatology, 2021, 141, 2018-2027.e4.	0.3	8
5380	Crosstalk of the Wnt/Î²-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells. Pharmaceuticals, 2021, 14, 871.	1.7	25
5381	Pharmaco-omics data sheds light on therapy-oriented prospects of precision medicine. EBioMedicine, 2021, 70, 103493.	2.7	0
5382	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 2021, 27, 6197-6208.	3.2	20
5383	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opinion on Drug Safety, 2022, 21, 107-119.	1.0	2
5384	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. Journal of Investigative Dermatology, 2021, 141, 2028-2036.e2.	0.3	17
5385	Pan-Cancer Molecular Biomarkers. Surgical Pathology Clinics, 2021, 14, 507-516.	0.7	4
5386	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. Cancer Treatment Reviews, 2021, 99, 102253.	3.4	26
5387	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. Journal of Geriatric Oncology, 2021, 12, 1031-1038.	0.5	2

#	Article	IF	Citations
5388	Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-Î³ (RORÎ³) Agonist for Use in Treating Cancer. Journal of Medicinal Chemistry, 2021, 64, 13410-13428.	2.9	11
5389	Recent contributions of quinolines to antimalarial and anticancer drug discovery research. European Journal of Medicinal Chemistry, 2021, 226, 113865.	2.6	31
5390	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf IIIb study of trametinib in combination with dabrafenib. European Journal of Cancer, 2021, 154, 57-65.	1.3	9
5391	Identifying transcriptional programs underlying cancer drug response with TraCe-seq. Nature Biotechnology, 2022, 40, 86-93.	9.4	23
5392	High mutations in fatty acid metabolism contribute to a better prognosis of smallâ€cell lung cancer patients treated with chemotherapy. Cancer Medicine, 2021, 10, 7863-7876.	1.3	3
5393	Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?. Brain Sciences, 2021, 11, 1260.	1.1	4
5394	Advanced nanomedicine approaches applied for treatment of skin carcinoma. Journal of Controlled Release, 2021, 337, 589-611.	4.8	41
5395	Patients' Expectations of Benefits From Large-Panel Genomic Tumor Testing in Rural Community Oncology Practices. JCO Precision Oncology, 2021, 5, 1554-1562.	1.5	4
5396	Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5911-5925.	0.8	9
5397	Gibt es eine Ãœberbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1297-1306.	0.4	0
5398	Molecular Insights into Oral Malignancy. Indian Journal of Surgical Oncology, 2022, 13, 267-280.	0.3	4
5399	Molecular Markers and Targets in Melanoma. Cells, 2021, 10, 2320.	1.8	72
5400	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales De Dermatologie Et De Venereologie, 2021, 148, 145-155.	0.5	4
5401	Results of isolated limb perfusion for metastasized malignant melanoma. Surgical Oncology, 2021, 38, 101603.	0.8	1
5402	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. Journal of Clinical Investigation, 2021, 131, .	3.9	17
5403	Design, Synthesis and Anticancer Profile of New 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-Linked Sulfonamide Derivatives with V600EBRAF Inhibitory Effect. International Journal of Molecular Sciences, 2021, 22, 10491.	1.8	7
5404	The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-ÎºB signal transduction. Cancer Biology and Therapy, 2021, 22, 479-492.	1.5	9
5405	Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Reviews, 2022, 51, 100888.	2.8	4

#	Article	IF	Citations
5406	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nature Cell Biology, 2021, 23, 978-991.	4.6	29
5407	Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. Journal of Personalized Medicine, 2021, 11, 901.	1.1	11
5408	Combined targeted therapy and immunotherapy for cancer treatment. World Journal of Clinical Cases, 2021, 9, 7643-7652.	0.3	5
5409	Alternate dosage formulations of oral targeted anticancer agents. Journal of Oncology Pharmacy Practice, 2021, 27, 1963-1981.	0.5	3
5410	Targeting the mercapturic acid pathway for the treatment of melanoma. Cancer Letters, 2021, 518, 10-22.	3.2	5
5411	Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma. Clinics in Plastic Surgery, 2021, 48, 651-658.	0.7	5
5412	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	1.0	0
5413	Emerging Therapies in the Treatment of Advanced Melanoma. Clinics in Plastic Surgery, 2021, 48, 713-733.	0.7	3
5414	PhosphoFlowSeq â€“ A High-throughput Kinase Activity Assay for Screening Drug Resistance Mutations in EGFR. Journal of Molecular Biology, 2021, 433, 167210.	2.0	3
5415	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treatment Reviews, 2021, 100, 102282.	3.4	25
5416	Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics. Bioactive Materials, 2022, 8, 153-164.	8.6	20
5418	Rapid Tissue Donation (RTD) for Oncology Research. The International Library of Bioethics, 2021, , 1-17.	0.1	0
5419	Biomarkers in Pancreatic Cancer. , 2021, , 467-487.		1
5420	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies, 2021, 20, 153473542199007.	0.8	25
5421	Drug screening and kinase activity profiling of a novel patient-derived cell line of clear cell ovarian carcinoma. Journal of Electrophoresis, 2021, 65, 23-31.	0.2	1
5422	Do Carcinogens Have a Threshold Dose? The Pros and Cons. , 2021, , 555-573.		0
5423	Effect of antioxidants coenzyme Q10 and Î²â€˜carotene on the cytotoxicity of vemurafenib against human malignant melanoma. Oncology Letters, 2021, 21, 208.	0.8	3
5424	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthaseâ€“Low Squamous Cell Lung Cancer. Cancer Research and Treatment, 2021, 53, 87-92.	1.3	0

#	Article	IF	Citations
5425	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	1.5	2
5426	An Overview of Liver Directed Locoregional Therapies. Surgical Oncology Clinics of North America, 2021, 30, 103-123.	0.6	8
5427	Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1Î± to re-activate MAPK signaling. Journal of Cancer Research and Clinical Oncology, 2021, 147, 767-777.	1.2	11
5428	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110Î± in cell lines and tumor tissues. Analyst, The, 2021, 146, 6566-6575.	1.7	1
5430	Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. Journal of Surgical Oncology, 2020, 122, 555-561.	0.8	8
5431	Molecular Pathway Analysis of Mutation Data for Biomarkers Discovery and Scoring of Target Cancer Drugs. Methods in Molecular Biology, 2020, 2063, 207-234.	0.4	8
5432	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
5434	Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 47-67.	0.1	2
5435	Systemic Therapy in Melanoma. , 2014, , 461-474.		1
5437	MBP Technology: Composition and Design Considerations. Advances in Delivery Science and Technology, 2014, , 323-350.	0.4	2
5438	Targeted Therapies in Melanoma. Current Clinical Pathology, 2015, , 211-227.	0.0	4
5439	Oncogene Addiction in Solid Tumors. Current Clinical Pathology, 2015, , 3-7.	0.0	2
5440	Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems. Methods in Molecular Biology, 2016, 1386, 181-219.	0.4	12
5441	The MAPK Pathway in Melanoma. , 2016, , 151-163.		1
5442	The PI3K-AKT Pathway in Melanoma. , 2016, , 165-180.		3
5443	Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. Methods in Molecular Biology, 2017, 1636, 485-506.	0.4	11
5444	Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. , 2012, , 1-7.		1
5445	ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment. Methods in Molecular Biology, 2014, 1102, 461-480.	0.4	20

#	Article	IF	Citations
5446	Integrating Molecular Biomarkers into Current Clinical Management in Melanoma. Methods in Molecular Biology, 2014, 1102, 27-42.	0.4	7
5447	Tissue Resources for Clinical Use and Marker Studies in Melanoma. Methods in Molecular Biology, 2014, 1102, 679-695.	0.4	7
5448	Selecting Patients for KIT Inhibition in Melanoma. Methods in Molecular Biology, 2014, 1102, 137-162.	0.4	4
5449	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
5450	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
5451	Genetic Analysis of Circulating Tumour Cells. Recent Results in Cancer Research, 2020, 215, 57-76.	1.8	12
5453	Recent Advances in Skin Cancer Treatment in Older Adults. , 2015, , 97-103.		1
5454	Dysregulation of Sphingolipid Metabolism in Melanoma: Roles in Pigmentation, Cell Survival and Tumor Progression. , 2015, , 123-139.		2
5455	Optic Pathway Gliomas. , 2018, , 1-20.		2
5456	Title is missing!. , 2017, , .		82
5457	Title is missing!. , 2017, , .		13
5458	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
5459	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
5460	Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358.		1
5461	A Novel High-Throughput Multispectral Cell Segmentation Algorithm. Communications in Computer and Information Science, 2017, , 754-766.	0.4	2
5462	MedikamentÃ¶se Tumortherapie in der Dermato-Onkologie. , 2014, , .		2
5464	Melanom. , 2018, , 1869-1885.		1
5465	Understanding Melanoma Progression by Gene Expression Signatures. , 2013, , 47-78.		2

#	Article	IF	Citations
5466	Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments. , 2013, , 307-323.		2
5467	Melanoma and Non-Melanoma Skin Cancers. , 2014, , 435-452.		1
5468	Advancement of the Science and History of Cancer and Anticancer Drugs. , 2016, , 25-56.		1
5469	Utility of Reverse-Phase Protein Array for Refining Precision Oncology. Advances in Experimental Medicine and Biology, 2019, 1188, 239-249.	0.8	9
5470	Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide. Molecular Imaging and Biology, 2018, 20, 300-308.	1.3	18
5471	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. American Journal of Clinical Dermatology, 2019, 20, 315-323.	3.3	64
5472	Dermatologic Toxicities of Anticancer Therapy. , 2014, , 648-675.e4.		2
5474	Radioterapia estreotÃ¡xica corporal y cirugÃa mÃnimamente invasiva en el manejo de las metÃ¡stasis espinales: un cambio de paradigma. Neurocirugia, 2020, 31, 119-131.	0.2	5
5477	The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma. Clinical Science, 2020, 134, 193-205.	1.8	15
5478	Homologous recombination repair deficiency as a therapeutic target in sarcoma. Seminars in Oncology, 2020, 47, 380-389.	0.8	26
5479	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. Acta OncolÃ³gica, 2020, 59, 438-443.	0.8	7
5480	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. Expert Opinion on Orphan Drugs, 2013, 1, 67-76.	0.5	1
5481	SPRED1 deletion confers resistance to MAPK inhibition in melanoma. Journal of Experimental Medicine, 2021, 218, .	4.2	19
5482	Adult precision medicine: learning from the past to enhance the future. Neuro-Oncology Advances, 2021, 3, vdaa145.	0.4	11
5494	Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma. BMJ Case Reports, 2012, 2012, bcr1120115202-bcr1120115202.	0.2	2
5495	Xanthomicrol Exerts Antiangiogenic and Antitumor Effects in a Mouse Melanoma (B16F10) Allograft Model. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	10
5496	FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. Journal of Clinical Investigation, 2012, 122, 3048-3051.	3.9	45
5497	Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. Journal of Clinical Investigation, 2013, 123, 2155-2168.	3.9	215

#	Article	IF	Citations
5498	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Journal of Clinical Investigation, 2013, 123, 1371-1381.	3.9	256
5499	WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. Journal of Clinical Investigation, 2014, 124, 2877-2890.	3.9	144
5500	Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. Journal of Clinical Investigation, 2014, 124, 973-976.	3.9	9
5501	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. Journal of Clinical Investigation, 2015, 125, 3377-3383.	3.9	146
5502	Antisense oligonucleotideâ€“mediated MDM4 exon 6 skipping impairs tumor growth. Journal of Clinical Investigation, 2015, 126, 68-84.	3.9	138
5503	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. Journal of Clinical Investigation, 2017, 127, 2310-2325.	3.9	26
5504	Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma. Journal of Clinical Investigation, 2017, 128, 294-308.	3.9	55
5505	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. Journal of Clinical Investigation, 2018, 128, 4098-4114.	3.9	31
5506	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-666.	0.9	24
5508	Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET properties. Bulletin of the National Research Centre, 2020, 44, .	0.7	13
5509	Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.. Journal of Clinical Oncology, 2010, 28, e19008-e19008.	0.8	3
5510	The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Medical Science Monitor, 2018, 24, 3002-3010.	0.5	15
5511	A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. Medical Science Monitor, 2020, 26, e920957.	0.5	43
5512	Recent advances in methods to assess the activity of the kinome. F1000Research, 2017, 6, 1004.	0.8	8
5513	Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling. F1000Research, 2013, 2, 120.	0.8	13
5514	Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling. F1000Research, 2013, 2, 120.	0.8	31
5515	FAM129B is a novel regulator of Wnt/Î²-catenin signal transduction in melanoma cells. F1000Research, 2013, 2, 134.	0.8	12
5516	FAM129B is a novel regulator of Wnt/Î²-catenin signal transduction in melanoma cells. F1000Research, 2013, 2, 134.	0.8	21

#	Article	IF	Citations
5517	BRAF inhibitors in clinical oncology. F1000prime Reports, 2013, 5, 11.	5.9	32
5518	Current options and future directions in the systemic treatment of metastatic melanoma. Journal of Community and Supportive Oncology, 2014, 12, 20-26.	0.1	5
5519	Erdheim-Chester disease with asymmetric talus involvement: A case report. World Journal of Clinical Cases, 2020, 8, 614-623.	0.3	1
5520	Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle. PLoS Computational Biology, 2016, 12, e1005216.	1.5	5
5521	A Computational Approach for Identifying Synergistic Drug Combinations. PLoS Computational Biology, 2017, 13, e1005308.	1.5	77
5522	The RhoJ-BAD signaling network: An Achillesâ€™ heel for BRAF mutant melanomas. PLoS Genetics, 2017, 13, e1006913.	1.5	20
5523	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Medicine, 2016, 13, e1002196.	3.9	21
5524	Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. PLoS Medicine, 2017, 14, e1002230.	3.9	60
5525	Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials. PLoS ONE, 2012, 7, e35309.	1.1	173
5526	Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells. PLoS ONE, 2012, 7, e36762.	1.1	88
5527	Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension. PLoS ONE, 2012, 7, e38364.	1.1	46
5528	Mitochondrial Respiration - An Important Therapeutic Target in Melanoma. PLoS ONE, 2012, 7, e40690.	1.1	93
5529	Multiparametric Analysis of Cell-Free DNA in Melanoma Patients. PLoS ONE, 2012, 7, e49843.	1.1	60
5530	Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform. PLoS ONE, 2012, 7, e52760.	1.1	7
5531	High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. PLoS ONE, 2012, 7, e52795.	1.1	34
5532	Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. PLoS ONE, 2013, 8, e55096.	1.1	131
5533	Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600. PLoS ONE, 2013, 8, e59221.	1.1	13
5534	Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE, 2013, 8, e67583.	1.1	168

#	Article	IF	Citations
5535	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 2013, 8, e69748.	1.1	3
5536	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS ONE, 2013, 8, e77945.	1.1	104
5537	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Nonâ€“Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 2014, 9, e89518.	1.1	32
5538	Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers. PLoS ONE, 2014, 9, e93451.	1.1	39
5539	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/Î²-Catenin Signaling. PLoS ONE, 2014, 9, e94748.	1.1	35
5540	Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis. PLoS ONE, 2014, 9, e111920.	1.1	36
5541	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the CobasÂ® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232.	1.1	24
5542	CXCR3 Signaling in BRAFWT Melanoma Increases IL-8 Expression and Tumorigenicity. PLoS ONE, 2015, 10, e0121140.	1.1	16
5543	A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells. PLoS ONE, 2015, 10, e0123376.	1.1	11
5544	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	1.1	9
5545	Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS ONE, 2015, 10, e0125021.	1.1	16
5546	BRAF Mutations in Canine Cancers. PLoS ONE, 2015, 10, e0129534.	1.1	95
5547	The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS ONE, 2015, 10, e0145524.	1.1	16
5548	Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients. PLoS ONE, 2016, 11, e0147153.	1.1	13
5549	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 2016, 11, e0147682.	1.1	32
5550	Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study. PLoS ONE, 2016, 11, e0155242.	1.1	15
5551	Asymmetric Cancer Hallmarks in Breast Tumors on Different Sides of the Body. PLoS ONE, 2016, 11, e0157416.	1.1	8
5552	Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens. PLoS ONE, 2016, 11, e0158698.	1.1	8

#	Article	IF	Citations
5553	The prognostic significance of DAPK1 in bladder cancer. PLoS ONE, 2017, 12, e0175290.	1.1	17
5554	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
5555	Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma. PLoS ONE, 2017, 12, e0188602.	1.1	5
5556	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS ONE, 2017, 12, e0189651.	1.1	27
5557	Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 680-684.	1.8	7
5558	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 524-530.	1.8	3
5559	Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 675-678.	1.8	5
5560	Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 179-185.	1.8	3
5561	Early Integration of Palliative and Supportive Care in the Cancer Continuum: Challenges and Opportunities. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 144-150.	1.8	25
5562	Europe Does It Better: Molecular Testing across a National Health Care Systemâ€"The French Example. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 332-337.	1.8	7
5563	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
5564	A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1. World Journal of Oncology, 2018, 9, 56-61.	0.6	7
5565	New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell & Microenvironment, 2014, 1, .	0.8	12
5566	MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition. Endocrine-Related Cancer, 2019, 26, 699-712.	1.6	19
5567	AR-dependent phosphorylation and phospho-proteome targets in prostate cancer. Endocrine-Related Cancer, 2020, 27, R193-R210.	1.6	7
5568	Radiation Therapy for Melanoma. , 0, , 101-120.		5
5569	The prognostic significance ofBRAFmutation status in stage IIIBâ€"C melanoma. Expert Review of Dermatology, 2013, 8, 127-129.	0.3	2
5570	BRAFV600E and KIT immunoexpression in early-stage melanoma. Anais Brasileiros De Dermatologia, 2019, 94, 458-460.	0.5	3

#	Article	IF	Citations
5571	Liquid Biopsies for Assessing Metastatic Melanoma Progression. Critical Reviews in Oncogenesis, 2016, 21, 141-154.	0.2	15
5572	The genetics of cutaneous squamous cell carcinogenesis. European Journal of Dermatology, 2018, 28, 597-605.	0.3	8
5573	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. Tumori, 2014, 100, 144e-7e.	0.6	2
5574	Targeted Therapy for Cutaneous Melanoma: Beyond BRAF.... Journal of Patient-centered Research and Reviews, 2014, 1, 12-20.	0.6	3
5575	Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells. Global Journal of Cancer Therapy, 0, , 009-017.	0.4	2
5576	Melanoma of the lower female genital tract (vulva, vagina, and cervix): literature review and own cases. Opuholi Zenskoj Reproduktivnoj Sistemy, 2019, 15, 44-53.	0.1	5
5577	The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma. Journal of Liver Cancer, 2019, 19, 97-107.	0.3	7
5578	ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques.. Acta Biochimica Polonica, 2013, 60, .	0.3	16
5579	The Immunobiology of Cancer: An Update Review. Indonesian Biomedical Journal, 2017, 9, 53.	0.2	2
5580	Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma. Aging, 2019, 11, 2998-3011.	1.4	4
5581	Lycorine induces autophagy-associated apoptosis by targeting MEK2 and enhances vemurafenib activity in colorectal cancer. Aging, 2020, 12, 138-155.	1.4	18
5582	MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role. Aging, 2021, 13, 646-674.	1.4	5
5583	Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. Oncoscience, 2014, 2, 44-49.	0.9	18
5584	The combinatorial complexity of cancer precision medicine. Oncoscience, 2014, 1, 504-509.	0.9	48
5585	A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 2014, 1, 614-623.	0.9	26
5586	MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget, 2016, 7, 55128-55140.	0.8	11
5587	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget, 2018, 9, 12408-12417.	0.8	11
5588	Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget, 2016, 7, 60310-60331.	0.8	31

#	Article	IF	Citations
5589	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget, 2016, 7, 60858-60871.	0.8	14
5590	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget, 2016, 7, 68314-68327.	0.8	56
5591	Improving apoptotic responses to targeted therapy. Oncotarget, 2013, 4, 1331-1331.	0.8	5
5592	Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget, 2016, 7, 84594-84607.	0.8	23
5593	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget, 2016, 7, 81995-82012.	0.8	18
5594	Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget, 2016, 7, 85929-85936.	0.8	77
5595	Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget, 2017, 8, 14158-14172.	0.8	8
5596	Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. Oncotarget, 2017, 8, 5349-5360.	0.8	7
5597	Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget, 2013, 4, 1986-1998.	0.8	145
5598	MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget, 2017, 8, 17795-17809.	0.8	35
5599	Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. Oncotarget, 2017, 8, 23436-23447.	0.8	61
5600	Combined MEK and Pi3â€²-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo. Oncotarget, 2017, 8, 24604-24620.	0.8	24
5601	Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 32258-32269.	0.8	37
5602	Detection ofBRAF,NRAS,KIT,GNAQ,GNA11andMAP2K1/2mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis. Oncotarget, 2017, 8, 52304-52320.	0.8	18
5603	NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget, 2017, 8, 45687-45697.	0.8	7
5604	BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. Oncotarget, 2017, 8, 69477-69492.	0.8	28
5605	Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. Oncotarget, 2017, 8, 49839-49850.	0.8	24
5606	Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death. Oncotarget, 2017, 8, 43114-43129.	0.8	19

#	Article	IF	Citations
5607	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
5608	PDGFRÎ± up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget, 2014, 5, 1926-1941.	0.8	57
5609	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. Oncotarget, 2017, 8, 80393-80404.	0.8	16
5610	Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy. Oncotarget, 2014, 5, 3273-3286.	0.8	47
5611	Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget, 2017, 8, 69756-69767.	0.8	10
5612	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget, 2017, 8, 85516-85525.	0.8	67
5613	Inhibition of retinoic acid receptor Î² signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells. Oncotarget, 2017, 8, 84210-84223.	0.8	12
5614	The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget, 2014, 5, 5040-5053.	0.8	33
5615	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget, 2017, 8, 105000-105010.	0.8	10
5616	Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase Ib study. Oncotarget, 2017, 8, 89182-89193.	0.8	33
5617	Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget, 2014, 5, 5559-5569.	0.8	51
5618	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. Oncotarget, 2017, 8, 103207-103222.	0.8	18
5619	Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget, 2017, 8, 109457-109467.	0.8	32
5620	New role of ID3 in melanoma adaptive drug-resistance. Oncotarget, 2017, 8, 110166-110175.	0.8	20
5621	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
5622	CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget, 2018, 9, 1091-1106.	0.8	5
5623	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. Oncotarget, 2018, 9, 915-923.	0.8	42
5624	The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget, 2018, 9, 3815-3829.	0.8	17

#	Article	IF	Citations
5625	Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo. Oncotarget, 2018, 9, 5861-5875.	0.8	5
5626	Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma. Oncotarget, 2018, 9, 10905-10919.	0.8	17
5627	Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget, 2018, 9, 13834-13847.	0.8	9
5628	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	0.8	31
5629	Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas. Oncotarget, 2018, 9, 16832-16846.	0.8	5
5630	Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 2018, 9, 22243-22253.	0.8	15
5631	Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients. Oncotarget, 2018, 9, 24097-24108.	0.8	11
5632	Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget, 2018, 9, 25386-25401.	0.8	3
5633	Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget, 2018, 9, 31888-31903.	0.8	18
5634	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. Oncotarget, 2018, 9, 32570-32579.	0.8	15
5635	B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. Oncotarget, 2014, 5, 12607-12620.	0.8	16
5636	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 2014, 5, 11237-11251.	0.8	34
5637	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. Oncotarget, 2019, 10, 1669-1687.	0.8	12
5638	Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. Oncotarget, 2019, 10, 3818-3826.	0.8	33
5639	Dissecting the role of RNA modification regulatory proteins in melanoma. Oncotarget, 2019, 10, 3745-3759.	0.8	6
5640	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 2020, 11, 4016-4027.	0.8	6
5641	The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis. Oncotarget, 2015, 6, 1821-1833.	0.8	28
5642	Stage-specific prognostic biomarkers in melanoma. Oncotarget, 2015, 6, 4180-4189.	0.8	26

#	Article	IF	Citations
5643	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget, 2015, 6, 3479-3492.	0.8	146
5644	Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget, 2015, 6, 2779-2793.	0.8	56
5645	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget, 2015, 6, 5118-5133.	0.8	37
5646	Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. Oncotarget, 2015, 6, 11683-11693.	0.8	44
5647	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 2015, 6, 12297-12309.	0.8	148
5648	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	0.8	41
5649	Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget, 2015, 6, 18945-18955.	0.8	57
5650	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget, 2015, 6, 22348-22360.	0.8	12
5651	Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget, 2015, 6, 28502-28512.	0.8	19
5652	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget, 2015, 6, 24823-24841.	0.8	29
5653	Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget, 2015, 6, 19868-19879.	0.8	8
5654	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 2015, 6, 20863-20874.	0.8	41
5655	ErbB-3 activation by NRG-1Î² sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget, 2015, 6, 16902-16911.	0.8	29
5656	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	0.8	45
5657	Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget, 2015, 6, 23026-23035.	0.8	12
5658	A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation. Oncotarget, 2015, 6, 29347-29356.	0.8	52
5659	Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. Oncotarget, 2015, 6, 30592-30603.	0.8	13
5660	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget, 2015, 6, 32602-32609.	0.8	15

#	Article	IF	Citations
5661	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 2015, 6, 39891-39907.	0.8	40
5662	Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget, 2015, 6, 42183-42196.	0.8	40
5663	Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget, 2015, 6, 37895-37905.	0.8	26
5664	MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget, 2015, 6, 38854-38865.	0.8	54
5665	Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget, 2015, 6, 40535-40556.	0.8	59
5666	Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget, 2012, 3, 882-892.	0.8	107
5667	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	0.8	27
5668	Effects of a novel Nodal-targeting monoclonal antibody in melanoma. Oncotarget, 2015, 6, 34071-34086.	0.8	24
5669	Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget, 2015, 6, 37426-37442.	0.8	21
5670	Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Oncotarget, 2016, 7, 3171-3185.	0.8	41
5671	Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget, 2016, 7, 2734-2753.	0.8	19
5672	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget, 2016, 7, 3947-3965.	0.8	45
5673	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 4024-4035.	0.8	36
5674	Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells. Oncotarget, 2016, 7, 8676-8687.	0.8	8
5675	BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget, 2016, 7, 17665-17680.	0.8	13
5676	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget, 2016, 7, 7297-7306.	0.8	29
5677	Validation of a preclinical model for assessment of drug efficacy in melanoma. Oncotarget, 2016, 7, 13069-13081.	0.8	12
5678	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget, 2016, 7, 22543-22555.	0.8	11

#	Article	IF	Citations
5679	Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget, 2016, 7, 30907-30923.	0.8	52
5680	Efficacy of the combination of MEK and CDK4/6 inhibitorsin vitroandin vivoin KRAS mutant colorectal cancer models. Oncotarget, 2016, 7, 39595-39608.	0.8	101
5681	Future paradigms for precision oncology. Oncotarget, 2016, 7, 46813-46831.	0.8	23
5682	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene. Oncotarget, 2013, 4, 584-599.	0.8	166
5683	Medical management of malignant melanoma. Australian Prescriber, 2015, 38, 74-78.	0.5	24
5684	Melanoma immunotherapy dominates the field. Annals of Translational Medicine, 2016, 4, 269-269.	0.7	19
5685	Colorectal cancer genomics and designing rational trials. Annals of Translational Medicine, 2018, 6, 159-159.	0.7	19
5686	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	0.4	46
5687	Next frontiers in systemic therapy for soft tissue sarcoma. Chinese Clinical Oncology, 2018, 7, 43-43.	0.4	11
5688	Nanoparticles in Melanoma. Current Medicinal Chemistry, 2014, 21, 3701-3716.	1.2	7
5689	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Current Medicinal Chemistry, 2020, 27, 2792-2813.	1.2	12
5690	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	0.9	10
5691	Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors. Current Drug Targets, 2014, 15, 785-796.	1.0	1
5692	Epidemics and Peptide Vaccine Response: A Brief Review. Current Topics in Medicinal Chemistry, 2019, 18, 2202-2208.	1.0	12
5693	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 1415-1430.	0.9	3
5694	LETTER TO THE EDITOR: Management of Vemurafenib Induced Severe Arthralgia and Pyrexia in a Patient with BRAF V600E Mutated Melanoma: First Experience with a Switch to Dabrafenib. Open Dermatology Journal, 2015, 9, 1-3.	0.5	2
5695	The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway. , 2013, , 63-94.		2
5696	Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. Anticancer Research, 2017, 37, 651-658.	0.5	17

#	Article	IF	Citations
5697	Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. Anticancer Research, 2017, 37, 5033-5037.	0.5	6
5698	New Drug Combination Strategies in Melanoma: Current Status and Future DirectionsNew Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Research, 2017, 37, 5941-5953.	0.5	27
5699	BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. Anticancer Research, 2018, 38, 1335-1341.	0.5	9
5701	Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007â€“2017. Acta Dermato-Venereologica, 2020, 100, adv00147.	0.6	15
5702	Current Therapy for Advanced Melanoma and a Look at Future Signaling Pathways to Target. SKIN the Journal of Cutaneous Medicine, 2018, 2, 224-235.	0.1	1
5703	The evolution of surgical management for vertebral column tumors. Journal of Neurosurgery: Spine, 2019, 30, 417-423.	0.9	15
5704	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. Deutsches Ärzteblatt International, 2019, 116, 497-504.	0.6	15
5705	Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?. Cancers, 2015, 7, 1900-1924.	1.7	18
5706	Complete therapeutic response to anti-PD1 therapy in patient with advanced melanoma and resistance to targeted therapy of BRAF inhibitors. Onkologie (Czech Republic), 2018, 12, 21-24.	0.0	1
5707	Combined Inhibition of NF-Î¹B and Bcl-2 Triggers Synergistic Reduction of Viability and Induces Apoptosis in Melanoma Cells. Oncology Research, 2014, 21, 173-180.	0.6	5
5708	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World Journal of Gastroenterology, 2015, 21, 8271.	1.4	36
5710	Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenibâ€‘resistant melanoma cell lines. Molecular Medicine Reports, 2018, 18, 5151-5158.	1.1	3
5711	The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncology Letters, 2013, 5, 424-426.	0.8	7
5712	Upregulation of microRNAâ€‘31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncology Letters, 2020, 19, 2685-2694.	0.8	6
5713	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncology Reports, 2017, 38, 3291-3296.	1.2	46
5714	New Systemic Treatment for Malignant Melanoma. Korean Journal of Medicine, 2013, 85, 357.	0.1	3
5715	Cutaneous adverse effects of biologic medications. Cleveland Clinic Journal of Medicine, 2020, 87, 288-299.	0.6	11
5716	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	0.6	21

#	Article	IF	Citations
5717	BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Translational Lung Cancer Research, 2013, 2, 244-50.	1.3	45
5718	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational Lung Cancer Research, 2015, 4, 36-54.	1.3	499
5719	Lung cancer biomarkers, targeted therapies and clinical assays. Translational Lung Cancer Research, 2015, 4, 503-14.	1.3	23
5720	Cancer biomarker discovery and validation. Translational Cancer Research, 2015, 4, 256-269.	0.4	354
5721	Somatic DNA mutation analysis in targeted therapy of solid tumours. Translational Pediatrics, 2015, 4, 125-38.	0.5	19
5722	Targeted therapy for lung cancer: present and future. Annals of Palliative Medicine, 2014, 3, 229-35.	0.5	32
5723	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
5724	Biomarker based clinical trial design. Chinese Clinical Oncology, 2014, 3, 39.	0.4	25
5725	Genotyping of cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 27.	0.4	17
5726	BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chinese Clinical Oncology, 2014, 3, 29.	0.4	44
5727	Adjuvant therapy of mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 33.	0.4	2
5728	Treatment algorithm of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 38.	0.4	16
5729	Genomic profiling of brain metastases: current knowledge and new frontiers. Chinese Clinical Oncology, 2015, 4, 22.	0.4	16
5730	Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Annals of Translational Medicine, 2015, 3, 24.	0.7	31
5731	Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208.	0.7	27
5732	Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Annals of Translational Medicine, 2015, 3, 207.	0.7	16
5733	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
5734	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	0.7	47

#	Article	IF	Citations
5735	cfDNA analysis from blood in melanoma. Annals of Translational Medicine, 2015, 3, 309.	0.7	14
5736	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of Translational Medicine, 2015, 3, 322.	0.7	32
5737	Malignt melanom â€“ diagnostikk, behandling og oppfÃ¸lging i Norge. Tidsskrift for Den Norske Laegeforening, 2013, 133, 2154-2158.	0.2	10
5738	Acral, superficial spreading melanoma arising on melanocytic nevus in a pregnant woman: A case report with review. Indian Journal of Dermatology, 2015, 60, 609.	0.1	2
5739	Vemurafenib-induced bilateral facial palsy. Journal of Postgraduate Medicine, 2014, 60, 187-188.	0.2	16
5740	Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. Journal of Cancer Research and Therapeutics, 2015, 11, 647.	0.3	4
5741	Systemic drug-induced chronic paronychia and periungual pyogenic granuloma. Indian Dermatology Online Journal, 2018, 9, 293.	0.2	14
5742	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Translational Oncogenomics, 2015, Suppl. 1, 1-11.	1.7	19
5743	c-Met as a Target for Personalized Therapy. Translational Oncogenomics, 2015, Suppl. 1, 13-31.	1.7	102
5744	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. Cancer Research and Treatment, 2017, 49, 44-53.	1.3	27
5745	Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, s5, .	0.2	9
5746	The Future of Melanoma Therapy is the Combination Approach. Journal of Molecular Biomarkers & Diagnosis, 2011, 02, .	0.4	2
5747	Tumor Plasticity Driven by Spatial Micro-heterogeneity in the Tumor Microenvironment Contributes to Therapy Resistance. Journal of Carcinogenesis & Mutagenesis, 2014, s8, .	0.3	1
5748	Ritalin Use Modifies Alcohol Effects in Rats. Journal of Behavioral and Brain Science, 2014, 04, 453-464.	0.2	1
5749	Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, <i>in Situ</i> Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy. Journal of Biomaterials and Nanobiotechnology, 2012, 03, 140-153.	1.0	12
5750	A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting. Journal of Cancer Therapy, 2014, 05, 1049-1058.	0.1	4
5751	Distinct Subcellular Localization of GSK-3<i>Î²</i> in Melanocytic Nevi: Implications in Melanocyte Senescence. Open Journal of Pathology, 2012, 02, 113-119.	0.0	1
5752	Operable gastro-oesophageal junctional adenocarcinoma: Where to next?. World Journal of Gastrointestinal Oncology, 2014, 6, 145.	0.8	2

#	Article	IF	Citations
5753	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology, 2015, 7, 2245.	0.8	8
5754	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Molecular Imaging and Radionuclide Therapy, 2017, 26, 80-86.	0.3	8
5755	A Rare Cause of Uveitis: Vemurafenib. TÃ¼rk Oftalmoloji Dergisi, 2018, 48, 323-325.	0.4	10
5756	Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma. TÃ¼rk Oftalmoloji Dergisi, 2020, 50, 50-52.	0.4	8
5757	An extremely rare case of concurrent BRAF V600E mutation driven hairy cell leukemia and melanoma: Case report and review of literature. Autopsy and Case Reports, 2017, 7, 13-19.	0.2	10
5758	The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2016, 146, w14279.	0.8	35
5759	Nephrotoxicity in cancer treatment: An overview. World Journal of Clinical Oncology, 2020, 11, 190-204.	0.9	64
5760	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
5761	The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China. Chinese Journal of Cancer, 2013, 32, 410-414.	4.9	5
5762	Molecular targeted agents–where we are and where we are going. Chinese Journal of Cancer, 2013, 32, 225-232.	4.9	4
5763	Adoptive Cell Therapy of Melanoma: The Challenges of Targeting the Beating Heart. , 0, , .		2
5764	Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma. Journal of the Advanced Practitioner in Oncology, 2014, 5, .	0.2	9
5765	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 234-8.	0.2	3
5766	Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, S-1-S-5.	2.3	5
5767	Cotreatment of Hairy Cell Leukemia and Melanoma With theBRAFInhibitor Dabrafenib. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 9-13.	2.3	26
5768	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	2.3	326
5769	Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 36-43.	2.3	21
5770	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	2.3	253

#	Article	IF	Citations
5771	The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals. Reviews in Health Care, 2014, 5, 3-6.	0.1	2
5772	Enhanced Antitumor Efficacy with Combined Administration of Astragalus and Pterostilbene for Melanoma. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1163-1169.	0.5	7
5773	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine, 2014, 11, 237-46.	1.4	64
5774	BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. ELife, 2013, 2, e00969.	2.8	67
5775	Perturbation biology nominates upstreamâ€“downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4, .	2.8	95
5776	Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. ELife, 2020, 9, .	2.8	27
5777	A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. ELife, 2020, 9, .	2.8	16
5778	Metastatic melanoma â€“ a review of current and future drugs. Drugs in Context, 2012, 2012, 1-17.	1.0	25
5779	Finding melanoma drugs through a probabilistic knowledge graph. PeerJ Computer Science, 0, 3, e106.	2.7	16
5780	Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review. Cureus, 2019, 11, e6147.	0.2	7
5781	Recognizing Paradigm Instability in Theories of Carcinogenesis. British Journal of Medicine and Medical Research, 2014, 4, 1149-1163.	0.2	19
5782	Therapeutic Potential. , 2021, , 465-518.		0
5783	90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary. Frontiers in Oncology, 2021, 11, 722808.	1.3	5
5784	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Current Oncology, 2021, 28, 3978-3986.	0.9	7
5785	Small Molecule Kinase Inhibitor Drugs (1995â€“2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.	2.9	114
5786	Metagenomic analysis of gut microbiome reveals a dynamic change in Alistipes onderdonkii in the preclinical model of pancreatic cancer, suppressing its proliferation. Applied Microbiology and Biotechnology, 2021, 105, 8343-8358.	1.7	5
5787	Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment. Journal of Investigative Dermatology, 2022, 142, 1435-1443.e2.	0.3	2
5788	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naÃ¯ve study. Genome Medicine, 2021, 13, 155.	3.6	44

#	Article	IF	Citations
5789	Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells. Toxicological Research, 2022, 38, 35-44.	1.1	3
5790	Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition. Molecular and Cellular Proteomics, 2021, 20, 100163.	2.5	7
5791	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 328.	3.5	62
5792	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. ELife, 2021, 10, .	2.8	22
5793	Contextualizing Genes by Using Text-Mined Co-Occurrence Features for Cancer Gene Panel Discovery. Frontiers in Genetics, 2021, 12, 771435.	1.1	3
5794	Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, .	0.7	0
5795	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. Journal of Clinical Investigation, 2021, 131, .	3.9	40
5796	Sorafenib treatment of metastatic melanoma with câ€'Kit aberration reduces tumor growth and promotes survival. Oncology Letters, 2021, 22, 827.	0.8	7
5797	The BRAF V600E Mutation Detection by quasa Sensitive Real-Time PCR Assay in Northeast Romania Melanoma Patients. Applied Sciences (Switzerland), 2021, 11, 9511.	1.3	7
5798	HSP70 Inhibition Blocks Adaptive Resistance and Synergizes with MEK Inhibition for the Treatment of NRAS-Mutant Melanoma. Cancer Research Communications, 2021, 1, 17-29.	0.7	5
5799	RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy. Biomedicines, 2021, 9, 1498.	1.4	10
5800	Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors. IScience, 2021, 24, 103343.	1.9	3
5801	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer, 2022, 128, 47-58.	2.0	132
5802	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1
5804	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317.		1
5806	Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2011, 141, w13320.	0.8	41
5807	Melanom. , 2012, , 1710-1726.		0
5808	Understanding the Molecular and Functional Mechanisms that Underlie Pharamcogenomics-Based Therapy. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, 03, .	0.2	1

#	Article	IF	Citations
5809	A Review of Novel Systemic Therapies and Brain Radiosurgery for Metastatic Melanoma. World Journal of Oncology, 2012, 3, 93-96.	0.6	1
5810	Possibilities of Targeted Therapies for Brain Metastasis. , 2012, , 87-107.		0
5811	Is There a Role for Systemic Chemotherapy in the Treatment of Brain Metastases?. , 2012, , 133-151.		0
5813	Surgery for Brain Metastasis. , 2012, , 109-132.		0
5814	45 Melanoom en andere huidtumoren. , 2012, , 541-550.		0
5815	Current Trends and Future Directions in Clinical Trials for Malignant Melanoma Treatment Using Anti-Angiogenic Strategies. Journal of Cancer Therapy, 2012, 03, 312-320.	0.1	0
5816	Translational Medicine: Are we Ready for the Prime Time?. Translational Medicine (Sunnyvale, Calif), 2012, 02, .	0.4	0
5817	ERK1/ERK2. , 2012, , 586-593.		0
5819	Protein Methyltransferases as Targets for Personalized Cancer Therapeutics. AACR Education Book, 2012, 2012, 107-112.	0.0	1
5820	Genotipo complejo en un paciente con GIST.. Revista Colombiana De Hematologìa Y Oncologìa, 2012, 1, 70-77.	0.0	0
5821	Dermatologic Side Effects of Systemic Anticancer Therapy. , 2013, , 381-419.		1
5822	From Transplant to Tablets : A Paradigm Shift in Oncology = Ù...Ù† Ø²Ø±Ø¹ Ø§Ù„Ù†Ø®Ø§Ø¹ Ø¥Ù„Ù‰ Ø§Ù„Ø¨Ø¯ÙŠÙ„ : Ù†Ù‚Ù„Ø© Journal, 2012, 12, 402-405.	0.3	1
5824	Melanoma of the Oral Cavity: About Two Cases and Review of Literature. International Journal of Clinical Medicine, 2013, 04, 191-194.	0.1	0
5825	B-Raf. , 2013, , 1-9.		0
5826	Interleukin 2. , 2013, , 1-12.		0
5827	Recent Advances in Cancer Treatment. , 2013, , 25-35.		0
5828	Vemurafenib (PLX4032, ZelborafÂ®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance. Journal of Cancer Research Updates, 0, , .	0.3	0
5829	Detection of BRAF V600E Mutation in Langerhans Cell Histiocytosis Using High-resolution Melting Analysis in Decalcified, Paraffin-embedded Tissue. Journal of Leukemia (Los Angeles, Calif), 2013, 01, .	0.1	0

#	Article	IF	Citations
5830	Neue Arzneimittel 2012. , 2013, , 47-120.		1
5831	Elastography as a New Screening Tool for Metastatic Lymph Nodes in Melanoma Patients. Journal of Clinical & Experimental Oncology, 2013, 02, .	0.1	2
5832	Fortschritte der Dermatotherapie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 312-316.	0.0	0
5833	Malignant Melanoma of Unknown Primary Origin. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314 rgBT /Ove	0.0	0
5835	Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.		1
5836	Two cases of melanoma to cervical lymph nodes from an unknown primary site. Japanese Journal of Head and Neck Cancer, 2013, 39, 72-76.	0.0	0
5837	Therapeutic Agents for Advanced Melanoma. , 0, , .		0
5838	Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .	0.4	0
5839	Next-Generation Sequencing for Cancer Genomics. , 2013, , 55-74.		1
5840	Recent New Drug Approvals, Part 2: Drugs Undergoing Active Clinical Studies in Children. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 14-38.	0.3	7
5841	The Efficacy and Cost of Biological Targeted Agents in Oncology. SSRN Electronic Journal, 0, , .	0.4	0
5842	Diversifying and Specifying Palliative Care for Patients with Metastatic Cancer by Therapeutic Implementation of Non-Normative Boundary Conditions. , 2013, , 365-395.		0
5843	Zielgerichtete und Immuntherapien beim fernmetastasierten Melanom. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 17-29.	0.0	0
5846	Abstract PL03-04: Using functional genetics to optimize the treatment of cancer.. , 2013, , .		0
5847	Melanoma: Molecular Classification and Therapy. , 2014, , 461-471.		0
5848	BRAF-Targeted Therapy in Metastatic Melanoma. , 2013, , 473-490.		0
5849	Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. , 2014, , 29-57.		0
5850	Druggable Drivers of Lung Cancer. Oncotarget, 2013, 4, 1334-1335.	0.8	2

#	Article	IF	Citations
5851	Non-epidermoid Malignancies of the Lips. , 2014, , 153-160.		0
5852	Role of Next-Generation Sequencing Technologies. , 2013, , 1-16.		0
5853	Marker Utility for Combination Therapy. Methods in Molecular Biology, 2014, 1102, 97-115.	0.4	0
5854	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. , 2014, , 233-258.		0
5855	GenotipificaciÃ³n del melanoma en Colombia.. Revista Colombiana De HematologÌìa Y OncologÌìa, 2013, 2, 14-23.	0.0	4
5856	Emerging Clinical Issues in Melanoma in the Molecularly Targeted Era. Methods in Molecular Biology, 2014, 1102, 11-26.	0.4	0
5857	Nanotechnology Applications in Dermatology. , 2013, , 85-194.		0
5858	Novel Insights/Translational Implication from the Emerging Biology of Melanoma. Methods in Molecular Biology, 2014, 1102, 3-9.	0.4	3
5860	Pharmacodynamic Modeling. Cancer Drug Discovery and Development, 2014, , 193-208.	0.2	0
5861	Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms. Cancer Drug Discovery and Development, 2014, , 255-272.	0.2	0
5862	Targeted therapieÃ«n. , 2014, , 55-66.		1
5863	The Role of Phase III Trials in Modern Drug Development. Cancer Drug Discovery and Development, 2014, , 763-783.	0.2	0
5864	Melanom. , 2014, , 31-97.		0
5865	Melanoom: systemische behandeling. , 2014, , 189-197.		0
5867	10.4172/2157-2518.1000169. Journal of Carcinogenesis & Mutagenesis, 2014, 05, .	0.3	0
5868	Immunotherapy of Malignant Melanoma. , 2014, , 139-154.		0
5869	Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer. , 2014, , 1-27.		0
5870	Diagnostic Effectiveness of PCR-based Tests DetectingBRAFMutation for Treating Malignant Melanoma: A Systematic Review. Laboratory Medicine Online, 2014, 4, 203.	0.0	0

#	Article	IF	Citations
5871	BO-110, a dsRNA-Based Anticancer Agent. Advances in Delivery Science and Technology, 2014, , 453-470.	0.4	0
5872	Metastatic Melanoma. , 2014, , 529-567.		0
5873	New Therapies for Hairy Cell Leukemia. Journal of Leukemia (Los Angeles, Calif), 2014, 02, .	0.1	0
5874	Tumors of the Soft Tissue: Using Molecular Tools to Aid in the Diagnosis of Soft Tissue Tumors and the Management of the Sarcoma Patient. , 2014, , 199-229.		0
5875	Intracellular Signaling. , 2014, , 22-39.e8.		1
5876	Vemurafenib in the treatment of brain metastases from melanoma. Onkologiya Zhurnal Imeni P A Gertsena, 2014, 3, 85.	0.0	1
5877	Biopsies, Tissue Processing, Immunohistochemistry, and Ancillary Techniques. , 2014, , 13-32.		0
5878	Pharmacogenomics in Molecular Oncology. , 2014, , 405-421.		0
5879	Genetic and Epigenetic Alterations in Cancer. , 2014, , 188-203.		0
5880	Melanoma. Part II. Personalized Medicine: Using Molecular Tools to Guide Targeted Therapy. , 2014, , 97-131.		1
5881	Cancer Stem Cells in Melanoma. , 2014, , 203-228.		0
5882	A surgical case of primary amelanotic malignant melanoma of the lung. The Journal of the Japanese Association for Chest Surgery, 2014, 28, 241-248.	0.0	1
5884	Emerging Molecular Applications and Summary. , 2014, , 341-354.		0
5885	Diagnostic molÃ©culaire des tumeurs solides. , 2014, , 39-56.		0
5886	Future Perspective of Chemotherapy for Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2014, 67, 906-918.	0.1	0
5887	A Case of Metastatic Gastric Malignant Melanoma Diagnosed by Tarry Stool 8 Years after the Resection of the Primary Skin Lesion. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2014, 75, 1577-1582.	0.0	2
5888	Melanoma. Part I. Risk Assessment, Diagnosis, and Prognosis: Using Molecular Tools to Diagnose Melanoma, Predict Its Behavior, and Evaluate for Inheritable Forms. , 2014, , 63-96.		1
5889	Therapeutic Targeting of Cancer Cells. , 2014, , 423-433.e2.		1

#	Article	IF	Citations
5890	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
5891	Metastatic Melanoma with Spontaneous Regression, Psoriasis and HLA-Cw6: Case Report and a Hypothesis to Explore. Tumori, 2014, 100, e144-e147.	0.6	1
5892	Nonlymphoid Tumors Mimicking Lymphoma. , 2014, , 539-583.		0
5893	The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations. Journal of Patient-centered Research and Reviews, 2014, 1, 21-26.	0.6	0
5894	Pitfalls in Clinical Research. The Case of the New Antineoplastic Agents. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.5000183.	0.2	1
5895	METASTAZAVUSIOS MELANOMOS GYDYMAS BRAF INHIBITORIAIS KLAIPÄ–DOS UNIVERSITETINÄ–JE LIGONINÄ–JE. NEPAGEIDAUJAMI REIÅKINIAI. Health Sciences, 2014, 24, 39-42.	0.0	0
5896	Current therapeutic options in hairy cell leukemia. Journal of Community and Supportive Oncology, 2014, 12, 104-108.	0.1	0
5897	Using a 980 nm, 7w/cm2 Diode Laser in Oral Surgeries. American Journal of BioMedicine, 2014, 2, 160-169.	0.0	0
5898	Combined BRAF and MEK inhibition of BRAF mutated metastatic melanoma: incremental progress?. Journal of Community and Supportive Oncology, 2014, 12, 232-233.	0.1	0
5900	An Uncommon Presentation for Cardiac Melanoma. Journal of Patient-centered Research and Reviews, 2014, 1, 128-132.	0.6	1
5903	Evaluation of Small Biopsy Material in Patients with Multiple and Secondary Tumors. , 2015, , 155-196.		1
5905	Croatian Perspectives for Person Centered Care in Oncology. International Journal of Person Centered Medicine, 2014, 4, 19-22.	0.2	1
5907	Melanomagenic Gene Alterations Viewed from a Redox Perspective: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 285-309.		2
5909	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2015, , 87-129.		0
5910	Less Common Rectal Tumors. , 2015, , 323-347.		0
5912	Development and Incorporation of Biomarkers in RCC Therapeutics. , 2015, , 527-539.		0
5913	Molecular Diagnostics and Tumor Mutational Analysis. Cancer Drug Discovery and Development, 2015, , 47-65.	0.2	2
5914	Clinical Utility of BRAF-Targeted Therapy in Melanoma. Cancer Drug Discovery and Development, 2015, , 67-84.	0.2	0

#	Article	IF	Citations
5915	Combination BRAF-Directed Therapy and Immunotherapy. Cancer Drug Discovery and Development, 2015, , 163-182.	0.2	0
5916	Lungenmetastasen beim Melanom. , 2015, , 139-149.		0
5918	Basis for Molecular Genetics in Cancer. , 2015, , 15-30.		0
5919	Next-Generation Sequencing Applications in Head and Neck Oncology. , 2015, , 401-422.		0
5921	Pharmacogenetics and Antineoplastic Therapies. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 275-305.	0.6	0
5922	Molekulare Diagnostik und Techniken. , 2015, , 1-12.		0
5923	Phase I Trials Today. , 2015, , 661-676.e2.		0
5924	A Novel Method for Mutation Analysis Using Genomic DNA Obtained from Immunohistochemistry-Stained Sections. Journal of Molecular Biomarkers & Diagnosis, 2015, 06, .	0.4	0
5925	The Role of Pharmacogenomics in Individualized Medicine. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 93-112.	0.6	3
5926	é€²è¡Œãƒ¡ãƒ©ãƒŽãƒ¼ãƒžã«å¯¾ã™ã‚‹åŒ–å¦ç™‚æ³•ï¼ASCO2014ã®ãƒˆãƒ”ãƒƒã‚¯ã‚¹ã‚’ãµã¾ãˆã¦. Skin Cancer, 2015, 29, 155-157.	0.1	1
5927	Skin toxicity of targeted therapy: Vemurafenib, first experiences from Montenegro. Sanamed, 2015, 10, 109-114.	0.1	0
5928	Translation: Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer. Laboratory Medicine Online, 2015, 5, 44.	0.0	0
5929	Application of Molecular Pathology to Cutaneous Melanocytic Lesions. Molecular Pathology Library, 2015, , 103-124.	0.1	0
5930	Universal BRAF State Detection by the PyrosequencingÂ®-Based U-BRAFV600 Assay. Methods in Molecular Biology, 2015, 1315, 63-82.	0.4	0
5931	Clinical Approach to Advanced Melanoma for Today and Tomorrow. , 2015, , 637-662.		0
5932	Computational Data Integration in Toxicogenomics. Methods in Pharmacology and Toxicology, 2015, , 371-392.	0.1	0
5933	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
5934	Molekulare Grundlagen der malignen Transformation. , 2015, , 1-16.		0

#	Article	IF	Citations
5936	Melanoma and immunotherapy. , 2015, , 199-212.		0
5937	Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 361-5.	0.2	16
5938	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget, 2015, 6, 25452-25465.	0.8	3
5939	Advanced skin melanoma â€“ systemic treatment. OnCOReview, 2015, 5, 133-138.	0.1	0
5940	Pharmacoeconomic analysis of vemurafenib in treatment of inoperable or metastatic melanoma in patients with BRAF V600 mutation. Pharmacoeconomics Theory and Practice, 2015, 3, 22-27.	0.0	0
5941	Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma. Cureus, 2015, 7, e410.	0.2	6
5942	Entering an era of intelligent combination therapy in cancer. Journal of Community and Supportive Oncology, 2015, 13, 446-450.	0.1	1
5943	Therapie des malignen Melanoms. , 2016, , 169-178.		0
5944	Dermatologic Toxicities to Melanoma Targeted Therapies. , 2016, , 267-277.		1
5945	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2016, , 1-39.		0
5946	Melanom. , 2016, , 1-17.		0
5948	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
5949	Transcription Factors Synergistically Activated at the Crossing of the Restriction Point between G1 and S Cell Cycle Phases. Pathologic Gate Opening during Multi-Hit Malignant Transformation. Nuclear Receptor Research, 2016, 3, .	2.5	0
5950	Therapeutic Potential. , 2016, , 437-488.		0
5951	Future Directions for Advanced Thyroid Cancer Therapy. , 2016, , 991-999.		0
5952	Kutane Nebenwirkungen neuer Krebsmedikamente. , 2016, , 305-312.		0
5953	Simultaneous Treatment of Severe Vemurafenib-induced Uveitis and Metastatic Melanoma. Journal of Clinical & Experimental Ophthalmology, 2016, 07, .	0.1	1
5954	Targeted Cancer Therapy. Nishinihon Journal of Dermatology, 2016, 78, 221-228.	0.0	0

#	Article	IF	Citations
5955	New Treatments for Advanced Melanoma. Nishinihon Journal of Dermatology, 2016, 78, 5-12.	0.0	0
5956	Biomarker Analysis of Gene-Mutated Protein Products by Immunohistochemistry in Melanoma. , 2016, , 181-191.		0
5957	Isolated Limb Infusion. , 2016, , 375-390.		0
5958	Primary Mucosal Melanomas of the Head and Neck. , 2016, , 641-656.		0
5959	Melanomaâ€”Treatment. , 2016, , 79-109.		0
5960	Personalized Medicine in the Era of Genomics. Advances in Bioinformatics and Biomedical Engineering Book Series, 2016, , 296-327.	0.2	1
5961	Targeted Therapy in Melanoma. , 2016, , 237-265.		0
5962	Controversies in the Surgical Management of Melanoma. , 2016, , 159-184.		0
5963	BRAF Mutations. , 2016, , 4-16-4-17.		0
5964	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
5965	Immunohistology of Melanocytic Lesions. , 2016, , 311-334.		0
5966	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-188.	0.1	0
5967	Head and Neck Cutaneous Melanoma. , 2016, , 657-663.		0
5968	Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.. University of Ottawa Journal of Medicine, 2016, 6, 49-52.	0.0	0
5969	Metastatic Anorectal Melanoma: A Case Report. Iranian Journal of Cancer Prevention, 2016, In Press, .	0.7	0
5971	The Role and Importance of Molecular Tests in Approach to Thyroid Nodules. Turkish Archives of Otorhinolaryngology, 2016, 54, 74-78.	0.2	0
5972	Analyzing the Effect of c-myc Oncogene and Matrix Mettalloproteinase-2 Enzyme Ekspression on Metastasis and Prognosis of Malignant Melanoma. Journal of Clinical and Experimental Investigations, 2016, 7, .	0.1	0
5973	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267.	0.5	0

#	Article	IF	Citations
5974	Personalized Medicine for the Treatment of Human Cancer. , 2017, , 843-855.		0
5975	Cancer Drug Delivery. , 2017, , 185-228.		0
5977	Melanoma Genetics and Genomics. , 2017, , 63-93.		0
5978	Stereotactic irradiation of brain metastasis from malignant melanoma during short-term vemurafenib withdrawal : a case report. Skin Cancer, 2017, 32, 76-81.	0.1	0
5979	Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
5980	New Approaches to Signaling. , 2017, , 399-425.		0
5981	Personalized Medicine in the Era of Genomics. , 2017, , 297-327.		0
5982	Management of Melanoma. , 2017, , 15-23.		0
5984	A Case of Pilocytic Astrocytoma with BRAF V600E Mutation and Anaplastic Features occurred in Adult Temporal Lobe. Japanese Journal of Neurosurgery, 2017, 26, 452-458.	0.0	0
5985	Erdheim-Chester Disease and Other Histiocytoses. Rare Diseases of the Immune System, 2017, , 155-172.	0.1	0
5986	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 35.	0.0	0
5987	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2017, , 1065-1102.		0
5988	Management of Patients With Skin Cancers: Basal Cell Carcinoma and Melanoma. Journal of the Advanced Practitioner in Oncology, 2017, 8, 244-248.	0.2	0
5989	Tissue-independent cancer drug gets fast-track approval from US regulator. Nature, 0, , .	13.7	0
5994	BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma. OnCOReview, 2017, 7, 139-143.	0.1	0
5995	Adjuvant Therapy. , 2018, , 1-25.		0
5996	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
5997	Molecular Genetics of Melanocytic Neoplasia. , 2018, , 1-23.		1

#	Article	IF	Citations
5998	Primary sinonasal mucosal melanoma â€“ Case report and literature review. Romanian Journal of Rhinology, 2017, 7, 241-249.	0.1	0
6000	Heterogeneity and Plasticity of Melanoma: Challenges of Current Therapies. , 0, , 57-65.		2
6002	Cutaneous melanoma. Journal of the Korean Medical Association, 2018, 61, 662.	0.1	0
6003	Tongue metastasis of cutaneous melanoma: Report of two cases and literature review. Journal of Clinical and Experimental Dentistry, 2018, 10, 0-0.	0.5	5
6004	Cancer in Older Adults. , 2018, , 1-21.		0
6005	Malignes Melanom beim alten und geriatrischen Patienten. , 2018, , 527-534.		0
6006	Challenges in Molecular Pathology. , 2018, , 17-52.		0
6007	New (Medical) Treatment for Thyroid Carcinoma. Endocrinology, 2018, , 1-26.	0.1	0
6009	A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells. SSRN Electronic Journal, 0, , .	0.4	0
6010	Analysis of Advanced Melanomas Changed from Immune Checkpoint Blockade Therapy to Palliative Care. Nishinihon Journal of Dermatology, 2018, 80, 51-55.	0.0	0
6015	Neurocutaneous Melanosis with Leptomeningeal Melanoma Involving Supratentorium and Infratentorium. Cureus, 2018, 10, e3275.	0.2	3
6016	The role of prophylactic radiotherapy in prevention of brain metastasis. The Egyptian Journal of Hospital Medicine, 2018, 73, 5976-5981.	0.0	0
6017	Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event. Journal of the Portuguese Society of Dermatology and Venereology, 2018, 76, 329-332.	0.0	0
6018	Cutaneous side effects of oncology treatments. Part I. Chemotherapy. Ukrainian Journal of Dermatology Venerology Cosmetology, 2018, .	0.0	0
6019	Where Weâ€™ve Been and Where Weâ€™re Going. , 2018, , 2-23.		0
6020	Management of QT Prolongation Induced by Anticancer Drugs. Current Clinical Pathology, 2019, , 123-132.	0.0	0
6022	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
6023	Personalized Cancer Immunotherapy: Todayâ€™s Challenge and Tomorrowâ€™s Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4

#	Article	IF	Citations
6024	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2019, , 1-19.		0
6025	Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients. , 2018, 14, 8-16.		4
6026	Prioritization not Rationing in Cancer Care. Recent Results in Cancer Research, 2019, 213, 189-205.	1.8	1
6028	Large-scale Genomic Testing Facilitates Precision Medicine in Routine Cancer Care. Oncology & Hematology Review, 2019, 15, 25.	0.2	0
6029	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
6030	Non small cell lung cancer with targetable driver alterations: Imaging perspective. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	0
6031	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
6032	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
6033	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
6034	Melanom. , 2019, , 45-134.		0
6035	Targeted and Immune Therapy for Periocular and Orbital Malignancies. Current Practices in Ophthalmology, 2019, , 83-97.	0.1	0
6036	KRAS as Potential Target in Colorectal Cancer Therapy. , 2019, , 389-424.		1
6037	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.	0.0	1
6038	Ethical Considerations of Neuro-oncology Trial Design in the Era of Precision Medicine. , 2019, , 121-128.		0
6039	Cancer Therapy. , 2019, , 7-76.		0
6040	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
6041	Application of Biomarkers for Common Cancers in Molecular Diagnosis. Medical Diagnosis, 2019, 09, 17-23.	0.0	0
6042	A Case of Multiple Small Bowel Metastases from Cutaneous Malignant Melanoma with Gastrointestinal Bleeding. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 2213-2220.	0.0	0

#	Article	IF	Citations
6045	Dermatology Free from Ointments. Research in Medical & Engineering Sciences, 2019, 7, .	0.0	0
6048	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
6049	The Cancer Precision Medicine Diagnosis and Treatment (K-MASTER) Enterprise. Korean Journal of Medicine, 2019, 94, 246-251.	0.1	1
6050	Mutation alleleâ€specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas. World Academy of Sciences Journal, 0, , .	0.4	0
6053	Prediction of Drug Potency and Latent Relation Analysis in Precision Cancer Treatment. Advances in Intelligent Systems and Computing, 2020, , 188-195.	0.5	0
6054	Common Cutaneous Side Effects ofÂAnti-cancer Agents. , 2020, , 289-306.		0
6057	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
6058	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
6060	Genomic Characterization of Brain Metastases: Implications for Precision Medicine. , 2020, , 43-58.		0
6061	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 203-225.	0.8	1
6062	Isolated Limb Perfusion and Infusion in theÂManagement of In-Transit Melanoma of theÂExtremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
6064	Particle Therapy: Protons and Heavy Ions. Advances in Oto-Rhino-Laryngology, 2020, 84, 87-105.	1.6	4
6065	Cancer in Older Adults. , 2020, , 189-209.		0
6066	Survival in melanoma brain metastases in the era of novel systemic therapies. Neuro-Oncology Advances, 2020, 2, vdaa144.	0.4	2
6067	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
6068	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
6070	CusVarDB: A tool for building customized sample-specific variant protein database from next-generation sequencing datasets. F1000Research, 2020, 9, 344.	0.8	0
6073	Endobronchial Malignant Melanoma: An Exceedingly Rare Occurrence. Cureus, 2020, 12, e8619.	0.2	0

#	Article	IF	Citations
6074	BRAF Mutant Metastatik Melanomda Dabrafenib-trametinib Kombinasyon Tedavisi SonrasÄ± GeliÅŸen Yan Etki YÃ¶netimi: Ä°ki Olgu Sunumuyla Birlikte LiteratÃ¼r Derlemesi. OsmangazÄ° Journal of Medicine, 0, , .	0.1	0
6075	Spinal Metastatic Melanoma with Unknown Primary Lesions Presenting as Radiculopathy: Case Report and Literature Review. World Neurosurgery, 2020, 140, 320-324.	0.7	5
6076	Current prospects of successful therapeutic procedures in advanced stage melanoma â€“ the short review. Journal of Education, Health and Sport, 2020, 10, 308.	0.0	0
6078	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
6079	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
6080	Getting personal about skin: Realizing precision medicine in dermatology. Dermatological Reviews, 2021, 2, 289-295.	0.3	3
6081	BRAF inhibition and the spectrum of granulomatous reactions. Journal of the American Academy of Dermatology, 2021, , .	0.6	5
6082	Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 11726.	1.8	3
6083	Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review. Genes, 2021, 12, 1751.	1.0	7
6084	Biological Therapies in the Treatment of Cancerâ€"Update and New Directions. International Journal of Molecular Sciences, 2021, 22, 11694.	1.8	17
6085	The role of PI3'â€kipid signalling in melanoma initiation, progression and maintenance. Experimental Dermatology, 2022, 31, 43-56.	1.4	7
6086	Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.	0.6	26
6087	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers, 2021, 13, 5411.	1.7	1
6088	High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma. Journal of Computer-Aided Molecular Design, 2021, 35, 1165-1176.	1.3	5
6089	The Relationship between BRAF V600E Mutation and the Clinicopathological Features of the Papillary Thyroid Carcinoma. International Journal of Clinical Medicine, 2020, 11, 216-227.	0.1	0
6090	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. Topics in Medicinal Chemistry, 2020, , 125-153.	0.4	0
6091	A CRISPR Competition Assay to Identify Cancer Genetic Dependencies. Bio-protocol, 2020, 10, e3682.	0.2	6
6092	Unique k-mer sequences for validating cancer-related substitution, insertion and deletion mutations. NAR Cancer, 2020, 2, zcaa034.	1.6	5

#	Article	IF	Citations
6094	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
6095	MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 2021, 33, 139-145.	1.1	3
6096	Potentially lifeâ€'threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Oncology Reports, 2020, 45, 891-898.	1.2	6
6097	Cancer Treatment Modalities Systemic and Locoregional Approaches: Challenges and Opportunities of Multidisciplinary Approaches. , 2021, , 17-37.		1
6099	Re-Exploring Biomarkers and Therapeutic Targets in Primary Melanoma Patients: Insights from Network-Based Analysis of Microarray Data. Chinese Journal of Plastic and Reconstructive Surgery, 2020, 2, 228-240.	0.1	0
6100	The Role of BRAF Gene in Cancer: Literature Review and Future Directions. Journal of Cancer Research Updates, 2020, 9, 11-19.	0.3	1
6102	Signaling pathways in CRC. , 2022, , 519-528.		1
6103	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
6104	Neoadjuvant and Adjuvant Approach Treatment of B-RAF Positive Limited Metastatic Melanoma. SunText Review of Medical & Clinical Research, 2020, 01, .	0.1	0
6105	Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. , 2020, , .		0
6106	Mechanisms of Toxicities Associated With Targeted Therapy. , 2020, , 113-118.		0
6107	Pharmacodynamic Evaluation: Dermatology. , 2020, , 299-315.		0
6108	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
6109	Recent Advances in Systemic Therapy for Malignant Melanoma. SKIN the Journal of Cutaneous Medicine, 2020, 4, 4-14.	0.1	0
6110	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
6111	Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis. JMA Journal, 2020, 3, 274-279.	0.6	0
6112	Glimmers of Hopeâ€"New Strategies for Overcoming Treatment Resistance in Patients with BRAF V600E-mutated Metastatic Colorectal Cancer. Oncology & Hematology Review, 2020, 16, 31.	0.2	1
6113	PD-1 Inhibitor Nivolumab for a Primary Central Nerve System Melanoma Developing Spinal Cord Symptom : A Case Report. Spinal Surgery, 2020, 34, 73-78.	0.0	0

#	Article	IF	Citations
6114	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
6115	Endoplasmic Reticulum Stress and Autophagy in Cancer. , 2020, , 355-402.		0
6116	Cutaneous Melanoma â€“ A Review of Systemic Therapies. Acta Dermato-Venereologica, 2020, 100, adv00141.	0.6	7
6117	Tumoren der Haut. , 2020, , 899-914.		0
6118	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
6119	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
6120	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
6121	A Case of Emergency Laparoscopic Surgery for Intestinal Intussusception and Obstruction due to Jejunal Metastasis of Malignant Melanoma. Nihon Daicho Komonbyo Gakkai Zasshi, 2020, 73, 121-126.	0.1	1
6122	Treatment resistance and a glimmer of hope, the promise of new agents. , 2020, , 81-102.		0
6123	Therapeutic strategies and potential implications of silver nanoparticles in the management of skin cancer. Nanotechnology Reviews, 2020, 9, 1500-1521.	2.6	19
6124	Tumours of the skin. , 2020, , 5732-5742.		0
6126	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
6127	A Rare Case of Non-Small Cell Lung Cancer with BRAF V600E Gene: Case Report and Literature Review. Cureus, 2020, 12, e7055.	0.2	1
6128	Next-Generation Sequencing in Prostate Cancer. The Korean Journal of Urological Oncology, 2020, 18, 18-23.	0.1	0
6129	Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma. Dermatology Practical and Conceptual, 2020, 10, e2020029.	0.5	2
6130	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?. Frontiers in Oncology, 2021, 11, 775100.	1.3	6
6131	The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncologyâ€"When and Why?. International Journal of Molecular Sciences, 2021, 22, 12089.	1.8	8
6132	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. Frontiers in Oncology, 2021, 11, 772052.	1.3	18

#	Article	IF	Citations
6133	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discovery, 2022, 12, 712-729.	7.7	15
6135	Cancer Drug Delivery. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 52-95.	0.3	0
6136	Vemurafenib. BioDrugs, 2012, 26, 325-334.	2.2	5
6137	In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions. Future Journal of Pharmaceutical Sciences, 2020, 6, .	1.1	10
6138	KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute. Blood Research, 2020, 55, 159-168.	0.5	0
6144	Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors. Egyptian Journal of Medical Human Genetics, 2020, 21, .	0.5	10
6146	CusVarDB: A tool for building customized sample-specific variant protein database from next-generation sequencing datasets. F1000Research, 0, 9, 344.	0.8	1
6147	Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2599-2607.	1.1	2
6150	Angiogenesis and melanoma - from basic science to clinical trials. American Journal of Cancer Research, 2011, 1, 852-68.	1.4	21
6151	Next-generation sequencing for cancer diagnostics: a practical perspective. Clinical Biochemist Reviews, 2011, 32, 177-95.	3.3	271
6152	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. Yale Journal of Biology and Medicine, 2011, 84, 381-9.	0.2	36
6153	Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale Journal of Biology and Medicine, 2011, 84, 371-80.	0.2	47
6154	What's New in the Treatment of Melanoma. MÃ¦dica, 2011, 6, 235-6.	0.4	0
6155	Two cases of partial hepatectomy for malignant melanoma. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2012, 71, 92-6.	0.4	1
6156	Breast metastasis from a melanoma. Ochsner Journal, 2012, 12, 149-51.	0.5	15
6157	Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. American Journal of Cancer Research, 2012, 2, 726-35.	1.4	10
6159	The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P and T, 2013, 38, 96-108.	1.0	69
6161	Absence of BRAF exon 15 mutations in multiple myeloma and WaldenstrÃ¶m's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. American Journal of Blood Research, 2013, 3, 181-5.	0.6	1

#	Article	IF	Citations
6162	Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. Journal of Clinical and Aesthetic Dermatology, 2013, 6, 27-37.	0.1	14
6163	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 153-9.	1.0	25
6164	Melanoma metastasis to the gastric mucosa preceded by guillain-barrÃ© as a paraneoplastic syndrome. Gastrointestinal Cancer Research: GCR, 2013, 6, 150-1.	0.8	4
6165	Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis. International Journal of Clinical and Experimental Pathology, 2014, 7, 468-73.	0.5	0
6166	Ewing's sarcoma: overcoming the therapeutic plateau. Discovery Medicine, 2012, 13, 405-15.	0.5	22
6167	Diagnostic and prognostic biomarkers in melanoma. Journal of Clinical and Aesthetic Dermatology, 2014, 7, 13-24.	0.1	65
6168	The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy. American Health and Drug Benefits, 2011, 4, 387-8.	0.5	1
6169	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discovery Medicine, 2014, 17, 101-14.	0.5	41
6171	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 14.	0.4	9
6172	Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression. American Journal of Cancer Research, 2015, 5, 433-41.	1.4	9
6173	Melanoma: Molecular Pathogenesis and Therapeutic Management. Molecular and Cellular Pharmacology, 2014, 6, 228.	1.7	72
6174	On the Bayesian Derivation of a Treatment-based Cancer Ontology. AMIA Summits on Translational Science Proceedings, 2014, 2014, 209-17.	0.4	3
6175	Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. American Journal of Cancer Research, 2015, 5, 1507-18.	1.4	15
6176	Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma. Journal of the Advanced Practitioner in Oncology, 2014, 5, 400-10.	0.2	13
6177	Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. International Journal of Clinical and Experimental Pathology, 2015, 8, 8487-93.	0.5	9
6179	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Annals of Translational Medicine, 2015, 3, 272.	0.7	0
6180	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. Yale Journal of Biology and Medicine, 2015, 88, 389-95.	0.2	3
6182	Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma. International Journal of Clinical and Experimental Medicine, 2015, 8, 20722-31.	1.3	3

#	Article	IF	Citations
6183	Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States. American Health and Drug Benefits, 2016, 9, 203-13.	0.5	24
6184	Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 277-285.	1.0	9
6185	A Sensitive Peptide Nucleic Acid Probe Assay for Detection of BRAF V600 Mutations in Melanoma. Cancer Genomics and Proteomics, 2016, 13, 381-6.	1.0	2
6186	Conceptual Knowledge Discovery in Databases for Drug Combinations Predictions in Malignant Melanoma. Studies in Health Technology and Informatics, 2015, 216, 663-7.	0.2	2
6187	Systemic Therapies for Late-stage Melanoma. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 36-40.	0.1	1
6188	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. American Journal of Cancer Research, 2016, 6, 2514-2531.	1.4	35
6190	Integrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma. AMIA Summits on Translational Science Proceedings, 2017, 2017, 247-256.	0.4	9
6191	Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2016, 4, 97-106.	0.2	1
6192	Tyrosine-kinase Inhibitors Treatment in Advanced Malignant Melanoma. MÃ¦dica, 2017, 12, 293-296.	0.4	2
6195	Advances in the systemic treatment of metastatic melanoma. Oncology, 2013, 27, 374-81.	0.4	3
6196	Proteomics and melanoma: a current perspective. Global Dermatology, 2016, 3, 366-370.	0.1	1
6197	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-6.	0.9	17
6198	Droplet digital PCR for detection of mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. American Journal of Translational Research (discontinued), 2018, 10, 3773-3781.	0.0	12
6199	Systemic Therapy in Metastatic Melanoma. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 57S-65S.	0.6	1
6200	Regression of mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. Oncotarget, 2019, 10, 3818-3826.	0.8	16
6201	Dissecting the role of RNA modification regulatory proteins in melanoma. Oncotarget, 2019, 10, 3745-3759.	0.8	4
6202	Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells. International Journal of Clinical and Experimental Pathology, 2018, 11, 2550-2560.	0.5	1
6203	Conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between EGFR and MEK or CDK4/6 inhibitors. American Journal of Cancer Research, 2020, 10, 249-262.	1.4	7

#	Article	IF	Citations
6204	Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges. Yale Journal of Biology and Medicine, 2020, 93, 207-213.	0.2	5
6205	BRAF in malignant melanoma progression and metastasis: potentials and challenges. American Journal of Cancer Research, 2020, 10, 1103-1114.	1.4	10
6206	Data-driven Sublanguage Analysis for Cancer Genomics Knowledge Modeling: Applications in Mining Oncological Genetics Information from Patients' Genetic Reports. AMIA Summits on Translational Science Proceedings, 2020, 2020, 720-729.	0.4	1
6207	Clinicopathologic features and prognosis of epithelioid glioblastoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 1529-1539.	0.5	1
6208	Management of nephrotoxicity of chemotherapy and targeted agents: 2020. American Journal of Cancer Research, 2020, 10, 4151-4164.	1.4	4
6209	CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade. American Journal of Translational Research (discontinued), 2021, 13, 286-300.	0.0	4
6210	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	1.3	2
6211	BRAF Mutation Analysis in Primary AcralÂMelanoma of 41 Cases from South of Iran. Iranian Journal of Pathology, 2021, 16, 370-375.	0.2	0
6212	Cell-SELEX-based selection of ssDNA aptamers for specifically targeting BRAF V600E-mutated melanoma. Analyst, The, 2021, 147, 187-195.	1.7	6
6213	Systemic Therapy of Advanced Melanoma. , 2021, , 219-237.		0
6214	SignificÃ¢ncia prognÃ³stica da expressÃ£o de ki-67, receptores de estrÃ³geno e receptores de progesterona em pacientes com melanoma cutÃ¢neo / Prognostic significance of ki-67, estrogen receptors and progesterone receptors expression in patients with cutaneous melanoma. Brazilian Journal of Development, 2021, 7, 100118-100146.	0.0	0
6215	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 47-55.	0.7	1
6216	BRAF Mutation Is Associated with Hyperplastic Polyp-Associated Gastric Cancer. International Journal of Molecular Sciences, 2021, 22, 12724.	1.8	4
6217	Early Experience with Dabrafenibâ€“Trametinib Combination in Patients with BRAF-Mutated Malignant Melanomaâ€”A Single-Center Experience. South Asian Journal of Cancer, 2021, 10, 187-189.	0.2	1
6218	A sociology of precisionâ€inâ€practice: The affective and temporal complexities of everyday clinical care. Sociology of Health and Illness, 2021, 43, 2178-2195.	1.1	14
6219	The Influences of Omega-3 Polyunsaturated Fatty Acids on the Development of Skin Cancers. Diagnostics, 2021, 11, 2149.	1.3	6
6220	IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers, 2021, 13, 5863.	1.7	15
6221	External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	1

#	Article	IF	Citations
6222	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. Journal of Clinical Medicine, 2021, 10, 5475.	1.0	8
6223	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
6224	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. Health Technology Assessment, 2021, 25, 1-178.	1.3	4
6225	Suppressive Effects of Anisomycin on the Proliferation of B16 Mouse Melanoma Cells In Vitro. Anticancer Research, 2021, 41, 6113-6121.	0.5	0
6226	Community oncologistsâ€™ perceptions and utilization of large-panel genomic tumor testing. BMC Cancer, 2021, 21, 1273.	1.1	6
6227	Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors. Italian Journal of Dermatology and Venereology, 2021, 156, .	0.1	1
6228	Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21. Cancer Research, 2022, 82, 447-457.	0.4	16
6229	Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study. Frontiers in Immunology, 2021, 12, 609728.	2.2	9
6230	Single-cell transcriptome identifies molecular subtype of autism spectrum disorder impacted by de novo loss-of-function variants regulating glial cells. Human Genomics, 2021, 15, 68.	1.4	20
6231	In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines. Cancer Research Communications, 2021, 1, 115-126.	0.7	1
6232	Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. OncoTargets and Therapy, 2021, Volume 14, 5345-5352.	1.0	5
6233	Near-infrared photoimmunotherapy for the treatment of skin disorders. Expert Opinion on Biological Therapy, 2022, 22, 509-517.	1.4	0
6234	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Cancer Discovery, 2022, 12, 938-948.	7.7	19
6236	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. Oncologist, 2022, 27, e463-e470.	1.9	7
6237	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Review of Anticancer Therapy, 2022, 22, 17-25.	1.1	7
6238	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
6239	Psychological impact of BRAF mutational status in advanced melanoma patients. Italian Journal of Dermatology and Venereology, 2021, , .	0.1	0
6240	Signal pathways of melanoma and targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 424.	7.1	115

#	Article	IF	Citations
6241	Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity. Frontiers in Oncology, 2022, 12, 827985.	1.3	3
6242	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer. Journal of Personalized Medicine, 2022, 12, 99.	1.1	16
6243	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	0.7	21
6245	Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
6246	Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling. EBioMedicine, 2022, 75, 103809.	2.7	9
6248	Low-molecular-weight biomarkers: types and detection strategies. , 2022, , 23-69.		2
6250	Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma. Cancers, 2022, 14, 271.	1.7	18
6251	Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma. Melanoma Research, 2022, Publish Ahead of Print, 79-87.	0.6	3
6252	Fused pyrrolo-pyridines and pyrrolo-(iso)quinoline as anticancer agents. ChemistrySelect, 2023, 8, 2583-2645.	0.7	2
6253	Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer Discovery, 2022, 12, 606-624.	7.7	93
6254	Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors. ACS Omega, 2022, 7, 3293-3311.	1.6	3
6255	Using Optical Tweezers to Dissect Allosteric Communication Networks in Protein Kinases. Methods in Molecular Biology, 2022, 2394, 485-498.	0.4	0
6256	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
6257	New Therapeutic Approaches for Conjunctival Melanomaâ€"What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. International Journal of Molecular Sciences, 2022, 23, 1478.	1.8	4
6258	Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma. Scientific Reports, 2022, 12, 779.	1.6	1
6259	Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene. Cancer Cell International, 2022, 22, 9.	1.8	2
6260	The Identification of Prognostic and Metastatic Alternative Splicing in Skin Cutaneous Melanoma. Cancer Control, 2022, 29, 107327482110515.	0.7	2
6261	Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review. Frontiers in Medicine, 2021, 8, 652005.	1.2	3

#	Article	IF	Citations
6262	A Retrospective Statistical Validation Approach for Panel of Normalâ€“Based Single-Nucleotide Variant Detection in Tumor Sequencing. Journal of Molecular Diagnostics, 2022, 24, 41-47.	1.2	1
6263	Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells. Frontiers in Oncology, 2022, 12, 794216.	1.3	10
6264	Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience. Journal of Personalized Medicine, 2022, 12, 195.	1.1	1
6265	Molecular Genetic Investigation of Digital Melanoma in Dogs. Veterinary Sciences, 2022, 9, 56.	0.6	6
6266	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports, 2022, 38, 110291.	2.9	7
6267	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	3.4	21
6269	Cytoskeletal Remodelling as an Achillesâ€™ Heel for Therapy Resistance in Melanoma. Cells, 2022, 11, 518.	1.8	1
6270	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. Cancers, 2022, 14, 777.	1.7	3
6271	Epstein Barr virusâ€“positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Advances, 2022, 6, 891-901.	2.5	2
6272	Recent advances in B-RAF inhibitors as anticancer agents. Bioorganic Chemistry, 2022, 120, 105597.	2.0	10
6273	Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2022, 29, 3709-3723.	0.7	13
6274	BRAF Immunoexpression Can Be Intralesionally Heterogeneous but BRAF V600E Mutation Status Is Intralesionally Homogeneous and Interlesionally Concordant in Melanoma. American Journal of Dermatopathology, 2022, Publish Ahead of Print, .	0.3	1
6275	Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastasesâ€”From Biology to Clinical Utility. Diseases (Basel, Switzerland), 2022, 10, 11.	1.0	1
6276	Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process. Cells, 2022, 11, 577.	1.8	13
6277	FAK in Cancer: From Mechanisms to Therapeutic Strategies. International Journal of Molecular Sciences, 2022, 23, 1726.	1.8	61
6278	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 413-418.	0.4	7
6279	Bis-nor-diterpene from Cnidoscolus quercifolius (Euphorbiaceae) induces tubulin depolymerization-mediated apoptosis in BRAF-mutated melanoma cells. Chemico-Biological Interactions, 2022, 355, 109849.	1.7	2
6280	How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood, 2022, 139, 2294-2305.	0.6	9

#	Article	IF	Citations
6281	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. Annals of Diagnostic Pathology, 2022, 58, 151909.	0.6	1
6282	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	5.8	78
6283	Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. Antioxidants, 2021, 10, 1942.	2.2	33
6284	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. Springer Reference Medizin, 2021, , 1-57.	0.0	0
6285	Even a patient with BRAF-mutated malignant melanoma has a chance for long-term survival. Onkologie (Czech Republic), 2021, 15, 40-42.	0.0	0
6286	Suppression of CCT3 inhibits melanoma cell proliferation by downregulating CDK1 expression. Journal of Cancer, 2022, 13, 1958-1971.	1.2	5
6287	The Architecture of a Precision Oncology Platform. Advances in Experimental Medicine and Biology, 2022, 1361, 1-22.	0.8	1
6288	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.5	3
6289	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. Scripta Medica, 2022, 53, 29-35.	0.0	0
6290	Discovery of the First-in-Class Mek Inhibitor Trametinib (Trade Name: Mekinist) and Other Molecular Targeting Agents by â€œRb-Reactivator Screeningâ€• SSRN Electronic Journal, 0, , .	0.4	0
6291	Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Frontiers in Molecular Biosciences, 2022, 9, 834841.	1.6	23
6292	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. ChemistrySelect, 2022, .	0.7	3
6293	The Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathway in Osteoblasts. Journal of Bone Metabolism, 2022, 29, 1-15.	0.5	7
6294	RAS pathway regulation in melanoma. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	11
6295	On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Research, 2022, 11, 237.	0.8	1
6296	Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatric Dermatology, 2022, 39, 409-419.	0.5	6
6297	Blockade of the proâ€fibrotic reaction mediated by the miRâ€143/â€145 cluster enhances the responses to targeted therapy in melanoma. EMBO Molecular Medicine, 2022, 14, e15295.	3.3	12
6298	Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy. Frontiers in Bioengineering and Biotechnology, 2022, 10, 847901.	2.0	13

#	Article	IF	Citations
6299	Systematic identification of biomarker-driven drug combinations to overcome resistance. Nature Chemical Biology, 2022, 18, 615-624.	3.9	14
6300	BRAF inhibitors and their immunological effects in malignant melanoma. Expert Review of Clinical Immunology, 2022, 18, 347-362.	1.3	8
6301	STARBOARD: encorafenibÂ+ÂbinimetinibÂ+ pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncology, 2022, 18, 2041-2051.	1.1	9
6302	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines, 2022, 10, 822.	1.4	18
6303	Outcomes of Patients with Metastatic Melanomaâ€"A Single-Institution Retrospective Analysis. Cancers, 2022, 14, 1672.	1.7	1
6304	Impact of Cannabinoid Compounds on Skin Cancer. Cancers, 2022, 14, 1769.	1.7	9
6305	A Commotion in the Skin: Developing Melanoma Immunotherapies. Journal of Investigative Dermatology, 2022, 142, 2055-2060.	0.3	4
6306	The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 2022, 23, 3324.	1.8	4
6308	Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. Journal of Personalized Medicine, 2022, 12, 444.	1.1	21
6309	Evolution of surgical treatment of metastatic spine tumors. Journal of Neuro-Oncology, 2022, 157, 277-283.	1.4	0
6310	Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 342-353.	0.5	0
6311	Melanoma and Nanotechnology-Based Treatment. Frontiers in Oncology, 2022, 12, 858185.	1.3	12
6312	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEKÂInhibitors. JACC: CardioOncology, 2022, 4, 1-18.	1.7	18
6313	Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes. PLoS ONE, 2022, 17, e0266017.	1.1	0
6314	Bispecific Antibodies Progression in Malignant Melanoma. Frontiers in Pharmacology, 2022, 13, 837889.	1.6	0
6315	NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation. Cancers, 2022, 14, 1531.	1.7	17
6316	Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma. International Journal of Molecular Sciences, 2022, 23, 3660.	1.8	18
6317	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology, 2022, 29, 1902-1918.	0.9	5

#	Article	IF	Citations
6318	Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer. Nature Chemical Biology, 2022, 18, 605-614.	3.9	24
6319	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	3.2	17
6320	Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s). Melanoma Research, 2022, 32, 150-158.	0.6	2
6321	Melanoma: An update on systemic therapies. Journal of the American Academy of Dermatology, 2022, 86, 515-524.	0.6	26
6322	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. Critical Reviews in Oncology/Hematology, 2022, 172, 103647.	2.0	10
6323	Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib. Scientific Reports, 2022, 12, 5706.	1.6	10
6324	Tyrosinase suppresses vasculogenic mimicry in human melanoma cells. Oncology Letters, 2022, 23, 169.	0.8	6
6325	Comprehensive Analysis of the Prognostic Signature of Mutation-Derived Genome Instability-Related lncRNAs for Patients With Endometrial Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 753957.	1.8	11
6326	Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	12
6327	Genetics Matters: Voyaging from the Past into the Future of Humanity and Sustainability. International Journal of Molecular Sciences, 2022, 23, 3976.	1.8	1
6328	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	0.8	96
6329	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. BioDrugs, 2022, 36, 373-380.	2.2	2
6330	The crucial roles of m6A RNA modifications in cutaneous cancers: Implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Genes and Diseases, 2022, , .	1.5	0
6331	Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal of Cancer, 2022, 165, 81-96.	1.3	2
6332	Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. , 2022, 10, e004095.		7
6333	Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo. Cells, 2022, 11, 1229.	1.8	2
6334	A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment. Bioorganic and Medicinal Chemistry Letters, 2022, 64, 128683.	1.0	3
6335	Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules, 2021, 26, 7561.	1.7	3

#	Article	IF	Citations
6337	Review of Clinical Equipoise: Examples from Oncology Trials. Current Reviews in Clinical and Experimental Pharmacology, 2023, 18, 22-30.	0.4	1
6338	Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Seminars in Cancer Biology, 2022, 86, 566-582.	4.3	33
6339	Molecular testing for melanocytic tumors: a practical update. Histopathology, 2022, 80, 150-165.	1.6	4
6340	Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas. Molecules, 2021, 26, 7362.	1.7	4
6341	The value of anticancer drugs â€" a regulatory view. Nature Reviews Clinical Oncology, 2022, 19, 207-215.	12.5	14
6342	Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A realâ€world study. Cancer Medicine, 2022, 11, 139-150.	1.3	6
6343	Novel Biomarkers and Druggable Targets in Advanced Melanoma. Cancers, 2022, 14, 81.	1.7	5
6344	Magnetic nanoparticles in theranostics of malignant melanoma. EJNMMI Research, 2021, 11, 127.	1.1	9
6345	Role of Biomarkers in the Integrated Management of Melanoma. Disease Markers, 2021, 2021, 1-13.	0.6	10
6346	Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E. Journal of Endocrinological Investigation, 2013, 36, 1099-104.	1.8	12
6347	Oncology Drug Repurposing for Sepsis Treatment. Biomedicines, 2022, 10, 921.	1.4	5
6348	Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment. Science Signaling, 2022, 15, eabl7989.	1.6	15
6349	LuminoCell: a versatile and affordable platform for real-time monitoring of luciferase-based reporters. Life Science Alliance, 2022, 5, e202201421.	1.3	3
6350	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro-Oncology, 2022, 24, 1964-1975.	0.6	15
6351	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 148.	3.5	10
6352	Targeting mutations in cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	56
6353	Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?. Annals of Surgical Oncology, 2022, , .	0.7	0
6354	The oral cavity. , 0, , 1597-1706.		1

#	Article	IF	Citations
6368	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e577-e583.	1.8	0
6426	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. Expert Review of Proteomics, 2022, 19, 115-129.	1.3	3
6427	18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients. Clinical Nuclear Medicine, 2022, 47, 583-589.	0.7	4
6428	Stratified Medicine: Maximizing Clinical Benefit by Biomarker-Driven Health Care. Nestle Nutrition Institute Workshop Series, 2016, 84, 91-102.	1.5	2
6429	Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?. Dermatology, 2022, 238, 517-526.	0.9	5
6431	A 41-Year-Old Woman with a Late Cerebral Metastasis 16 Years After an Initial Diagnosis of Cutaneous Melanoma. American Journal of Case Reports, 2022, 23, e935728.	0.3	1
6432	Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors. Tumori, 2012, 98, 185-90.	0.6	5
6433	Metastatic melanoma: a regional review and future directions. Tumori, 2012, 98, 575-80.	0.6	12
6435	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	1.3	8
6439	Treatment of BRAF-mutated advanced cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 28.	0.4	5
6440	Algorithm for the management of metastatic cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 32.	0.4	1
6441	Toxicity of checkpoint inhibitors. Chinese Clinical Oncology, 2014, 3, 31.	0.4	12
6442	Design and statistical principles of the SHIVA trial. Chinese Clinical Oncology, 2015, 4, 32.	0.4	1
6445	Neoadjuvant therapy for melanoma: new and evolving concepts.. Clinical Advances in Hematology and Oncology, 2022, 20, 47-55.	0.3	0
6447	Encoding BRAF inhibitor functions in protein degraders. RSC Medicinal Chemistry, 2022, 13, 731-736.	1.7	4
6448	Pro-Prion is a Membrane Adaptor Protein for E3 Ligase C-Cbl to Ubiquitinate IGF-IR Promoting Melanoma Metastasis. SSRN Electronic Journal, 0, , .	0.4	0
6449	Translating Molecules into Imagingâ€"The Development of New PET Tracers for Patients with Melanoma. Diagnostics, 2022, 12, 1116.	1.3	7
6450	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells, 2022, 11, 1466.	1.8	6

#	Article	IF	Citations
6451	LS-HB-Mediated Photodynamic Therapy Inhibits Proliferation and Induces Cell Apoptosis in Melanoma. Molecular Pharmaceutics, 2022, 19, 2607-2619.	2.3	8
6452	Functionalization of Nanomaterials for Skin Cancer Theranostics. Frontiers in Bioengineering and Biotechnology, 2022, 10, 887548.	2.0	1
6453	Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System. Frontiers in Surgery, 2022, 9, 868187.	0.6	3
6454	On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Research, 0, 11, 237.	0.8	4
6455	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. Journal of Personalized Medicine, 2022, 12, 669.	1.1	1
6456	Novel Al¹⁸F-NOTA-Conjugated Lactam-Cyclized Î±-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. Bioconjugate Chemistry, 2022, 33, 982-990.	1.8	1
6457	Novel ⁶⁴Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. Molecular Pharmaceutics, 2022, 19, 2535-2541.	2.3	6
6458	Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. Science Advances, 2022, 8, eabm6638.	4.7	17
6459	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 2022, 28, 4618-4628.	3.2	37
6460	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. American Journal of Clinical Dermatology, 2022, 23, 523-545.	3.3	2
6461	Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. International Journal of Molecular Sciences, 2022, 23, 5158.	1.8	16
6462	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 315-324.	0.4	2
6463	The translational challenges of precision oncology. Cancer Cell, 2022, 40, 458-478.	7.7	38
6464	Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2022, 13, .	1.6	2
6465	Ferrochelatase: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria. Frontiers in Cell and Developmental Biology, 2022, 10, .	1.8	13
6466	Nano-enabled photosynthesis in tumours to activate lipid peroxidation for overcoming cancer resistances. Biomaterials, 2022, 285, 121561.	5.7	32
6467	CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways. Saudi Journal of Biological Sciences, 2022, 29, 103285.	1.8	2
6468	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17

#	Article	IF	Citations
6470	Primary and Metastatic Bone Lesions. , 2017, , 937-952.e3.		0
6471	Systemic anticancer agents. , 2013, , 397-407.e2.		1
6472	Development of a potent smallâ€molecule degrader against oncogenic <scp>BRAF^{V600E}</scp> protein that evades paradoxical <scp>MAPK</scp> activation. Cancer Science, 2022, 113, 2828-2838.	1.7	5
6473	Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective. Journal of Immunotherapy, 2022, Publish Ahead of Print, .	1.2	1
6474	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
6476	Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy. , 2022, , 747-779.		0
6477	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 5731.	1.8	9
6478	Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics, 2022, 12, 1305.	1.3	14
6479	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases â€“ A multicenter cohort study. European Journal of Cancer, 2022, 169, 210-222.	1.3	12
6481	New Potential Agents for Malignant Melanoma Treatmentâ€”Most Recent Studies 2020â€“2022. International Journal of Molecular Sciences, 2022, 23, 6084.	1.8	10
6482	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. ACS Applied Materials & Interfaces, 2022, 14, 24113-24121.	4.0	5
6484	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer, 2022, 169, 102-114.	0.9	8
6485	Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study. Melanoma Research, 0, Publish Ahead of Print, .	0.6	2
6486	Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. Pathology, 2022, 54, 772-778.	0.3	2
6487	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. European Journal of Cancer, 2022, 170, 256-284.	1.3	92
6488	Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Molecular Therapy - Oncolytics, 2022, 26, 1-14.	2.0	11
6489	Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Cell Biology and Toxicology, 2023, 39, 2381-2399.	2.4	8
6490	Complex Elucidation of Cells-of-Origin in Pediatric Soft Tissue Sarcoma: From Concepts to Real Life, Hide-and-Seek through Epigenetic and Transcriptional Reprogramming. International Journal of Molecular Sciences, 2022, 23, 6310.	1.8	1

#	Article	IF	Citations
6491	A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer Science, 0, , .	1.7	4
6493	Progress in the Treatment of Advanced Melanoma. Advances in Clinical Medicine, 2022, 12, 5256-5262.	0.0	0
6496	CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	29
6498	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.4	5
6499	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. Journal of Computer Assisted Tomography, 2022, 46, 621-632.	0.5	2
6500	Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Frontiers in Oncology, 0, 12, .	1.3	5
6501	Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	0
6502	Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival. Laryngoscope, 2022, 132, 2350-2358.	1.1	7
6503	Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions. Cancer Research, 2022, 82, 2811-2820.	0.4	5
6504	M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors. British Journal of Cancer, 2022, 127, 1142-1152.	2.9	4
6505	â€œRB-reactivator screeningâ€•as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). , 2022, 236, 108234.		4
6506	Phasing analysis of lung cancer genomes using a long read sequencer. Nature Communications, 2022, 13, .	5.8	8
6507	Cancer treatment and survivorship statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 409-436.	157.7	897
6508	Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. European Journal of Endocrinology, 2022, 187, 185-196.	1.9	1
6509	How inclusive are cell lines in preclinical engineered cancer models?. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	5
6510	Nanoparticle-Based Combination Therapy for Melanoma. Frontiers in Oncology, 0, 12, .	1.3	3
6511	Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy. Journal of the American Chemical Society, 2022, 144, 12367-12380.	6.6	6
6512	Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Frontiers in Pharmacology, 0, 13, .	1.6	134

#	Article	IF	Citations
6513	La rÃ©sistance aux inhibiteurs de BRAF. Medecine/Sciences, 2022, 38, 570-578.	0.0	0
6514	Co-Treatment of Chloroquine and Trametinib Inhibits Melanoma Cell Proliferation and Decreases Immune Cell Infiltration. Frontiers in Oncology, 0, 12, .	1.3	2
6515	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. Journal of Neurosurgery Case Lessons, 2022, 4, .	0.1	0
6516	Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance. BMJ Open, 2022, 12, e058350.	0.8	1
6517	Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene, 2022, 41, 3953-3968.	2.6	4
6518	Dermatologic Conditions. , 2022, , 457-476.		0
6520	Management of cutaneous melanoma: radiologists challenging and risk assessment. Radiologia Medica, 2022, 127, 899-911.	4.7	20
6521	Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	8
6522	A Novel ERK2 Degrader Z734 Induces Apoptosis of MCFâ€“7 Cells via the HERC3/p53 Signaling Pathway. Molecules, 2022, 27, 4337.	1.7	1
6524	Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells. Biomolecules, 2022, 12, 993.	1.8	2
6525	Targeting EGFR in melanoma â€“ The sea of possibilities to overcome drug resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188754.	3.3	21
6526	Minimal residual disease in gastroesophageal adenocarcinoma: theÂsearch for the invisible. ESMO Open, 2022, 7, 100547.	2.0	3
6527	Patient with multiple genetically distinct thyroid nodules including papillary thyroid carcinoma harboring novel YWHAG-BRAF fusion. Cancer Genetics, 2022, 266-267, 51-56.	0.2	1
6529	What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?. Journal of Clinical Oncology, 2022, 40, 4161-4165.	0.8	6
6530	Gene Identification and Potential Drug Therapy for Drug-Resistant Melanoma with Bioinformatics and Deep Learning Technology. Disease Markers, 2022, 2022, 1-13.	0.6	1
6531	Prevalence and Detection of Actionable BRAF V600 and NRAS Q61 Mutations in Malignant Peripheral Nerve Sheath Tumor by Droplet Digital PCR. SSRN Electronic Journal, 0, , .	0.4	0
6532	Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. Current Research in Immunology, 2022, 3, 159-166.	1.2	0
6533	Identification of fusions with potential clinical significance in melanoma. Modern Pathology, 2022, 35, 1837-1847.	2.9	8

#	Article	IF	Citations
6534	Exploration and validation of metastasis-associated genes for skin cutaneous melanoma. Scientific Reports, 2022, 12, .	1.6	5
6535	Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. Endocrine-Related Cancer, 2022, , .	1.6	4
6536	Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. Cancer Research Communications, 2022, 2, 1061-1074.	0.7	4
6537	Radiotherapy and Immunotherapy, Combined Treatment for Unresectable Mucosal Melanoma with Vaginal Origin. Applied Sciences (Switzerland), 2022, 12, 7734.	1.3	2
6538	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. Cancers, 2022, 14, 3779.	1.7	18
6539	Oral melanoma: a multicenter study of 69 patients from Japan. Clinical Oral Investigations, 2022, 26, 6187-6193.	1.4	1
6540	Metabolic rewiring directs melanoma immunology. Frontiers in Immunology, 0, 13, .	2.2	4
6541	Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
6542	Olive leaf extract inhibits metastatic melanoma spread through suppression of epithelial to mesenchymal transition. Phytotherapy Research, 2022, 36, 4002-4013.	2.8	8
6543	Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. Frontiers in Pharmacology, 0, 13, .	1.6	5
6544	Vulvovaginal melanoma. , 2023, , 279-304.		0
6545	Primary lacrimal sac melanoma: a case report describing the novel use of fine needle aspiration cytology (FNAC) for diagnosis, together with literature review and immunotherapy treatment update. Orbit, 2024, 43, 270-279.	0.5	0
6546	Fifty years of progress in surgical oncology: Melanoma. Journal of Surgical Oncology, 2022, 126, 888-895.	0.8	0
6547	Caspase-8 mutants activate Nrf2 via phosphorylating SQSTM1 to protect against oxidative stress in esophageal squamous cell carcinoma. Free Radical Biology and Medicine, 2022, 192, 51-62.	1.3	5
6548	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treatment Reviews, 2022, 110, 102463.	3.4	10
6549	Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models?. Computational and Structural Biotechnology Journal, 2022, 20, 4003-4008.	1.9	4
6550	Conquering oncogenic KRAS and its bypass mechanisms. Theranostics, 2022, 12, 5691-5709.	4.6	1
6551	Nonsurgical Management of Cholangiocarcinoma. , 2022, , 307-323.		0

#	Article	IF	Citations
6552	Substanzen gegen molekulare Zielstrukturen. Springer Reference Medizin, 2022, , 1-14.	0.0	0
6553	Introduction of medical genomics and clinical informatics integration for p-Health care. Progress in Molecular Biology and Translational Science, 2022, , 1-37.	0.9	3
6554	Role and mechanism of miR-211 in human cancer. Journal of Cancer, 2022, 13, 2933-2944.	1.2	4
6555	Chapter 21: Oncology: Rasburicase/G6PD Case. , 2022, , .		0
6557	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. , 2022, , .		0
6559	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. , 2022, , .		0
6560	Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. , 2022, , .		0
6561	Chapter 28: Information Resources for Pharmacogenomics. , 2022, , .		0
6562	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. , 2022, , .		0
6563	Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance. International Journal of Molecular Sciences, 2022, 23, 9910.	1.8	10
6564	Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. , 2022, , .		0
6565	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. , 2022, , .		0
6566	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. , 2022, , .		0
6567	Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. , 2022, , .		0
6568	Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. , 2022, , .		0
6570	Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. , 2022, , .		0
6571	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. , 2022, , .		0
6572	Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. , 2022, , .		0

#	Article	IF	Citations
6574	Chapter 3: Pharmacogenomics Testing. , 2022, , .		0
6575	Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. , 2022, , .		0
6576	Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. , 2022, , .		0
6578	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
6579	Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. , 2022, , .		0
6580	Chapter 6: The Pharmacists' Patient Care Process (PPCP). , 2022, , .		0
6581	Chapter 10: Endocrinology: Glipizide/G6PD Case. , 2022, , .		0
6582	Chapter 1: Foundations of Pharmacogenomics. , 2022, , .		0
6583	Chapter 20: Oncology: Capecitabine/DPYD Case. , 2022, , .		0
6585	Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. , 2022, , .		0
6586	Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. , 2022, , .		0
6587	Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. , 2022, , .		0
6588	Chapter 4: Pharmacists' Competencies in Genomics. , 2022, , .		0
6589	UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. Life, 2022, 12, 1339.	1.1	7
6591	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. , 2022, , .		0
6592	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. , 2022, , .		0
6593	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. , 2022, , .		0
6595	Towards precision oncology with patient-derived xenografts. Nature Reviews Clinical Oncology, 2022, 19, 719-732.	12.5	33

#	Article	IF	Citations
6596	Opportunities for pharmacoproteomics in biomarker discovery. Proteomics, 2023, 23, .	1.3	7
6597	Role of the Hedgehog Pathway and CAXII in Controlling Melanoma Cell Migration and Invasion in Hypoxia. Cancers, 2022, 14, 4776.	1.7	3
6598	KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma. BioMed Research International, 2022, 2022, 1-9.	0.9	3
6599	Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. Cancers, 2022, 14, 4642.	1.7	5
6600	A preclinical model of cutaneous melanoma based on reconstructed human epidermis. Scientific Reports, 2022, 12, .	1.6	3
6601	Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs, 2022, 82, 1367-1388.	4.9	29
6602	From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. International Journal of Cancer, 2023, 152, 1304-1313.	2.3	4
6603	Novel Therapies in Clinical Development for Advanced Disease. , 0, , .		0
6604	Clinical predictors of survival in real world practice in stage <scp>IV</scp> melanoma. Cancer Reports, 0, , .	0.6	1
6605	Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis. Cancer Research, 2022, 82, 3751-3762.	0.4	0
6606	Carotenoids from Marine Microalgae as Antimelanoma Agents. Marine Drugs, 2022, 20, 618.	2.2	4
6607	Nondestructive protein sampling with electroporation facilitates profiling of spatial differential protein expression in breast tumors in vivo. Scientific Reports, 2022, 12, .	1.6	3
6608	Evolution of precision oncologyâ€guided treatment paradigms. WIREs Mechanisms of Disease, 2023, 15, .	1.5	5
6609	Perspective Chapter: RNA Therapeutics for Cancers. , 0, , .		2
6611	Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/Î²-Catenin Signaling in BRAF-mutant Colorectal Cancer Models. Molecular Cancer Therapeutics, 2022, 21, 1777-1787.	1.9	3
6612	Targeted therapy in oncology. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 222-228.	0.1	0
6613	Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR. Human Pathology, 2022, 129, 90-97.	1.1	3
6614	Prediction of BRAF V600E variant from cancer gene expression data. Translational Cancer Research, 2022, 11, 4051-4056.	0.4	2

#	Article	IF	Citations
6616	Cutaneous Reactions to Oncologic Targeted Therapy. Updates in Clinical Dermatology, 2022, , 303-316.	0.1	0
6617	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. Comprehensive Gynecology and Obstetrics, 2022, , 115-132.	0.0	0
6618	Targeted Therapy and Immunotherapy in Melanoma. Dermatologic Clinics, 2023, 41, 65-77.	1.0	14
6619	Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone. Npj Genomic Medicine, 2022, 7, .	1.7	2
6620	CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma. Nature Communications, 2022, 13, .	5.8	9
6624	BRAF Inhibitors in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 4863.	1.7	4
6625	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
6626	Ophthalmic adverse effects of BRAF inhibitors. European Journal of Ophthalmology, 0, , 112067212211328.	0.7	3
6627	Immune Checkpoint Inhibitors and RASâ€“ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules, 2022, 12, 1562.	1.8	5
6628	Currently available molecular analyses for personalized tumor therapy (Review). Biomedical Reports, 2022, 17, .	0.9	3
6629	TRIP13/FLNA Complex Promotes Tumor Progression and Is Associated with Unfavorable Outcomes in Melanoma. Journal of Oncology, 2022, 2022, 1-14.	0.6	3
6632	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	3.1	25
6633	Clinical associations and genetic interactions of oncogenic BRAF alleles. PeerJ, 0, 10, e14126.	0.9	0
6634	Melanoma classification and management in the era of molecular medicine. Dermatologic Clinics, 2023, 41, 49-63.	1.0	15
6635	<scp>MYC</scp> and therapy resistance in cancer: risks and opportunities. Molecular Oncology, 2022, 16, 3828-3854.	2.1	20
6636	Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. BMC Medicine, 2022, 20, .	2.3	6
6637	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Communications, 2023, 43, 42-74.	3.7	9
6638	Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?. Cancers, 2022, 14, 5184.	1.7	7

#	Article	IF	Citations
6640	Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma. Molecular Pharmaceutics, 2022, 19, 4487-4505.	2.3	11
6641	Clinical Trials in Melanoma. Surgical Oncology Clinics of North America, 2023, 32, 47-63.	0.6	2
6642	PROTACs in gastrointestinal cancers. Molecular Therapy - Oncolytics, 2022, 27, 204-223.	2.0	10
6643	Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation. Biochemical Pharmacology, 2022, 206, 115336.	2.0	3
6644	Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. European Journal of Pharmaceutical Sciences, 2023, 180, 106311.	1.9	2
6645	Raman spectroscopy combined with deep learning for rapid detection of melanoma at the single cell level. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023, 286, 122029.	2.0	9
6646	WEMURAFENIB JAKO SELEKTYWNY INHIBITOR KINAZY SERONINOWO-TREONINOWEJ B-RAF STOSOWANY W LECZENIU CZERNIAKA. , 2016, 14, 52-56.		0
6647	A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation. European Journal of Oncology Pharmacy, 2022, 5, e00033.	0.5	0
6648	Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences, 2022, 23, 14121.	1.8	4
6649	Overlapping pathogenic de novo CNVs in neurodevelopmental disorders and congenital anomalies impacting constraint genes regulating early development. Human Genetics, 2023, 142, 1201-1213.	1.8	5
6650	Melanoma Treatment. JACC: CardioOncology, 2022, 4, 549-551.	1.7	0
6651	CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy. Cancers, 2022, 14, 5449.	1.7	4
6652	BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 5593.	1.7	6
6653	A CRISPR Path to Finding Vulnerabilities and Solving Drug Resistance: Targeting the Diverse Cancer Landscape and Its Ecosystem. Genetics & Genomics Next, 2022, 3, .	0.8	3
6654	Multi-Omics Alleviates the Limitations of Panel Sequencing for Cancer Drug Response Prediction. Cancers, 2022, 14, 5604.	1.7	0
6655	Cellular and Molecular Mechanisms of MEK1 Inhibitorâ€"Induced Cardiotoxicity. JACC: CardioOncology, 2022, 4, 535-548.	1.7	3
6656	MEK-inhibitors in treatment of Langerhans cell histiocytosis. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 42-47.	0.1	3
6657	HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy. Cell Death and Disease, 2022, 13, .	2.7	1

#	Article	IF	Citations
6658	Dieckol Inhibits Autophagic Flux and Induces Apoptotic Cell Death in A375 Human Melanoma Cells via Lysosomal Dysfunction and Mitochondrial Membrane Impairment. International Journal of Molecular Sciences, 2022, 23, 14149.	1.8	8
6659	The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review. Endocrine Journal, 2022, , .	0.7	0
6660	Drug Addiction in Cancer. , 2022, , 1-17.		0
6661	Photosensitization of human skin fibroblasts by vemurafenib promotes pleiotropic effects on membrane-enclosed organelles and apoptosis. Journal of Photochemistry and Photobiology B: Biology, 2023, 238, 112600.	1.7	0
6662	BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway. Pharmacological Research, 2023, 187, 106609.	3.1	7
6663	Predicting BRAF V600E variants: yet another new method. Translational Cancer Research, 2021, .	0.4	0
6664	Principalele abordÄƒri de profilare moleculÄƒ Ã®n oncologie: tehnologie, avantaje ÅŸi limitÄƒri. Oncolog-Hematolog Ro, 2022, 4, 34.	0.0	0
6665	Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma. Cureus, 2022, , .	0.2	1
6666	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. Cancers, 2022, 14, 5858.	1.7	2
6667	Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. Current Oncology, 2022, 29, 9255-9270.	0.9	1
6668	BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer. Hormone and Metabolic Research, 2022, 54, 852-858.	0.7	2
6669	PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Communication and Signaling, 2022, 20, .	2.7	8
6670	Histology-Agnostic Drugs: A Paradigm Shiftâ€"A Narrative Review. Advances in Therapy, 2023, 40, 1379-1392.	1.3	3
6671	3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. International Journal of Molecular Sciences, 2022, 23, 15650.	1.8	4
6672	BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities. Molecular Cancer Research, 2023, 21, 293-300.	1.5	2
6673	BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 2023, 15, 141.	1.7	14
6674	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. Cell Reports, 2022, 41, 111834.	2.9	3
6675	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41.	1.8	6

#	Article	IF	Citations
6677	Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy. Archives of Medical Research, 2022, 53, 794-806.	1.5	5
6678	New Insights into the Phenotype Switching of Melanoma. Cancers, 2022, 14, 6118.	1.7	7
6679	A narrative review of cancer molecular diagnostics: past, present, and future. Journal of Bio-X Research, 0, Publish Ahead of Print, .	0.3	0
6680	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 7523.	1.0	1
6681	Guidelines for DC preparation and flow cytometry analysis of mouse nonlymphoid tissues. European Journal of Immunology, 2023, 53, .	1.6	5
6682	p53 Family in Resistance to Targeted Therapy of Melanoma. International Journal of Molecular Sciences, 2023, 24, 65.	1.8	8
6683	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Network Open, 2022, 5, e2245269.	2.8	19
6685	Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules, 2022, 12, 1874.	1.8	9
6686	screenwerk: a modular tool for the design and analysis of drug combination screens. Bioinformatics, 2023, 39, .	1.8	2
6687	Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics, 2023, 13, 302.	1.3	1
6688	Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. Journal of Translational Medicine, 2023, 21, .	1.8	12
6689	High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma. Cells, 2023, 12, 254.	1.8	1
6690	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. Frontiers in Pharmacology, 0, 13, .	1.6	2
6691	MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
6692	NCCN GuidelinesÂ® Insights: Central Nervous System Cancers, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 12-20.	2.3	44
6693	When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective. Frontiers in Oncology, 0, 12, .	1.3	6
6695	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. International Journal of Molecular Sciences, 2023, 24, 1294.	1.8	6
6696	Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer, 2023, 23, .	1.1	4

#	Article	IF	Citations
6697	Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell Reports, 2023, 42, 111972.	2.9	2
6698	Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?. Frontiers in Oncology, 0, 12, .	1.3	3
6699	BRAF gene as a potential target to attenuate drug resistance and treat cancer. Gene Reports, 2023, 30, 101740.	0.4	1
6700	Molecular testing in melanoma for the surgical pathologist. Pathology, 2023, 55, 245-257.	0.3	2
6701	Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. European Journal of Cancer, 2023, 182, 163-169.	1.3	6
6702	Genomics for Clinical Practice in Oncology. , 2019, , 531-541.		0
6704	MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. Cancers, 2023, 15, 710.	1.7	11
6705	Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. International Journal of Molecular Sciences, 2023, 24, 1963.	1.8	3
6706	Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma. Biomedicines, 2023, 11, 394.	1.4	0
6707	Computational assessment of chemicals from Morinda citrifolia as potential inhibitors of B-Raf kinase in hepatocellular carcinoma treatment. Journal of Biomolecular Structure and Dynamics, 2023, 41, 13271-13286.	2.0	1
6709	Antiangiogenic activity of the penicillin derivative TAP7f in melanoma. Journal of Molecular Medicine, 0, , .	1.7	0
6710	Tumour DNA Sequencing. , 2023, , 81-99.		0
6711	Treatment and outcome trends and predictors of overall survival of rectal melanoma: Analysis of the National Cancer Database. European Journal of Surgical Oncology, 2023, 49, 1275-1282.	0.5	1
6713	Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Medica Academica, 2023, 51, 217-231.	0.3	2
6714	Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreenÂ® FFPE BRAF qPCR assay. PLoS ONE, 2023, 18, e0281558.	1.1	0
6715	Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma. Molecular Cancer Research, 2023, 21, 397-410.	1.5	4
6716	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology, 0, 29, 926-948.	1.4	4
6717	Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways. International Journal of Molecular Sciences, 2023, 24, 3418.	1.8	3

#	Article	IF	Citations
6718	Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient. Cancer Biology and Therapy, 2023, 24, .	1.5	1
6719	Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews, 2023, 42, 481-505.	2.7	2
6720	Pigmented Lesions of the Oral Cavity. Oral and Maxillofacial Surgery Clinics of North America, 2023, 35, 153-158.	0.4	0
6721	Expression changes of multiple marker genes and analysis of circulating tumour cells and dehydrogenase for prognostic and pharmacodynamic measures. Journal of King Saud University - Science, 2023, 35, 102638.	1.6	0
6722	Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies. , 2023, 4, 41-49.		1
6723	Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open, 2023, 8, 100788.	2.0	22
6724	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
6725	Multiple predictive biomarker testing in melanoma: Another challenge in identifying the optimal approach on cytological samples. Cytopathology, 2023, 34, 198-203.	0.4	0
6726	Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. Cancer Journal (Sudbury, Mass), 2023, 29, 3-8.	1.0	0
6727	Extracellular vesicles as a liquid biopsy for melanoma: Are we there yet?. Seminars in Cancer Biology, 2023, 89, 92-98.	4.3	2
6728	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. Translational Medicine Communications, 2023, 8, .	0.5	2
6729	Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. Critical Reviews in Oncology/Hematology, 2023, 183, 103919.	2.0	3
6730	Helper Innate Lymphoid Cellsâ€"Unappreciated Players in Melanoma Therapy. Cancers, 2023, 15, 933.	1.7	1
6731	Establishment of a <scp>BRAF V595E</scp>â€mutant canine prostate cancer cell line and the antitumor effects of <scp>MEK</scp> inhibitors against canine prostate cancer. Veterinary and Comparative Oncology, 2023, 21, 221-230.	0.8	1
6732	Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy. Cancers, 2023, 15, 1074.	1.7	2
6733	Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review. Journal of the National Cancer Institute, 0, , .	3.0	0
6734	The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma. British Journal of Dermatology, 2023, 188, 482-490.	1.4	2
6735	BRAF v600Eâ€"mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. Npj Precision Oncology, 2023, 7, .	2.3	4

#	Article	IF	Citations
6736	Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback. BMC Medical Ethics, 2023, 24, .	1.0	0
6737	Increasing the Capture Rate of Circulating Tumor DNA in Unaltered Plasma Using Passive Microfluidic Mixer Flow Cells. Langmuir, 2023, 39, 3225-3234.	1.6	1
6738	Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). Frontiers in Oncology, 0, 13, .	1.3	0
6739	Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. Drug Research, 2023, 73, 189-199.	0.7	4
6740	Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers. Biomedicines, 2023, 11, 694.	1.4	5
6741	Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer. Thyroid Research, 2023, 16, .	0.7	5
6742	Melanoma: A Historical Walk-through from Palliative Treatment to Modern-day Practice. , 2023, 126, 266-274.		0
6743	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. Journal of Gastrointestinal Cancer, 2023, 54, 1276-1285.	0.6	0
6744	Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	10
6745	Tâ€cell exhaustion: A potential target biomarker of the tumour microenvironment affecting oesophageal adenocarcinoma. Journal of Gene Medicine, 2023, 25, .	1.4	2
6747	Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status. International Journal of Molecular Sciences, 2023, 24, 5110.	1.8	1
6748	Urban-Rural and Socioeconomic Differences in Patient Knowledge and Perceptions of Genomic Tumor Testing. JCO Precision Oncology, 2023, , .	1.5	2
6749	Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenibâ€‰+â€‰Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. Targeted Oncology, 2023, 18, 235-245.	1.7	1
6750	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. Cancers, 2023, 15, 1766.	1.7	6
6751	Pathway Alterations in Stage II/III Primary Melanoma. JCO Precision Oncology, 2023, , .	1.5	0
6752	Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases. Cancers, 2023, 15, 1884.	1.7	4
6753	Clinical Trials for Personalized Medicine: Design and Data Analysis. Japanese Journal of Biometrics, 2022, 43, 97-119.	0.0	0
6754	Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma. Journal of Medicinal Chemistry, 2023, 66, 5171-5184.	2.9	5

#	Article	IF	Citations
6755	Discovery of novel <scp>CDK2</scp> inhibitors using multistage virtual screening and in vitro melanoma cell lines. FASEB Journal, 2023, 37, .	0.2	0
6756	Multi-targeted therapy resistance via drug-induced secretome fucosylation. ELife, 0, 12, .	2.8	2
6757	Precision oncology comes of age. JAAPA: Official Journal of the American Academy of Physician Assistants, 2023, 36, 28-31.	0.1	1
6758	Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. Current Oncology Reports, 2023, 25, 623-634.	1.8	3
6760	Do more targets allow more cancer treatments, or not?. European Journal of Cancer, 2023, 187, 99-104.	1.3	0
6761	Accelerating the understanding of cancer biology through the lens of genomics. Cell, 2023, 186, 1755-1771.	13.5	9
6762	Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precision Oncology, 2023, , .	1.5	5
6763	BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. Frontiers in Oncology, 0, 13, .	1.3	1
6764	Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clinical Cancer Research, 2023, 29, 2753-2760.	3.2	19
6765	Selected Approaches to Disrupting Proteinâ€“Protein Interactions within the MAPK/RAS Pathway. International Journal of Molecular Sciences, 2023, 24, 7373.	1.8	2
6766	Therapeutic Potential of Clostridium novyi-NT in Cancer: Current Knowledge and Future Perspectives. Current Cancer Drug Targets, 2023, 23, 682-696.	0.8	1
6770	General aspects of cancer therapy. , 2023, , 1-35.		0
6774	Precision medicine-based cancer care. , 2024, , 272-283.		0
6784	Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. Npj Precision Oncology, 2023, 7, .	2.3	1
6805	Protein kinases: drug targets for immunological disorders. Nature Reviews Immunology, 2023, 23, 787-806.	10.6	11
6811	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. American Journal of Clinical Dermatology, 0, , .	3.3	0
6814	Zukunftspotenziale der Labormedizin. , 2023, , 181-231.		0
6815	Endoplasmic Reticulum Stress and Emerging Therapeutic Targets in Cancer. , 2023, , 1-54.		0

#	Article	IF	Citations
6836	Oncolytic intralesional therapy for metastatic melanoma. Clinical and Experimental Metastasis, 0, , .	1.7	0
6846	From target discovery to clinical drug development with human genetics. Nature, 2023, 620, 737-745.	13.7	14
6864	Precision Medicine. , 2023, , 199-214.		0
6871	Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds. , 2024, , 283-292.		0
6883	Molecular pathology and testing in melanocytic tumors. , 2024, , 359-384.		0
6901	Molecular diagnostics tailoring personalized cancer therapyâ€"an oncologistâ€™s view. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2024, 484, 169-179.	1.4	1
6907	Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
6933	Multifunctional nanocarrier-mediated delivery for targeting and treating skin cancer. , 2024, , 113-138.		1
6934	Fighting melanoma and resistant phenotypes African medicinal plants and their phytoconstituents. Advances in Botanical Research, 2024, , .	0.5	0
6938	BRAF â€" a tumour-agnostic drug target with lineage-specific dependencies. Nature Reviews Clinical Oncology, 2024, 21, 224-247.	12.5	1
6967	Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors. Frontiers in Oncology, 0, 14, .	1.3	0